https://lymphoma-stg.clarovantdigital.com/library/ibrutinib-added-to-standard-conditioning-and-as-consolidation-therapy-following-autologous-hematopoietic-stem-cell-transplantation-autohct-for-relapsed-refractory-activated-b-cell-subtype-diffuse-la/2023-12-14T16:55:58+00:00https://lymphoma-stg.clarovantdigital.com/library/treatment-effectiveness-with-venetoclax-based-therapy-after-bruton-tyrosine-kinase-inhibitors-in-chronic-lymphocytic-leukemia-an-international-real-world-study/2023-12-14T16:55:59+00:00https://lymphoma-stg.clarovantdigital.com/library/real-world-outcomes-of-brexucabtagene-autoleucel-brexu-cel-for-relapsed-or-refractory-r-r-mantle-cell-lymphoma-mcl-a-cibmtr-subgroup-analysis-of-high-risk-characteristics/2023-12-14T16:55:59+00:00https://lymphoma-stg.clarovantdigital.com/library/outcomes-of-patients-with-relapsed-refractory-mantle-cell-lymphoma-r-r-mcl-treated-with-brexucabtagene-autoleucel-brexu-cel-in-zuma-2-and-zuma-18-an-expanded-access-study/2023-12-14T16:55:59+00:00https://lymphoma-stg.clarovantdigital.com/library/standardization-of-outpatient-care-after-car-t-therapy-across-a-large-cell-therapy-network-through-technology-and-decentralized-virtual-nurses-preliminary-results/2023-12-14T16:56:00+00:00https://lymphoma-stg.clarovantdigital.com/library/ibrutinib-plus-venetoclax-with-mrd-directed-duration-of-treatment-is-superior-to-fcr-and-is-a-new-standard-of-care-for-previously-untreated-cll-report-of-the-phase-iii-uk-ncri-flair-study/2026-01-14T21:03:22+00:00https://lymphoma-stg.clarovantdigital.com/library/nivolumab-avd-is-better-tolerated-and-improves-progression-free-survival-compared-to-bv-avd-in-older-patients-aged-60-years-with-advanced-stage-hodgkin-lymphoma-enrolled-on-swog-s1826/2023-12-14T16:56:00+00:00https://lymphoma-stg.clarovantdigital.com/library/brentuximab-vedotin-nivolumab-doxorubicin-and-dacarbazine-for-advanced-stage-classical-hodgkin-lymphoma-efficacy-and-safety-results-from-the-single-arm-phase-2-study/2023-12-14T16:56:00+00:00https://lymphoma-stg.clarovantdigital.com/library/improved-overall-survival-with-axicabtagene-ciloleucel-vs-standard-of-care-in-second-line-large-b-cell-lymphoma-among-the-elderly-a-subgroup-analysis-of-zuma-7/2023-12-14T16:56:01+00:00https://lymphoma-stg.clarovantdigital.com/library/efficacy-and-safety-of-valemetostat-monotherapy-in-patients-with-relapsed-or-refractory-peripheral-t-cell-lymphomas-primary-results-of-the-phase-2-valentine-ptcl01-study/2025-12-10T19:45:02+00:00https://lymphoma-stg.clarovantdigital.com/library/clinical-outcomes-of-patients-with-relapsed-refractory-follicular-lymphoma-treated-with-tisagenlecleucel-phase-2-elara-3-year-follow-up/2023-12-14T16:56:01+00:00https://lymphoma-stg.clarovantdigital.com/library/primary-analysis-and-results-of-bendamustine-rituximab-and-venetoclax-br-ven-for-initial-treatment-of-mantle-cell-lymphoma-in-subjects-over-60-years-of-age-pre0405/2023-12-14T16:56:01+00:00https://lymphoma-stg.clarovantdigital.com/library/subcutaneous-sc-mosunetuzumab-mosun-as-first-line-therapy-for-patients-pts-with-high-tumor-burden-follicular-lymphoma-fl-first-results-of-a-multicenter-phase-2-study/2026-01-14T18:00:31+00:00https://lymphoma-stg.clarovantdigital.com/library/pirtobrutinib-a-highly-selective-non-covalent-reversible-btk-inhibitor-in-relapsed-refractory-follicular-lymphoma-results-from-the-phase-1-2-bruin-study/2023-12-14T16:56:02+00:00https://lymphoma-stg.clarovantdigital.com/library/pirtobrutinib-in-post-cbtki-cll-sll-30-months-follow-up-and-subgroup-analysis-with-without-prior-bcl2i-from-the-phase-1-2-bruin-study/2025-03-03T20:45:24+00:00https://lymphoma-stg.clarovantdigital.com/library/progression-free-survival-pfs-and-toxicity-with-nivolumab-avd-compared-to-brentuximab-vedotin-avd-in-pediatric-advanced-stage-as-classic-hodgkin-lymphoma-chl-results-of-swog-s1826/2023-12-14T16:56:02+00:00https://lymphoma-stg.clarovantdigital.com/library/subcutaneous-epcoritamab-plus-lenalidomide-in-patients-with-relapsed-refractory-diffuse-large-b-cell-lymphoma-from-epcore-nhl-5/2026-01-14T17:59:44+00:00https://lymphoma-stg.clarovantdigital.com/library/epcoritamab-sc-monotherapy-leads-to-deep-and-durable-responses-in-patients-with-relapsed-or-refractory-follicular-lymphoma-first-data-disclosure-from-the-epcore-nhl-1-follicular-lymphoma-dose-expansi/2026-01-14T19:38:36+00:00https://lymphoma-stg.clarovantdigital.com/library/cd3xcd20-bispecific-antibodies-yields-long-term-survival-in-relapsed-refractory-b-cell-lymphoma-a-follow-up-study-of-patients-treated-in-pivotal-phase-1-2-trials/2026-01-14T19:37:49+00:00https://lymphoma-stg.clarovantdigital.com/library/incidence-of-infections-associated-with-the-use-of-bispecific-antibodies-in-b-cell-non-hodgkin-lymphomas/2026-01-14T19:35:52+00:00https://lymphoma-stg.clarovantdigital.com/library/epcoritamab-sc-gemox-leads-to-high-complete-metabolic-response-rates-in-patients-with-relapsed-refractory-diffuse-large-b-cell-lymphoma-ineligible-for-autologous-stem-cell-transplant-updated-result/2026-01-14T19:35:15+00:00https://lymphoma-stg.clarovantdigital.com/library/results-of-a-second-prespecified-analysis-of-the-phase-2-study-elm-2-confirm-high-rates-of-durable-complete-response-with-odronextamab-in-patients-with-relapsed-refractory-r-r-follicular-lymphoma/2023-12-14T16:56:04+00:00https://lymphoma-stg.clarovantdigital.com/library/circulating-tumor-dna-analysis-associates-with-progression-free-survival-pfs-with-odronextamab-monotherapy-in-relapsed-refractory-r-r-follicular-lymphoma-fl-and-diffuse-large-b-cell-lymphoma-dl/2026-01-14T21:02:08+00:00https://lymphoma-stg.clarovantdigital.com/library/odronextamab-demonstrates-durable-complete-responses-in-patients-with-diffuse-large-b-cell-lymphoma-dlbcl-progressing-after-car-t-therapy-outcomes-from-the-elm-1-study/2023-12-14T16:56:05+00:00https://lymphoma-stg.clarovantdigital.com/library/final-analysis-of-the-phase-2-elm-2-study-odronextamab-in-patients-with-relapsed-refractory-r-r-diffuse-large-b-cell-lymphoma-dlbcl/2023-12-14T16:56:05+00:00https://lymphoma-stg.clarovantdigital.com/library/maintenance-of-moderate-to-high-levels-of-functioning-and-quality-of-life-with-odronextamab-monotherapy-in-patients-with-relapsed-or-refractory-follicular-lymphoma/2023-12-14T16:56:05+00:00https://lymphoma-stg.clarovantdigital.com/library/a-multicenter-phase-2-trial-of-zanubrutinib-obinutuzumab-and-venetoclax-boven-in-patients-with-treatment-naive-tp53-mutant-mantle-cell-lymphoma/2023-12-14T16:56:05+00:00https://lymphoma-stg.clarovantdigital.com/library/limited-duration-loncastuximab-tesirine-with-rituximab-induces-high-complete-metabolic-response-rate-in-high-risk-relapsed-refractory-follicular-lymphoma-a-phase-2-study/2023-12-14T16:56:06+00:00https://lymphoma-stg.clarovantdigital.com/library/long-term-outcomes-in-chronic-lymphocytic-leukemia-treated-with-ibrutinib-10-year-follow-up-of-a-phase-2-study/2023-12-14T16:56:06+00:00https://lymphoma-stg.clarovantdigital.com/library/real-world-effectiveness-and-safety-outcomes-of-acalabrutinib-treatment-by-line-of-therapy-in-patients-with-chronic-lymphocytic-leukemia-and-or-small-lymphocytic-lymphoma-2/2025-03-03T20:42:28+00:00https://lymphoma-stg.clarovantdigital.com/library/second-line-chimeric-antigen-receptor-t-cell-therapy-car-t-as-standard-of-care-for-relapsed-refractory-large-b-cell-lymphoma-lbcl/2023-12-14T16:56:06+00:00https://lymphoma-stg.clarovantdigital.com/library/five-year-outcomes-of-patients-with-large-b-cell-lymphoma-treated-with-standard-of-care-axicabtagene-ciloleucel-results-from-the-us-lymphoma-car-t-cell-consortium/2023-12-14T16:56:07+00:00https://lymphoma-stg.clarovantdigital.com/library/pembrolizumab-pembro-in-children-and-young-adults-with-low-risk-classical-hodgkin-lymphoma-chl-with-slow-early-response-ser-to-front-line-chemotherapy-chemo-early-results-from-the-phase-2-key/2023-12-14T16:56:07+00:00https://lymphoma-stg.clarovantdigital.com/library/pembrolizumab-pembro-in-children-and-young-adults-with-high-risk-classical-hodgkin-lymphoma-chl-with-slow-early-response-ser-to-front-line-chemotherapy-chemo-updated-results-from-the-phase-2/2023-12-14T16:56:07+00:00https://lymphoma-stg.clarovantdigital.com/library/first-line-fixed-duration-ibrutinib-plus-venetoclax-ibrven-versus-chlorambucil-plus-obinutuzumab-clbo-55-month-follow-up-from-the-glow-study/2023-12-14T16:56:07+00:00https://lymphoma-stg.clarovantdigital.com/library/relapse-after-first-line-fixed-duration-ibrutinib-venetoclax-high-response-rates-to-ibrutinib-retreatment-and-absence-of-btk-mutations-in-patients-with-chronic-lymphocytic-leukemia-cll-small-lymp/2026-01-14T21:00:26+00:00https://lymphoma-stg.clarovantdigital.com/library/ibrutinib-fludarabine-cyclophosphamide-and-obinutuzumab-ifcg-for-firstline-treatment-of-patients-with-cll-with-mutated-ighv-and-without-del17p-tp53-mutation-six-year-follow-up-analyses/2023-12-14T16:56:08+00:00https://lymphoma-stg.clarovantdigital.com/library/ibrutinib-and-rituximab-versus-fludarabine-cyclophosphamide-and-rituximab-for-patients-in-ncri-flair-study-with-previously-untreated-cll-assessment-of-mutational-landscape-of-patients-at-baseline-a/2023-12-14T16:56:08+00:00https://lymphoma-stg.clarovantdigital.com/library/ibrutinib-combined-with-venetoclax-in-patients-with-relapsed-refractory-mantle-cell-lymphoma-primary-analysis-results-from-the-randomized-phase-3-sympatico-study/2023-12-14T16:56:08+00:00https://lymphoma-stg.clarovantdigital.com/library/early-complete-responses-with-mosunetuzumab-monotherapy-in-treatment-naive-follicular-and-marginal-zone-lymphomas-with-only-low-grade-cytokine-release-syndrome/2023-12-14T16:56:09+00:00https://lymphoma-stg.clarovantdigital.com/library/real-world-incidence-characteristics-and-management-of-cytokine-release-syndrome-induced-by-chimeric-antigen-receptor-t-cell-therapy-across-hematologic-malignancies/2023-12-14T16:56:09+00:00https://lymphoma-stg.clarovantdigital.com/library/autologous-transplant-auto-hct-is-associated-with-improved-clinical-outcomes-compared-to-car-t-therapy-in-patients-pts-with-large-b-cell-lymphoma-lbcl-achieving-a-complete-remission/2023-12-14T16:56:09+00:00https://lymphoma-stg.clarovantdigital.com/library/brentuximab-vedotin-nivolumab-doxorubicin-and-dacarbazine-anad-for-early-stage-classical-hodgkin-lymphoma-sgn35-027-part-c/2023-12-14T16:56:09+00:00https://lymphoma-stg.clarovantdigital.com/library/phase-ib-ii-study-of-multi-targeted-therapy-with-venetoclax-ibrutinib-prednisone-obinutuzumab-and-lenalidomide-vipor-in-relapsed-refractory-r-r-diffuse-large-b-cell-lymphoma-dlbcl/2023-12-14T16:56:10+00:00https://lymphoma-stg.clarovantdigital.com/library/mosunetuzumab-monotherapy-continues-to-demonstrate-durable-responses-in-patients-with-relapsed-and-or-refractory-follicular-lymphoma-after-2-prior-therapies-3-year-follow-up-from-a-pivotal-phase-ii/2023-12-14T16:56:10+00:00https://lymphoma-stg.clarovantdigital.com/library/loncastuximab-tesirine-demonstrated-substantial-single-agent-efficacy-and-manageable-safety-profile-in-heavily-pretreated-chinese-patients-with-relapsed-or-refractory-r-r-diffuse-large-b-cell-lympho/2023-12-14T16:56:10+00:00https://lymphoma-stg.clarovantdigital.com/library/integrative-ngs-testing-reveals-clonal-dynamics-of-adverse-genomic-defects-contributing-to-a-natural-progression-in-treatment-naive-cll-patients/2023-12-14T16:56:11+00:00https://lymphoma-stg.clarovantdigital.com/library/frailty-impact-on-outcomes-of-patients-undergoing-chimeric-antigen-receptor-t-cell-car-t-therapy-at-princess-margaret-cancer-centre-a-prospective-pilot-study/2023-12-14T16:56:11+00:00https://lymphoma-stg.clarovantdigital.com/library/clinical-efficacy-and-safety-of-subcutaneous-rituximab-in-non-hodgkin-lymphoma-a-systematic-literature-review-and-meta-analysis/2026-03-27T13:14:22+00:00https://lymphoma-stg.clarovantdigital.com/library/r-minichop-versus-r-chop-in-elderly-patients-with-diffuse-large-b-cell-lymphoma-a-propensity-matched-population-based-study/2023-12-14T18:24:02+00:00https://lymphoma-stg.clarovantdigital.com/library/developing-new-strategies-for-relapsed-refractory-diffuse-large-b-cell-lymphoma/2023-12-14T19:37:14+00:00https://lymphoma-stg.clarovantdigital.com/library/timing-of-bnt162b2-vaccine-prior-to-covid-19-infection-influence-disease-severity-in-patients-with-hematologic-malignancies-results-from-a-cohort-study/2024-01-16T14:12:35+00:00https://lymphoma-stg.clarovantdigital.com/library/clonal-relationship-and-mutation-analysis-in-lymphoplasmacytic-lymphoma-waldenstrom-macroglobulinemia-associated-with-diffuse-large-b-cell-lymphoma-2/2023-12-14T19:34:49+00:00https://lymphoma-stg.clarovantdigital.com/library/car-modified-cellular-therapies-in-chronic-lymphocytic-leukemia-is-the-uphill-road-getting-less-steep/2023-12-14T19:44:18+00:00https://lymphoma-stg.clarovantdigital.com/library/car-t-cell-therapy-shows-similar-efficacy-and-toxicity-in-patients-with-dlbcl-regardless-of-cns-involvement/2023-12-14T19:51:12+00:00https://lymphoma-stg.clarovantdigital.com/library/safety-and-efficacy-of-zanubrutinib-in-relapsed-refractory-marginal-zone-lymphoma-final-analysis-of-the-magnolia-study/2023-12-14T20:21:37+00:00https://lymphoma-stg.clarovantdigital.com/library/optimizing-treatment-for-relapsed-refractory-classic-hodgkin-lymphoma-in-the-era-of-immunotherapy/2023-12-14T21:19:49+00:00https://lymphoma-stg.clarovantdigital.com/library/tumor-location-relative-to-the-spleen-is-a-prognostic-factor-in-lymphoma-patients-a-demonstration-from-the-remarc-trial/2023-12-14T21:35:26+00:00https://lymphoma-stg.clarovantdigital.com/library/favorable-outcomes-of-front-line-risk-adapted-therapy-in-young-patients-with-diffuse-large-b-cell-lymphoma-with-clinically-or-biologically-high-risk-features/2023-12-14T21:43:52+00:00https://lymphoma-stg.clarovantdigital.com/library/long-term-analysis-of-the-ribvd-phase-ii-trial-reveals-the-unfavorable-impact-of-tp53-mutations-and-hypoalbuminemia-in-older-adults-with-mantle-cell-lymphoma-for-the-lysa-group/2023-12-14T21:48:40+00:00https://lymphoma-stg.clarovantdigital.com/library/risk-of-cutaneous-tcell-lymphoma-with-psoriasis-biologic-therapies/2023-12-14T22:31:04+00:00https://lymphoma-stg.clarovantdigital.com/library/burden-of-illness-in-follicular-lymphoma-with-multiple-lines-of-treatment-italian-rwe-analysis/2023-12-14T22:37:40+00:00https://lymphoma-stg.clarovantdigital.com/library/radiotherapy-of-orbital-and-ocular-adnexa-lymphoma-literature-review-and-university-of-catania-experience/2023-12-14T22:42:27+00:00https://lymphoma-stg.clarovantdigital.com/library/mosunetuzumab-with-polatuzumab-vedotin-in-relapsed-or-refractory-aggressive-large-b-cell-lymphoma-a-phase-1b-2-trial/2026-01-14T21:35:07+00:00https://lymphoma-stg.clarovantdigital.com/library/impact-of-primary-organ-site-of-involvement-by-peripheral-t-cell-lymphoma-not-otherwise-specified-on-survival/2023-12-14T22:50:21+00:00https://lymphoma-stg.clarovantdigital.com/library/steroid-induced-hyperglycemia-and-its-effect-on-outcomes-of-r-chop-chemotherapy-for-diffuse-large-b-cell-lymphoma/2023-12-14T22:53:09+00:00https://lymphoma-stg.clarovantdigital.com/library/major-impact-of-prognosis-by-age-and-sex-in-patients-with-primary-mediastinal-large-b%e2%80%91cell-lymphoma/2023-12-14T22:57:22+00:00https://lymphoma-stg.clarovantdigital.com/library/appraisal-of-novel-oncological-therapies-by-the-scottish-medicines-consortium-and-the-national-institute-for-health-and-care-excellence-a-comparative-study-of-six-years-of-data/2023-12-22T16:15:54+00:00https://lymphoma-stg.clarovantdigital.com/library/bleomycin-affects-lung-function-for-at-least-5-years-after-treatment-for-hodgkin-lymphoma-data-from-the-international-randomised-phase-3-rathl-trial/2023-12-22T16:15:54+00:00https://lymphoma-stg.clarovantdigital.com/library/safety-and-efficacy-of-relmacabtagene-autoleucel-relma-cel-in-adults-with-relapsed-refractory-mantle-cell-lymphoma-r-r-mcl-updated-results-from-a-phase-ii-open-label-study-in-china/2026-01-16T14:53:48+00:00https://lymphoma-stg.clarovantdigital.com/library/a-window-study-of-acalabrutinib-rituximab-followed-by-chemotherapy-autograft-asct-in-fit-patients-with-treatment-naive-mantle-cell-lymphoma-mcl-first-report-of-the-investigator-initiated-aus/2023-12-22T16:15:55+00:00https://lymphoma-stg.clarovantdigital.com/library/minimal-residual-disease-status-predicts-outcome-in-patients-with-previously-untreated-follicular-lymphoma-a-prospective-analysis-of-the-phase-iii-gallium-study/2026-01-14T20:59:30+00:00https://lymphoma-stg.clarovantdigital.com/library/long-term-efficacy-of-a-6-month-regimen-of-rituximab-and-lenalidomide-in-follicular-lymphoma-patients-in-need-of-first-therapy-updated-analysis-of-the-sakk-35-10-randomized-trial/2023-12-22T16:15:55+00:00https://lymphoma-stg.clarovantdigital.com/library/induction-and-maintenance-therapy-in-elderly-patients-with-mantle-cell-lymphoma-double-randomized-mcl-r2-elderly-clinical-trial-by-the-european-mantle-cell-lymphoma-network/2023-12-22T16:15:55+00:00https://lymphoma-stg.clarovantdigital.com/library/preliminary-results-of-a-phase-ii-study-of-lenalidomide-combined-with-immunochemotherapy-in-patients-with-primary-central-nervous-system-lymphoma/2023-12-22T16:15:56+00:00https://lymphoma-stg.clarovantdigital.com/library/spatially-resolved-tumor-microenvironment-predicts-treatment-outcomes-in-relapsed-refractory-hodgkin-lymphoma/2023-12-22T16:15:56+00:00https://lymphoma-stg.clarovantdigital.com/library/primary-analysis-of-varnimcabtagene-autoleucel-imn-003a-in-phase-2-study-imagine-a-first-in-india-industry-cd19-directed-car-t-cell-therapy-for-patients-with-relapsed-refractory-b-cell-malignanci/2023-12-22T16:15:56+00:00https://lymphoma-stg.clarovantdigital.com/library/varnimcabtagene-autoleucel-ari-0001-for-relapsed-or-refractory-chronic-lymphocytic-leukemia-cll-and-richter-transformation-rt/2023-12-22T16:15:56+00:00https://lymphoma-stg.clarovantdigital.com/library/lenalidomide-consolidation-improves-measurable-residual-disease-mrd-rates-and-progression-free-survival-in-patients-with-chronic-lymphocytic-leukemia-following-initial-fcr-chemotherapy-final-analy/2026-01-14T20:58:54+00:00https://lymphoma-stg.clarovantdigital.com/library/infections-drive-non-relapse-mortality-following-car-t-therapy-across-disease-entities-and-car-products-a-meta-analysis-of-clinical-trials-and-real-world-studies/2023-12-22T16:15:57+00:00https://lymphoma-stg.clarovantdigital.com/library/extended-follow-up-of-a-phase-2-study-of-early-intervention-with-lenalidomide-in-patients-with-high-risk-chronic-lymphocytic-leukemia/2023-12-22T16:15:57+00:00https://lymphoma-stg.clarovantdigital.com/library/broad-superiority-of-zanubrutinib-over-bendamustine-rituximab-across-multiple-high-risk-factors-biomarker-subgroup-analysis-in-the-phase-3-sequoia-study-in-patients-with-treatment-naive-chronic-lym/2025-03-03T20:36:17+00:00https://lymphoma-stg.clarovantdigital.com/library/longitudinal-analysis-of-patient-reported-quality-of-life-in-newly-diagnosed-chronic-lymphocytic-leukemia-stratified-by-initial-management-strategy-a-multi-institutional-prospective-cohort-study/2023-12-22T16:15:58+00:00https://lymphoma-stg.clarovantdigital.com/library/results-from-an-intergroup-randomized-phase-ii-study-of-the-combinations-of-ipilimumab-nivolumab-and-brentuximab-vedotin-in-patients-with-relapsed-refractory-classic-hodgkin-lymphoma-a-trial-of-the/2023-12-22T16:15:58+00:00https://lymphoma-stg.clarovantdigital.com/library/ibrutinib-plus-rchop-versus-rchop-only-in-young-patients-with-activated-b-cell-like-diffuse-large-b-cell-lymphoma-abc-dlbcl-a-cost-effectiveness-analysis/2023-12-22T16:15:58+00:00https://lymphoma-stg.clarovantdigital.com/library/real-world-experience-of-car-t-cell-therapy-in-older-patients-with-relapsed-refractory-diffuse-large-b-cell-lymphoma/2023-12-22T16:15:58+00:00https://lymphoma-stg.clarovantdigital.com/library/long-term-toxicities-associated-with-ibrutinib-in-patients-with-cll/2023-12-22T16:15:58+00:00https://lymphoma-stg.clarovantdigital.com/library/adaptive-manufacturing-of-lv20-19-car-t-cells-for-relapsed-refractory-mantle-cell-lymphoma/2023-12-22T16:15:59+00:00https://lymphoma-stg.clarovantdigital.com/library/outcomes-in-patients-with-classical-hodgkin-lymphoma-refractory-or-intolerant-to-brentuximab-vedotin-and-anti-pd-1-therapy-real-world-analysis-from-14-u-s-academic-centers/2023-12-22T16:15:59+00:00https://lymphoma-stg.clarovantdigital.com/library/zanubrutinib-or-ibrutinib-in-relapsed-or-refractory-chronic-lymphocytic-leukemia/2023-12-22T16:15:59+00:00https://lymphoma-stg.clarovantdigital.com/library/multicenter-development-of-a-pet%e2%80%91based-risk-assessment-tool-for-product%e2%80%91specific-outcome-prediction-in-large-b%e2%80%91cell-lymphoma-patients-undergoing-car-t%e2%80%91cell-therapy/2023-12-22T16:23:15+00:00https://lymphoma-stg.clarovantdigital.com/library/characteristics-and-outcomes-of-children-adolescents-and-young-adults-with-relapsed-refractory-non%e2%80%91hodgkin-lymphoma-undergoing-autologous-stem-cell-transplant/2025-12-15T19:26:08+00:00https://lymphoma-stg.clarovantdigital.com/library/current-perspectives-on-the-management-of-refractory-or-relapsed-classic-hodgkin-lymphoma-in-brazil-balancing-efficacy-safety-and-tolerability/2024-01-11T21:01:27+00:00https://lymphoma-stg.clarovantdigital.com/library/tislelizumab-plus-zanubrutinib-for-richter-transformation-the-phase-2-rt1-trial/2024-01-11T21:15:36+00:00https://lymphoma-stg.clarovantdigital.com/library/mrd-driven-treatment-with-venetoclax-r2-in-mantle-cell-lymphoma-the-nordic-lymphoma-group-mcl7-valeria-trial/2026-01-14T20:38:55+00:00https://lymphoma-stg.clarovantdigital.com/library/impairment-of-vocational-activities-and-financial-problems-are-frequent-among-german-blood-cancer-survivors/2024-01-11T21:31:32+00:00https://lymphoma-stg.clarovantdigital.com/library/integrative-analysis-of-clinicopathological-features-defines-novel-prognostic-models-for-mantle-cell-lymphoma-in-the-immunochemotherapy-era-a-report-from-the-north-american-mantle-cell-lymphoma-conso/2024-01-11T21:40:58+00:00https://lymphoma-stg.clarovantdigital.com/library/impact-of-targeted-agents-on-survival-of-chronic-lymphocytic-leukemia-patients-age-65-relative-to-age-and-sex-matched-population/2024-01-11T21:50:46+00:00https://lymphoma-stg.clarovantdigital.com/library/autologous-stem-cell-transplant-in-hodgkins-and-non-hodgkins-lymphoma-multiple-myeloma-and-al-amyloidosis/2024-01-11T21:59:25+00:00https://lymphoma-stg.clarovantdigital.com/library/challenges-of-chimeric-antigen-receptor-t-cell-therapy-in-chronic-lymphocytic-leukemia-lessons-learned/2024-01-11T22:09:20+00:00https://lymphoma-stg.clarovantdigital.com/library/ibrutinib-as-first-line-therapy-for-mantle-cell-lymphoma-a-multicentre-realworld-uk-study/2024-01-11T22:19:20+00:00https://lymphoma-stg.clarovantdigital.com/library/hysterectomy-oophorectomy-and-risk-of-non-hodgkins-lymphoma/2024-01-11T22:24:20+00:00https://lymphoma-stg.clarovantdigital.com/library/efficacy-and-safety-of-first%e2%80%91line-combination-therapy-versus-monotherapy-for-vitreoretinal-lymphoma-a-systematic-review-and-meta%e2%80%91analysis/2024-01-11T22:30:45+00:00https://lymphoma-stg.clarovantdigital.com/library/the-role-of-geriatric-assessment-in-the-management-of-diffuse-large-b-cell-lymphoma/2024-01-12T14:54:32+00:00https://lymphoma-stg.clarovantdigital.com/library/association-between-nutritional-status-and-biochemical-markers-among-hematopoietic-stem-cell-transplant-candidates-a-cross-sectional-study/2024-01-12T15:07:37+00:00https://lymphoma-stg.clarovantdigital.com/library/distribution-and-clinical-impact-of-molecular-subtypes-with-dark-zone-signature-of-dlbcl-in-a-japanese-real-world-study/2024-01-12T15:12:55+00:00https://lymphoma-stg.clarovantdigital.com/library/treatment-and-outcomes-for-patients-with-relapsed-or-refractory-diffuse-large-b-cell-lymphoma-a-contemporary-nationwide-population-based-study-in-the-netherlands/2024-01-12T15:31:57+00:00https://lymphoma-stg.clarovantdigital.com/library/angioimmunoblastic-t-cell-lymphoma-after-treatment-of-classic-hodgkin-lymphoma-a-case-report/2024-01-12T17:28:05+00:00https://lymphoma-stg.clarovantdigital.com/library/recent-updates-on-central-nervous-system-prophylaxis-in-patients-with-high%e2%80%91risk-diffuse-large-b%e2%80%91cell-lymphoma/2024-01-12T18:04:37+00:00https://lymphoma-stg.clarovantdigital.com/library/drug-induced-pneumonitis-risk-in-diffuse-large-b-cell-follicular-lymphoma-patients-treated-with-r-chop-like-regimen-is-associated-with-the-use-of-granulocyte-colony-stimulating-growth-factors/2024-01-12T18:14:37+00:00https://lymphoma-stg.clarovantdigital.com/library/chronic-lymphocytic-leukemia-time%e2%80%91limited-therapy-in-the-first%e2%80%91line-setting-and-role-of-minimal-residual-disease/2026-01-14T20:37:51+00:00https://lymphoma-stg.clarovantdigital.com/library/long-term-outcomes-of-patients-with-large-b-cell-lymphoma-treated-with-axicabtagene-ciloleucel-and-prophylactic-corticosteroids/2024-01-12T18:45:33+00:00https://lymphoma-stg.clarovantdigital.com/library/treatment-outcomes-of-mantle-cell-lymphoma-in-real-world-practice-analysis-of-forty-one-patients/2024-01-12T19:15:28+00:00https://lymphoma-stg.clarovantdigital.com/library/the-asymptomatic-follicular-lymphoma-afl-trial-single-agent-rituximab-immunotherapy-versus-90y-ibritumomab-tiuxetan-radioimmunotherapy-rit-for-patients-with-new-untreated-follicular-lymphoma/2024-01-12T19:27:45+00:00https://lymphoma-stg.clarovantdigital.com/library/new-frontiers-in-monoclonal-antibodies-for-relapsed-refractory-diffuse-large-b-cell-lymphoma/2024-01-12T19:38:14+00:00https://lymphoma-stg.clarovantdigital.com/library/phase-2-study-of-ibrutinib-plus-venetoclax-in-japanese-patients-with-relapsed-refractory-mantle-cell-lymphoma/2024-01-12T19:45:53+00:00https://lymphoma-stg.clarovantdigital.com/library/clinical-outcomes-of-older-and-younger-patients-treated-with-loncastuximab-tesirine-in-the-lotis-2-clinical-trial/2024-01-12T19:55:33+00:00https://lymphoma-stg.clarovantdigital.com/library/treatment-of-chronic-lymphocytic-leukemia-in-the-personalized-medicine-era/2024-01-12T20:01:09+00:00https://lymphoma-stg.clarovantdigital.com/library/a-retrospective-analysis-of-ibrutinib-outcomes-in-relapsed-or-refractory-mantle-cell-lymphoma/2024-01-12T20:56:09+00:00https://lymphoma-stg.clarovantdigital.com/library/correlation-between-red-blood-cell-distribution-width-platelet-count-and-prognosis-of-newly-diagnosed-diffuse-large-b-cell-lymphoma/2024-01-12T21:31:17+00:00https://lymphoma-stg.clarovantdigital.com/library/nonrelapse-mortality-after-car-t-cell-therapy-for-large-b-cell-lymphoma-a-lysa-study-from-the-descar-t-registry/2024-01-12T21:36:26+00:00https://lymphoma-stg.clarovantdigital.com/library/the-biology-and-treatment-of-epstein-barr-virus-positive-diffuse-large-b-cell-lymphoma-nos/2026-09-02T16:15:49+00:00https://lymphoma-stg.clarovantdigital.com/library/improved-outcomes-of-localized-diffuse-large-b-cell-lymphoma-at-the-waldeyer-ring-in-comparison-to-the-sinonasal-area-in-the-rituximab-era/2024-01-12T21:51:13+00:00https://lymphoma-stg.clarovantdigital.com/library/treatment-of-relapsed-or-refractory-diffuse-large-b-cell-lymphoma-new-approved-options/2024-01-12T22:12:09+00:00https://lymphoma-stg.clarovantdigital.com/library/outcomes-of-patients-with-advanced-stage-classical-hodgkins-lymphoma-and-human-immunodeficiency-virus-infection-treated-with-abvd/2025-12-15T21:10:34+00:00https://lymphoma-stg.clarovantdigital.com/library/real-world-adherence-and-discontinuation-among-medicare-beneficiaries-initiating-venetoclax-vs-btkis-in-relapsed-refractory-chronic-lymphocytic-leukemia-2/2025-12-19T18:12:28+00:00https://lymphoma-stg.clarovantdigital.com/library/transfusion-needs-after-car-t-cell-therapy-for-large-b-cell-lymphoma-predictive-factors-and-outcome-a-descar-t-study/2024-01-12T22:49:57+00:00https://lymphoma-stg.clarovantdigital.com/library/durable-response-after-tisagenlecleucel-in-adults-with-relapsed-refractory-follicular-lymphoma-elara-trial-update/2024-01-12T22:54:07+00:00https://lymphoma-stg.clarovantdigital.com/library/a-systematic-literature-review-of-health%e2%80%91related-quality-of-life-outcomes-and-associated-utility-values-in-relapsed-and-or-refractory-large-b-cell-lymphoma/2024-01-12T22:58:22+00:00https://lymphoma-stg.clarovantdigital.com/library/real%e2%80%91world-effectiveness-and-safety-of-ibrutinib-in-relapsed-refractory-mantle-cell-lymphoma-in-japan-post%e2%80%91marketing-surveillance/2024-01-12T23:02:59+00:00https://lymphoma-stg.clarovantdigital.com/library/lisocabtagene-maraleucel-in-relapsed-refractory-mantle-cell-lymphoma-primary-analysis-of-the-mantle-cell-lymphoma-cohort-from-transcend-nhl-001-a-phase-i-multicenter-seamless-design-study/2024-01-19T16:27:20+00:00https://lymphoma-stg.clarovantdigital.com/library/incidence-of-richter-transformation-in-patients-with-chronic-lymphocytic-leukemia-cll-small-lymphocytic-lymphoma-sll-a-cohort-study-evaluating-different-therapeutic-eras/2025-03-03T20:35:29+00:00https://lymphoma-stg.clarovantdigital.com/library/a-myc-rearrangement-is-a-negative-prognostic-factor-in-stage-ii-but-not-in-stage-i-diffuse-large-b-cell-lymphoma/2024-01-19T16:27:21+00:00https://lymphoma-stg.clarovantdigital.com/library/long-term-remissions-with-mrd-guided-acalabrutinib-venetoclax-and-obinutuzumab-in-relapsed-refractory-cll-follow-up-efficacy-and-circulating-tumor-dna-analysis-of-the-cll2-baag-trial/2026-01-14T20:58:21+00:00https://lymphoma-stg.clarovantdigital.com/library/tazemetostat-in-combination-with-r-chop-in-patients-with-high-risk-frontline-follicular-lymphoma-epi-rchop-a-phase-ii-study-from-the-lysa/2024-01-19T16:27:22+00:00https://lymphoma-stg.clarovantdigital.com/library/long-lasting-sars-cov-2-infection-with-post-covid-19-chronic-interstitial-pneumonia-in-a-patient-with-chronic-lymphocytic-leukemia-treated-successfully-with-intravenous-immunoglobulin/2024-01-19T16:27:22+00:00https://lymphoma-stg.clarovantdigital.com/library/role-of-radiation-in-combination-with-cd30-directed-chimeric-antigen-receptor-t-cell-therapy-for-relapsed-refractory-hodgkin-lymphoma-bridging-and-salvage-rt-for-hodgkin-lymphoma/2026-01-16T14:58:23+00:00https://lymphoma-stg.clarovantdigital.com/library/risk-of-severe-infections-secondary-to-the-use-of-targeted-therapies-in-hematological-malignancies/2025-12-15T22:31:25+00:00https://lymphoma-stg.clarovantdigital.com/library/multicenter-study-of-mantle-cell-lymphoma-outcomes-following-first-line-bendamustine-rituximab-and-second-line-brutons-tyrosine-kinase-inhibitor-therapy/2024-01-19T16:27:23+00:00https://lymphoma-stg.clarovantdigital.com/library/minimal-residual-disease-mrd-status-predicts-outcomes-in-patients-with-follicular-lymphoma-fl-treated-with-chemo-immunotherapy-on-swog-s0016/2026-01-14T20:57:44+00:00https://lymphoma-stg.clarovantdigital.com/library/a-systematic-review-of-clinical-applications-of-anti-cd20-radioimmunotherapy-for-lymphoma/2026-01-06T20:58:27+00:00https://lymphoma-stg.clarovantdigital.com/library/high-pdl1-pdl2-gene-expression-correlates-with-worse-outcome-in-primary-mediastinal-large-b-cell-lymphoma/2024-01-19T16:27:23+00:00https://lymphoma-stg.clarovantdigital.com/library/frailty-impact-on-outcomes-of-patients-undergoing-chimeric-antigen-receptor-t-cell-car-t-therapy-at-princess-margaret-cancer-centre-a-prospective-pilot-study-2/2024-01-19T16:27:23+00:00https://lymphoma-stg.clarovantdigital.com/library/safety-efficacy-and-determinants-of-response-of-allogeneic-cd19-specific-car-nk-cells-in-cd19-b-cell-tumors-a-phase-1-2-trial/2024-04-02T17:49:03+00:00https://lymphoma-stg.clarovantdigital.com/library/impact-of-tumor-microenvironment-on-efficacy-of-anti-cd19-car-t-cell-therapy-or-chemotherapy-and-transplant-in-large-b-cell-lymphoma/2024-01-19T16:27:24+00:00https://lymphoma-stg.clarovantdigital.com/library/prognostic-value-of-clonal-evolution-identified-by-sequential-fish-in-untreated-chronic-lymphocytic-leukaemia/2024-01-19T20:33:52+00:00https://lymphoma-stg.clarovantdigital.com/library/an-immunohistochemical-study-of-diffuse-large-b%e2%80%91cell-lymphoma-with-molecular-subtyping-based-on-hans-algorithm/2024-01-19T20:40:27+00:00https://lymphoma-stg.clarovantdigital.com/library/hypofractionated-radiotherapy-for-refractory-or-relapsed-aggressive-b%e2%80%91cell-lymphoma-in-the-rituximab-era/2024-01-19T20:52:44+00:00https://lymphoma-stg.clarovantdigital.com/library/genetic-mechanisms-underlying-tumor-microenvironment-composition-and-function-in-diffuse-large-b-cell-lymphoma/2024-01-19T21:36:29+00:00https://lymphoma-stg.clarovantdigital.com/library/circulating-tumor-dna-assessment-in-diffuse-large-b-cell-lymphoma-to-determine-up-front-stem-cell-transplantation-a-pilot-study/2024-01-19T22:03:23+00:00https://lymphoma-stg.clarovantdigital.com/library/low-serum-apolipoprotein-a1-level-predicts-poor-prognosis-of-patients-with-diffuse-large-b-cell-lymphoma-in-the-real-world-a-retrospective-study/2024-01-19T22:09:54+00:00https://lymphoma-stg.clarovantdigital.com/library/outcomes-of-allogeneic-hematopoietic-stem-cell-transplantation-in-r-r-dlbcl-patients-with-failure-of-car%e2%80%91t-therapy/2024-01-19T22:15:52+00:00https://lymphoma-stg.clarovantdigital.com/library/feasibility-of-circulating-tumor-dna-analysis-in-patients-with-follicular-lymphoma/2024-01-19T22:20:56+00:00https://lymphoma-stg.clarovantdigital.com/library/management-and-use-of-healthcare-resources-in-patients-with-chronic-lymphocytic-leukemia-initiating-venetoclax-in-routine-clinical-practice/2024-01-19T22:24:52+00:00https://lymphoma-stg.clarovantdigital.com/library/glofitamab-in-relapsed-refractory-diffuse-large-b%e2%80%90cell-lymphoma-real%e2%80%90world-data/2024-01-19T22:29:38+00:00https://lymphoma-stg.clarovantdigital.com/library/survival-outcomes-of-patients-with-mantle-cell-lymphoma-a-retrospective-15-year-real-life-study/2024-01-19T22:45:22+00:00https://lymphoma-stg.clarovantdigital.com/library/treatment-patterns-and-costs-among-us-patients-with-diffuse-large-b-cell-lymphoma-not-treated-with-2l-stem-cell-transplantation/2025-12-19T18:11:59+00:00https://lymphoma-stg.clarovantdigital.com/library/prediction-of-severe-infections-in-chronic-lymphocytic-leukemia-a-simple-risk-score-to-stratify-patients-at-diagnosis/2024-01-19T22:52:47+00:00https://lymphoma-stg.clarovantdigital.com/library/late-cardiac-toxic-effects-associated-with-treatment-protocols-for-hodgkin-lymphoma-in-children/2024-01-19T22:56:57+00:00https://lymphoma-stg.clarovantdigital.com/library/severe-arboviral-neuroinvasive-disease-in-patients-on-rituximab-therapy-a-review/2024-01-23T19:14:56+00:00https://lymphoma-stg.clarovantdigital.com/library/utility-of-low-dose-duvelisib-for-advanced-mycosis-fungoides-a-single-institution-study/2024-01-23T19:19:41+00:00https://lymphoma-stg.clarovantdigital.com/library/the-gut-microbiome-correlated-to-chemotherapy-efficacy-in-diffuse-large-b-cell-lymphoma-patients/2024-01-23T19:23:47+00:00https://lymphoma-stg.clarovantdigital.com/library/venetoclax-plus-dose%e2%80%91adjusted-r%e2%80%91epoch-vr%e2%80%91da%e2%80%91epoch-or-g%e2%80%91epoch-bridging-to-subsequent-cellular-therapy-for-the-patients-with-transformed-lymphoma-a-single-cente/2024-01-23T21:39:52+00:00https://lymphoma-stg.clarovantdigital.com/library/allogeneic-hematopoietic-stem-cell-transplantation-for-b-cell-lymphoma-in-taiwan/2024-01-23T22:03:14+00:00https://lymphoma-stg.clarovantdigital.com/library/autologous-stem-cell-transplant-in-fit-patients-with-refractory-or-early-relapsed-diffuse-large-b-cell-lymphoma-that-responded-to-salvage-chemotherapy/2024-01-23T22:10:53+00:00https://lymphoma-stg.clarovantdigital.com/library/bi-and-tri-specific-antibodies-in-non-hodgkin-lymphoma-current-data-and-perspectives/2026-01-14T21:34:22+00:00https://lymphoma-stg.clarovantdigital.com/library/idelalisib-pi3k%ce%b4-inhibitor-therapy-for-patients-with-relapsed-refractory-chronic-lymphocytic-leukemia-a-swedish-nation-wide-real-world-report-on-consecutively-identified-patients/2024-01-25T21:03:40+00:00https://lymphoma-stg.clarovantdigital.com/library/additional-booster-doses-in-patients-with-chronic-lymphocytic-leukemia-induce-humoral-and-cellular-immune-responses-to-sars-cov-2-similar-to-natural-infection-regardless-ongoing-treatments-a-study-by/2024-01-25T21:33:15+00:00https://lymphoma-stg.clarovantdigital.com/library/biological-heterogeneity-in-diffuse-large-b-cell-lymphoma/2024-01-25T21:43:21+00:00https://lymphoma-stg.clarovantdigital.com/library/long-term-outcomes-with-hlx01-hanlikang-a-rituximab-biosimilar-in-previously-untreated-patients-with-diffuse-large-b-cell-lymphoma-5-year-follow-up-results-of-the-phase-3-hlx01-nhl03-study/2024-01-25T21:51:10+00:00https://lymphoma-stg.clarovantdigital.com/library/three-year-cardiovascular-and-non-cardiovascular-adverse-events-in-patients-with-chronic-lymphocytic-leukemia-or-small-cell-lymphocytic-lymphoma-treated-with-bruton-tyrosine-kinase-inhibitors-acalabru/2024-01-25T21:57:38+00:00https://lymphoma-stg.clarovantdigital.com/library/final-results-and-overall-survival-data-from-a-phase-ii-study-of-acalabrutinib-monotherapy-in-patients-with-relapsed-refractory-mantle-cell-lymphoma-including-those-with-poor-prognostic-factors/2024-01-25T22:04:47+00:00https://lymphoma-stg.clarovantdigital.com/library/a-phase-ii-japanese-trial-of-90-minute-rituximab-infusion-for-untreated-b-cell-lymphoma/2024-01-25T22:10:05+00:00https://lymphoma-stg.clarovantdigital.com/library/a-phase-iii-open%e2%80%91label-randomized-study-to-compare-the-efficacy-of-lenalidomide-rituximab-with-bendamustine-rituximab-in-treatment%e2%80%91naive-follicular-lymphoma/2024-02-05T21:12:58+00:00https://lymphoma-stg.clarovantdigital.com/library/nk-cells-in-chronic-lymphocytic-leukemia-and-their-therapeutic-implications/2024-04-02T18:00:03+00:00https://lymphoma-stg.clarovantdigital.com/library/stem-cell-transplantation-in-adult-patients-with-relapsed-refractory-hodgkin-lymphoma/2024-02-05T21:23:02+00:00https://lymphoma-stg.clarovantdigital.com/library/secondary-central-nervous-system-involvement-in-patients-with-diffuse-large-b%e2%80%91cell-lymphoma-treated-with-rituximab-combined-chop-therapy-a-supplementary-analysis-of-jcog0601/2024-02-05T21:28:06+00:00https://lymphoma-stg.clarovantdigital.com/library/follicular-helper-t%e2%80%91cell-lymphomas-disease-spectrum-relationship-with-clonal-hematopoiesis-and-mimics-a-report-of-the-2022-ea4hp-sh-lymphoma-workshop/2024-02-06T00:20:51+00:00https://lymphoma-stg.clarovantdigital.com/library/treatment-patterns-healthcare-resource-utilization-and-costs-of-patients-with-chronic-lymphocytic-leukemia-or-small-lymphocytic-lymphoma-in-the-us/2025-12-19T18:11:37+00:00https://lymphoma-stg.clarovantdigital.com/library/lifetime-risks-of-second-primary-malignancies-after-pediatric-hodgkin-lymphoma-and-non%e2%80%91hodgkin-lymphoma/2024-02-06T19:23:04+00:00https://lymphoma-stg.clarovantdigital.com/library/clinical-features-of-neurotoxicity-following-cd19-car-t-cell-therapy-in-mantle-cell-lymphoma/2024-02-06T19:40:11+00:00https://lymphoma-stg.clarovantdigital.com/library/assessment-of-second-primary-malignancies-among-treated-and-untreated-patients-with-chronic-lymphocytic-leukemia-using-real-world-data-from-the-usa/2024-02-06T21:15:19+00:00https://lymphoma-stg.clarovantdigital.com/library/baseline-serum-inflammatory-proteins-predict-poor-car-t-outcomes-in-diffuse-large-b-cell-lymphoma/2024-02-06T19:58:39+00:00https://lymphoma-stg.clarovantdigital.com/library/treatment-outcomes-with-standard-of-care-in-relapsed-refractory-diffuse-large-b-cell-lymphoma-real-world-data-analysis/2024-02-06T20:08:15+00:00https://lymphoma-stg.clarovantdigital.com/library/conditional-survival-to-assess-prognosis-in-patients-with-chronic-lymphocytic-leukemia/2024-02-06T21:12:29+00:00https://lymphoma-stg.clarovantdigital.com/library/vitamin-d-level-in-patients-with-chronic-lymphocytic-leukemia-and-relationship-between-rai-stage/2024-02-06T21:18:45+00:00https://lymphoma-stg.clarovantdigital.com/library/hybrid-immunity-to-sars-cov-2-in-patients-with-chronic-lymphocytic-leukemia/2024-02-06T21:22:59+00:00https://lymphoma-stg.clarovantdigital.com/library/a-nationwide-analysis-of-the-treatment-patterns-survival-and-medical-costs-in-korean-patients-with-relapsed-or-refractory-diffuse-large-b-cell-lymphoma/2026-04-24T19:46:20+00:00https://lymphoma-stg.clarovantdigital.com/library/cost-analysis-of-patients-undergoing-allogeneic-stem-cell-transplantation-or-chimeric-antigen-receptor-t-cell-therapy-in-relapsed-or-refractory-diffuse-large-b-cell-lymphoma-from-a-german-healthcare-p/2024-02-06T21:38:44+00:00https://lymphoma-stg.clarovantdigital.com/library/blinatumomab-consolidation-post-autologous-stem-cell-transplantation-in-patients-with-diffuse-large-b-cell-lymphoma-2/2024-02-09T18:23:01+00:00https://lymphoma-stg.clarovantdigital.com/library/factors-associated-with-long-term-outcomes-of-cd19-car-t-cell-therapy-for-relapsed-refractory-cll/2024-02-09T18:23:02+00:00https://lymphoma-stg.clarovantdigital.com/library/the-management-of-newly-diagnosed-large-b-cell-lymphoma-a-british-society-for-haematology-guideline/2026-01-02T14:44:25+00:00https://lymphoma-stg.clarovantdigital.com/library/real-world-outcomes-with-tafasitamab-less-promising-than-l-mind-trial-for-lbcl/2024-02-09T18:23:02+00:00https://lymphoma-stg.clarovantdigital.com/library/multicenter-real-world-study-in-patients-with-r-r-large-b-cell-lymphoma-lbcl-who-received-lisocabtagene-maraleucel-liso-cel-in-the-united-states-us/2025-12-19T18:38:25+00:00https://lymphoma-stg.clarovantdigital.com/library/use-of-health-technology-assessment-in-drug-reimbursement-decisions-in-china/2024-02-09T18:23:03+00:00https://lymphoma-stg.clarovantdigital.com/library/health-technology-assessment-to-inform-decision-making-in-china-progress-challenges-and-sustainability/2024-02-09T18:23:03+00:00https://lymphoma-stg.clarovantdigital.com/library/development-of-the-indian-reference-case-for-undertaking-economic-evaluation-for-health-technology-assessment/2024-02-09T18:23:03+00:00https://lymphoma-stg.clarovantdigital.com/library/real-world-analysis-of-adverse-event-rates-after-initiation-of-ibrutinib-among-medicare-beneficiaries-with-chronic-lymphocytic-leukemia/2025-12-15T19:31:52+00:00https://lymphoma-stg.clarovantdigital.com/library/chronic-lymphocytic-leukemia-therapy-guided-by-measurable-residual-disease/2024-02-09T18:23:03+00:00https://lymphoma-stg.clarovantdigital.com/library/axicabtagene-ciloleucel-versus-tisagenlecleucel-for-relapsed-or-refractory-large-b-cell-lymphoma-a-systematic-review-and-meta-analysis/2024-02-09T18:23:03+00:00https://lymphoma-stg.clarovantdigital.com/library/bispecific-antibodies-and-car-t-cells-dueling-immunotherapies-for-large-b-cell-lymphomas/2026-01-14T22:09:56+00:00https://lymphoma-stg.clarovantdigital.com/library/real-world-tisagenlecleucel-outcomes-in-richter-transformed-chronic-lymphocytic-leukemia-a-center-for-international-blood-marrow-transplant-research-cibmtr-analysis/2024-02-09T18:23:04+00:00https://lymphoma-stg.clarovantdigital.com/library/age-and-lymphocyte-monocyte-ratio-as-prognostic-factors-for-autologous-transplantation-in-the-treatment-of-patients-with-follicular-lymphoma/2024-02-14T22:23:51+00:00https://lymphoma-stg.clarovantdigital.com/library/development-and-validation-of-a-nomogram-for-predicting-cardiovascular-mortality-risk-for-diffuse-large-b-cell-lymphoma-in-children-adolescents-and-adults/2024-02-14T22:28:48+00:00https://lymphoma-stg.clarovantdigital.com/library/sinonasal-dlbcl-molecular-profiling-identifies-subtypes-with-distinctive-prognoses-and-targetable-genetic-features/2024-02-15T14:58:01+00:00https://lymphoma-stg.clarovantdigital.com/library/micrornas-potential-prognostic-and-theranostic-biomarkers-in-chronic-lymphocytic-leukemia/2024-02-15T15:08:22+00:00https://lymphoma-stg.clarovantdigital.com/library/treatment-specific-risk-of-subsequent-malignant-neoplasms-in-five-year-survivors-of-diffuse-large-b-cell-lymphoma/2024-02-15T15:25:49+00:00https://lymphoma-stg.clarovantdigital.com/library/diffuse-large-b-cell-lymphoma-involving-the-central-nervous-system-biologic-rationale-for-targeted-therapy/2024-02-15T15:47:42+00:00https://lymphoma-stg.clarovantdigital.com/library/tafasitamab-for-patients-with-relapsed-or-refractory-diffuse-large-b-cell-lymphoma-final-5-year-efficacy-and-safety-findings-in-the-phase-ii-l-mind-study/2024-02-15T16:25:43+00:00https://lymphoma-stg.clarovantdigital.com/library/hypertension-treatment-in-patients-receiving-ibrutinib-a-multicenter-retrospective-study/2024-02-15T16:30:28+00:00https://lymphoma-stg.clarovantdigital.com/library/analysis-of-mutational-status-of-ighv-and-cytokine-polymorphisms-as-prognostic-factors-in-chronic-lymphocytic-leukemia-the-romanian-experience/2024-02-15T16:34:58+00:00https://lymphoma-stg.clarovantdigital.com/library/brentuximab-vedotin-resistance-in-classic-hodgkins-lymphoma-and-its-therapeutic-strategies-a-review/2024-02-15T16:44:15+00:00https://lymphoma-stg.clarovantdigital.com/library/genomic-and-transcriptomic-profiling-of-peripheral-t-cell-lymphoma-reveals-distinct-molecular-and-microenvironment-subtypes/2024-02-15T17:23:22+00:00https://lymphoma-stg.clarovantdigital.com/library/sequential-treatment-escalation-improves-survival-in-patients-with-waldenstrom-macroglobulinemia/2024-02-15T17:30:15+00:00https://lymphoma-stg.clarovantdigital.com/library/assessment-of-quality-of-data-submitted-for-nice-technology-appraisals-over-two-decades/2024-02-15T17:36:34+00:00https://lymphoma-stg.clarovantdigital.com/library/bone-damage-and-health-related-quality-of-life-in-hodgkin-lymphoma-survivors-closing-the-gaps/2024-02-16T19:06:43+00:00https://lymphoma-stg.clarovantdigital.com/library/the-treatment-of-burkitt-lymphoma-with-the-berlin-frankfurt-munster-protocol-with-rituximab-and-consolidative-autologous-transplantation/2024-02-23T22:16:02+00:00https://lymphoma-stg.clarovantdigital.com/library/myc-rearrangements-in-hiv-associated-large-b-cell-lymphomas-euromyc-a-european-retrospective-study/2024-02-23T22:18:58+00:00https://lymphoma-stg.clarovantdigital.com/library/doxorubicin-exposure-and-breast-cancer-risk-in-survivors-of-adolescent-and-adult-hodgkin-lymphoma/2024-02-23T22:18:58+00:00https://lymphoma-stg.clarovantdigital.com/library/update-on-the-management-of-relapsed-refractory-chronic-lymphocytic-leukemia/2024-02-23T22:18:58+00:00https://lymphoma-stg.clarovantdigital.com/library/safety-efficacy-and-affordability-of-abvd-for-hodgkin-lymphoma-in-malawi-a-prospective-cohort-study/2026-03-13T19:34:40+00:00https://lymphoma-stg.clarovantdigital.com/library/assessing-the-impact-of-comorbid-hypercalcemia-on-inpatient-outcomes-of-patients-with-diffuse-large-b-cell-lymphoma-during-admission-for-chemotherapy/2024-02-23T22:18:59+00:00https://lymphoma-stg.clarovantdigital.com/library/deep-and-durable-remissions-with-liso-cel-in-relapsed-refractory-cll-sll/2026-01-16T14:57:32+00:00https://lymphoma-stg.clarovantdigital.com/library/therapeutic-vaccines-for-follicular-lymphoma-a-systematic-review/2024-02-23T22:31:29+00:00https://lymphoma-stg.clarovantdigital.com/library/safety-of-a-90-min-duration-of-intravenous-infusion-of-obinutuzumab-in-patients-with-b-cell-non-hodgkins-lymphoma-in-a-tertiary-hospital-in-china-a-prospective-open-label-exploratory-clini/2024-02-28T18:57:28+00:00https://lymphoma-stg.clarovantdigital.com/library/late-morbidity-and-mortality-after-autologous-blood-or-marrow-transplantation-for-lymphoma-in-children-adolescents-and-young-adults-a-bmtss-report/2024-02-28T19:17:08+00:00https://lymphoma-stg.clarovantdigital.com/library/epidemiology-and-real-world-treatment-of-incident-diffuse-large-b-cell-lymphoma-dlbcl-a-german-claims-data-analysis/2024-02-28T19:29:01+00:00https://lymphoma-stg.clarovantdigital.com/library/decitabine-combined-with-rdhap-regimen-in-relapsed-refractory-diffuse-large-b-cell-lymphoma/2024-02-28T19:33:30+00:00https://lymphoma-stg.clarovantdigital.com/library/investigation-of-occupational-risk-factors-for-the-development-of-non-hodgkins-lymphoma-in-adults-a-hospital-based-case-control-study/2024-02-28T19:38:41+00:00https://lymphoma-stg.clarovantdigital.com/library/matched-control-analysis-suggests-r-chop-followed-by-r-ice-may-improve-outcome-in-non-gcb-dlbcl-compared-to-r-chop/2025-12-10T19:49:40+00:00https://lymphoma-stg.clarovantdigital.com/library/recent-preclinical-and-clinical-advances-in-radioimmunotherapy-for-non-hodgkins-lymphoma/2024-02-28T19:48:59+00:00https://lymphoma-stg.clarovantdigital.com/library/venetoclax-initiation-in-chronic-lymphocytic-leukemia-international-insights-and-innovative-approaches-for-optimal-patient-care/2025-04-14T20:52:48+00:00https://lymphoma-stg.clarovantdigital.com/library/evaluation-of-all-cause-mortality-and-cardiovascular-safety-in-patients-receiving-chimeric-antigen-receptor-t-cell-therapy-a-prospective-cohort-study/2024-02-28T19:59:22+00:00https://lymphoma-stg.clarovantdigital.com/library/hepatic-diffuse-large-b-cell-lymphoma-a-case-report-and-review-of-literature-of-primary-liver-tumors/2024-02-29T19:42:32+00:00https://lymphoma-stg.clarovantdigital.com/library/poor-outcomes-for-trial-ineligible-patients-receiving-polatuzumab-for-relapsed-refractory-diffuse-large-b-cell-lymphoma-in-routine-care-an-australian-lymphoma-and-related-diseases-registry-project/2024-02-29T19:42:33+00:00https://lymphoma-stg.clarovantdigital.com/library/risk-factors-for-fragility-fractures-in-chronic-lymphocytic-leukemia/2024-02-29T19:42:33+00:00https://lymphoma-stg.clarovantdigital.com/library/circulating-tumor-dna-for-monitoring-classic-hodgkin-lymphoma-patients-correlation-with-fdg-pet-ct/2024-02-29T19:42:33+00:00https://lymphoma-stg.clarovantdigital.com/library/outcome-of-malignant-lymphoma-in-ukraine-analysis-of-563-cases-registered-in-the-ukrainian-lymphoma-registry-in-2019-2021/2024-02-29T19:42:33+00:00https://lymphoma-stg.clarovantdigital.com/library/distinct-peripheral-t-cell-and-nk-cell-profiles-in-hgbl-myc-bcl2-vs-patients-with-dlbcl-nos/2024-02-29T19:42:34+00:00https://lymphoma-stg.clarovantdigital.com/library/long-term-monitoring-of-gastric-mucosa-associated-lymphoid-tissue-lymphoma-in-patients-with-extra-copies-of-the-malt1-gene/2024-03-05T20:07:40+00:00https://lymphoma-stg.clarovantdigital.com/library/socioeconomic-status-and-overall-survival-among-patients-with-hematological-malignant-neoplasms/2024-03-05T20:34:53+00:00https://lymphoma-stg.clarovantdigital.com/library/clinical-outcomes-in-patients-with-dlbcl-treated-with-r-chop-according-to-radiotherapy-and-interim-pet-response/2025-05-27T12:08:15+00:00https://lymphoma-stg.clarovantdigital.com/library/clinical-significance-of-bone-marrow-involvement-by-immunoglobulin-gene-rearrangement-in-de-novo-diffuse-large-b-cell-lymphoma-a-multicenter-retrospective-study/2024-03-05T21:10:17+00:00https://lymphoma-stg.clarovantdigital.com/library/economic-burden-in-treated-japanese-patients-with-relapsed-refractory-large-b-cell-lymphoma/2024-03-05T21:23:18+00:00https://lymphoma-stg.clarovantdigital.com/library/low-incidence-of-tumor-lysis-syndrome-in-elderly-patients-with-chronic-lymphocytic-leukemia-treated-with-venetoclax-under-real-world-conditions-results-from-the-prospective-observational-verve-study/2024-03-05T21:27:45+00:00https://lymphoma-stg.clarovantdigital.com/library/angioimmunoblastic-t-cell-lymphoma-involving-the-nasopharynx-an-easily-misdiagnosed-disease-with-atypical-histopathological-features/2024-03-05T21:34:40+00:00https://lymphoma-stg.clarovantdigital.com/library/ibrutinib-as-first-line-therapy-for-mantle-cell-lymphoma-a-multicenter-real-world-uk-study/2024-03-08T17:47:55+00:00https://lymphoma-stg.clarovantdigital.com/library/effect-of-rituximab-on-immune-status-in-children-with-aggressive-mature-b-cell-lymphoma-leukemia-a-prospective-study-from-cccg-bnhl-2015/2024-03-08T17:47:56+00:00https://lymphoma-stg.clarovantdigital.com/library/real-world-survival-healthcare-resource-utilization-and-costs-among-u-s-elderly-patients-with-diffuse-large-b-cell-lymphoma-dlbcl-treated-with-r-gemox-in-the-relapsed-refractory-setting/2024-03-08T17:47:57+00:00https://lymphoma-stg.clarovantdigital.com/library/molecular-characterization-of-diffuse-large-b-cell-lymphomas-associated-with-hepatitis-c-virus-infection/2024-03-08T17:47:57+00:00https://lymphoma-stg.clarovantdigital.com/library/anti-metabolic-agent-pegaspargase-plus-pd-1-antibody-sintilimab-for-first-line-treatment-in-advanced-natural-killer-t-cell-lymphoma/2024-03-08T17:47:57+00:00https://lymphoma-stg.clarovantdigital.com/library/camrelizumab-plus-gemcitabine-and-oxaliplatin-for-relapsed-or-refractory-classical-hodgkin-lymphoma-a-phase-ii-trial/2024-03-08T17:47:57+00:00https://lymphoma-stg.clarovantdigital.com/library/results-of-voice-a-global-survey-of-disease-specific-knowledge-and-perspectives-of-real-world-patients-with-cll/2024-03-26T22:35:50+00:00https://lymphoma-stg.clarovantdigital.com/library/tp53-mutation-is-frequent-in-mantle-cell-lymphoma-with-ezh2-expression-and-have-dismal-outcome-when-both-are-present/2024-03-08T17:47:58+00:00https://lymphoma-stg.clarovantdigital.com/library/reducing-and-controlling-metabolic-active-tumor-volume-prior-to-car-t-cell-infusion-can-improve-survival-outcomes-in-patients-with-large-b-cell-lymphoma/2024-03-08T17:47:58+00:00https://lymphoma-stg.clarovantdigital.com/library/baseline-circulating-tumour-dna-and-interim-pet-predict-response-in-relapsed-refractory-classical-hodgkin-lymphoma/2024-03-08T17:47:58+00:00https://lymphoma-stg.clarovantdigital.com/library/final-results-on-effectiveness-and-safety-of-ibrutinib-in-patients-with-chronic-lymphocytic-leukemia-from-the-non-interventional-fire-study/2024-03-08T17:58:59+00:00https://lymphoma-stg.clarovantdigital.com/library/prevalence-and-demographic-characteristics-of-hodgkin-lymphoma-in-colombia-according-to-ministry-of-health-data/2024-03-08T18:07:39+00:00https://lymphoma-stg.clarovantdigital.com/library/update-on-management-of-diffuse-large-b-cell-lymphoma-richters-transformation/2024-03-08T18:15:33+00:00https://lymphoma-stg.clarovantdigital.com/library/impact-of-targeted-agents-on-survival-of-chronic-lymphocytic-leukemia-patients-fit-for-fludarabine-cyclophosphamide-and-rituximab-fcr-relative-to-age-and-sex-matched-population/2024-03-08T18:31:08+00:00https://lymphoma-stg.clarovantdigital.com/library/the-genetic-profile-of-large-b-cell-lymphomas-presenting-in-the-ocular-adnexa/2024-03-08T18:35:48+00:00https://lymphoma-stg.clarovantdigital.com/library/liquid-biopsy-in-t%e2%80%91cell-lymphoma-biomarker-detection-techniques-and-clinical-application/2024-03-08T18:41:38+00:00https://lymphoma-stg.clarovantdigital.com/library/taking-the-next-step-in-double-refractory-disease-current-and-future-treatment-strategies-for-chronic-lymphocytic-leukemia/2024-03-12T15:52:10+00:00https://lymphoma-stg.clarovantdigital.com/library/rituximab-gemcitabine-and-oxaliplatin-in-relapsed-or-refractory-indolent-and-mantle-cell-lymphoma-results-of-a-multicenter-phase-i-ii-study-of-the-german-low-grade-lymphoma-study-group/2024-03-12T15:56:40+00:00https://lymphoma-stg.clarovantdigital.com/library/the-influence-of-marital-status-at-diagnosis-on-survival-of-adult-patients-with-mantle-cell-lymphoma/2024-03-12T17:11:32+00:00https://lymphoma-stg.clarovantdigital.com/library/estimation-of-mediastinal-toxicities-after-radiotherapy-for-hodgkin-lymphoma-a-normal-tissue-complication-analysis-of-the-hd16-17-trial-by-the-german-hodgkin-study-group/2024-03-18T18:53:25+00:00https://lymphoma-stg.clarovantdigital.com/library/leveraging-genomics-transcriptomics-and-epigenomics-to-understand-chemoimmunotherapy-resistance-in-chronic-lymphocytic-leukemia/2024-03-18T20:00:50+00:00https://lymphoma-stg.clarovantdigital.com/library/realm-study-a-retrospective-evaluation-of-treatment-patterns-in-patients-with-mantle-cell-lymphoma-in-a-q1-routine-single-private-practice-in-brazil/2025-12-15T20:58:54+00:00https://lymphoma-stg.clarovantdigital.com/library/efficacy-of-intravenous-high-dose-methotrexate-in-preventing-relapse-to-the-central-nervous-system-in-r-chop-like-treated-high-risk-diffuse-large-b-cell-lymphoma-patients-and-its-effect-on-mortali/2024-03-18T20:11:14+00:00https://lymphoma-stg.clarovantdigital.com/library/the-relationship-and-clinical-significance-of-serum-cytokine-expression-level-and-skin-pruritus-in-patients-with-hodgkin-lymphoma-and-angioimmunoblastic-t-cell-lymphoma/2024-03-18T20:18:24+00:00https://lymphoma-stg.clarovantdigital.com/library/cd8-nks-as-a-potential-biomarker-of-complete-response-and-survival-with-lenalidomide-plus-r-gdp-in-the-r2-gdpgotel-trial-in-recurrent-refractory-diffuse-large-b-cell-lymphoma/2024-04-02T18:01:02+00:00https://lymphoma-stg.clarovantdigital.com/library/tp53-mutation-is-frequent-in-mantle-cell-lymphoma-with-ezh2-expression-and-have-dismal-outcome-when-both-are-present-2/2024-03-18T20:37:53+00:00https://lymphoma-stg.clarovantdigital.com/library/characteristics-and-prognostic-value-of-gut-microbiota-in-follicular-lymphoma/2024-03-18T20:43:22+00:00https://lymphoma-stg.clarovantdigital.com/library/refractory-burkitt-lymphoma-diagnosis-and-interventional-strategies/2024-03-18T20:49:23+00:00https://lymphoma-stg.clarovantdigital.com/library/incidence-and-survival-of-second-primary-non-hodgkin-lymphoma-a-surveillance-epidemiology-and-end-results-based-cohort-study/2025-12-19T18:10:30+00:00https://lymphoma-stg.clarovantdigital.com/library/are-changes-in-patient-reported-outcomes-prognostic-for-diffuse-large-b-cell-lymphoma-survival-results-from-the-goya-trial/2024-03-18T21:01:26+00:00https://lymphoma-stg.clarovantdigital.com/library/matching-adjusted-indirect-comparison-of-brexucabtagene-autoleucel-zuma-2-and-pirtobrutinib-bruin-in-patients-with-relapsed-refractory-mantle-cell-lymphoma-previously-treated-with-a-covalent-bruto/2024-03-18T21:17:35+00:00https://lymphoma-stg.clarovantdigital.com/library/patient-industry-and-regulatory-perspective-on-antibody-drug-conjugates-dose-optimization/2024-03-21T21:24:23+00:00https://lymphoma-stg.clarovantdigital.com/library/navigating-lymphomas-through-bcr-signaling-and-double-hit-insights-overview/2024-03-21T21:27:58+00:00https://lymphoma-stg.clarovantdigital.com/library/real-world-outcome-of-treatment-with-single-agent-ibrutinib-in-italian-patients-with-chronic-lymphocytic-leukemia-final-results-of-the-evidence-study/2024-03-22T16:48:33+00:00https://lymphoma-stg.clarovantdigital.com/library/brentuximab-vedotin-and-chemotherapy-in-relapsed-refractory-hodgkin-lymphoma-a-propensity-score-matched-analysis/2024-03-22T16:53:25+00:00https://lymphoma-stg.clarovantdigital.com/library/characterization-of-primary-small-intestinal-lymphoma-a-retrospective-study-based-on-double-balloon-endoscopy/2024-03-22T16:58:26+00:00https://lymphoma-stg.clarovantdigital.com/library/occupational-exposure-to-pesticides-and-chronic-lymphocytic-leukaemia-in-the-mcc-spain-study/2024-03-22T17:33:36+00:00https://lymphoma-stg.clarovantdigital.com/library/impact-of-diagnostic-investigations-in-the-management-of-car-t-cell-associated-neurotoxicity/2024-03-22T17:42:15+00:00https://lymphoma-stg.clarovantdigital.com/library/trial-watch-bispecific-antibodies-for-the-treatment-of-relapsed-or-refractory-large-b-cell-lymphoma/2024-03-22T18:15:36+00:00https://lymphoma-stg.clarovantdigital.com/library/second-primary-malignancies-after-commercial-car-t-cell-therapy-analysis-of-fda-adverse-events-reporting-system-faers/2024-03-22T18:20:10+00:00https://lymphoma-stg.clarovantdigital.com/library/activity-of-venetoclax-in-patients-with-relapsed-or-refractory-chronic-lymphocytic-leukaemia-analysis-of-the-venice-1-multicentre-open-label-single-arm-phase-3b-trial/2024-03-22T18:31:47+00:00https://lymphoma-stg.clarovantdigital.com/library/axicabtagene-ciloleucel-treatment-is-more-effective-in-primary-mediastinal-large-b-cell-lymphomas-than-in-diffuse-large-b-cell-lymphomas-the-italian-cart-sie-study/2024-03-22T18:31:47+00:00https://lymphoma-stg.clarovantdigital.com/library/efficacy-and-safety-of-different-chemotherapy-regimens-combined-with-thalidomide-in-the-treatment-of-diagnosed-hiv-associated-diffuse-large-b-cell-lymphoma/2024-03-22T18:31:48+00:00https://lymphoma-stg.clarovantdigital.com/library/pathological-and-imaging-features-treatment-and-prognosis-of-primary-intraventricular-lymphoma-a-review-of-cases-from-a-single-center/2024-03-22T18:31:48+00:00https://lymphoma-stg.clarovantdigital.com/library/a-single-centre-real-world-study-of-btk-inhibitors-for-the-initial-treatment-of-myd88mut-cd79bmut-diffuse-large-b-cell-lymphoma/2024-03-22T18:31:48+00:00https://lymphoma-stg.clarovantdigital.com/library/global-burden-risk-factors-and-trends-of-non-hodgkin-lymphoma-a-worldwide-analysis-of-cancer-registries/2024-03-22T18:31:48+00:00https://lymphoma-stg.clarovantdigital.com/library/perceiving-a-need-for-dietary-change-in-adults-living-with-and-beyond-cancer-a-cross-sectional-study/2024-03-22T18:31:48+00:00https://lymphoma-stg.clarovantdigital.com/library/long-term-follow-up-of-the-combination-of-ofatumumab-high-dose-methylprednisolone-and-lenalidomide-for-untreated-chronic-lymphocytic-leukemia-with-biomarker-analysis/2024-03-22T18:31:49+00:00https://lymphoma-stg.clarovantdigital.com/library/ibrutinib-and-venetoclax-as-primary-therapy-in-symptomatic-treatment-naive-waldenstrom-macroglobulinemia/2024-03-22T18:31:49+00:00https://lymphoma-stg.clarovantdigital.com/library/a-phase-2-study-of-the-pi3k-inhibitor-parsaclisib-in-relapsed-and-refractory-marginal-zone-lymphoma-citadel-204/2024-03-22T18:31:49+00:00https://lymphoma-stg.clarovantdigital.com/library/chronic-lymphocytic-leukemia-time-to-care-for-the-survivors/2024-03-22T18:41:07+00:00https://lymphoma-stg.clarovantdigital.com/library/systemic-diffuse-large-b-cell-lymphoma-involving-the-central-nervous-system-have-high-rates-of-defective-antigen-presentation-and-immune-surveillance/2024-03-27T18:19:27+00:00https://lymphoma-stg.clarovantdigital.com/library/radiotherapy-for-advanced-hodgkin-lymphoma-with-initial-bulk-a-combined-analysis-of-two-randomized-trials/2024-04-02T23:43:29+00:00https://lymphoma-stg.clarovantdigital.com/library/combination-of-acalabrutinib-with-lenalidomide-and-rituximab-in-relapsed-refractory-aggressive-b-cell-non-hodgkin-lymphoma-a-single-arm-phase-ii-trial/2024-04-02T23:48:55+00:00https://lymphoma-stg.clarovantdigital.com/library/improving-cell-reinfusion-to-enhance-the-efficacy-of-chimeric-antigen-receptor-t-cell-therapy-and-alleviate-complications/2024-04-02T23:53:40+00:00https://lymphoma-stg.clarovantdigital.com/library/the-effect-of-metabolic-syndrome-on-prognosis-of-diffuse-large-b%e2%80%91cell-lymphoma/2024-04-03T16:29:10+00:00https://lymphoma-stg.clarovantdigital.com/library/a-multicenter-study-of-venetoclax-based-treatment-for-patients-with-richter-transformation-of-chronic-lymphocytic-leukemia/2025-12-10T18:20:59+00:00https://lymphoma-stg.clarovantdigital.com/library/declining-incidence-and-improving-survival-of-ocular-and-orbital-lymphomas-in-the-us-between-1995-and-2018/2025-12-19T18:09:57+00:00https://lymphoma-stg.clarovantdigital.com/library/long-term-cardiac-effects-of-modern-treatment-for-hodgkins-lymphoma/2024-04-05T15:18:11+00:00https://lymphoma-stg.clarovantdigital.com/library/immune-cells-in-the-b-cell-lymphoma-microenvironment-from-basic-research-to-clinical-applications/2024-04-05T15:22:24+00:00https://lymphoma-stg.clarovantdigital.com/library/impaired-global-longitudinal-strain-is-associated-with-cardiovascular-events-in-hodgkin-lymphoma-survivors/2024-04-05T15:26:12+00:00https://lymphoma-stg.clarovantdigital.com/library/it-is-feasible-and-safe-to-stop-specialized-follow-up-of-asymptomatic-lower-risk-chronic-lymphocytic-leukemia/2024-04-05T15:31:38+00:00https://lymphoma-stg.clarovantdigital.com/library/challenges-associated-with-the-use-of-brutons-tyrosine-kinase-inhibitors-a-life%e2%80%91saving-therapy-for-chronic-lymphocytic-leukemia/2024-04-05T15:39:04+00:00https://lymphoma-stg.clarovantdigital.com/library/geographic-racial-disparities-exist-in-car-t-bispecific-access-in-dlbcl/2024-04-05T18:25:14+00:00https://lymphoma-stg.clarovantdigital.com/library/radiotherapy-in-younger-patients-with-advanced-aggressive-b-cell-lymphoma-long-term-results-from-the-phase-3-r-megachoep-trial/2024-04-05T18:25:18+00:00https://lymphoma-stg.clarovantdigital.com/library/frequency-of-complete-remission-with-r-chop-therapy-in-patients-with-diffuse-large-b-cell-lymphoma/2024-04-05T18:25:19+00:00https://lymphoma-stg.clarovantdigital.com/library/emerging-frontiers-in-immunotherapy-the-promise-of-nk-cell-therapies/2024-04-05T18:25:20+00:00https://lymphoma-stg.clarovantdigital.com/library/b-cell-receptor-signaling-activity-identifies-patients-with-mantle-cell-lymphoma-at-higher-risk-of-progression/2024-04-05T18:25:22+00:00https://lymphoma-stg.clarovantdigital.com/library/durable-responses-with-mosunetuzumab-in-relapsed-refractory-indolent-and-aggressive-b-cell-non-hodgkin-lymphomas-extended-follow-up-of-a-phase-i-ii-study/2024-04-05T18:25:23+00:00https://lymphoma-stg.clarovantdigital.com/library/epidemiologic-associations-between-inflammatory-bowel-disease-and-hodgkin-lymphoma-or-multiple-sclerosis/2026-09-02T16:02:39+00:00https://lymphoma-stg.clarovantdigital.com/library/diffuse-large-b-cell-lymphoma-with-contemporary-involvement-of-central-and-peripheral-nervous-system-a-case-report-and-literature-review/2024-04-05T18:25:25+00:00https://lymphoma-stg.clarovantdigital.com/library/chimeric-antigen-receptor%e2%80%90t-cell-therapy-shows-similar-efficacy-and-toxicity-in-patients-with-diffuse-large-b%e2%80%90cell-lymphoma-aged-70-and-older-compared-to-younger-patients-a-multicente/2024-04-10T12:16:05+00:00https://lymphoma-stg.clarovantdigital.com/library/patient-reported-outcomes-in-hodgkin-lymphoma-trials-a-systematic-review/2024-04-10T12:19:27+00:00https://lymphoma-stg.clarovantdigital.com/library/phase-ii-single-arm-study-of-a-combination-of-obinutuzumab-and-venetoclax-in-early-relapsed-or-refractory-diffuse-large-b-cell-lymphoma-final-results-of-the-agmt-nhl15b-study/2024-04-10T12:24:39+00:00https://lymphoma-stg.clarovantdigital.com/library/outcomes-after-chimeric-antigen-receptor-t-cell-therapy-across-large-b-cell-lymphoma-subtypes/2024-04-10T13:02:05+00:00https://lymphoma-stg.clarovantdigital.com/library/efficacy-and-safety-of-lenalidomide-in-the-treatment-of-b%e2%80%91cell-non%e2%80%91hodgkin-lymphoma/2024-04-10T13:05:49+00:00https://lymphoma-stg.clarovantdigital.com/library/successful-treatment-of-paediatric-refractory-hodgkin-lymphoma-with-immunotherapy-a-case-report-and-literature-review/2024-04-10T13:15:39+00:00https://lymphoma-stg.clarovantdigital.com/library/tafasitamab-for-the-treatment-of-patients-with-diffuse-large-b-cell-lymphoma/2024-04-11T13:52:56+00:00https://lymphoma-stg.clarovantdigital.com/library/clinical-features-and-prognostic-analysis-of-the-blastoid-variant-of-mantle-cell-lymphoma-an-analysis-of-20-patients-from-two-centers/2024-04-11T14:01:25+00:00https://lymphoma-stg.clarovantdigital.com/library/an-indirect-comparison-of-acalabrutinib-with-and-without-obinutuzumab-versus-zanubrutinib-in-treatment-naive-cll/2024-04-12T12:55:58+00:00https://lymphoma-stg.clarovantdigital.com/library/predictors-of-survival-treatment-modalities-and-clinical-outcomes-of-diffuse-large-b-cell-lymphoma-in-patients-older-than-70-years-still-an-unmet-medical-need-in-2024-based-on-real-world-evidence/2024-04-12T13:00:29+00:00https://lymphoma-stg.clarovantdigital.com/library/prediction-of-immunochemotherapy-response-for-diffuse-large-b-cell-lymphoma-using-artificial-intelligence-digital-pathology/2024-04-12T18:30:53+00:00https://lymphoma-stg.clarovantdigital.com/library/real-world-experience-of-australian-and-new-zealand-patients-with-chronic-lymphocytic-leukemia-and-mantle-cell-lymphoma-accessing-ibrutinib-through-a-named-patient-program/2024-04-12T18:30:54+00:00https://lymphoma-stg.clarovantdigital.com/library/abstract-ct244-hr001-a-novel-cd19-targeted-car-t-cell-therapy-for-patients-with-relapsed-refractory-non-hodgkins-lymphoma-primary-results-of-a-phase-ii-study-hrain01-nhl01-ii/2024-04-12T18:30:55+00:00https://lymphoma-stg.clarovantdigital.com/library/bendamustine-followed-by-obinutuzumab-and-idelalisib-in-chronic-lymphocytic-leukemia-cll2-bcg-final-analysis-of-a-multicenter-open-label-phase-ii-trial/2024-04-12T18:30:56+00:00https://lymphoma-stg.clarovantdigital.com/library/clinical-outcomes-of-etoposide-and-cytarabine-as-consolidation-in-elderly-patients-with-primary-cns-lymphoma/2024-04-12T18:30:57+00:00https://lymphoma-stg.clarovantdigital.com/library/real-world-patient-characteristics-treatment-patterns-and-treatment-outcomes-of-patients-with-diffuse-large-b-cell-lymphoma-by-line-of-therapy/2025-12-19T18:37:57+00:00https://lymphoma-stg.clarovantdigital.com/library/real-world-challenges-of-managing-diffuse-large-b-cell-lymphoma-in-a-developing-country/2026-03-13T19:33:55+00:00https://lymphoma-stg.clarovantdigital.com/library/a-decade-of-chronic-lymphocytic-leukaemia-therapy-in-germany-real-world-treatment-patterns-and-outcomes-2010-2022/2024-04-12T18:33:26+00:00https://lymphoma-stg.clarovantdigital.com/library/ibrutinib-in-primary-central-nervous-system-diffuse-large-b-cell-lymphoma/2024-04-15T13:45:00+00:00https://lymphoma-stg.clarovantdigital.com/library/a-phase-2-open%e2%80%91label-study-of-ibrutinib-plus-rituximab-in-japanese-patients-with-waldenstroms-macroglobulinemia/2024-04-15T13:51:13+00:00https://lymphoma-stg.clarovantdigital.com/library/hla-variations-in-patients-with-diffuse-large-b-cell-lymphoma-and-association-with-disease-risk-and-prognosis-a-case-control-study/2024-04-15T14:09:19+00:00https://lymphoma-stg.clarovantdigital.com/library/cost-effectiveness-analysis-3l-of-axicabtagene-ciloleucel-vs-tisagenlecleucel-and-lisocabtagene-maraleucel-in-japan/2024-04-15T14:16:53+00:00https://lymphoma-stg.clarovantdigital.com/library/phase-ii-study-of-novel-orally-pi3k-inhibitor-tq-b3525-in-relapsed-and-or-refractory-follicular-lymphoma/2024-04-17T19:28:48+00:00https://lymphoma-stg.clarovantdigital.com/library/mosquito-bed-net-use-and-burkitt-lymphoma-incidence-in-sub-saharan-africa-a-systematic-review-and-meta-analysis/2024-04-19T14:38:31+00:00https://lymphoma-stg.clarovantdigital.com/library/a-single-bout-of-vigorous-intensity-exercise-enhances-the-efficacy-of-rituximab-against-human-chronic-lymphocytic-leukaemia-b-cells-ex-vivo/2024-04-19T18:14:36+00:00https://lymphoma-stg.clarovantdigital.com/library/real-world-rw-dosing-patterns-and-outcomes-among-chronic-lymphocytic-leukemia-cll-patients-pts-with-or-without-an-ibrutinib-ibr-dose-adjustment-da-in-first-line-1l/2024-04-19T19:02:43+00:00https://lymphoma-stg.clarovantdigital.com/library/involved-site-radiotherapy-is-equally-effective-and-less-toxic-than-involved-field-radiotherapy-in-patients-receiving-combined-modality-treatment-for-early-stage-unfavorable-hodgkin-lymphoma-an-anal/2025-05-27T12:20:19+00:00https://lymphoma-stg.clarovantdigital.com/library/fetal-hemophagocytic-lymphohistiocytosis-with-intravascular-large-b-cell-lymphoma-following-coronavirus-disease-2019-vaccination-in-a-patient-with-systemic-lupus-erythematosus-an-intertwined-case/2024-04-19T19:02:46+00:00https://lymphoma-stg.clarovantdigital.com/library/outcomes-of-the-transformation-of-follicular-lymphoma-to-diffuse-large-b-cell-lymphoma-in-the-rituximab-era-a-population-based-study/2024-04-19T19:02:46+00:00https://lymphoma-stg.clarovantdigital.com/library/primary-lymphoma-of-the-female-genital-tract-masquerading-as-gynecological-malignancy/2024-04-19T19:02:47+00:00https://lymphoma-stg.clarovantdigital.com/library/primary-gastric-diffuse-large-b-cell-lymphoma-a-multicentre-retrospective-study/2024-04-19T19:02:47+00:00https://lymphoma-stg.clarovantdigital.com/library/outcome-in-patients-with-hiv-associated-hodgkin-lymphoma-treated-with-chemotherapy-using-doxorubicin-bleomycin-vinblastine-and-dacarbazine-in-the-combination-antiretroviral-therapy-cart-era-resu/2024-04-19T19:02:48+00:00https://lymphoma-stg.clarovantdigital.com/library/treatment-of-catheter-associated-internal-jugular-vein-thrombosis-using-apixaban-for-less-than-three-months-in-two-patients-with-aggressive-b-cell-lymphoma-undergoing-rituximab-cyclophosphamide-doxo/2024-04-19T19:02:49+00:00https://lymphoma-stg.clarovantdigital.com/library/covid-19-severity-in-patients-with-chronic-lymphocytic-leukemia-treated-with-venetoclax-a-single-center-observational-cohort-study/2024-04-19T19:02:50+00:00https://lymphoma-stg.clarovantdigital.com/library/higher-mortality-risk-from-gynaecological-neoplasms-and-non-hodgkins-lymphoma-in-patients-with-systemic-lupus-erythematosus-an-observational-study-from-the-spanish-national-registry/2024-04-19T19:02:51+00:00https://lymphoma-stg.clarovantdigital.com/library/real-world-health-care-resource-use-and-costs-among-patients-with-chronic-lymphocytic-leukemia-treated-with-venetoclax-based-and-bruton-tyrosine-kinase-inhibitor-based-regimens-in-the-second-line-sett/2025-12-15T20:13:15+00:00https://lymphoma-stg.clarovantdigital.com/library/real-world-and-clinical-trial-outcomes-in-large-b-cell-lymphoma-with-axicabtagene-ciloleucel-across-race-and-ethnicity/2025-12-19T18:09:23+00:00https://lymphoma-stg.clarovantdigital.com/library/a-retrospective-cohort-study-describing-chemotherapy-induced-peripheral-neuropathy-in-non-hodgkin-lymphoma-patients-treated-with-epoch-%c2%b1-r-does-hiv-status-matter/2024-04-24T20:37:28+00:00https://lymphoma-stg.clarovantdigital.com/library/new-therapies-for-relapsed-or-refractory-aggressive-b%e2%80%90cell-lymphoma-increase-survival-analysis-from-the-relinf-registry-of-the-geltamo-group/2024-04-24T21:08:23+00:00https://lymphoma-stg.clarovantdigital.com/library/clinical-efficacy-of-prophylactic-intravenous-immunoglobulin-for-elderly-dlbcl-patients-with-hypogammaglobulinemia-in-the-covid-19-pandemic-era/2024-04-24T21:13:24+00:00https://lymphoma-stg.clarovantdigital.com/library/myc-protein-is-a-high-risk-factor-in-mantle-cell-lymphoma-and-identifies-cases-beyond-morphology-proliferation-and-tp53-p53-a-nordic-lymphoma-group-study/2026-07-05T14:23:20+00:00https://lymphoma-stg.clarovantdigital.com/library/sequencing-of-anti-cd19-therapies-in-the-management-of-diffuse-large-b-cell-lymphoma/2024-04-26T16:30:03+00:00https://lymphoma-stg.clarovantdigital.com/library/real-life-study-on-the-use-of-response-adapted-therapy-in-patients-with-hodgkin-lymphoma-results-from-a-multicenter-experience/2024-04-26T16:37:11+00:00https://lymphoma-stg.clarovantdigital.com/library/gene-mutations-associated-with-chronic-lymphocytic-leukemia-cll-among-saudi-cll-patients-and-treatment-outcomes-a-singlecenter-experience/2024-04-26T18:39:17+00:00https://lymphoma-stg.clarovantdigital.com/library/specific-mortality-in-patients-with-diffuse-large-b-cell-lymphoma-a-retrospective-analysis-based-on-the-surveillance-epidemiology-and-end-results-database/2024-04-26T19:55:31+00:00https://lymphoma-stg.clarovantdigital.com/library/risk-of-non-hodgkin-lymphoma-in-breast-cancer-survivors-a-nationwide-cohort-study/2024-04-26T19:55:34+00:00https://lymphoma-stg.clarovantdigital.com/library/a-pilot-randomized-controlled-trial-of-an-online-intervention-for-hodgkin-lymphoma-survivors-to-increase-knowledge-about-late-effects-and-recommended-screening/2024-04-26T19:55:36+00:00https://lymphoma-stg.clarovantdigital.com/library/outcomes-of-burkitt-lymphoma-with-bone-marrow-involvement-or-burkitt-leukemia-in-chinese-children/2024-04-26T19:55:37+00:00https://lymphoma-stg.clarovantdigital.com/library/still-far-to-go-with-characterisation-of-molecular-and-genetic-features-of-diffuse-large-b-cell-lymphoma-in-people-living-with-hiv-a-scoping-review/2024-04-26T19:55:38+00:00https://lymphoma-stg.clarovantdigital.com/library/long-term-follow-up-of-patients-with-follicular-lymphoma-using-next-generation-sequencing-to-detect-minimal-residual-disease/2024-04-26T19:55:39+00:00https://lymphoma-stg.clarovantdigital.com/library/rapid-immune-reconstitution-following-the-infusion-of-autologous-blinatumomab-expanded-t-cells-bet-in-patients-with-b-cell-indolent-nhl-or-cll/2025-05-26T19:46:13+00:00https://lymphoma-stg.clarovantdigital.com/library/unusually-aggressive-primary-testicular-diffuse-large-b-cell-lymphoma-initially-presenting-as-systemic-disseminating-metastases-in-older-adult-men-a-case-report/2024-04-29T18:58:28+00:00https://lymphoma-stg.clarovantdigital.com/library/pan-immune-inflammation-value-and-body-mass-index-to-predict-survival-in-diffuse-large-b-cell-lymphoma/2024-04-29T19:05:06+00:00https://lymphoma-stg.clarovantdigital.com/library/current-therapeutic-sequencing-in-chronic-lymphocytic-leukemia/2026-05-12T14:33:30+00:00https://lymphoma-stg.clarovantdigital.com/library/inflammatory-and-subtype-dependent-serum-protein-signatures-predict-survival-beyond-the-ctdna-in-aggressive-b-cell-lymphomas/2024-04-30T13:48:37+00:00https://lymphoma-stg.clarovantdigital.com/library/impact-of-preexisting-heart-failure-on-treatment-and-outcomes-in-older-patients-with-hodgkin-lymphoma/2024-05-02T13:15:18+00:00https://lymphoma-stg.clarovantdigital.com/library/baseline-immunoglobulin-g-and-immune-function-in-non-hodgkin-lymphoma-a-retrospective-analysis/2024-05-02T13:20:16+00:00https://lymphoma-stg.clarovantdigital.com/library/real-world-total-cost-of-care-by-line-of-therapy-in-relapsed-refractory-diffuse-large-b-cell-lymphoma/2025-12-19T18:08:51+00:00https://lymphoma-stg.clarovantdigital.com/library/real-world-patterns-and-sequences-of-targeted-therapy-use-in-chronic-lymphocytic-leukemia-and-small-lymphocytic-lymphoma-in-the-united-states-a-longitudinal-study/2025-12-19T18:08:26+00:00https://lymphoma-stg.clarovantdigital.com/library/comparison-of-car-t-cell-vs-bispecific-antibody-as-third-or-later-line-large-b-cell-lymphoma-therapy-a-meta-analysis/2024-05-03T19:04:34+00:00https://lymphoma-stg.clarovantdigital.com/library/brentuximab-vedotin-retreatment-in-patients-with-relapsed-or-refractory-classical-hodgkin-lymphoma-or-peripheral-t-cell-lymphoma-a-retrospective-united-states-claims-analysis/2024-05-03T19:12:38+00:00https://lymphoma-stg.clarovantdigital.com/library/the-addition-of-bortezomib-to-rituximab-high-dose-cytarabine-and-dexamethasone-in-relapsed-or-refractory-mantle-cell-lymphoma-a-randomized-open-label-phase-iii-trial-of-the-european-mantle-cell-lym/2024-05-03T19:59:20+00:00https://lymphoma-stg.clarovantdigital.com/library/combining-obinutuzumab-with-radiation-for-refractory-dlbcl-retrospective-safety-and-efficacy-analysis/2024-05-03T19:59:24+00:00https://lymphoma-stg.clarovantdigital.com/library/genetic-polymorphisms-and-clinical-parameters-associated-with-renal-toxicity-in-thai-hematologic-malignancy-patients-receiving-high-dose-methotrexate/2024-05-03T19:59:25+00:00https://lymphoma-stg.clarovantdigital.com/library/the-potential-value-of-ultrasound-in-predicting-local-refractory-relapse-events-in-primary-thyroid-lymphoma-patients/2024-05-03T19:59:27+00:00https://lymphoma-stg.clarovantdigital.com/library/pulmonary-diseases-in-patients-with-classical-hodgkin-lymphoma-relative-to-a-matched-background-population-a-danish-national-cohort-study/2024-05-03T19:59:28+00:00https://lymphoma-stg.clarovantdigital.com/library/genomic-landscape-and-distinct-molecular-subtypes-of-primary-testicular-lymphoma/2024-05-03T19:59:29+00:00https://lymphoma-stg.clarovantdigital.com/library/fludarabine-cyclophosphamide-and-rituximab-as-first-line-treatment-in-patients-with-chronic-lymphocytic-leukemia-a-long-term-analysis-of-the-german-cll-study-group-gcllsg-registry/2024-05-03T19:59:30+00:00https://lymphoma-stg.clarovantdigital.com/library/ibrutinib-combined-with-immunochemotherapy-with-or-without-autologous-stem-cell-transplantation-versus-immunochemotherapy-and-autologous-stem-cell-transplantation-in-previously-untreated-patients-with/2024-05-03T19:59:31+00:00https://lymphoma-stg.clarovantdigital.com/library/what-are-the-strategies-to-manage-toxicities-with-car-t-cell-therapies/2024-05-31T17:11:07+00:00https://lymphoma-stg.clarovantdigital.com/library/polatuzumab-vedotin-in-combination-with-venetoclax-and-rituximab-for-patients-with-r-r-dlbcl/2025-12-19T18:05:06+00:00https://lymphoma-stg.clarovantdigital.com/library/mrd-at-the-end-of-induction-and-efs-in-t-cell-lymphoblastic-lymphoma-childrens-oncology-group-trial-aall1231/2024-05-03T20:42:30+00:00https://lymphoma-stg.clarovantdigital.com/library/lisocabtagene-maraleucel-for-second-line-relapsed-or-refractory-large-b-cell-lymphoma-patient-reported-outcomes-from-the-pilot-study/2024-05-03T20:46:16+00:00https://lymphoma-stg.clarovantdigital.com/library/allogeneic-hematopoietic-cell-transplantation-after-chimeric-antigen-receptor-t-cell-therapy-in-large-b-cell-lymphoma/2024-05-06T13:40:36+00:00https://lymphoma-stg.clarovantdigital.com/library/flow-cytometry-quantification-of-tumor-infiltrating-lymphocytes-to-predict-the-survival-of-patients-with-diffuse-large-b-cell-lymphoma/2024-05-06T13:47:10+00:00https://lymphoma-stg.clarovantdigital.com/library/car-t-cell-therapy-in-mantle-cell-lymphoma-with-secondary-cns-involvement-a-multicenter-experience/2024-05-06T13:53:56+00:00https://lymphoma-stg.clarovantdigital.com/library/immune-checkpoint-inhibitors-in-advanced-and-relapsed-refractory-hodgkin-lymphoma-current-applications-and-future-prospects/2024-05-06T13:58:16+00:00https://lymphoma-stg.clarovantdigital.com/library/progression-free-survival-after-front-line-second-line-and-third-line-in-patients-with-follicular-lymphoma-treated-in-clinical-practice/2024-05-08T00:11:43+00:00https://lymphoma-stg.clarovantdigital.com/library/cost-effectiveness-analysis-of-mosunetuzumab-for-treatment-of-relapsed-or-refractory-follicular-lymphoma/2024-05-08T00:16:09+00:00https://lymphoma-stg.clarovantdigital.com/library/intensive-care-in-children-with-non-hodgkin-lymphoma-in-sweden/2024-05-09T15:21:50+00:00https://lymphoma-stg.clarovantdigital.com/library/comparing-r-bendamustine-vs-r-chop-plus-maintenance-therapy-as-first-line-systemic-treatment-in-follicular-lymphoma-a-multicenter-retrospective-geltamo-study/2024-05-09T15:27:45+00:00https://lymphoma-stg.clarovantdigital.com/library/comparative-effectiveness-study-of-chemotherapy-in-follicular-lymphoma-patients-in-the-rituximab-era-a-japanese-claims-database-study/2024-05-10T14:03:05+00:00https://lymphoma-stg.clarovantdigital.com/library/advances-in-hodgkin-lymphoma-treatment-from-molecular-biology-to-clinical-practice/2024-05-10T18:59:49+00:00https://lymphoma-stg.clarovantdigital.com/library/economic-evaluation-of-anti-cd19-car-t-cell-pathway-for-large-b-cell-lymphomas-in-the-real-life-setting-the-experience-of-an-italian-hub-center-in-the-first-three-years-of-activity/2024-05-10T19:04:49+00:00https://lymphoma-stg.clarovantdigital.com/library/tissue-matched-igh-gene-rearrangement-of-circulating-tumor-dna-shows-significant-value-in-predicting-the-progression-of-diffuse-large-b-cell-lymphoma/2024-05-10T19:04:52+00:00https://lymphoma-stg.clarovantdigital.com/library/risk-factors-for-treatment-related-bone-loss-and-osteoporosis-in-patients-with-follicular-lymphoma/2024-05-10T19:04:53+00:00https://lymphoma-stg.clarovantdigital.com/library/should-all-patients-with-stage-ie-gastric-mucosa-associated-lymphoid-tissue-lymphoma-receive-antibiotic-eradication-therapy-for-helicobacter-pylori/2024-05-10T19:04:54+00:00https://lymphoma-stg.clarovantdigital.com/library/primary-gynecologic-lymphoma-when-diagnosed-by-a-gynecologist-a-case-series/2024-05-13T20:43:08+00:00https://lymphoma-stg.clarovantdigital.com/library/a-review-of-resistance-mechanisms-to-brutons-kinase-inhibitors-in-chronic-lymphocytic-leukemia/2024-05-13T20:48:33+00:00https://lymphoma-stg.clarovantdigital.com/library/risk-of-invasive-fungal-infections-in-patients-with-chronic-lymphocytic-leukemia-treated-with-bruton-tyrosine-kinase-inhibitors-a-case-control-propensity-score-matched-analysis/2024-05-13T20:55:43+00:00https://lymphoma-stg.clarovantdigital.com/library/biomarkers-and-novel-therapeutic-approaches-for-diffuse-large-b-cell-lymphoma-in-the-era-of-precision-medicine/2024-05-13T21:02:01+00:00https://lymphoma-stg.clarovantdigital.com/library/interventions-about-physical-activity-and-diet-and-their-impact-on-adolescent-and-young-adult-cancer-survivors-a-prisma-systematic-review/2024-05-15T11:58:50+00:00https://lymphoma-stg.clarovantdigital.com/library/predictive-model-for-the-risk-of-cytokine-release-syndrome-with-glofitamab-treatment-for-diffuse-large-b-cell-lymphoma/2024-05-16T11:49:03+00:00https://lymphoma-stg.clarovantdigital.com/library/patient-perspectives-on-treatment-for-mantle-cell-lymphoma-and-chronic-lymphocytic-leukemia-in-japan/2024-05-16T14:09:50+00:00https://lymphoma-stg.clarovantdigital.com/library/biological-and-clinical-determinants-shaping-heterogeneity-in-mantle-cell-lymphoma/2024-05-17T14:03:54+00:00https://lymphoma-stg.clarovantdigital.com/library/treatment-outcome-and-prognostic-factors-in-children-and-adolescents-with-relapsed-and-refractory-classic-hodgkin-lymphoma/2024-05-17T18:35:43+00:00https://lymphoma-stg.clarovantdigital.com/library/mutational-profile-of-previously-treated-chronic-lymphocytic-leukemia-patients-progressing-on-acalabrutinib-or-ibrutinib/2024-05-17T18:42:35+00:00https://lymphoma-stg.clarovantdigital.com/library/paradigm-shifts-in-hodgkin-lymphoma-treatment-from-frontline-therapies-to-relapsed-disease/2024-05-17T20:36:13+00:00https://lymphoma-stg.clarovantdigital.com/library/prognostic-impact-of-chronic-lymphocytic-leukemia-comorbidity-index-in-a-young-population-a-real-world-evidence-study-of-a-national-gulf-region-cohort/2024-05-17T20:36:15+00:00https://lymphoma-stg.clarovantdigital.com/library/clinical-experiences-with-venetoclax-and-other-pro-apoptotic-agents-in-lymphoid-malignancies-lessons-from-monotherapy-and-chemotherapy-combination/2024-05-17T20:36:16+00:00https://lymphoma-stg.clarovantdigital.com/library/chronic-lymphocytic-leukemia-cll-real-world-data-from-lebanon/2026-03-13T19:33:20+00:00https://lymphoma-stg.clarovantdigital.com/library/efficacy-and-safety-of-netupitant-palonosetron-in-preventing-nausea-and-vomiting-in-diffuse-large-b-cell-lymphoma-patients-undergoing-r-chop-chemotherapy/2024-05-17T20:36:18+00:00https://lymphoma-stg.clarovantdigital.com/library/recent-advances-in-treatment-of-follicular-lymphoma-efficacy-of-pi3k-inhibitor-tq-b3525/2024-05-17T20:36:19+00:00https://lymphoma-stg.clarovantdigital.com/library/eric-recommendations-for-tp53-mutation-analysis-in-chronic-lymphocytic-leukemia-2024-update/2024-05-17T20:36:20+00:00https://lymphoma-stg.clarovantdigital.com/library/infections-in-patients-with-chronic-lymphocytic-leukemia-treated-with-time-limited-targeted-drug-combinations/2024-05-17T20:36:21+00:00https://lymphoma-stg.clarovantdigital.com/library/compatibility-study-of-topical-0-25-hypericin-hybrytetm-application-in-subjects-with-mycosis-fungoides-results-of-the-hpn-ctcl-02-study/2024-05-23T13:14:19+00:00https://lymphoma-stg.clarovantdigital.com/library/a-rare-case-of-primary-pulmonary-diffuse-large-b-cell-lymphoma-transformed-from-marginal-zone-mucosa-associated-lymphoid-tissue-lymphoma/2024-05-23T20:50:03+00:00https://lymphoma-stg.clarovantdigital.com/library/complications-of-brentuximab-therapy-in-patients-with-hodgkins-lymphoma-and-concurrent-autoimmune-pathology-a-case-series/2024-05-23T20:53:57+00:00https://lymphoma-stg.clarovantdigital.com/library/optimal-number-of-cycles-of-bendamustine-as-initial-chemoimmunotherapy-for-older-patients-with-follicular-lymphoma/2024-05-23T21:08:18+00:00https://lymphoma-stg.clarovantdigital.com/library/the-impact-of-brutons-tyrosine-kinase-inhibitor-treatment-on-covid-19-outcomes-in-chinese-patients-with-chronic-lymphocytic-leukemia/2024-05-24T00:09:59+00:00https://lymphoma-stg.clarovantdigital.com/library/clinical-features-of-cutaneous-paraneoplastic-syndromes-in-hodgkin-lymphoma/2024-05-24T16:20:52+00:00https://lymphoma-stg.clarovantdigital.com/library/response-guided-first-line-therapy-and-treatment-of-relapse-in-aggressive-lymphoma-10-year-follow-up-of-the-petal-trial/2024-05-24T16:26:59+00:00https://lymphoma-stg.clarovantdigital.com/library/treatment-outcomes-in-patients-with-large-b%e2%80%90cell-lymphoma-after-progression-to-chimeric-antigen-receptor-t%e2%80%90cell-therapy/2026-01-15T14:09:23+00:00https://lymphoma-stg.clarovantdigital.com/library/targeting-the-tumor-microenvironment-for-treating-double-refractory-chronic-lymphocytic-leukemia/2024-05-24T16:36:59+00:00https://lymphoma-stg.clarovantdigital.com/library/a-single-bout-of-vigorous-intensity-exercise-enhances-the-efficacy-of-rituximab-against-human-chronic-lymphocytic-leukaemia-b-cells-ex-vivo-2/2024-05-24T16:41:25+00:00https://lymphoma-stg.clarovantdigital.com/library/relapsed-refractory-diffuse-large-b-cell-lymphoma-is-there-still-a-role-for-autologous-stem-cell-transplantation-in-the-car-t-cell-era/2024-05-24T17:51:58+00:00https://lymphoma-stg.clarovantdigital.com/library/treatment-of-follicular-lymphoma-with-a-focus-on-radiotherapy/2025-05-27T12:08:48+00:00https://lymphoma-stg.clarovantdigital.com/library/cost-effectiveness-of-treating-relapsed-or-refractory-3l-follicular-lymphoma-with-axicabtagene-ciloleucel-vs-mosunetuzumab-in-the-united-states/2025-12-19T18:08:07+00:00https://lymphoma-stg.clarovantdigital.com/library/real-world-evidence-of-relapsed-refractory-mantle-cell-lymphoma-patients-and-treatments-a-systematic-review/2024-05-24T18:52:53+00:00https://lymphoma-stg.clarovantdigital.com/library/appropriate-treatment-intensity-for-diffuse-large-b-cell-lymphoma-in-the-older-population-a-review-of-the-literature/2024-05-24T19:03:58+00:00https://lymphoma-stg.clarovantdigital.com/library/burden-of-infection-in-patients-with-and-without-secondary-immunodeficiency-disease-following-diagnosis-of-a-mature-b-cell-malignancy/2024-05-24T20:40:09+00:00https://lymphoma-stg.clarovantdigital.com/library/residential-proximity-to-dioxin-emitting-facilities-and-risk-of-non-hodgkin-lymphoma-in-the-nih-aarp-diet-and-health-study/2024-05-24T20:40:11+00:00https://lymphoma-stg.clarovantdigital.com/library/artificial-intelligence-based-prognostic-model-accurately-predicts-the-survival-of-patients-with-diffuse-large-b-cell-lymphomas-analysis-of-a-large-cohort-in-china/2024-05-24T20:40:12+00:00https://lymphoma-stg.clarovantdigital.com/library/glofitamab-associated-immune-effector-cell-associated-neurotoxicity-syndrome-icans-presenting-as-serial-seizures-and-responding-positively-to-antiseizure-drugs-and-anakinra-a-case-report/2024-05-24T20:40:13+00:00https://lymphoma-stg.clarovantdigital.com/library/mucosa-associated-lymphoid-tissue-malt-lymphoma-of-the-urinary-bladder-a-case-report-of-a-rare-presentation/2024-05-24T20:40:14+00:00https://lymphoma-stg.clarovantdigital.com/library/outcomes-of-pirtobrutinib-for-relapsed-refractory-mantle-cell-lymphoma-in-compassionate-use-program-in-europe/2024-05-24T20:40:15+00:00https://lymphoma-stg.clarovantdigital.com/library/the-complexities-of-t-cell-dysfunction-in-chronic-lymphocytic-leukemia/2024-05-24T20:40:16+00:00https://lymphoma-stg.clarovantdigital.com/library/concurrent-pembrolizumab-with-avd-for-untreated-classic-hodgkin-lymphoma/2024-05-26T14:15:07+00:00https://lymphoma-stg.clarovantdigital.com/library/tattoos-as-a-risk-factor-for-malignant-lymphoma-a-population-based-case-control-study/2024-05-26T14:19:36+00:00https://lymphoma-stg.clarovantdigital.com/library/first%e2%80%90line-ibrutinib-treatment-in-patients-with-chronic-lymphocytic-leukemia-is-associated-with-overall-survival-rates-similar-to-those-of-an-age%e2%80%90matched-general-population-a-pooled-p/2024-05-29T14:58:51+00:00https://lymphoma-stg.clarovantdigital.com/library/monitoring-response-and-resistance-to-treatment-in-chronic-lymphocytic-leukemia/2024-05-29T15:02:50+00:00https://lymphoma-stg.clarovantdigital.com/library/a-meta-analysis-on-the-diagnostic-performance-of-whole-body-mri-for-the-initial-staging-of-hodgkin-lymphoma-in-children-and-adults-using-fdg-pet-ct-as-a-reference-standard/2024-05-29T15:07:00+00:00https://lymphoma-stg.clarovantdigital.com/library/the-phase-iii-duo-trial-of-pi3k-inhibitor-duvelisib-versus-ofatumumab-in-relapsed-refractory-chronic-lymphocytic-leukemia-small-lymphocytic-lymphoma-final-analysis-including-overall-survival/2025-03-03T19:33:33+00:00https://lymphoma-stg.clarovantdigital.com/library/pediatric-and-adolescent-hodgkin-lymphoma-paving-the-way-for-standards-of-care-and-shared-decision-making/2024-05-31T17:34:54+00:00https://lymphoma-stg.clarovantdigital.com/library/gene-mutations-associated-with-chronic-lymphocytic-leukemia-cll-among-saudi-cll-patients-and-treatment-outcomes-a-single-center-experience/2024-05-31T17:34:56+00:00https://lymphoma-stg.clarovantdigital.com/library/outdoor-air-pollution-and-risk-of-incident-adult-haematologic-cancer-subtypes-in-a-large-us-prospective-cohort/2025-12-19T18:37:15+00:00https://lymphoma-stg.clarovantdigital.com/library/zanubrutinib-is-effective-in-non-germinal-center-b-cell-like-diffuse-large-b-cell-lymphoma-with-mutated-cd79b-high-tcl1a-expression-or-over-expressed-myc-bcl-2/2024-05-31T17:34:57+00:00https://lymphoma-stg.clarovantdigital.com/library/first-line-venetoclax-combinations-versus-chemoimmunotherapy-in-fit-patients-with-chronic-lymphocytic-leukaemia-gaia-cll13-4-year-follow-up-from-a-multicentre-open-label-randomised-phase-3-trial/2025-05-13T13:38:36+00:00https://lymphoma-stg.clarovantdigital.com/library/simplified-risk-stratification-model-for-patients-with-waldenstrom-macroglobulinemia/2024-05-31T17:34:59+00:00https://lymphoma-stg.clarovantdigital.com/library/carfilzomib-plus-rituximab-ifosfamide-carboplatin-and-etoposide-c-rice-led-to-higher-response-os-and-pfs-in-patients-with-transplant-eligible-relapsed-or-refractory-r-r-diffuse-large-b-cell-ly/2024-05-31T17:34:59+00:00https://lymphoma-stg.clarovantdigital.com/library/randomized-phase-ii-iii-study-of-r-chop-venetoclax-in-previously-untreated-myc-bcl2-double-expressor-diffuse-large-b-cell-lymphoma-dlbcl-alliance-a051701/2024-05-31T17:35:00+00:00https://lymphoma-stg.clarovantdigital.com/library/liquid-biopsy-for-molecular-characterization-of-diffuse-large-b-cell-lymphoma-and-early-assessment-of-minimal-residual-disease/2024-05-31T17:35:01+00:00https://lymphoma-stg.clarovantdigital.com/library/benefit-of-rituximab-maintenance-after-first-line-bendamustine-rituximab-in-mantle-cell-lymphoma/2024-05-31T17:35:02+00:00https://lymphoma-stg.clarovantdigital.com/library/combined-modality-for-localized-gastric-diffuse-large-b-cell-lymphoma-long-term-outcomes-of-50-patients/2025-05-27T12:20:50+00:00https://lymphoma-stg.clarovantdigital.com/library/characteristics-treatment-and-outcomes-of-cutaneous-mantle-cell-lymphoma-a-decade-long-study-at-md-anderson-cancer-center/2024-05-31T17:35:03+00:00https://lymphoma-stg.clarovantdigital.com/library/results-from-the-follicular-lymphoma-fl-outcomes-in-patients-pts-with-relapsed-refractory-r-r-disease-treated-with-systemic-therapy-in-a-real-world-assessment-flora-study/2024-05-31T17:35:04+00:00https://lymphoma-stg.clarovantdigital.com/library/real-world-adherence-and-healthcare-resource-utilization-of-bruton-tyrosine-kinase-inhibitors-btki-in-mantle-cell-lymphoma/2024-05-31T17:35:05+00:00https://lymphoma-stg.clarovantdigital.com/library/clinical-features-and-outcomes-of-patients-with-follicular-lymphoma-grade-3a-a-real-world-study-in-single-center/2024-05-31T17:35:05+00:00https://lymphoma-stg.clarovantdigital.com/library/canadian-cancer-trials-group-ly-17-a-randomized-phase-ii-study-evaluating-novel-salvage-therapy-pre-autologous-stem-cell-transplant-in-relapsed-refractory-diffuse-large-b-cell-lymphoma-outcome-of-r/2026-01-15T14:12:01+00:00https://lymphoma-stg.clarovantdigital.com/library/management-of-fatigue-in-adult-survivors-of-cancer-asco-society-for-integrative-oncology-guideline-update/2024-05-31T17:35:07+00:00https://lymphoma-stg.clarovantdigital.com/library/relapse-hodgkin-lymphoma-autologous-stem-cell-transplant-long-term-follow-up/2024-05-31T17:35:08+00:00https://lymphoma-stg.clarovantdigital.com/library/nivolumab-plus-brentuximab-vedotin-for-relapsed-refractory-peripheral-t-cell-lymphoma-and-cutaneous-t-cell-lymphoma/2025-12-15T19:55:05+00:00https://lymphoma-stg.clarovantdigital.com/library/machine-learning-based-survival-prediction-models-for-progression-free-and-overall-survival-in-advanced-stage-hodgkin-lymphoma/2024-05-31T17:35:09+00:00https://lymphoma-stg.clarovantdigital.com/library/anti-cd19-car-t-cell-therapy-for-patients-with-primary-or-secondary-cns-lymphoma/2024-05-31T17:35:10+00:00https://lymphoma-stg.clarovantdigital.com/library/nivolumab-with-car-t-cell-therapy-in-progressive-dlbcl-final-analysis-of-a-phase-ii-study/2024-05-31T17:35:11+00:00https://lymphoma-stg.clarovantdigital.com/library/brutons-tyrosine-kinase-inhibitor-related-cardiotoxicity-the-quest-for-predictive-biomarkers-and-improved-risk-stratification/2024-06-05T18:47:46+00:00https://lymphoma-stg.clarovantdigital.com/library/patient-preferences-for-chronic-lymphocytic-leukemia-treatments-a-discrete-choice-experiment/2024-06-05T19:51:34+00:00https://lymphoma-stg.clarovantdigital.com/library/combination-brecadd-is-significantly-more-effective-than-beacopp-for-classical-hodgkin-lymphoma-study-finds/2024-06-05T19:57:44+00:00https://lymphoma-stg.clarovantdigital.com/library/seven-year-overall-survival-analysis-from-echelon-1-study-of-aavd-versus-abvd-in-patients-with-previously-untreated-stage-iii-iv-classical-hodgkin-lymphoma/2024-06-05T19:57:46+00:00https://lymphoma-stg.clarovantdigital.com/library/frontline-brentuximab-vedotin-and-chp-achp-in-patients-pts-with-peripheral-t-cell-lymphoma-with-less-than-10-percent-cd30-expression-results-from-the-phase-2-sgn35-032-study/2024-06-05T19:57:47+00:00https://lymphoma-stg.clarovantdigital.com/library/real-world-outcomes-of-lisocabtagene-maraleucel-liso-cel-in-patients-pt-with-richter-transformation-rt-from-the-center-for-international-blood-and-marrow-transplant-research-cibmtr/2024-06-05T19:57:48+00:00https://lymphoma-stg.clarovantdigital.com/library/mosunetuzumab-with-polatuzumab-vedotin-subgroup-analyses-in-patients-pts-with-primary-refractory-or-early-relapsed-large-b-cell-lymphoma-lbcl/2024-06-05T19:57:49+00:00https://lymphoma-stg.clarovantdigital.com/library/subcutaneous-epcoritamab-sc-epcor-administered-outpatient-outpt-for-relapsed-or-refractory-r-r-diffuse-large-b-cell-lymphoma-dlbcl-and-follicular-lymphoma-fl-results-from-phase-2-epcore-nhl/2026-01-14T17:58:59+00:00https://lymphoma-stg.clarovantdigital.com/library/secondary-myeloid-malignancy-after-car-t-cell-therapy-for-non-hodgkin-lymphoma-nhl/2024-06-05T19:57:51+00:00https://lymphoma-stg.clarovantdigital.com/library/subcutaneous-epcoritamab-gemox-in-patients-with-relapsed-or-refractory-dlbcl-updated-results-from-epcore-nhl-2/2026-01-14T17:57:44+00:00https://lymphoma-stg.clarovantdigital.com/library/extended-follow-up-results-beyond-2-5-years-from-the-pivotal-nhl-1-epcore-trial-subcutaneous-epcoritamab-monotherapy-in-patients-with-relapsed-refractory-large-b-cell-lymphoma-r-r-lbcl/2026-01-14T17:57:08+00:00https://lymphoma-stg.clarovantdigital.com/library/efficacy-of-pembrolizumab-monotherapy-and-in-combination-with-bcr-inhibitors-for-richter-transformation-of-chronic-lymphocytic-leukemia-cll/2024-06-05T19:57:54+00:00https://lymphoma-stg.clarovantdigital.com/library/ibrutinib-followed-by-ofatumumab-consolidation-in-previously-untreated-patients-with-chronic-lymphocytic-leukemia-cll-gellc-7-trial-from-the-spanish-group-of-cll-gellc/2024-06-05T19:57:56+00:00https://lymphoma-stg.clarovantdigital.com/library/tucidinostat-plus-r-chop-improves-efs-in-dlbcl-expressing-myc-and-bcl2/2024-06-05T19:57:57+00:00https://lymphoma-stg.clarovantdigital.com/library/glofitamab-monotherapy-in-patients-with-heavily-pretreated-relapsed-refractory-r-r-mantle-cell-lymphoma-mcl-updated-analysis-from-a-phase-i-ii-study/2024-06-05T19:57:58+00:00https://lymphoma-stg.clarovantdigital.com/library/glofitamab-monotherapy-retreatment-in-patients-with-heavily-pre-treated-relapsed-or-refractory-r-r-non-hodgkin-lymphoma-nhl-results-from-a-phase-i-ii-study/2024-06-05T19:57:59+00:00https://lymphoma-stg.clarovantdigital.com/library/prevalence-of-adverse-events-following-bispecific-antibody-therapy-in-non-hodgkin-lymphoma-a-meta-analysis/2025-06-09T15:26:18+00:00https://lymphoma-stg.clarovantdigital.com/library/lost-in-the-plot-missing-visual-elements-in-kaplan-meier-plots-of-phase-iii-oncology-trials/2024-06-05T19:58:01+00:00https://lymphoma-stg.clarovantdigital.com/library/phase-2-study-of-pegylated-liposomal-doxorubicin-plus-cyclophosphamide-vincristine-vindesine-and-prednisone-in-newly-diagnosed-ptcl-8-year-results/2024-06-05T19:58:02+00:00https://lymphoma-stg.clarovantdigital.com/library/impact-of-eligibility-criteria-discordance-on-clinical-trial-accrual-in-diffuse-large-b-cell-lymphoma-dlbcl/2024-06-05T19:58:03+00:00https://lymphoma-stg.clarovantdigital.com/library/the-role-of-upfront-lenalidomide-maintenance-for-primary-central-nervous-system-lymphoma-following-first-line-methotrexate-treatment-a-retrospective-study/2024-06-05T19:58:04+00:00https://lymphoma-stg.clarovantdigital.com/library/performance-of-myc-bcl2-and-bcl6-break-apart-fish-in-small-biopsies-with-large-b-cell-lymphoma-a-retrospective-cytopathology-hematopathology-interinstitutional-consortium-study/2024-06-11T12:22:53+00:00https://lymphoma-stg.clarovantdigital.com/library/post-marketing-risk-analysis-of-bendamustine-a-real-world-approach-based-on-the-faers-database/2024-06-11T12:26:33+00:00https://lymphoma-stg.clarovantdigital.com/library/molecular-subtypes-and-the-role-of-tp53-in-diffuse-large-b-cell-lymphoma-and-richter-syndrome/2024-06-11T13:14:26+00:00https://lymphoma-stg.clarovantdigital.com/library/long%e2%80%91term-safety-and-effectiveness-of-rituximab-biosimilar-rtxm83-a-retrospective-extension-study-in-brazilian-patients-with-diffuse-large-b%e2%80%91cell-lymphoma/2026-01-06T21:08:56+00:00https://lymphoma-stg.clarovantdigital.com/library/supplement-of-vitamin-d-for-early-stage-chronic-lymphocytic-leukemia-patients-is-associated-with-a-longer-time-to-first-treatment/2024-06-11T13:38:55+00:00https://lymphoma-stg.clarovantdigital.com/library/impact-of-leukemia-associated-macrophages-on-the-progression-and-therapy-response-of-chronic-lymphocytic-leukemia/2024-06-11T13:50:50+00:00https://lymphoma-stg.clarovantdigital.com/library/advancing-car-t-cell-therapy-for-chronic-lymphocytic-leukemia-exploring-resistance-mechanisms-and-the-innovative-strategies-to-overcome-them/2024-06-11T13:56:13+00:00https://lymphoma-stg.clarovantdigital.com/library/the-treatment-of-follicular-lymphoma-with-cd19-directed-chimeric-antigen-receptor-t-cell-therapy/2024-06-11T14:00:54+00:00https://lymphoma-stg.clarovantdigital.com/library/cardiotoxic-profiles-of-car-t-therapy-and-bispecific-t-cell-engagers-in-hematological-cancers/2024-06-13T13:23:37+00:00https://lymphoma-stg.clarovantdigital.com/library/prognostic-significance-of-bcl-2-expression-in-non-germinal-center-b-cell-like-diffuse-large-b-cell-lymphoma/2024-06-14T14:28:22+00:00https://lymphoma-stg.clarovantdigital.com/library/a-pilot-study-of-axicabtagene-ciloleucel-axi-cel-for-relapsed-refractory-primary-and-secondary-central-nervous-system-lymphoma-pcnsl-and-scnsl/2024-06-14T14:28:24+00:00https://lymphoma-stg.clarovantdigital.com/library/new-clues-to-origin-of-t-cell-lymphoma-after-car-t-therapy/2024-06-14T14:28:25+00:00https://lymphoma-stg.clarovantdigital.com/library/real-world-treatment-patterns-and-outcomes-of-zanubrutinib-in-chronic-lymphocytic-leukemia-and-small-lymphocytic-leukemia-cll-sll/2025-03-03T20:33:57+00:00https://lymphoma-stg.clarovantdigital.com/library/long-term-cause-specific-mortality-in-adolescent-and-young-adult-hodgkin-lymphoma-patients-treated-with-contemporary-regimens-a-nationwide-danish-cohort-study/2024-06-14T14:28:28+00:00https://lymphoma-stg.clarovantdigital.com/library/brexucabtagene-autoleucel-for-relapsed-or-refractory-mantle-cell-lymphoma-in-the-united-kingdom-a-real-world-intention-to-treat-analysis/2024-06-14T14:28:29+00:00https://lymphoma-stg.clarovantdigital.com/library/immunogenicity-of-covid-19-vaccines-in-patients-with-follicular-lymphoma-receiving-frontline-chemoimmunotherapy/2024-06-14T14:28:31+00:00https://lymphoma-stg.clarovantdigital.com/library/real-world-outcomes-following-adverse-events-and-dose-reduction-of-first-line-ibrutinib-in-medicare-beneficiaries-with-chronic-lymphocytic-leukemia-small-lymphocytic-lymphoma-cll-sll/2025-03-03T20:33:17+00:00https://lymphoma-stg.clarovantdigital.com/library/histopathologic-features-and-differential-diagnosis-in-challenging-cases-of-nodular-lymphocyte-predominant-b-cell-lymphoma-nodular-lymphocyte-predominant-hodgkin-lymphoma/2024-06-21T12:32:12+00:00https://lymphoma-stg.clarovantdigital.com/library/epstein-barr-virus-and-the-pathogenesis-of-diffuse-large-b-cell-lymphoma/2026-09-02T16:15:19+00:00https://lymphoma-stg.clarovantdigital.com/library/brexucabtagene-autoleucel-in-relapsed-or-refractory-mantle-cell-lymphoma-intention-to-treat-use-in-the-descar-t-registry/2024-06-21T13:04:35+00:00https://lymphoma-stg.clarovantdigital.com/library/follicular-lymphoma-with-epstein-barr-virus-associated-transformation-a-case-report-and-review-of-the-literature/2026-09-02T16:14:47+00:00https://lymphoma-stg.clarovantdigital.com/library/igg-testing-immunoglobulin-replacement-therapy-and-infection-outcomes-in-patients-with-cll-or-nhl-real-world-evidence/2024-06-21T17:20:11+00:00https://lymphoma-stg.clarovantdigital.com/library/first-line-1l-treatment-of-follicular-lymphoma-fl-with-atezolizumab-and-obinutuzumab-ao-radiotherapy-rt-results-from-the-fluoro-study/2024-06-21T17:42:59+00:00https://lymphoma-stg.clarovantdigital.com/library/cardiovascular-events-reported-in-patients-with-b-cell-malignancies-treated-with-zanubrutinib/2024-06-21T17:43:02+00:00https://lymphoma-stg.clarovantdigital.com/library/combination-of-zanubrutinib-venetoclax-for-treatment-naive-tn-cll-sll-with-del17p-and-or-tp53-preliminary-results-from-sequoia-arm-d/2025-03-03T20:32:23+00:00https://lymphoma-stg.clarovantdigital.com/library/real-world-risk-of-bleeding-events-in-patients-with-chronic-lymphocytic-leukemia-or-small-lymphocytic-lymphoma-cll-sll-treated-with-btki/2025-03-03T20:31:33+00:00https://lymphoma-stg.clarovantdigital.com/library/preliminary-safety-and-efficacy-of-boven-zanubrutinib-obinutuzumab-and-venetoclax-for-frontline-therapy-for-older-patients-with-mantle-cell-lymphoma/2024-06-21T17:43:05+00:00https://lymphoma-stg.clarovantdigital.com/library/glofitamab-plus-gemcitabine-and-oxaliplatin-glofit-gemox-for-relapsed-refractory-r-r-diffuse-large-b-cell-lymphoma-dlbcl-results-of-a-global-randomized-phase-iii-trial-starglo/2024-06-21T17:43:06+00:00https://lymphoma-stg.clarovantdigital.com/library/acalabrutinib-plus-bendamustine-and-rituximab-in-untreated-mantle-cell-lymphoma-results-from-the-phase-3-double-blind-placebo-controlled-echo-trial/2024-06-21T17:43:07+00:00https://lymphoma-stg.clarovantdigital.com/library/matchingadjusted-indirect-comparisons-of-axicabtagene-ciloleucel-to-mosunetuzumab-for-the-treatment-of-relapsed-refractory-follicular-lymphoma/2024-06-21T17:43:08+00:00https://lymphoma-stg.clarovantdigital.com/library/improved-efficacy-and-safety-of-zanubrutinib-versus-ibrutinib-in-patients-with-relapsed-refractory-chronic-lymphocytic-leukemia-r-r-cll-in-china-a-subgroup-of-alpine/2024-06-21T17:43:09+00:00https://lymphoma-stg.clarovantdigital.com/library/leukemia-in-india-insights-into-incidence-prevalence-mortality-and-disability-adjusted-life-years/2026-03-13T19:32:38+00:00https://lymphoma-stg.clarovantdigital.com/library/updated-trends-in-real-world-outpatient-op-administration-of-axicabtagene-ciloleucel-axi-cel-and-brexucabtagene-autoleucel-brexu-cel-in-relapsed-refractory-r-r-non-hodgkin-lymphoma-nhl/2024-06-21T17:43:11+00:00https://lymphoma-stg.clarovantdigital.com/library/impact-of-bridging-therapy-bt-on-lisocabtagene-maraleucel-liso-cel-treatment-in-patients-pt-with-r-r-follicular-lymphoma-fl/2024-06-21T17:43:12+00:00https://lymphoma-stg.clarovantdigital.com/library/real-world-bruton-tyrosine-kinase-inhibitor-treatment-patterns-and-outcomes-among-patients-with-chronic-lymphocytic-leukemia-or-small-lymphocytic-lymphoma-in-us-community-oncology-practices/2025-03-03T20:30:46+00:00https://lymphoma-stg.clarovantdigital.com/library/7-year-update-on-a-phase-2-trial-of-fixed-duration-obinutuzumab-ibrutinib-and-venetoclax-for-cll/2025-05-13T13:37:42+00:00https://lymphoma-stg.clarovantdigital.com/library/characteristics-associated-with-response-to-lisocabtagene-maraleucel-lisocel-in-patients-pts-with-r-r-cll-sll-exploratory-analyses-from-transcend-cll-004/2026-01-16T14:56:11+00:00https://lymphoma-stg.clarovantdigital.com/library/primary-analysis-of-the-phase-2-elm-2-study-odronextamab-in-patients-with-relapsed-refractory-follicular-lymphoma/2024-06-21T17:43:16+00:00https://lymphoma-stg.clarovantdigital.com/library/odronextamab-demonstrates-durable-complete-responses-in-patients-with-diffuse-large-b-cell-lymphoma-dlbcl-progressing-after-car-t-therapy-outcomes-from-the-elm-1-study-2/2024-06-21T17:43:17+00:00https://lymphoma-stg.clarovantdigital.com/library/feasibility-and-clinical-efficacy-of-atezolizumab-consolidation-in-high-risk-diffuse-large-b-cell-lymphoma-final-analysis-of-the-hovon-151/2024-06-21T17:43:18+00:00https://lymphoma-stg.clarovantdigital.com/library/health-related-quality-of-life-functioning-and-symptoms-with-odronextamab-monotherapy-in-patients-with-relapsed-or-refractory-follicular-lymphoma-by-pod24-status-in-the-elm-2-study/2024-06-21T17:43:19+00:00https://lymphoma-stg.clarovantdigital.com/library/real-world-analysis-of-glofitamab-for-relapsed-refractory-large-b-cell-lymphoma-in-germany-austria-and-switzerland/2024-06-21T17:43:20+00:00https://lymphoma-stg.clarovantdigital.com/library/glofitamab-monotherapy-in-patients-with-heavily-pretreated-relapsed-or-refractory-mantle-cell-lymphoma-updated-analysis-from-a-phase-i-ii-study/2024-06-21T17:43:21+00:00https://lymphoma-stg.clarovantdigital.com/library/response-adapted-treatment-with-mosunetuzumab-with-or-without-obinutuzumab-and-polatuzumab-vedotin-in-treatment-naive-follicular-and-marginal-zone-lymphoma-interim-results-and-phased-seq-mrd-analysis/2026-01-06T21:08:10+00:00https://lymphoma-stg.clarovantdigital.com/library/real-life-study-of-polatuzumab-vedotin-bendamustine-and-rituximab-for-stage-iv-high-intermediate-high-risk-dlbcl-or-indolent-transformed-in-relapsed-refractory-situation/2024-06-21T17:43:24+00:00https://lymphoma-stg.clarovantdigital.com/library/lisocabtagene-maraleucel-liso-cel-in-patients-pt-with-r-r-mantle-cell-lymphoma-mcl-subgroup-analyses-by-number-of-prior-systemic-lines-of-therapy-lot-and-by-response-to-prior-bruton-tyrosine/2024-06-21T17:43:25+00:00https://lymphoma-stg.clarovantdigital.com/library/high-efficacy-and-favorable-safety-of-cd20-targeted-car-t-therapy-for-btk-inhibitor-refractory-waldenstrom-macroglobulinemia-wm-lymphoplasmacytic-lymphoma-lpl/2024-06-21T17:43:26+00:00https://lymphoma-stg.clarovantdigital.com/library/novel-targets-and-advanced-therapies-in-diffuse-large-b-cell-lymphomas/2024-06-24T18:44:24+00:00https://lymphoma-stg.clarovantdigital.com/library/cost-effectiveness-of-brentuximab-vedotin-compared-with-conventional-chemotherapy-for-relapsed-or-refractory-classic-hodgkin-lymphoma-in-china/2024-06-24T18:48:32+00:00https://lymphoma-stg.clarovantdigital.com/library/real-world-evaluation-of-health-related-quality-of-life-in-patients-with-diffuse-large-b-cell-lymphoma-based-on-a-multinational-survey/2024-06-25T13:28:59+00:00https://lymphoma-stg.clarovantdigital.com/library/molecular-characterization-of-a-rare-case-of-high%e2%80%91grade-b%e2%80%91cell-lymphoma-with-myc-bcl2-bcl6-and-ccnd1-rearrangements/2024-06-25T17:44:58+00:00https://lymphoma-stg.clarovantdigital.com/library/social-deprivation-independently-impacts-clinical-outcomes-in-patients-with-chronic-lymphocytic-leukemia/2024-06-25T17:53:02+00:00https://lymphoma-stg.clarovantdigital.com/library/a-real-world-pharmacovigilance-study-of-polatuzumab-vedotin-based-on-the-fda-adverse-event-reporting-system-faers/2024-06-25T19:02:47+00:00https://lymphoma-stg.clarovantdigital.com/library/an-approach-to-anxiety-during-watch-and-wait-for-chronic-lymphocytic-leukemia-monitor-and-move-on/2024-06-28T19:12:21+00:00https://lymphoma-stg.clarovantdigital.com/library/non-hodgkins-anaplastic-large-t-cell-lymphoma-a-case-report/2024-06-28T19:17:56+00:00https://lymphoma-stg.clarovantdigital.com/library/lisocabtagene-maraleucel-liso-cel-vs-standard-of-care-soc-with-salvage-chemotherapy-ct-followed-by-autologous-stem-cell-transplantation-asct-as-second-line-2l-treatment-in-patients-pt-with/2024-06-28T19:17:58+00:00https://lymphoma-stg.clarovantdigital.com/library/quality-of-life-qol-in-patients-with-hematologic-malignancies-receiving-rituximab-biosimilars-results-from-a-real-world-setting/2024-06-28T19:17:58+00:00https://lymphoma-stg.clarovantdigital.com/library/comparative-efficacy-of-bruton-tyrosine-kinase-inhibitors-in-the-treatment-of-relapsed-refractory-chronic-lymphocytic-leukemia-a-network-meta-analysis-nma/2024-06-28T19:17:59+00:00https://lymphoma-stg.clarovantdigital.com/library/occurrence-of-secondary-non-hodgkin-lymphomas-among-our-classical-hodgkin-lymphoma-patients-a-single-centre-experience/2024-06-28T19:17:59+00:00https://lymphoma-stg.clarovantdigital.com/library/chimeric-antigen-receptor-t-cell-therapy-for-aggressive-b-cell-lymphomas/2024-07-02T19:14:26+00:00https://lymphoma-stg.clarovantdigital.com/library/hodgkin-lymphoma-in-children-a-16-year-experience-at-the-childrens-welfare-teaching-hospital-of-baghdad-iraq/2024-07-02T19:23:05+00:00https://lymphoma-stg.clarovantdigital.com/library/the-association-between-statin-use-and-non-hodgkin-lymphoma-a-systematic-review-and-meta-analysis/2024-07-02T19:27:33+00:00https://lymphoma-stg.clarovantdigital.com/library/a-comparison-of-clinical-profile-and-treatment-outcome-of-hodgkins-lymphoma-in-tanzania-according-to-hiv-status-during-the-haart-era/2024-07-04T11:15:46+00:00https://lymphoma-stg.clarovantdigital.com/library/decision-science-can-inform-clinical-trade-offs-regarding-cardiotoxic-cancer-treatments/2024-07-04T16:32:29+00:00https://lymphoma-stg.clarovantdigital.com/library/unraveling-the-immune-microenvironment-in-diffuse-large-b-cell-lymphoma-prognostic-and-potential-therapeutic-implications/2024-07-05T18:26:57+00:00https://lymphoma-stg.clarovantdigital.com/library/utility-of-targeted-sequencing-compared-to-fish-for-detection-of-chronic-lymphocytic-leukemia-copy-number-alterations/2024-07-05T18:32:06+00:00https://lymphoma-stg.clarovantdigital.com/library/ibrutinib-use-treatment-duration-and-concomitant-medications-in-australian-patients-with-relapsed-or-refractory-chronic-lymphocytic-leukaemia/2024-07-05T18:39:11+00:00https://lymphoma-stg.clarovantdigital.com/library/treatment-patterns-in-patients-with-mantle-cell-lymphoma-updated-report-of-the-asia-pacific-multinational-retrospective-registry-study/2024-07-05T18:39:14+00:00https://lymphoma-stg.clarovantdigital.com/library/tandem-versus-single-haematopoietic-stem-cell-transplant-and-bv-maintenance-in-relapsed-refractory-hodgkin-lymphoma-a-matched-cohort-analysis-from-the-lysa/2024-07-05T18:39:15+00:00https://lymphoma-stg.clarovantdigital.com/library/long-term-follow-up-of-lenalidomide-and-rituximab-as-initial-treatment-of-follicular-lymphoma/2024-07-05T18:39:16+00:00https://lymphoma-stg.clarovantdigital.com/library/efficacy-and-safety-of-ibrutinib-plus-venetoclax-in-patients-with-mantle-cell-lymphoma-mcl-and-tp53-mutations-in-the-sympatico-study/2024-07-05T18:39:17+00:00https://lymphoma-stg.clarovantdigital.com/library/real-world-use-and-acceptance-of-rituximab-biosimilars-in-non-hodgkin-lymphoma-in-an-oncologist-network-in-germany/2024-07-05T18:39:18+00:00https://lymphoma-stg.clarovantdigital.com/library/remission-with-radiation-therapy-in-primary-tongue-mucosa-associated-lymphoid-tissue-lymphoma-a-case-report/2024-07-05T18:39:19+00:00https://lymphoma-stg.clarovantdigital.com/library/orelabrutinib-fludarabine-cyclophosphamide-and-obinutuzumab-ofcg-for-first-line-treatment-of-chronic-lymphocytic-leukemia-a-multicenter-investigator-initiated-study-cwcll-001-study/2024-07-05T18:39:20+00:00https://lymphoma-stg.clarovantdigital.com/library/efficacy-and-safety-of-mil62-a-novel-glycoengineered-type-anti-cd20-monoclonal-antibody-combined-with-lenalidomide-in-patients-with-relapsed-refractory-follicular-lymphoma-or-marginal-zone-lymphom/2024-07-05T20:19:26+00:00https://lymphoma-stg.clarovantdigital.com/library/hematopoietic-stem-cell-transplantation-for-dlbcl-a-report-from-the-european-society-for-blood-and-marrow-transplantation-on-more-than-40000-patients-over-32-years/2024-07-05T18:39:22+00:00https://lymphoma-stg.clarovantdigital.com/library/nivolumab-and-brentuximab-vedotin-with-or-without-bendamustine-for-r-r-hodgkin-lymphoma-in-children-adolescents-and-young-adults/2024-07-05T18:39:23+00:00https://lymphoma-stg.clarovantdigital.com/library/posterior-uveitis-in-ocular-involving-chronic-lymphocytic-leukemia-and-the-utility-of-negative-myd88-l265p-testing-in-the-diagnosis/2024-07-08T20:22:42+00:00https://lymphoma-stg.clarovantdigital.com/library/infections-in-patients-with-mantle-cell-lymphoma/2024-07-08T20:35:36+00:00https://lymphoma-stg.clarovantdigital.com/library/effects-of-supervised-exercise-program-on-rituximab-induced-lung-toxicity-in-follicular-lymphoma-a-case-report/2024-07-08T20:41:34+00:00https://lymphoma-stg.clarovantdigital.com/library/loncastuximab-tesirine-in-the-treatment-of-relapsed-or-refractory-diffuse-large-b-cell-lymphoma/2024-07-10T18:35:21+00:00https://lymphoma-stg.clarovantdigital.com/library/efficacy-and-safety-of-first-versus-second-generation-bruton-tyrosine-kinase-inhibitors-in-chronic-lymphocytic-leukemia-a-systematic-review-and-meta-analysis/2024-07-10T18:39:47+00:00https://lymphoma-stg.clarovantdigital.com/library/treatment-outcomes-in-patients-with-conjunctival-mucosa-associated-lymphoid-tissue-malt-lymphoma/2024-07-10T19:46:02+00:00https://lymphoma-stg.clarovantdigital.com/library/late-events-after-anti-cd19-car-t-cell-therapy-for-relapsed-refractory-b-cell-non-hodgkin-lymphoma/2024-07-10T20:09:42+00:00https://lymphoma-stg.clarovantdigital.com/library/chemotherapys-effects-on-autophagy-in-the-treatment-of-hodgkins-lymphoma-a-scoping-review/2024-07-10T20:13:44+00:00https://lymphoma-stg.clarovantdigital.com/library/characterization-of-zanubrutinib-safety-and-tolerability-profile-and-comparison-with-ibrutinib-safety-profile-in-patients-with-b-cell-malignancies-post-hoc-analysis-of-a-large-clinical-trial-safety-d/2024-07-10T23:31:14+00:00https://lymphoma-stg.clarovantdigital.com/library/assessing-the-efficacy-and-tolerability-of-pet-guided-brecadd-versus-ebeacopp-in-advanced-stage-classical-hodgkin-lymphoma-hd21-a-randomised-multicentre-parallel-open-label-phase-3-trial/2024-07-12T17:04:33+00:00https://lymphoma-stg.clarovantdigital.com/library/efficacy-of-idelalisib-and-rituximab-in-relapsed-refractory-chronic-lymphocytic-leukemia-treated-outside-of-clinical-trials-a-report-of-the-gimema-working-group/2024-07-12T17:04:37+00:00https://lymphoma-stg.clarovantdigital.com/library/clinical-practice-recommendations-for-hematopoietic-cell-transplantation-and-cellular-therapies-in-follicular-lymphoma-a-collaborative-effort-on-behalf-of-the-american-society-of-transplantation-and/2024-07-12T17:04:37+00:00https://lymphoma-stg.clarovantdigital.com/library/a-retrospective-observational-study-of-ibrutinib-in-chronic-lymphocytic-leukaemia-in-a-real-life-setting-in-france-using-the-national-claims-database-osiris/2024-07-12T17:04:38+00:00https://lymphoma-stg.clarovantdigital.com/library/autologous-transplant-vs-car-t-therapy-in-patients-with-dlbcl-treated-while-in-complete-remission/2024-07-12T17:04:38+00:00https://lymphoma-stg.clarovantdigital.com/library/real-world-treatment-patterns-and-outcomes-for-patients-with-cll-using-the-australian-pharmaceutical-benefits-scheme-pbs-dataset/2024-07-12T17:04:39+00:00https://lymphoma-stg.clarovantdigital.com/library/central-nervous-system-involvement-in-chronic-lymphocytic-leukemia-a-case-report-and-review-of-literature/2024-07-12T17:04:40+00:00https://lymphoma-stg.clarovantdigital.com/library/lisocabtagene-maraleucel-in-follicular-lymphoma-the-phase-2-transcend-fl-study/2026-01-14T22:07:22+00:00https://lymphoma-stg.clarovantdigital.com/library/outcomes-in-high-risk-subgroups-after-fixed-duration-ibrutinib-venetoclax-for-chronic-lymphocytic-leukemia-cll-small-lymphocytic-lymphoma-sll-up-to-5-5-years-of-follow-up-in-the-phase-2-captiva/2025-05-23T19:13:17+00:00https://lymphoma-stg.clarovantdigital.com/library/fixed-duration-pirtobrutinib-plus-venetoclax-with-or-without-rituximab-in-relapsed-refractory-cll-phase-1b-bruin-trial/2024-07-15T15:23:43+00:00https://lymphoma-stg.clarovantdigital.com/library/cost-utility-analysis-of-second-line-axicabtagene-ciloleucel-versus-standard-of-care-in-japan-based-on-the-zuma-7-trial/2024-07-15T15:42:04+00:00https://lymphoma-stg.clarovantdigital.com/library/clinical-benefit-reimbursement-outcomes-and-prices-of-fda-approved-cancer-drugs-reviewed-through-project-orbis-in-the-usa-canada-england-and-scotland-a-retrospective-comparative-analysis/2024-07-17T17:28:51+00:00https://lymphoma-stg.clarovantdigital.com/library/venetoclax-obinutuzumab-for-previously-untreated-chronic-lymphocytic-leukemia-6-year-results-of-the-phase-3-cll14-study/2024-07-17T19:03:00+00:00https://lymphoma-stg.clarovantdigital.com/library/characteristics-of-relapsed-and-refractory-paediatric-hodgkin-lymphoma-a-10-year-retrospective-study-of-an-lmic/2024-07-17T19:21:04+00:00https://lymphoma-stg.clarovantdigital.com/library/a-systematic-review-and-meta-analysis-on-utilizing-anti-cd19-chimeric-antigen-receptor-t-cell-therapy-as-a-second-line-treatment-for-relapsed-and-refractory-diffuse-large-b-cell-lymphoma/2024-07-22T14:39:25+00:00https://lymphoma-stg.clarovantdigital.com/library/chidamide-beac-plus-autologous-stem-cell-transplantation-in-high-risk-non-hodgkin-lymphoma-a-phase-ii-clinical-trial/2024-07-22T14:49:45+00:00https://lymphoma-stg.clarovantdigital.com/library/sequencing-of-cellular-therapy-and-bispecific-antibodies-for-the-management-of-diffuse-large-b-cell-lymphoma/2024-07-22T14:54:33+00:00https://lymphoma-stg.clarovantdigital.com/library/healthcare-utilization-and-costs-in-frail-versus-non-frail-patients-with-diffuse-large-b-cell-lymphoma/2024-07-24T21:38:38+00:00https://lymphoma-stg.clarovantdigital.com/library/understanding-the-interplay-between-chronic-lymphocytic-leukemia-and-type-2-diabetes/2024-07-24T21:42:19+00:00https://lymphoma-stg.clarovantdigital.com/library/optimization-of-older-adults-by-a-geriatric-assessment-guided-multidisciplinary-clinic-before-car-t-cell-therapy/2024-07-24T21:45:56+00:00https://lymphoma-stg.clarovantdigital.com/library/optimizing-the-post-car-t-monitoring-period-for-axicabtagene-ciloleucel-tisagenlecleucel-and-lisocabtagene-maraleucel/2024-07-26T12:34:35+00:00https://lymphoma-stg.clarovantdigital.com/library/possible-role-of-a-malfunctioning-immune-system-in-discordant-lymphoma-with-peripheral-t%e2%80%91cell-lymphoma-secondary-to-classical-hodgkin-lymphoma-a-case-report/2024-07-26T12:38:14+00:00https://lymphoma-stg.clarovantdigital.com/library/mosunetuzumab-demonstrates-clinically-meaningful-outcomes-in-high-risk-patients-with-heavily-pre-treated-r-r-fl-after-3-years-of-follow-up-subgroup-analysis-of-a-pivotal-phase-ii-study/2024-07-26T17:47:54+00:00https://lymphoma-stg.clarovantdigital.com/library/sequencing-of-anti-cd19-therapies-in-the-management-of-diffuse-large-b-cell-lymphoma-2/2024-07-26T17:47:57+00:00https://lymphoma-stg.clarovantdigital.com/library/real-world-outcomes-with-novel-therapies-in-relapsed-refractory-diffuse-large-b-cell-lymphoma/2024-07-26T17:48:00+00:00https://lymphoma-stg.clarovantdigital.com/library/advances-in-biology-diagnosis-and-treatment-of-dlbcl/2024-07-26T17:48:01+00:00https://lymphoma-stg.clarovantdigital.com/library/the-evaluation-of-risk-factors-for-prolonged-viral-shedding-during-anti-sars-cov-2-monoclonal-antibodies-and-long-term-administration-of-antivirals-in-covid-19-patients-with-b-cell-lymphoma-treated-by/2024-07-26T17:48:03+00:00https://lymphoma-stg.clarovantdigital.com/library/clinicopathological-characteristics-local-treatment-and-prognostic-factors-in-ie-iie-primary-breast-lymphoma-a-retrospective-study-of-67-patients/2025-05-27T12:21:30+00:00https://lymphoma-stg.clarovantdigital.com/library/a-64-year-old-male-with-primary-diffuse-renal-large-b-cell-non-hodgkin-lymphoma-a-rare-case-report/2024-07-26T17:48:06+00:00https://lymphoma-stg.clarovantdigital.com/library/real-life-clinical-outcomes-of-relapsed-refractory-diffuse-large-b-cell-lymphoma-in-the-rituximab-era-the-strider-study/2024-07-26T17:48:07+00:00https://lymphoma-stg.clarovantdigital.com/library/health-equity-principles-for-oncology-real-world-evidence-studies/2024-07-26T17:48:09+00:00https://lymphoma-stg.clarovantdigital.com/library/primary-diffuse-large-b-cell-lymphoma-of-the-central-nervous-system-identified-with-csf-biomarkers/2024-07-26T17:48:10+00:00https://lymphoma-stg.clarovantdigital.com/library/exposure-to-obinutuzumab-does-not-affect-outcomes-of-sars-cov-2-infection-in-vaccinated-patients-with-newly-diagnosed-advanced-stage-follicular-lymphoma/2024-07-26T17:48:12+00:00https://lymphoma-stg.clarovantdigital.com/library/toward-a-paradigm-shift-in-prognostication-and-treatment-of-early-stage-hodgkin-lymphoma/2025-05-27T12:22:08+00:00https://lymphoma-stg.clarovantdigital.com/library/network-meta-analysis-of-upfront-fixed-duration-therapies-in-chronic-lymphocytic-leukemia/2024-07-26T17:48:15+00:00https://lymphoma-stg.clarovantdigital.com/library/brentuximab-vedotin-in-combination-with-lenalidomide-and-rituximab-in-patients-with-relapsed-refractory-diffuse-large-b-cell-lymphoma-results-from-the-phase-3-echelon-3-study/2024-07-26T17:48:17+00:00https://lymphoma-stg.clarovantdigital.com/library/automated-lugano-metabolic-response-assessment-in-18f-fluorodeoxyglucose-avid-non-hodgkin-lymphoma-with-deep-learning-on-18f-fluorodeoxyglucose-positron-emission-tomography/2024-07-26T17:48:18+00:00https://lymphoma-stg.clarovantdigital.com/library/assessment-for-acceleration-and-transformation-of-chronic-lymphocytic-leukemia-small-lymphocytic-lymphoma-using-histologic-and-immunohistochemical-features-a-case-series/2025-03-03T19:32:27+00:00https://lymphoma-stg.clarovantdigital.com/library/promising-immunotherapeutic-approaches-for-primary-effusion-lymphoma/2024-07-30T14:41:12+00:00https://lymphoma-stg.clarovantdigital.com/library/identifying-relevant-factors-influencing-cancer-related-fatigue-in-patients-with-diffuse-large-b-cell-lymphoma-during-chemotherapy/2024-07-30T14:47:25+00:00https://lymphoma-stg.clarovantdigital.com/library/relapsed-gray-zone-lymphoma-a-rare-clinical-challenge/2024-07-30T15:55:06+00:00https://lymphoma-stg.clarovantdigital.com/library/assay-guided-treatment-sequencing-in-chronic-lymphocytic-leukemia-cll-a-cost-effectiveness-analysis/2024-07-30T15:55:12+00:00https://lymphoma-stg.clarovantdigital.com/library/correlation-between-the-hepatitis-c-virus-ns3-protein-and-cd30-expression-in-diffuse-large-b-cell-lymphoma/2024-07-30T15:55:13+00:00https://lymphoma-stg.clarovantdigital.com/library/primary-hodgkin-lymphoma-of-the-breast-a-case-report-and-literature-review-examining-the-use-of-different-chemotherapy-regimens/2024-07-30T15:55:15+00:00https://lymphoma-stg.clarovantdigital.com/library/plasma-circulating-tumour-dna-is-a-better-source-for-diagnosis-and-mutational-analysis-of-ivlbcl-than-tissue-dna/2024-07-30T15:55:16+00:00https://lymphoma-stg.clarovantdigital.com/library/the-impact-of-anemia-on-the-survival-of-patients-diagnosed-with-low-grade-malignant-b-cell-lymphomas/2024-07-30T15:55:17+00:00https://lymphoma-stg.clarovantdigital.com/library/assessment-of-circulating-free-dna-as-a-non-invasive-biomarker-for-diffuse-large-b-cell-lymphoma-in-egyptian-patients/2024-07-30T15:55:19+00:00https://lymphoma-stg.clarovantdigital.com/library/a-generic-model-for-follicular-lymphoma-predicting-cost-life-expectancy-and-quality-adjusted-life-year-using-uk-population-based-observational-data/2025-12-15T22:17:38+00:00https://lymphoma-stg.clarovantdigital.com/library/real-world-incidence-and-prevention-of-tumor-lysis-syndrome-in-chronic-lymphocytic-leukemia-treated-with-venetoclax/2024-08-13T00:11:58+00:00https://lymphoma-stg.clarovantdigital.com/library/effect-of-vitamin-d-and-skeletal-muscle-mass-on-prognosis-of-patients-with-diffuse-large-b-cell-lymphoma/2024-08-13T00:19:18+00:00https://lymphoma-stg.clarovantdigital.com/library/characteristics-and-clinical-value-of-myc-bcl2-and-bcl6-rearrangement-detected-by-next-generation-sequencing-in-dlbcl/2024-08-13T13:51:46+00:00https://lymphoma-stg.clarovantdigital.com/library/prognostic-value-of-lactate-dehydrogenase-to-absolute-lymphocyte-count-ratio-and-albumin-to-fibrinogen-ratio-in-diffuse-large-b-cell-lymphoma/2024-08-13T14:10:12+00:00https://lymphoma-stg.clarovantdigital.com/library/cd49d-expression-is-included-in-a-revised-4%e2%80%90factor-model-predicting-outcome-in-patients-with-chronic-lymphocytic-leukemia-treated-with-ibrutinib-a-multicenter-real%e2%80%90world-experience/2024-08-13T15:30:50+00:00https://lymphoma-stg.clarovantdigital.com/library/applications-of-multimodal-artificial-intelligence-in-non-hodgkin-lymphoma-b-cells/2024-08-13T15:34:56+00:00https://lymphoma-stg.clarovantdigital.com/library/clinico-pathologic-profile-of-filipino-patients-diagnosed-with-diffuse-large-b-cell-lymphoma-germinal-center-or-non-germinal-center-subtype-treated-in-a-public-tertiary-hospital-from-2016-to-2021/2024-08-13T15:49:14+00:00https://lymphoma-stg.clarovantdigital.com/library/distressed-personality-is-associated-with-late-adverse-effects-in-long-term-survivors-of-hodgkin-lymphoma/2024-08-13T15:58:07+00:00https://lymphoma-stg.clarovantdigital.com/library/radiation-exposure-of-the-glandular-mammary-tissue-in-womenpatients-with-mediastinal-hodgkin-lymphoma-treated-with-protons/2024-08-13T16:03:14+00:00https://lymphoma-stg.clarovantdigital.com/library/prospective-therapeutic-studies-of-disseminated-extranodal-large-b-cell-lymphoma-including-intravascular-large-b-cell-lymphoma/2024-08-13T16:11:07+00:00https://lymphoma-stg.clarovantdigital.com/library/risk-of-transformation-by-frontline-management-in-follicular-and-marginal-zone-lymphomas-a-us-population-based-analysis/2024-08-13T16:16:01+00:00https://lymphoma-stg.clarovantdigital.com/library/clinical-and-biomarker-characteristic-of-lymphoma-patients-in-hasan-sadikin-lymphoma-registry/2024-08-13T17:57:29+00:00https://lymphoma-stg.clarovantdigital.com/library/pd-1-inhibitor-in-the-treatment-of-relapsed-primary-mediastinal-large-b-cell-lymphoma-follow-up-by-18-f-fdg-pet-ct-a-case-report-and-literature-review/2024-08-13T18:04:29+00:00https://lymphoma-stg.clarovantdigital.com/library/modeling-historic-environmental-pollutant-exposures-and-non-hodgkin-lymphoma-risk/2024-08-13T18:10:14+00:00https://lymphoma-stg.clarovantdigital.com/library/re-examining-the-role-of-hematopoietic-stem-cell-transplantation-in-relapsed-large-b-cell-lymphoma-in-the-era-of-chimeric-antigen-receptor-car-t-cell-therapy/2024-08-15T19:32:30+00:00https://lymphoma-stg.clarovantdigital.com/library/association-of-mthfr-gene-polymorphisms-with-non-hodgkin-lymphoma-risk-evidence-from-31-articles/2024-08-16T10:36:55+00:00https://lymphoma-stg.clarovantdigital.com/library/suicide-attempt-and-suicide-death-among-spouses-of-patients-with-cancer/2024-08-16T13:44:49+00:00https://lymphoma-stg.clarovantdigital.com/library/cytokine-release-syndrome-after-chimeric-antigen-receptor-t-cell-therapy-in-patients-with-diffuse-large-b-cell-lymphoma-a-systematic-review/2024-08-16T18:08:30+00:00https://lymphoma-stg.clarovantdigital.com/library/clinical-relevance-of-brain-mri-changes-in-primary-central-nervous-system-lymphoma-after-high-dose-chemotherapy-and-autologous-stem-cell-transplantation/2024-08-16T18:16:41+00:00https://lymphoma-stg.clarovantdigital.com/library/blinatumomab-after-r-chop-bridging-therapy-for-patients-with-richter-transformation-a-phase-2-multicentre-trial/2024-08-16T18:16:44+00:00https://lymphoma-stg.clarovantdigital.com/library/efficacy-and-safety-of-bendamustine-rituximab-as-frontline-therapy-for-indolent-non-hodgkin-lymphoma-a-real-world-single-center-retrospective-study/2026-01-16T14:51:45+00:00https://lymphoma-stg.clarovantdigital.com/library/safety-and-activity-of-lenalidomide-in-combination-with-obinutuzumab-in-patients-with-relapsed-indolent-non-hodgkin-lymphoma-a-single-group-open-label-phase-1-2-trial/2024-08-16T18:16:47+00:00https://lymphoma-stg.clarovantdigital.com/library/prolonged-responses-in-central-nervous-system-relapsed-diffuse-large-b-cell-lymphoma-after-chimeric-antigen-receptor-t-cell-therapy-using-targeted-treatments/2024-08-16T18:16:48+00:00https://lymphoma-stg.clarovantdigital.com/library/the-pi3k-inhibitor-zandelisib-on-intermittent-dosing-in-relapsed-refractory-follicular-lymphoma-results-from-a-global-phase-2-study/2024-08-16T18:16:50+00:00https://lymphoma-stg.clarovantdigital.com/library/identification-of-genetic-subtypes-in-follicular-lymphoma/2024-08-16T18:16:51+00:00https://lymphoma-stg.clarovantdigital.com/library/novel-prognostic-scoring-systems-for-severe-crs-and-icans-after-anti-cd19-car-t-cells-in-large-b-cell-lymphoma/2024-08-16T18:16:52+00:00https://lymphoma-stg.clarovantdigital.com/library/single-gene-mutations-and-prognosis-in-limited-stage-follicular-lymphoma-treated-with-radiation-therapy/2025-05-27T12:22:43+00:00https://lymphoma-stg.clarovantdigital.com/library/real-world-data-mcl2-protocol-demonstrates-excellent-treatment-results-among-patients-with-mantle-cell-lymphoma-not-fulfilling-the-original-trial-inclusion-criteria/2024-08-16T18:16:55+00:00https://lymphoma-stg.clarovantdigital.com/library/treatment-adherence-and-adverse-event-management-in-chronic-lymphocytic-leukemia-challenges-and-strategies-for-the-future/2024-08-16T18:16:56+00:00https://lymphoma-stg.clarovantdigital.com/library/waldenstroms-macroglobulinemia-an-overview/2024-08-16T18:16:58+00:00https://lymphoma-stg.clarovantdigital.com/library/central-nervous-system-prophylaxis-in-large-b-cell-lymphoma-a-british-society-for-haematology-good-practice-paper/2024-08-16T18:16:59+00:00https://lymphoma-stg.clarovantdigital.com/library/feasibility-of-collecting-longitudinal-patient-reported-outcomes-in-individuals-with-relapsed-or-refractory-large-b-cell-lymphoma-who-received-chimeric-antigen-receptor-t-cell-cart-therapy/2024-08-16T18:17:00+00:00https://lymphoma-stg.clarovantdigital.com/library/safety-and-efficacy-of-odronextamab-in-patients-with-relapsed-or-refractory-follicular-lymphoma/2025-06-12T19:28:07+00:00https://lymphoma-stg.clarovantdigital.com/library/knowledge-skills-and-confidence-gaps-impacting-treatment-decision-making-in-relapsed-refractory-chronic-lymphocytic-leukemia-and-mantle-cell-lymphoma-a-quantitative-survey-study-in-france-germany/2024-08-16T18:17:04+00:00https://lymphoma-stg.clarovantdigital.com/library/increased-risk-of-cutaneous-t-cell-lymphoma-development-after-dupilumab-use-for-atopic-dermatitis/2024-08-16T18:17:06+00:00https://lymphoma-stg.clarovantdigital.com/library/identify-truly-high-risk-tp53-mutated-diffuse-large-b-cell-lymphoma-patients-and-explore-the-underlying-biological-mechanisms/2024-08-16T18:17:07+00:00https://lymphoma-stg.clarovantdigital.com/library/comparisons-of-treatment-outcomes-of-epcoritamab-versus-chemoimmunotherapy-polatuzumab-based-regimens-tafasitamab-based-regimens-or-chimeric-antigen-receptor-t-cell-therapy-in-third-line-or-later/2026-01-14T19:34:07+00:00https://lymphoma-stg.clarovantdigital.com/library/outcomes-of-covid-19-infection-in-patients-with-chronic-lymphocytic-leukemia-a-systematic-review-and-meta-analysis/2024-08-19T13:03:13+00:00https://lymphoma-stg.clarovantdigital.com/library/prevalence-of-non-hodgkin-lymphoma-patients-at-high-risk-of-failure-after-car-t-cell-therapy-eligible-for-bridging-radiation-therapy/2024-08-19T13:17:46+00:00https://lymphoma-stg.clarovantdigital.com/library/car-t-therapy-pulmonary-adverse-event-profile-a-pharmacovigilance-study-based-on-faers-database-2017-2023/2025-01-28T20:45:22+00:00https://lymphoma-stg.clarovantdigital.com/library/symptomatic-osteonecrosis-in-children-treated-for-hodgkin-lymphoma-a-population-based-study-in-sweden-finland-and-denmark/2024-08-23T17:33:17+00:00https://lymphoma-stg.clarovantdigital.com/library/atrial-fibrillation-burden-and-clinical-outcomes-following-btk-inhibitor-initiation/2025-04-15T14:07:21+00:00https://lymphoma-stg.clarovantdigital.com/library/real-world-results-of-car-t-cell-therapy-for-large-b-cell-lymphoma-with-cns-involvement-a-gla-drst-study/2024-08-23T17:33:23+00:00https://lymphoma-stg.clarovantdigital.com/library/survival-of-patients-with-classical-hodgkin-lymphoma-in-finland-a-national-population-based-analysis/2024-08-23T17:33:24+00:00https://lymphoma-stg.clarovantdigital.com/library/infections-and-their-prognostic-significance-before-diagnosis-of-chronic-lymphocytic-leukemia-non-hodgkin-lymphoma-or-multiple-myeloma/2024-08-23T17:33:25+00:00https://lymphoma-stg.clarovantdigital.com/library/venetoclax-treatment-for-chronic-lymphocytic-leukemia-small-lymphocytic-leukemia-in-japan-post-marketing-surveillance/2025-05-13T13:36:38+00:00https://lymphoma-stg.clarovantdigital.com/library/survival-with-axicabtagene-ciloleucel-in-large-b-cell-lymphoma/2024-08-23T17:33:28+00:00https://lymphoma-stg.clarovantdigital.com/library/current-and-future-therapies-for-follicular-lymphoma/2024-08-23T17:33:29+00:00https://lymphoma-stg.clarovantdigital.com/library/real-life-data-a-retrospective-report-from-romania-hodgkin-lymphoma-registry-single-center-experience/2024-08-27T16:16:31+00:00https://lymphoma-stg.clarovantdigital.com/library/outcome-of-large-b-cell-lymphoma-patients-treated-with-tafasitamab-plus-lenalidomide-either-before-or-after-car-t-cells/2024-08-27T16:23:11+00:00https://lymphoma-stg.clarovantdigital.com/library/the-safety-of-novel-therapies-in-chronic-lymphocytic-leukemia-in-the-era-of-intermittent-fasting-a-pharmacology-based-review/2025-12-28T19:37:51+00:00https://lymphoma-stg.clarovantdigital.com/library/association-of-race-ethnicity-and-insurance-with-survival-in-patients-with-diffuse-large-b-cell-lymphoma-in-a-large-real-world-cohort/2025-12-19T18:36:31+00:00https://lymphoma-stg.clarovantdigital.com/library/tazemetostat-for-relapsed-refractory-b-cell-non-hodgkin-lymphoma-with-ezh2-mutation-in-japan-3-year-follow-up-for-a-phase-ii-study/2025-12-19T20:56:01+00:00https://lymphoma-stg.clarovantdigital.com/library/hl-365-demographic-analysis-of-survival-trends-in-extranodal-hodgkin-lymphoma-a-population-based-study/2025-12-19T20:55:04+00:00https://lymphoma-stg.clarovantdigital.com/library/abcl-309-survival-disparities-among-indolent-and-aggressive-non-hodgkin-lymphomas-in-armenia/2025-12-19T20:36:52+00:00https://lymphoma-stg.clarovantdigital.com/library/third-generation-anti-cd19-car-t-cells-for-relapsed-refractory-chronic-lymphocytic-leukemia-a-phase-1-2-study/2025-12-19T20:34:42+00:00https://lymphoma-stg.clarovantdigital.com/library/ibcl-383-follicular-lymphoma-impact-of-complete-response-on-outcomes-in-fl-a-tertiary-care-analysis/2025-12-19T20:33:35+00:00https://lymphoma-stg.clarovantdigital.com/library/ibcl-271-clinical-outcomes-of-patients-with-relapsed-refractory-follicular-lymphoma-r-r-fl-treated-with-tisagenlecleucel-phase-2-elara-3-year-follow-up/2025-12-19T20:32:33+00:00https://lymphoma-stg.clarovantdigital.com/library/radiological-follow-up-of-osteonecrosis-lesions-in-children-and-adolescents-with-hodgkin-lymphoma/2025-12-19T20:31:42+00:00https://lymphoma-stg.clarovantdigital.com/library/vitamin-d-supplement-for-patients-with-early-stage-chronic-lymphocytic-leukemia-is-associated-with-a-longer-time-to-first-treatment/2025-12-19T20:30:51+00:00https://lymphoma-stg.clarovantdigital.com/library/the-biosimilar-revolution-assessing-the-european-unions-approach-to-biosimilarity-interchangeability-patient-access-and-its-market-analysis/2025-12-19T20:29:42+00:00https://lymphoma-stg.clarovantdigital.com/library/waldenstrom-macroglobulinaemia-lymphoma-patients-have-impaired-platelet-and-coagulation-function/2025-12-28T19:34:57+00:00https://lymphoma-stg.clarovantdigital.com/library/magrolimab-plus-rituximab-in-relapsed-refractory-indolent-non-hodgkin-lymphoma-phase-1-2-trial-3-year-follow-up/2025-12-28T19:31:50+00:00https://lymphoma-stg.clarovantdigital.com/library/autologous-stem-cell-transplantation-in-t-cell-histiocyte-rich-large-b-cell-lymphoma-ebmt-lymphoma-working-party-study/2025-12-28T19:28:30+00:00https://lymphoma-stg.clarovantdigital.com/library/evaluation-of-prognostic-factors-for-high-risk-classical-hodgkin-lymphoma-undergoing-autologous-transplantation/2025-12-28T19:25:30+00:00https://lymphoma-stg.clarovantdigital.com/library/systemic-diffuse-large-b-cell-lymphoma-involving-the-central-nervous-system-has-high-rates-of-defective-antigen-presentation-and-immune-surveillance/2025-12-28T19:22:52+00:00https://lymphoma-stg.clarovantdigital.com/library/the-immune-response-to-covid-19-mrna-vaccination-among-lymphoma-patients-receiving-anti-cd20-treatment/2026-01-15T16:38:08+00:00https://lymphoma-stg.clarovantdigital.com/library/safety-and-efficacy-of-acalabrutinib-plus-bendamustine-and-rituximab-in-patients-with-treatment-naive-or-relapsed-refractory-mantle-cell-lymphoma-phase-ib-trial/2025-12-28T19:17:23+00:00https://lymphoma-stg.clarovantdigital.com/library/nodular-lymphocyte-predominant-hodgkin-lymphoma-advances-in-disease-biology-risk-stratification-and-treatment/2025-12-28T19:14:41+00:00https://lymphoma-stg.clarovantdigital.com/library/chidamide-plus-r-gdp-for-relapsed-refractory-diffuse-large-b-cell-lymphoma-in-patients-ineligible-for-autologous-transplantation-a-prospective-single-arm-phase-ii-study/2025-12-19T20:28:56+00:00https://lymphoma-stg.clarovantdigital.com/library/medical-history-and-lifestyle-factors-have-limited-impact-on-time-to-first-treatment-in-patients-with-chronic-lymphocytic-leukemia/2025-12-19T20:28:13+00:00https://lymphoma-stg.clarovantdigital.com/library/occupational-exposure-to-benzene-and-risk-of-non-hodgkin-lymphoma-in-an-extended-follow-up-of-two-population-based-prospective-cohorts-of-chinese-men-and-women/2025-12-19T20:27:27+00:00https://lymphoma-stg.clarovantdigital.com/library/sintilimab-anti-pd-1-antibody-combined-with-high-dose-methotrexate-temozolomide-and-rituximab-anti-cd20-antibody-in-primary-central-nervous-system-lymphoma-a-phase-2-study/2025-12-19T20:26:32+00:00https://lymphoma-stg.clarovantdigital.com/library/adult-hodgkin-lymphoma-incidence-trends-in-the-united-states-from-2000-to-2020/2026-01-20T19:41:58+00:00https://lymphoma-stg.clarovantdigital.com/library/acalabrutinib-plus-venetoclax-and-rituximab-in-treatment-naive-mantle-cell-lymphoma-2-year-safety-and-efficacy-analysis-2/2025-05-14T18:58:55+00:00https://lymphoma-stg.clarovantdigital.com/library/implicit-flow-cytometric-diagnosis-of-classic-hodgkin-lymphoma-using-cd3cd4cd26-t-cells/2025-12-19T20:24:47+00:00https://lymphoma-stg.clarovantdigital.com/library/chimeric-antigen-receptor-t-cell-therapy-in-relapsed-or-refractory-mantle-cell-lymphoma-a-systematic-review-and-meta-analysis/2025-12-28T19:11:52+00:00https://lymphoma-stg.clarovantdigital.com/library/valemetostat-demonstrates-clinically-meaningful-efficacy-in-r-r-ptcl/2025-12-19T20:23:35+00:00https://lymphoma-stg.clarovantdigital.com/library/cll-184-characteristics-associated-with-response-to-lisocabtagene-maraleucel-liso-cel-in-patients-with-r-r-cll-sll-exploratory-analyses-from-the-phase-1-2-transcend-cll-004-study/2025-03-03T20:23:06+00:00https://lymphoma-stg.clarovantdigital.com/library/safety-and-efficacy-of-bispecific-antibodies-in-adults-with-large-b-cell-lymphomas-a-systematic-review-of-clinical-trial-data/2026-01-14T19:33:34+00:00https://lymphoma-stg.clarovantdigital.com/library/loncastuximab-tesirine-in-chinese-patients-with-relapsed-or-refractory-diffuse-large-b-cell-lymphoma-a-multicenter-open-label-single-arm-phase-ii-trial/2025-12-28T18:54:48+00:00https://lymphoma-stg.clarovantdigital.com/library/network-meta-analysis-of-novel-targeted-therapies-for-relapsed-refractory-chronic-lymphocytic-leukemia/2025-12-28T18:49:46+00:00https://lymphoma-stg.clarovantdigital.com/library/identification-of-early-predictive-biomarkers-for-severe-cytokine-release-syndrome-in-pediatric-patients-with-chimeric-antigen-receptor-t-cell-therapy/2025-12-28T18:30:59+00:00https://lymphoma-stg.clarovantdigital.com/library/ibrutinib-plus-rituximab-and-mini-chop-in-very-elderly-patients-with-newly-diagnosed-dlbcl-a-phase-ii-allg-study/2025-12-28T18:23:15+00:00https://lymphoma-stg.clarovantdigital.com/library/outcomes-of-covid-19-in-patients-with-obinutuzumab-compared-with-patients-with-rituximab-a-retrospective-cohort-study/2025-12-19T20:22:28+00:00https://lymphoma-stg.clarovantdigital.com/library/ibcl-523-comparative-efficacy-safety-and-cost-effectiveness-of-subcutaneous-versus-intravenous-rituximab-in-non-hodgkin-lymphoma-a-systematic-review-and-meta-analysis/2025-12-19T20:16:28+00:00https://lymphoma-stg.clarovantdigital.com/library/durable-remission-of-refractory-and-advanced-stage-mycosis-fungoides-sezary-syndrome-utilizing-an-outpatient-alemtuzumab-fludarabine-based-reduced-intensity-allogeneic-hematopoietic-cell-transplantat/2025-12-19T20:15:37+00:00https://lymphoma-stg.clarovantdigital.com/library/esmo-clinical-practice-guideline-interim-update-on-new-targeted-therapies-in-the-first-line-and-at-relapse-of-chronic-lymphocytic-leukaemia/2026-01-02T14:43:54+00:00https://lymphoma-stg.clarovantdigital.com/library/impact-of-positive-cd4-cells-on-event-free-survival-in-follicular-lymphoma-patients/2025-12-19T20:11:20+00:00https://lymphoma-stg.clarovantdigital.com/library/several-factors-that-predict-the-outcome-of-large-b-cell-lymphoma-patients-who-relapse-progress-after-chimeric-antigen-receptor-car-t-cell-therapy-can-be-identified-before-cell-administration/2025-12-19T19:49:11+00:00https://lymphoma-stg.clarovantdigital.com/library/atezolizumab-venetoclax-and-obinutuzumab-combination-in-richter-transformation-diffuse-large-b-cell-lymphoma-molto-a-multicentre-single-arm-phase-2-trial/2026-01-20T19:16:11+00:00https://lymphoma-stg.clarovantdigital.com/library/the-rules-of-t-cell-engagement-current-state-of-car-t-cells-and-bispecific-antibodies-in-b-cell-lymphomas/2025-12-19T19:47:23+00:00https://lymphoma-stg.clarovantdigital.com/library/semen-analysis-and-reproductive-hormones-in-boys-with-classical-hodgkin-lymphoma-treated-according-to-the-euronet-phl-c2-protocol/2025-12-19T19:46:29+00:00https://lymphoma-stg.clarovantdigital.com/library/a-real-world-data-based-analysis-of-prognostic-indices-as-part-of-trial-eligibility-criteria-in-diffuse-large-b-cell-lymphoma-patients/2025-12-19T19:45:38+00:00https://lymphoma-stg.clarovantdigital.com/library/pre-existing-cardiovascular-disease-is-associated-with-an-increased-risk-of-cardiovascular-events-during-bruton-tyrosine-kinase-inhibitor-therapy/2025-12-19T19:44:15+00:00https://lymphoma-stg.clarovantdigital.com/library/clinical-characteristics-and-outcomes-of-brazilian-patients-with-duodenal-type-follicular-lymphoma-a-multicenter-retrospective-study/2025-12-19T19:41:58+00:00https://lymphoma-stg.clarovantdigital.com/library/tumour-associated-macrophages-in-diffuse-large-b-cell-lymphoma-the-prognostic-and-therapeutic-impact-in-a-south-african-centre-with-high-hiv-seroprevalence/2025-12-19T19:41:11+00:00https://lymphoma-stg.clarovantdigital.com/library/mutational-profile-in-previously-treated-patients-with-chronic-lymphocytic-leukemia-progression-on-acalabrutinib-or-ibrutinib/2025-12-19T19:39:58+00:00https://lymphoma-stg.clarovantdigital.com/library/treatment-patterns-and-burden-of-infection-in-patients-with-chronic-lymphocytic-leukemia-and-secondary-immunodeficiency-a-retrospective-database-study/2025-12-19T19:39:18+00:00https://lymphoma-stg.clarovantdigital.com/library/epidemiological-and-histopathological-profile-of-hodgkins-lymphoma-in-the-democratic-republic-of-congo/2025-12-28T18:20:13+00:00https://lymphoma-stg.clarovantdigital.com/library/outcomes-and-patterns-of-evolution-of-patients-with-hematological-malignancies-during-the-covid-19-pandemic-a-nationwide-study-2020-2022/2025-12-28T18:18:38+00:00https://lymphoma-stg.clarovantdigital.com/library/magrolimab-plus-rituximab-with-without-chemotherapy-in-patients-with-relapsed-refractory-diffuse-large-b-cell-lymphoma/2025-12-28T17:41:44+00:00https://lymphoma-stg.clarovantdigital.com/library/predicting-progression-free-survival-from-measurable-residual-disease-in-chronic-lymphocytic-leukemia/2025-12-19T19:38:30+00:00https://lymphoma-stg.clarovantdigital.com/library/outcomes-of-proton-therapy-to-infradiaphragmatic-sites-in-pediatric-patients-with-hodgkin-lymphoma/2025-05-27T12:24:21+00:00https://lymphoma-stg.clarovantdigital.com/library/acalabrutinib-in-chinese-patients-with-relapsed-refractory-chronic-lymphocytic-leukemia-primary-analysis-from-an-open-label-multicenter-phase-1-2-trial/2025-12-19T19:37:21+00:00https://lymphoma-stg.clarovantdigital.com/library/logistical-challenges-of-car-t-cell-therapy-in-non-hodgkin-lymphoma-a-survey-of-healthcare-professionals/2025-12-19T19:36:09+00:00https://lymphoma-stg.clarovantdigital.com/library/relapsed-mantle-cell-lymphoma-manifesting-with-soft-tissue-tumors-of-the-extremities-university-of-miami-experience-and-review-of-the-literature/2025-12-19T19:35:22+00:00https://lymphoma-stg.clarovantdigital.com/library/comparison-of-thiotepa-based-conditioning-regimens-for-older-adults-with-primary-diffuse-large-b-cell-lymphoma-of-the-central-nervous-system-undergoing-autologous-hematopoietic-cell-transplantation/2025-12-19T19:34:38+00:00https://lymphoma-stg.clarovantdigital.com/library/prognostic-and-survival-factors-in-head-and-neck-extra-nodal-non-hodgkin-lymphoma/2025-12-19T19:33:46+00:00https://lymphoma-stg.clarovantdigital.com/library/eq-5d-5l-and-sf-6dv2-health-utilities-scores-of-diffuse-large-b-cell-lymphoma-patients-in-china/2025-12-19T19:32:22+00:00https://lymphoma-stg.clarovantdigital.com/library/unmet-needs-in-relapsed-refractory-mantle-cell-lymphoma-r-r-mcl-post-covalent-bruton-tyrosine-kinase-inhibitor-btki-a-systematic-literature-review-and-meta-analysis/2025-12-19T19:30:52+00:00https://lymphoma-stg.clarovantdigital.com/library/phase-ii-study-of-pegaspargase-etoposide-gemcitabine-peg-followed-by-involved-field-radiation-therapy-in-early-stage-extranodal-natural-killer-t-cell-lymphoma/2025-12-19T19:29:57+00:00https://lymphoma-stg.clarovantdigital.com/library/comparative-effectiveness-of-6x-r-chop21-versus-6x-r-chop212r-for-patients-with-advanced-stage-diffuse-large-b-cell-lymphoma/2024-09-20T20:58:20+00:00https://lymphoma-stg.clarovantdigital.com/library/baseline-prognostic-predictors-in-classical-hodgkin-lymphoma-a-retrospective-single-center-analysis-on-patients-treated-with-pet-ct-guided-abvd/2025-12-28T18:16:20+00:00https://lymphoma-stg.clarovantdigital.com/library/common-for-covid-19-cytokine-storm-in-patients-with-sars-cov-2-infection-and-cll/2025-12-28T18:13:55+00:00https://lymphoma-stg.clarovantdigital.com/library/options-for-the-treatment-of-second-line-dlbcl/2025-12-19T19:12:40+00:00https://lymphoma-stg.clarovantdigital.com/library/a-retrospective-cohort-study-to-determine-real-world-treatment-patterns-in-patients-with-sezary-syndrome-in-the-united-states/2025-12-19T18:33:55+00:00https://lymphoma-stg.clarovantdigital.com/library/acalabrutinib-alone-or-in-combination-with-rituximab-for-follicular-lymphoma-an-open-label-study/2025-12-19T19:11:30+00:00https://lymphoma-stg.clarovantdigital.com/library/epcoritamab-in-relapsed-refractory-large-b-cell-lymphoma-2-year-follow-up-from-the-pivotal-epcore-nhl-1-trial/2026-01-14T19:33:04+00:00https://lymphoma-stg.clarovantdigital.com/library/pola-r-chp-or-r-choep-for-first-line-therapy-of-younger-patients-with-high-risk-diffuse-large-b-cell-lymphoma-a-retrospective-comparison-of-two-randomized-phase-3-trials/2025-12-19T19:10:01+00:00https://lymphoma-stg.clarovantdigital.com/library/the-future-of-immunotherapy-for-diffuse-large-b-cell-lymphoma/2025-12-19T19:09:11+00:00https://lymphoma-stg.clarovantdigital.com/library/long-term-immune-changes-in-patients-with-relapsed-refractory-chronic-lymphocytic-leukemia-following-treatment-with-venetoclax-plus-rituximab/2025-12-19T19:07:57+00:00https://lymphoma-stg.clarovantdigital.com/library/therapeutic-strategies-and-treatment-sequencing-in-patients-with-chronic-lymphocytic-leukemia-an-international-study-of-eric-the-european-research-initiative-on-cll/2025-12-19T19:06:48+00:00https://lymphoma-stg.clarovantdigital.com/library/real-world-experiences-of-cns-directed-chemotherapy-followed-by-autologous-stem-cell-transplantation-for-secondary-cns-involvement-in-relapsed-or-refractory-diffuse-large-b-cell-lymphoma/2025-12-28T18:12:04+00:00https://lymphoma-stg.clarovantdigital.com/library/outcomes-and-toxicities-in-patients-with-diffuse-large-b-cell-lymphoma-involving-the-gastrointestinal-tract-and-digestive-organs/2025-12-28T18:10:32+00:00https://lymphoma-stg.clarovantdigital.com/library/outreach-phase-2-study-of-lisocabtagene-maraleucel-as-outpatient-or-inpatient-treatment-at-community-sites-for-r-r-lbcl/2025-12-28T18:03:22+00:00https://lymphoma-stg.clarovantdigital.com/library/how-i-treat-older-patients-with-relapsed-and-refractory-diffuse-large-b-cell-lymphoma/2025-12-28T18:01:03+00:00https://lymphoma-stg.clarovantdigital.com/library/molecular-classification-of-large-b-cell-lymphoma-and-high-grade-b-cell-lymphoma-cases-and-association-with-outcomes-in-morocco/2025-12-28T17:57:23+00:00https://lymphoma-stg.clarovantdigital.com/library/outcomes-for-high-risk-defining-events-in-follicular-lymphoma-following-frontline-immunochemotherapy/2025-12-28T17:59:45+00:00https://lymphoma-stg.clarovantdigital.com/library/survival-outcomes-of-patients-with-diffuse-large-b-cell-lymphoma-undergoing-autologous-stem-cell-transplantation-in-germany-real-world-evidence-from-an-administrative-database-between-2010-and-2019/2025-12-28T17:54:06+00:00https://lymphoma-stg.clarovantdigital.com/library/hodgkin-lymphoma-as-the-underlying-cause-of-a-chronic-cough/2024-12-02T15:47:17+00:00https://lymphoma-stg.clarovantdigital.com/library/denmarks-hta-evolution/2024-12-19T15:59:31+00:00https://lymphoma-stg.clarovantdigital.com/library/predictors-of-early-safety-outcomes-with-axicabtagene-ciloleucel-axi-cel-in-patients-with-relapsed-or-refractory-r-r-large-b-cell-lymphoma-lbcl/2024-12-19T15:59:33+00:00https://lymphoma-stg.clarovantdigital.com/library/short-duration-infusion-obinutuzumab-with-venetoclax-in-chronic-lymphocytic-leukemia-a-prospective-observational-study/2025-12-15T20:10:56+00:00https://lymphoma-stg.clarovantdigital.com/library/pembrolizumab-pembro-in-children-and-young-adults-with-high-risk-classical-hodgkin-lymphoma-chl-with-slow-early-response-ser-to-front-line-chemotherapy-chemo-updated-results-from-the-phase-2-2/2024-12-13T20:01:32+00:00https://lymphoma-stg.clarovantdigital.com/library/the-association-between-radiotherapy-and-the-prognosis-of-follicular-lymphoma-patients-with-different-characteristics-in-the-rituximab-era-a-cohort-study-based-on-surveillance-epidemiology-and-end-r/2025-01-24T19:19:37+00:00https://lymphoma-stg.clarovantdigital.com/library/real-world-effectiveness-of-tafasitamab-tafa-for-the-treatment-of-relapsed-refractory-diffuse-large-b-cell-lymphoma-r-r-dlbcl-in-the-united-states/2025-12-19T18:31:03+00:00https://lymphoma-stg.clarovantdigital.com/library/updated-results-from-the-phase-2-waveline-004-study-of-zilovertamab-vedotin-in-relapsed-or-refractory-diffuse-large-b-cell-lymphoma/2024-12-13T20:01:35+00:00https://lymphoma-stg.clarovantdigital.com/library/cd22-directed-car-t-cell-therapy-for-large-b-cell-lymphomas-progressing-after-cd19-directed-car-t-cell-therapy-continued-durable-remissions-at-3-year-follow-up/2024-12-13T20:01:36+00:00https://lymphoma-stg.clarovantdigital.com/library/interim-results-from-a-phase-2-pivotal-study-daly-ii-usa-of-tandem-cd20-cd19-directed-non-cryopreserved-car-t-cells-zamtocabtagene-autoleucel-zamto-cel-in-patients-with-relapsed-refractory-diffu/2024-12-13T20:01:38+00:00https://lymphoma-stg.clarovantdigital.com/library/involved-field-radiotherapy-versus-no-further-treatment-in-patients-with-newly-diagnosed-stage-1a-or-2a-hodgkin-lymphoma-and-a-negative-pet-scan-after-3-cycles-abvd-survival-and-cause-of-death-after/2024-12-13T20:01:40+00:00https://lymphoma-stg.clarovantdigital.com/library/real-world-early-outcomes-of-second-line-axicabtagene-ciloleucel-axi-cel-therapy-in-patients-pts-with-relapsed-or-refractory-r-r-large-b-cell-lymphoma-lbcl/2024-12-13T20:01:41+00:00https://lymphoma-stg.clarovantdigital.com/library/real-world-trends-of-cytokine-release-syndrome-and-neurologic-events-and-pattern-of-their-management-among-patients-receiving-axicabtagene-ciloleucel-for-relapsed-or-refractory-r-r-large-b-cell-lym/2024-12-13T20:01:42+00:00https://lymphoma-stg.clarovantdigital.com/library/real-world-use-of-tafasitamab-preceding-cd19-directed-chimeric-antigen-receptor-t-cell-therapy-for-relapsed-or-refractory-diffuse-large-b-cell-lymphoma/2025-01-24T19:19:35+00:00https://lymphoma-stg.clarovantdigital.com/library/evaluation-of-treatment-for-diffuse-large-b-cell-lymphoma-using-plasma-d-dimer-levels/2025-01-24T19:19:36+00:00https://lymphoma-stg.clarovantdigital.com/library/health-related-quality-of-life-after-axi-cel-as-a-second-line-therapy-in-patients-with-high-risk-relapsed-refractory-large-b-cell-lymphoma-who-are-ineligible-for-autologous-stem-cell-transplantation/2024-12-13T20:01:44+00:00https://lymphoma-stg.clarovantdigital.com/library/five-year-analysis-of-the-polarix-study-prolonged-follow-up-confirms-positive-impact-of-polatuzumab-vedotin-plus-rituximab-cyclophosphamide-doxorubicin-and-prednisone-pola-r-chp-on-outcomes/2024-12-13T20:01:45+00:00https://lymphoma-stg.clarovantdigital.com/library/survival-outcomes-of-patients-with-relapsed-refractory-chronic-lymphocytic-leukemia-cll-treated-in-the-chemoimmunotherapy-vs-btk-inhibitor-btki-eras-a-european-research-initiative-on-cll-eric-s/2024-12-13T20:01:47+00:00https://lymphoma-stg.clarovantdigital.com/library/mosunetuzumab-with-response-driven-lenalidomide-augmentation-as-first-line-therapy-for-symptomatic-follicular-or-marginal-zone-lymphoma-interim-analysis-of-a-multi-center-phase-2-study/2024-12-13T20:01:48+00:00https://lymphoma-stg.clarovantdigital.com/library/epcoritamab-induced-fatal-pleural-effusion-in-diffuse-large-b-cell-lymphoma-a-case-report-and-literature-review/2026-01-14T18:51:10+00:00https://lymphoma-stg.clarovantdigital.com/library/acalabrutinib-in-high-risk-chronic-lymphocytic-leukaemia-naive-patients-an-italian-multicenter-retrospective-observational-real-life-experience/2025-01-24T19:19:31+00:00https://lymphoma-stg.clarovantdigital.com/library/clinical-outcomes-of-patients-with-high-risk-relapsed-refractory-follicular-lymphoma-treated-with-tisagenlecleucel-phase-2-elara-4-year-update/2024-12-13T20:01:50+00:00https://lymphoma-stg.clarovantdigital.com/library/real-world-comparison-of-efficacy-and-safety-of-fludarabine-versus-bendamustine-based-lymphodepleting-chemotherapy-for-cd19-chimeric-antigen-receptor-car-t-cell-therapy-in-relapse-refractory-r-r-l/2024-12-13T20:01:51+00:00https://lymphoma-stg.clarovantdigital.com/library/survival-of-hiv-associated-diffuse-large-b-cell-lymphoma-and-burkitt-lymphoma-in-china/2024-12-13T20:01:53+00:00https://lymphoma-stg.clarovantdigital.com/library/role-of-autologous-stem-cell-transplantation-in-the-context-of-ibrutinib-containing-first-line-treatment-in-younger-patients-with-mantle-cell-lymphoma-results-from-the-randomized-triangle-trial-by-th/2024-12-13T20:01:54+00:00https://lymphoma-stg.clarovantdigital.com/library/time-of-car-t-failure-is-a-strong-predictor-of-outcome-for-bispecific-antibody-therapy-in-relapsed-refractory-large-b-cell-lymphoma/2024-12-13T20:01:59+00:00https://lymphoma-stg.clarovantdigital.com/library/lack-of-benefit-of-autologous-hematopoietic-cell-transplantation-auto-hct-in-mantle-cell-lymphoma-mcl-patients-pts-in-first-complete-remission-cr-with-undetectable-minimal-residual-disease-um/2024-12-13T20:01:56+00:00https://lymphoma-stg.clarovantdigital.com/library/real-world-outcomes-with-bispecific-t-cell-engagers-realbite-for-relapsed-or-refractory-large-b-cell-lymphoma-a-multi-center-retrospective-cohort-study/2026-01-14T19:01:29+00:00https://lymphoma-stg.clarovantdigital.com/library/real-world-first-line-treatment-strategies-and-outcomes-in-tp53-mutated-and-unmutated-mantle-cell-lymphoma/2024-12-13T20:02:04+00:00https://lymphoma-stg.clarovantdigital.com/library/outpatient-administration-of-brexucabtagene-autoleucel-brexu-cel-for-acute-lymphoblastic-leukemia-all-and-mantle-cell-lymphoma-mcl-is-safe-and-feasible/2025-12-19T15:10:38+00:00https://lymphoma-stg.clarovantdigital.com/library/acalabrutinib-in-patients-with-mantle-cell-lymphoma-and-chronic-lymphocytic-leukemia-subjected-to-allogeneic-hematopoietic-stem-cell-transplantation-a-phase-2-study-by-the-polish-lymphoma-research-gr/2024-12-13T20:02:09+00:00https://lymphoma-stg.clarovantdigital.com/library/outcomes-in-older-patients-with-relapsed-refractory-r-r-diffuse-large-b-cell-lymphoma-dlbcl-from-the-echelon-3-study/2024-12-13T20:02:10+00:00https://lymphoma-stg.clarovantdigital.com/library/curing-cll-long-term-outcomes-of-chronic-lymphocytic-leukemia-patients-with-at-least-one-year-of-response-to-cart-19-therapy/2024-12-13T20:02:12+00:00https://lymphoma-stg.clarovantdigital.com/library/myd88-mutations-in-chronic-lymphocytic-leukemia-exhibit-distinct-biological-behaviors-and-prognostic-implications/2024-12-13T20:02:14+00:00https://lymphoma-stg.clarovantdigital.com/library/cardiac-safety-profiles-of-first-generation-vs-second-generation-btk-inhibitors-a-meta-analysis/2025-12-15T22:36:06+00:00https://lymphoma-stg.clarovantdigital.com/library/tp53-altered-aggressive-large-b-cell-lymphoma-lbcl-outcomes-by-treatment-modality-a-multicenter-cohort-from-14-u-s-centers/2024-12-13T20:02:17+00:00https://lymphoma-stg.clarovantdigital.com/library/primary-results-of-the-health-related-quality-of-life-hrqol-and-tolerability-assessments-from-the-phase-i-ii-np30179-study-of-glofitamab-monotherapy-in-patients-with-relapsed-refractory-r-r-large/2024-12-13T20:02:21+00:00https://lymphoma-stg.clarovantdigital.com/library/glofitamab-induces-high-response-rates-and-durable-remissions-in-patients-pts-with-heavily-pretreated-relapsed-refractory-r-r-mantle-cell-lymphoma-mcl-including-those-with-a-poor-prognosis-sub/2024-12-13T20:02:23+00:00https://lymphoma-stg.clarovantdigital.com/library/the-role-of-small-bowel-capsule-endoscopy-in-determining-the-treatment-strategy-for-duodenal-follicular-lymphoma-a-single-center-retrospective-study/2025-01-20T15:35:21+00:00https://lymphoma-stg.clarovantdigital.com/library/outcomes-with-venetoclax-based-treatment-in-patients-with-covalent-bruton-tyrosine-kinase-inhibitor-cbtki-treated-chemotherapy-naive-chronic-lymphocytic-leukemia-cll-an-international-retrospecti/2024-12-19T16:00:32+00:00https://lymphoma-stg.clarovantdigital.com/library/clinical-characteristics-and-outcomes-of-476-mantle-cell-lymphoma-patients-aged-80-years-and-older/2024-12-19T16:00:30+00:00https://lymphoma-stg.clarovantdigital.com/library/a-phase-2-study-of-duvelisib-and-venetoclax-in-patients-with-relapsed-or-refractory-r-r-chronic-lymphocytic-leukemia-cll-or-richters-syndrome-rs/2025-01-09T18:10:51+00:00https://lymphoma-stg.clarovantdigital.com/library/cristallo-results-from-a-phase-iii-trial-of-venetoclax-obinutuzumab-versus-fludarabine-cyclophosphamide-and-rituximab-or-bendamustine-rituximab-in-patients-with-untreated-chronic-lymphocytic-leukemi/2025-12-15T21:23:35+00:00https://lymphoma-stg.clarovantdigital.com/library/3-year-update-from-the-epcore-nhl-1-trial-epcoritamab-leads-to-deep-and-durable-responses-in-relapsed-or-refractory-large-b-cell-lymphoma/2026-01-14T18:51:41+00:00https://lymphoma-stg.clarovantdigital.com/library/real-world-results-of-brexucabtagene-autoleucel-for-patients-with-relapsed-refractory-mantle-cell-lymphoma-first-german-swiss-analysis/2024-12-19T16:00:24+00:00https://lymphoma-stg.clarovantdigital.com/library/primary-analysis-of-zuma-2-cohort-3-brexucabtagene-autoleucel-brexu-cel-in-patients-pts-with-relapsed-refractory-mantle-cell-lymphoma-r-r-mcl-who-were-naive-to-bruton-tyrosine-kinase-inhibitors/2024-12-19T16:00:23+00:00https://lymphoma-stg.clarovantdigital.com/library/five-year-outcomes-of-patients-pts-with-relapsed-refractory-mantle-cell-lymphoma-r-r-mcl-treated-with-brexucabtagene-autoleucel-brexu-cel-in-zuma-2-cohorts-1-and-2/2024-12-19T16:00:21+00:00https://lymphoma-stg.clarovantdigital.com/library/5-y-follow-up-of-combination-of-ibrutinib-obinutuzumab-and-venetoclax-for-patients-with-newly-diagnosed-mantle-cell-lymphoma-the-oasis-trial/2024-12-19T16:00:19+00:00https://lymphoma-stg.clarovantdigital.com/library/real-world-management-patterns-of-acute-toxicity-following-bispecific-antibody-therapy-for-patients-with-b-cell-lymphoma-the-geltamo-spanish-lymphoma-group-experience/2026-01-14T18:58:36+00:00https://lymphoma-stg.clarovantdigital.com/library/primary-results-of-patient-reported-outcomes-in-patients-with-relapsed-refractory-diffuse-large-b-cell-lymphoma-treated-with-glofitamab-plus-gemcitabine-and-oxaliplatin-glofit-gemox-versus-rituximab/2024-12-19T16:00:16+00:00https://lymphoma-stg.clarovantdigital.com/library/primary-results-of-the-health-related-quality-of-life-hrqol-and-tolerability-assessments-from-the-phase-i-ii-np30179-study-of-glofitamab-monotherapy-in-patients-with-relapsed-refractory-r-r-large-2/2024-12-19T16:00:14+00:00https://lymphoma-stg.clarovantdigital.com/library/the-clinical-efficacy-and-safety-of-glofitamab-in-chinese-relapsed-or-refractory-large-b-cell-lymphoma/2024-12-19T16:00:11+00:00https://lymphoma-stg.clarovantdigital.com/library/glofitamab-and-epcoritamab-in-the-real-world-a-uk-multicentre-retrospective-analysis-of-efficacy-tolerability-and-practical-implications/2026-01-14T18:59:15+00:00https://lymphoma-stg.clarovantdigital.com/library/real-world-data-of-glofitamab-in-relapsed-refractory-large-b-cell-lymphoma-in-non-western-population-from-a-tertiary-center-in-saudi-arabia/2024-12-19T16:00:08+00:00https://lymphoma-stg.clarovantdigital.com/library/real-world-study-of-glofitamab-for-the-treatment-of-relapse-or-refractory-diffuse-large-b-cell-lymphoma-in-east-china/2024-12-19T16:00:10+00:00https://lymphoma-stg.clarovantdigital.com/library/phase-1-trial-of-prizloncabtagene-autoleucel-a-cd19-20-car-t-for-relapsed-refractory-b-cell-non-hodgkin-lymphoma/2025-01-20T15:40:18+00:00https://lymphoma-stg.clarovantdigital.com/library/phase-ii-study-of-acalabrutinib-venetoclax-and-obinutuzumab-in-a-treatment-naive-chronic-lymphocytic-leukemia-population-enriched-for-high-risk-disease/2024-12-19T16:00:07+00:00https://lymphoma-stg.clarovantdigital.com/library/randomized-phase-2-trial-of-the-anti-pd-l1-monoclonal-antibody-durvalumab-plus-lenalidomide-versus-single-agent-durvalumab-in-patients-with-refractory-advanced-cutaneous-t-cell-lymphoma/2024-12-19T16:00:05+00:00https://lymphoma-stg.clarovantdigital.com/library/a-randomized-phase-2-investigator-led-trial-of-glofitamab-r-chop-or-glofitamab-polatuzumab-vedotin-r-chp-coalition-in-younger-patients-with-high-burden-high-risk-large-b-cell-lymphoma-demonstrates/2024-12-19T16:00:04+00:00https://lymphoma-stg.clarovantdigital.com/library/lisocabtagene-maraleucel-liso-cel-combined-with-ibrutinib-ibr-for-patients-pts-with-relapsed-or-refractory-r-r-chronic-lymphocytic-leukemia-cll-small-lymphocytic-lymphoma-sll-primary-resu/2025-03-03T20:02:28+00:00https://lymphoma-stg.clarovantdigital.com/library/circulating-tumor-dna-ctdna-as-an-early-outcome-predictor-in-patients-pts-with-second-line-2l-large-b-cell-lymphoma-lbcl-after-lisocabtagene-maraleucel-liso-cel-versus-standard-of-care-soc/2024-12-19T16:00:01+00:00https://lymphoma-stg.clarovantdigital.com/library/real-world-rw-outcomes-of-lisocabtagene-maraleucel-liso-cel-in-patients-pts-with-relapsed-or-refractory-r-r-large-b-cell-lymphoma-lbcl-and-secondary-central-nervous-system-scns-involvement/2024-12-19T15:59:59+00:00https://lymphoma-stg.clarovantdigital.com/library/incidence-of-secondary-malignancy-after-treatment-with-anti-cd19-and-anti-bcma-chimeric-antigen-receptor-t-cell-therapies/2024-12-19T15:59:58+00:00https://lymphoma-stg.clarovantdigital.com/library/combining-total-metabolic-tumor-volume-with-beta-2-microglobulin-levels-predicts-outcomes-in-high-burden-follicular-lymphoma-patients/2024-12-19T15:59:56+00:00https://lymphoma-stg.clarovantdigital.com/library/outcome-of-hematopoietic-stem-cell-transplantation-for-follicular-lymphoma-a-benchmark-study-from-the-lymphoma-working-party-of-the-european-society-for-blood-and-marrow-transplantation/2024-12-19T15:59:52+00:00https://lymphoma-stg.clarovantdigital.com/library/allogeneic-hematopoietic-stem-cell-transplantation-for-relapsed-or-refractory-b-cell-non-hodgkin-lymphoma-a-retrospective-multicenter-analysis-on-285-procedures-performed-between-2000-and-2020/2024-12-19T15:59:51+00:00https://lymphoma-stg.clarovantdigital.com/library/chimeric-antigen-receptor-car-t-cell-therapy-in-the-treatment-of-diffuse-large-b-cell-lymphoma-dlbcl-a-systematic-review/2024-12-19T15:59:49+00:00https://lymphoma-stg.clarovantdigital.com/library/real-world-experience-of-infections-with-t-cell-engagers-in-multiple-myeloma-and-non-hodgkins-lymphoma/2024-12-19T15:59:40+00:00https://lymphoma-stg.clarovantdigital.com/library/long-term-clinical-outcomes-in-patients-with-waldenstrom-macroglobulinemia-wm-who-received-zanubrutinib-in-the-phase-3-aspen-study-a-report-from-the-zanubrutinib-extension-study/2024-12-13T21:45:15+00:00https://lymphoma-stg.clarovantdigital.com/library/car-t-cell-therapy-in-early-relapsed-refractory-large-b-cell-lymphoma-real-world-analysis-from-the-cell-therapy-consortium/2024-12-19T15:59:37+00:00https://lymphoma-stg.clarovantdigital.com/library/outcomes-of-patients-with-refractory-and-relapsed-primary-mediastinal-b-cell-lymphoma-a-canadian-single-center-analysis/2024-12-19T15:59:34+00:00https://lymphoma-stg.clarovantdigital.com/library/a-real-world-weighted-comparison-of-tisagenlecleucel-and-axicabtagene-ciloleucel-car-t-cells-in-relapsed-or-refractory-diffuse-large-b-cell-lymphoma-aged-75-years-and-older-a-lysa-study-from-the-des/2024-12-19T15:59:36+00:00https://lymphoma-stg.clarovantdigital.com/library/odronextamab-monotherapy-in-previously-untreated-patients-with-high-risk-follicular-lymphoma-fl-results-of-the-safety-lead-in-of-the-phase-3-olympia-1-study/2024-12-19T15:59:30+00:00https://lymphoma-stg.clarovantdigital.com/library/real-world-outcomes-of-patients-with-high-grade-b-cell-lymphoma-with-myc-and-bcl2-rearrangements-treated-in-the-contemporary-era/2024-12-19T15:59:27+00:00https://lymphoma-stg.clarovantdigital.com/library/multi-centre-real-world-outcomes-of-large-b-cell-lymphoma-patients-treated-with-2l-axicabtagene-ciloleucel-in-the-uk/2026-01-16T14:55:03+00:00https://lymphoma-stg.clarovantdigital.com/library/impact-of-patient-distance-from-center-on-outcomes-and-cost-of-therapy-for-patients-undergoing-chimeric-antigen-receptor-t-cell-therapy-for-b-cell-lymphoma/2024-12-19T15:59:25+00:00https://lymphoma-stg.clarovantdigital.com/library/impact-of-icans-on-long-term-neurocognitive-function-in-patients-with-diffuse-large-b-cell-lymphoma-receiving-car-t-cell-therapy/2024-12-19T15:59:22+00:00https://lymphoma-stg.clarovantdigital.com/library/comparative-real-world-outcomes-of-commercial-cd19-directed-car-t-cell-therapies-in-large-b-cell-lymphoma/2024-12-19T15:59:24+00:00https://lymphoma-stg.clarovantdigital.com/library/limited-stage-mantle-cell-lymphoma-a-real-world-study-of-primary-treatment-and-prognosis-in-sweden-2006-2018/2025-01-31T19:53:39+00:00https://lymphoma-stg.clarovantdigital.com/library/inferior-outcomes-of-fludarabine-cyclophosphamide-rituximab-chemotherapy-in-korean-chronic-lymphocytic-leukemia-patients-with-concurrent-thrombocytopenia-and-anemia/2025-01-15T19:13:46+00:00https://lymphoma-stg.clarovantdigital.com/library/evaluation-of-outcomes-and-toxicities-of-commercial-axicabtagene-ciloleucel-axi-cel-and-tisagenlecleucel-tisa-cel-for-relapsed-or-refractory-r-r-follicular-lymphoma-fl-real-world-evidence-rw/2024-12-19T15:59:21+00:00https://lymphoma-stg.clarovantdigital.com/library/car-t-cells-treatment-for-relapsed-refractory-b-cell-lymphoma-is-effective-and-safe-in-people-living-with-hiv-plwh-a-lysa-study-from-the-descar-t-registry/2024-12-19T15:59:19+00:00https://lymphoma-stg.clarovantdigital.com/library/five-year-survival-of-patients-pts-from-transcend-nhl-001-transcend-supports-curative-potential-of-lisocabtagene-maraleucel-liso-cel-in-relapsed-or-refractory-r-r-large-b-cell-lymphoma-lbcl/2024-12-19T15:59:18+00:00https://lymphoma-stg.clarovantdigital.com/library/a-systematic-literature-review-of-clinical-outcomes-in-patients-with-relapsed-or-refractory-diffuse-large-b-cell-lymphoma-treated-in-the-third-line-or-later-setting/2024-12-19T15:59:15+00:00https://lymphoma-stg.clarovantdigital.com/library/outcomes-of-salvage-radiotherapy-in-relapsed-refractory-large-b-cell-lymphoma-patients-following-car-t-cell-therapy-failure-a-multicenter-pooled-analysis/2024-12-19T15:59:16+00:00https://lymphoma-stg.clarovantdigital.com/library/lisocabtagene-maraleucel-liso-cel-in-patients-pts-with-relapsed-or-refractory-r-r-follicular-lymphoma-fl-transcend-fl-2-year-follow-up/2025-12-15T19:36:54+00:00https://lymphoma-stg.clarovantdigital.com/library/randomized-phase-iii-study-of-watchful-waiting-vs-rituximab-as-first-line-treatment-in-patients-with-advanced-stage-low-tumor-burden-follicular-lymphoma-jcog1411-flora-study/2024-12-19T15:59:12+00:00https://lymphoma-stg.clarovantdigital.com/library/real-world-characteristics-treatment-patterns-and-outcomes-of-patients-with-mantle-cell-lymphoma-by-lot/2024-12-19T15:59:10+00:00https://lymphoma-stg.clarovantdigital.com/library/practices-and-outcomes-during-a-watch-and-wait-approach-for-follicular-lymphoma-a-study-from-the-australasian-lymphoma-alliance/2024-12-19T15:59:07+00:00https://lymphoma-stg.clarovantdigital.com/library/serum-immunoglobulins-are-an-independent-prognostic-marker-of-time-to-first-therapy-in-newly-diagnosed-chronic-lymphocytic-leukemia-cll-and-monoclonal-b-cell-lymphocytosis-mbl/2024-12-19T15:59:06+00:00https://lymphoma-stg.clarovantdigital.com/library/treatment-outcomes-for-patients-with-tp53-mutated-mantle-cell-lymphoma-a-systematic-review-and-meta-analysis/2024-12-19T15:59:03+00:00https://lymphoma-stg.clarovantdigital.com/library/adjuvant-rituximab-and-elevated-intratumoural-cd8-expression-are-associated-with-sustained-disease-control-after-radiotherapy-in-a-randomised-trial-of-systemic-therapy-in-early-stage-follicular-lympho/2024-12-19T15:59:04+00:00https://lymphoma-stg.clarovantdigital.com/library/excellent-clinical-outcomes-in-deeply-mutated-ighv-chronic-lymphocytic-leukemia-upon-fludarabine-and-cyclophosphamide-plus-rituximab/2025-12-15T21:24:31+00:00https://lymphoma-stg.clarovantdigital.com/library/mosunetuzumab-monotherapy-demonstrates-encouraging-activity-and-a-manageable-safety-profile-in-patients-with-heavily-pre-treated-relapsed-or-refractory-mantle-cell-lymphoma/2024-12-19T15:59:42+00:00https://lymphoma-stg.clarovantdigital.com/library/impact-of-prior-bendamustine-exposure-on-bispecific-antibody-treatment-outcomes-in-patients-with-relapsed-refractory-follicular-lymphoma/2024-12-19T15:59:01+00:00https://lymphoma-stg.clarovantdigital.com/library/limited-duration-loncastuximab-tesirine-induces-a-high-rate-of-complete-responses-in-patients-with-relapsed-refractory-marginal-zone-lymphoma-report-of-first-planned-interim-futility-analysis-of-a-m/2024-12-19T15:58:52+00:00https://lymphoma-stg.clarovantdigital.com/library/lisocabtagene-maraleucel-for-relapsed-refractory-large-b-cell-lymphoma-a-cell-therapy-consortium-real-world-analysis/2024-12-17T19:43:51+00:00https://lymphoma-stg.clarovantdigital.com/library/safety-and-efficacy-of-glofitamab-for-relapsed-refractory-large-b-cell-lymphoma-in-a-multinational-real-world-study/2025-11-10T16:51:09+00:00https://lymphoma-stg.clarovantdigital.com/library/a-phase-i-study-using-bortezomib-velcade-cladribine-and-rituximab-in-treating-patients-over-50-years-old-with-mantle-cell-lymphoma/2024-12-17T19:01:33+00:00https://lymphoma-stg.clarovantdigital.com/library/real-world-outcomes-of-early-relapsed-refractory-large-b-cell-lymphoma-patients-treated-with-2nd-line-car-t-therapy/2024-12-19T15:59:39+00:00https://lymphoma-stg.clarovantdigital.com/library/fixed-duration-acalabrutinib-plus-venetoclax-with-or-without-obinutuzumab-versus-chemoimmunotherapy-for-first-line-treatment-of-chronic-lymphocytic-leukemia-interim-analysis-of-the-multicenter-open/2024-12-13T20:01:05+00:00https://lymphoma-stg.clarovantdigital.com/library/preliminary-efficacy-and-safety-of-a-phase-1-2-study-of-acalabrutinib-venetoclax-and-obinutuzumab-in-patients-with-relapsed-refractory-and-previously-untreated-mantle-cell-lymphoma-mavo/2024-12-13T20:01:07+00:00https://lymphoma-stg.clarovantdigital.com/library/acalabrutinib-umbralisib-and-ublituximab-regimen-au2-demonstrates-high-response-rate-and-undetectable-molecular-minimal-residual-disease-mrd-in-patients-pts-with-de-novo-mantle-cell-lymphoma-m/2024-12-13T20:01:08+00:00https://lymphoma-stg.clarovantdigital.com/library/molecular-features-are-associated-with-disease-stage-in-diffuse-large-b-cell-lymphoma-and-reveal-heterogeneity-in-patient-outcomes/2024-12-13T20:01:10+00:00https://lymphoma-stg.clarovantdigital.com/library/loncastuximab-tesirine-with-rituximab-induces-robust-and-durable-complete-metabolic-responses-in-high-risk-relapsed-refractory-follicular-lymphoma/2024-12-13T20:01:11+00:00https://lymphoma-stg.clarovantdigital.com/library/results-of-the-regimen-dime-in-diffuse-large-b-cell-lymphoma-with-myc-over-expression-a-retrospective-analysis/2024-12-13T20:01:13+00:00https://lymphoma-stg.clarovantdigital.com/library/consistently-high-5-5-year-progression-free-survival-pfs-rates-in-patients-with-and-without-bulky-baseline-lymphadenopathy-5-cm-are-associated-with-high-undetectable-minimal-residual-disease-umrd4/2025-03-03T20:05:42+00:00https://lymphoma-stg.clarovantdigital.com/library/real-world-rw-outcomes-of-lisocabtagene-maraleucel-liso-cel-as-second-line-2l-therapy-in-patients-pts-with-relapsed-or-refractory-r-r-large-b-cell-lymphoma-lbcl-first-results-from-the-cen/2024-12-13T20:01:17+00:00https://lymphoma-stg.clarovantdigital.com/library/ibrutinib-rituximab-is-superior-to-rituximab-chemotherapy-in-previously-untreated-older-mantle-cell-lymphoma-patients-results-from-the-international-randomised-controlled-trial-enrich/2024-12-13T20:01:18+00:00https://lymphoma-stg.clarovantdigital.com/library/fixed-duration-epcoritamab-r-chop-induces-high-complete-response-rates-in-patients-with-previously-untreated-diffuse-large-b-cell-lymphoma-with-high-risk-features-long-term-results-from-the-epcore/2026-01-14T19:32:28+00:00https://lymphoma-stg.clarovantdigital.com/library/fixed-duration-epcoritamab-r2-drives-deep-and-durable-responses-in-patients-with-relapsed-or-refractory-follicular-lymphoma-2-year-follow-up-from-arm-2-of-the-epcore-nhl-2-trial/2026-01-14T19:21:48+00:00https://lymphoma-stg.clarovantdigital.com/library/impact-of-leukemia-subtype-and-demographics-on-patient-quality-of-life-in-76-countries-a-crosssectional-study/2025-01-23T00:47:24+00:00https://lymphoma-stg.clarovantdigital.com/library/comparison-of-zanubrutinib-and-ibrutinib-as-treatments-for-waldenstrom-macroglobulinemia-a-real-world-retrospective-study/2024-12-13T20:01:23+00:00https://lymphoma-stg.clarovantdigital.com/library/epcoritamab-monotherapy-in-patients-pts-with-relapsed-or-refractory-r-r-chronic-lymphocytic-leukemia-cll-results-from-cll-expansion-and-optimization-cohorts-of-epcore-cll-1/2026-01-14T19:02:09+00:00https://lymphoma-stg.clarovantdigital.com/library/bcl-2-inhibitors-in-hematological-malignancies-biomarkers-that-predict-response-and-management-strategies/2025-01-23T01:06:22+00:00https://lymphoma-stg.clarovantdigital.com/library/real-world-outcomes-of-cd19car-t-cell-therapy-in-adult-patients-with-relapsed-refractory-transformed-indolent-lymphoma/2024-12-13T20:01:26+00:00https://lymphoma-stg.clarovantdigital.com/library/is-first-line-treatment-with-polatuzumab-vedotin-rituximab-cyclophosphamide-doxorubicin-and-prednisone-pola-r-chp-for-previously-untreated-diffuse-large-b-cell-lymphoma-cost-effective-in-china-a-c/2025-01-21T15:42:57+00:00https://lymphoma-stg.clarovantdigital.com/library/definitions-and-use-of-tumour-bulk-in-phase-3-lymphoma-trials-a-comprehensive-literature-review/2025-01-23T00:44:05+00:00https://lymphoma-stg.clarovantdigital.com/library/the-development-and-application-of-bispecific-antibodies-in-b-cell-non-hodgkin-lymphoma/2025-01-28T14:43:58+00:00https://lymphoma-stg.clarovantdigital.com/library/pembrolizumab-in-children-adolescents-and-young-adults-with-low-risk-classic-hodgkin-lymphoma-chl-and-slow-early-response-to-front-line-chemotherapy-updated-results-from-the-phase-2-keynote-667-s/2024-12-13T20:01:29+00:00https://lymphoma-stg.clarovantdigital.com/library/nivolumab-and-rituximab-in-treatment-naive-follicular-lymphoma-the-phase-ii-1st-flor-study/2025-01-28T14:24:54+00:00https://lymphoma-stg.clarovantdigital.com/library/chimeric-antigen-receptor-t-cells-in-the-modern-era-of-chronic-lymphocytic-leukemia-treatment/2025-01-28T14:31:40+00:00https://lymphoma-stg.clarovantdigital.com/library/pembrolizumab-pembro-in-children-and-young-adults-with-low-risk-classical-hodgkin-lymphoma-chl-with-slow-early-response-ser-to-front-line-chemotherapy-chemo-early-results-from-the-phase-2-key-2/2024-12-13T20:01:30+00:00https://lymphoma-stg.clarovantdigital.com/library/fixed-duration-glofitamab-monotherapy-continues-to-demonstrate-durable-responses-in-patients-with-relapsed-or-refractory-large-b-cell-lymphoma-3-year-follow-up-from-a-pivotal-phase-ii-study/2024-12-13T20:02:24+00:00https://lymphoma-stg.clarovantdigital.com/library/mosunetuzumab-continues-to-demonstrate-clinically-meaningful-outcomes-in-patients-with-relapsed-and-or-refractory-follicular-lymphoma-after-2-prior-therapies-including-those-with-a-history-of-pod24/2024-12-13T20:02:26+00:00https://lymphoma-stg.clarovantdigital.com/library/5-year-follow-up-analysis-from-zuma-5-a-phase-2-trial-of-axicabtagene-ciloleucel-axi-cel-in-patients-with-relapsed-refractory-indolent-non-hodgkin-lymphoma/2024-12-13T20:02:27+00:00https://lymphoma-stg.clarovantdigital.com/library/subcutaneous-mosunetuzumab-leads-to-high-rates-of-durable-responses-low-rates-of-cytokine-release-syndrome-and-non-inferior-exposure-compared-with-intravenous-administration-in-patients-with-relapse/2024-12-13T20:02:29+00:00https://lymphoma-stg.clarovantdigital.com/library/glofitamab-in-combination-with-polatuzumab-vedotin-maintains-durable-responses-and-a-manageable-safety-profile-in-patients-with-heavily-pre-treated-relapsed-refractory-r-r-large-b-cell-lymphoma-lbc/2024-12-13T20:02:32+00:00https://lymphoma-stg.clarovantdigital.com/library/patient-reported-chemotherapy-induced-peripheral-neuropathy-cipn-in-advanced-stage-classical-hodgkin-lymphoma-treated-with-brecadd-and-ebeacopp-in-the-hd21-trial/2024-12-13T20:02:33+00:00https://lymphoma-stg.clarovantdigital.com/library/bruin-cll-321-randomized-phase-iii-trial-of-pirtobrutinib-versus-idelalisib-plus-rituximab-idelar-or-bendamustine-plus-rituximab-br-in-btk-inhibitor-pretreated-chronic-lymphocytic-leukemia-small/2025-03-03T20:04:14+00:00https://lymphoma-stg.clarovantdigital.com/library/dynamics-of-complete-responses-in-patients-with-relapsed-or-refractory-follicular-lymphoma-treated-with-odronextamab-in-the-elm-2-study/2024-12-13T20:02:38+00:00https://lymphoma-stg.clarovantdigital.com/library/efficacy-and-safety-of-odronextamab-monotherapy-in-patients-pts-with-diffuse-large-b-cell-lymphoma-dlbcl-progressing-after-car-t-cell-therapy-primary-analysis-from-the-elm-1-study/2024-12-13T20:02:39+00:00https://lymphoma-stg.clarovantdigital.com/library/efficacy-and-safety-of-odronextamab-in-relapsed-refractory-marginal-zone-lymphoma-r-r-mzl-data-from-the-r-r-mzl-cohort-in-the-elm-2-study/2024-12-13T20:02:40+00:00https://lymphoma-stg.clarovantdigital.com/library/long-term-efficacy-and-safety-of-odronextamab-in-relapsed-refractory-diffuse-large-b-cell-lymphoma-dlbcl-pooled-analysis-from-the-elm-1-and-elm-2-studies/2024-12-13T20:02:42+00:00https://lymphoma-stg.clarovantdigital.com/library/treatment-duration-and-risk-of-fatal-infections-in-patients-with-b-cell-non-hodgkin-lymphoma-achieving-complete-response-with-odronextamab/2024-12-13T20:02:43+00:00https://lymphoma-stg.clarovantdigital.com/library/fixed-duration-epcoritamab-in-combination-with-bendamustine-rituximab-for-first-line-treatment-of-follicular-lymphoma-initial-results-from-epcore-nhl-2-arm/2026-01-14T19:00:44+00:00https://lymphoma-stg.clarovantdigital.com/library/zilovertamab-vedotin-monotherapy-for-patients-with-relapsed-or-refractory-mantle-cell-lymphoma-cohort-a-of-the-multicenter-open-label-phase-2-waveline-006-study/2024-12-13T20:02:46+00:00https://lymphoma-stg.clarovantdigital.com/library/zilovertamab-vedotin-in-combination-with-nemtabrutinib-for-patients-with-relapsed-or-refractory-mantle-cell-lymphoma-cohort-c-of-the-open-label-phase-2-waveline-006-study/2024-12-13T20:02:48+00:00https://lymphoma-stg.clarovantdigital.com/library/tafasitamab-plus-lenalidomide-and-rituximab-for-relapsed-or-refractory-follicular-lymphoma-results-from-a-phase-3-study-inmind/2024-12-13T20:02:49+00:00https://lymphoma-stg.clarovantdigital.com/library/zanubrutinib-versus-bendamustine-and-rituximab-in-patients-with-treatment-naive-chronic-lymphocytic-leukemia-small-lymphocytic-lymphoma-median-5-year-follow-up-of-sequoia/2026-01-16T14:52:35+00:00https://lymphoma-stg.clarovantdigital.com/library/cutaneous-b-cell-lymphomas-2023-update-on-diagnosis-risk-stratification-and-management/2024-12-13T20:02:52+00:00https://lymphoma-stg.clarovantdigital.com/library/cutaneous-t-cell-lymphomas-2023-update-on-diagnosis-risk-stratification-and-management/2024-12-13T20:02:54+00:00https://lymphoma-stg.clarovantdigital.com/library/the-genomic-and-clinical-consequences-of-replacing-procarbazine-with-dacarbazine-in-escalated-beacopp-for-hodgkin-lymphoma-a-retrospective-observational-study/2024-12-13T20:02:55+00:00https://lymphoma-stg.clarovantdigital.com/library/outcomes-and-predictors-of-survival-for-patients-with-relapsed-or-refractory-diffuse-large-b-cell-lymphoma-a-large-population-based-analysis/2024-12-13T20:02:57+00:00https://lymphoma-stg.clarovantdigital.com/library/combined-pirtobrutinib-venetoclax-and-obinutuzumab-as-first-line-treatment-of-patients-with-chronic-lymphocytic-leukemia-cll/2024-12-13T20:02:58+00:00https://lymphoma-stg.clarovantdigital.com/library/epcore-dlbcl-3-first-disclosure-fixed-duration-epcoritamab-monotherapy-in-older-75-y-anthracycline-ineligible-patients-with-previously-untreated-large-b-cell-lymphoma/2026-01-14T18:59:56+00:00https://lymphoma-stg.clarovantdigital.com/library/outcomes-in-early-relapse-of-follicular-lymphoma-versus-early-histologic-transformation-following-firstline-immunochemotherapy-in-follicular-lymphoma/2024-12-13T20:03:06+00:00https://lymphoma-stg.clarovantdigital.com/library/fixed-duration-subcutaneous-mosunetuzumab-is-active-and-has-a-manageable-safety-profile-in-patients-with-previously-untreated-low-tumor-burden-follicular-lymphoma-updated-results-from-the-phase-ii-m/2026-01-14T17:55:51+00:00https://lymphoma-stg.clarovantdigital.com/library/characteristics-of-relapsed-refractory-diffuse-large-b-cell-lymphoma-patients-with-durable-responses-to-maveropepimut-s-pembrolizumab-and-cyclophosphamide-long-term-follow-up-from-the-spirel-trial/2024-12-13T20:03:09+00:00https://lymphoma-stg.clarovantdigital.com/library/acalabrutinib-in-combination-with-rituximab-and-lenalidomide-in-patients-with-relapsed-or-refractory-follicular-lymphoma-results-of-the-phase-1b-open-label-study-ace-ly-003/2024-12-13T20:03:11+00:00https://lymphoma-stg.clarovantdigital.com/library/treatment-of-relapsed-refractory-cll-patients-with-pi3k-inhibitor-and-anti-cd20-antibody-rapidly-decreases-tumor-burden-but-could-induce-resistance/2025-01-10T18:21:02+00:00https://lymphoma-stg.clarovantdigital.com/library/outcomes-of-cd19-car-t-in-transformed-indolent-lymphoma-compared-to-de-novo-aggressive-large-b-cell-lymphoma/2025-01-10T18:21:03+00:00https://lymphoma-stg.clarovantdigital.com/library/real-world-characterization-of-toxicities-and-medication-management-in-recipients-of-car-t-cell-therapy-for-relapsed-or-refractory-large-b-cell-lymphoma-in-nova-scotia-canada/2025-01-09T15:36:41+00:00https://lymphoma-stg.clarovantdigital.com/library/the-impact-of-trial-inclusion-criteria-on-outcomes-in-dlbcl-patients-treated-with-r-chop-in-the-first-line-a-danish-nationwide-study/2025-01-10T18:20:49+00:00https://lymphoma-stg.clarovantdigital.com/library/real-world-treatment-patterns-after-discontinuation-of-venetoclax-or-btkis-in-the-frontline-setting-among-older-adults-with-chronic-lymphocytic-leukemia/2025-05-13T13:34:11+00:00https://lymphoma-stg.clarovantdigital.com/library/the-efficacy-and-safety-of-obinutuzumab-with-zanubrutinib-as-first-line-treatment-in-older-patients-with-mantle-cell-lymphoma/2025-01-10T18:20:52+00:00https://lymphoma-stg.clarovantdigital.com/library/underrepresentation-of-small-lymphocytic-lymphoma-in-clinical-trials-for-chronic-lymphocytic-leukemia/2025-01-10T18:20:50+00:00https://lymphoma-stg.clarovantdigital.com/library/real-world-safety-profile-of-therapy-with-ibrutinib-or-acalabrutinib-in-patients-with-chronic-lymphocytic-leukemia-cll/2025-01-09T15:16:50+00:00https://lymphoma-stg.clarovantdigital.com/library/molecular-diagnosis-of-vitreoretinal-lymphoma/2025-01-09T15:25:16+00:00https://lymphoma-stg.clarovantdigital.com/library/minimizing-long-term-toxicities-for-patients-with-primary-mediastinal-b-cell-lymphoma-undergoing-modern-radiotherapy/2025-01-09T15:30:48+00:00https://lymphoma-stg.clarovantdigital.com/library/primary-diffuse-large-b-cell-lymphoma-of-the-clivus-systematic-review-and-illustrative-case-example/2025-01-07T23:38:28+00:00https://lymphoma-stg.clarovantdigital.com/library/efficacy-safety-and-cost-effectiveness-of-obinutuzumab-in-patients-with-follicular-lymphoma-a-rapid-review/2025-01-07T22:25:35+00:00https://lymphoma-stg.clarovantdigital.com/library/managing-novel-therapies-and-concomitant-medications-in-chronic-lymphocytic-leukemia-key-challenges/2025-01-07T23:33:45+00:00https://lymphoma-stg.clarovantdigital.com/library/molecular-measurable-residual-disease-by-immunoglobulin-gene-rearrangements-on-circulating-tumor-dna-predicts-outcome-in-diffuse-large-b-cell-lymphoma/2025-01-09T15:41:48+00:00https://lymphoma-stg.clarovantdigital.com/library/high-risk-subgroups-and-mrd-an-updated-analysis-of-the-phase-3-echo-trial-of-acalabrutinib-with-bendamustine-rituximab-in-previously-untreated-mantle-cell-lymphoma/2025-01-10T18:20:53+00:00https://lymphoma-stg.clarovantdigital.com/library/risk-analysis-of-cardiovascular-toxicity-in-patients-with-lymphoma-treated-with-cd19-car-t-cells/2025-01-10T18:20:55+00:00https://lymphoma-stg.clarovantdigital.com/library/transplant-and-nontransplant-salvage-therapy-in-pediatric-relapsed-or-refractory-hodgkin-lymphoma-the-euronet-phl-r1-phase-3-nonrandomized-clinical-trial/2025-01-10T18:20:56+00:00https://lymphoma-stg.clarovantdigital.com/library/transplant-free-approach-in-relapsed-hodgkin-lymphoma-in-children-adolescents-and-young-adults-a-nonrandomized-clinical-trial/2025-01-10T18:20:58+00:00https://lymphoma-stg.clarovantdigital.com/library/relative-efficacy-of-systemic-treatments-for-patients-with-relapsed-refractory-chronic-lymphocytic-leukemia-a-network-meta-analysis-according-to-17p-deletion-tp53-mutations/2025-01-10T18:20:59+00:00https://lymphoma-stg.clarovantdigital.com/library/real-world-outcomes-following-ibrutinib-dose-reduction-in-patients-with-chronic-lymphocytic-leukemia-small-lymphocytic-lymphoma/2025-03-03T19:56:57+00:00https://lymphoma-stg.clarovantdigital.com/library/complete-remission-of-plasmablastic-lymphoma-with-daratumumab-and-a-mild-regimen-of-cyclophosphamide-doxorubicin-vincristine-and-prednisolone-mini-chop/2025-01-10T18:21:05+00:00https://lymphoma-stg.clarovantdigital.com/library/different-role-of-pet-ct-evaluation-in-newly-diagnosed-follicular-lymphoma-upon-rituximab-based-chemotherapy-and-chemo-free-immunotherapy/2025-01-10T18:21:06+00:00https://lymphoma-stg.clarovantdigital.com/library/a-prospective-analysis-of-outcomes-following-successive-lines-of-treatment-in-mantle-cell-lymphoma-in-an-unselected-previously-untreated-population-the-uk-mcl-biobank/2025-01-10T18:21:08+00:00https://lymphoma-stg.clarovantdigital.com/library/mrd-driven-venetoclax-and-rituximab-combination-in-previously-untreated-chronic-lymphocytic-leukemia-first-results-of-the-prospective-multicenter-phase-ii-trial-of-the-polish-adult-leukemia-group/2025-05-13T13:35:33+00:00https://lymphoma-stg.clarovantdigital.com/library/management-strategies-for-patients-with-chronic-lymphocytic-leukaemia-harbouring-complex-karyotype/2025-01-10T18:21:09+00:00https://lymphoma-stg.clarovantdigital.com/library/how-are-patient-inputs-considered-in-hta-a-thematic-document-analysis-of-nice-ultra-rare-disease-appraisals/2025-01-10T18:21:11+00:00https://lymphoma-stg.clarovantdigital.com/library/primary-thyroid-b-cell-lymphoma-molecular-insights-into-its-clonal-evolution-and-relapse/2025-01-10T18:21:15+00:00https://lymphoma-stg.clarovantdigital.com/library/the-long-term-risk-of-immune-related-conditions-in-survivors-of-diffuse-large-b-cell-lymphoma-a-danish-nationwide-registry-study/2025-01-10T18:21:14+00:00https://lymphoma-stg.clarovantdigital.com/library/the-role-of-the-gut-microbiota-in-infectious-complications-during-immunochemotherapy-for-diffuse-large-b-cell-lymphoma/2025-01-10T18:21:17+00:00https://lymphoma-stg.clarovantdigital.com/library/pediatric-lymphomas-overview-and-diagnostic-challenges/2025-01-10T18:21:18+00:00https://lymphoma-stg.clarovantdigital.com/library/brexucabtagene-autoleucel-in-vivo-expansion-and-btki-refractoriness-have-a-negative-influence-on-progression-free-survival-in-mantle-cell-lymphoma-results-from-cart-sie-study/2025-01-10T18:21:20+00:00https://lymphoma-stg.clarovantdigital.com/library/a-phase-2-study-of-zanubrutinib-and-venetoclax-zv-in-relapsed-or-refractory-r-r-chronic-lymphocytic-leukemia-cll/2025-01-10T18:21:27+00:00https://lymphoma-stg.clarovantdigital.com/library/clinical-outcomes-of-transformed-follicular-lymphoma-with-car-t-cell-therapy-a-us-multicenter-real-world-analysis/2025-01-10T18:21:28+00:00https://lymphoma-stg.clarovantdigital.com/library/targeting-cd30-in-diffuse-large-b-cell-lymphoma-where-does-it-fit-in/2025-01-10T18:21:30+00:00https://lymphoma-stg.clarovantdigital.com/library/safety-and-efficacy-of-amulirafusp-alfa-imm0306-a-fusion-protein-of-cd20-monoclonal-antibody-with-the-cd47-binding-domain-of-sirp-in-patients-with-relapsed-or-refractory-b-cell-non-hodgkin-lymphom/2025-01-10T18:21:31+00:00https://lymphoma-stg.clarovantdigital.com/library/real-world-effectiveness-and-safety-of-ibrutinib-in-patients-with-chronic-lymphocytic-leukemia-in-japan-the-orbit-study/2025-01-10T18:21:33+00:00https://lymphoma-stg.clarovantdigital.com/library/recent-advances-in-understanding-the-clinical-responses-of-brentuximab-vedotin-in-lymphoma-and-the-correlation-with-cd30-expression/2025-01-10T18:21:34+00:00https://lymphoma-stg.clarovantdigital.com/library/real-world-outcomes-in-patients-with-follicular-lymphoma-treated-with-rchop-vs-br/2024-12-06T19:45:54+00:00https://lymphoma-stg.clarovantdigital.com/library/recurrent-primary-cutaneous-marginal-zone-lymphoma-a-comparative-study-of-initial-tumours-recurrences-and-outcomes-in-61-patients/2024-12-06T19:45:55+00:00https://lymphoma-stg.clarovantdigital.com/library/impact-of-t-cell-characteristics-on-car-t-cell-therapy-in-hematological-malignancies/2024-12-06T19:45:52+00:00https://lymphoma-stg.clarovantdigital.com/library/mosunetuzumab-plus-polatuzumab-vedotin-induces-early-complete-responses-in-previously-untreated-high-tumor-burden-follicular-lymphoma/2024-12-19T15:59:43+00:00https://lymphoma-stg.clarovantdigital.com/library/single-agent-mosunetuzumab-produces-high-complete-response-rates-in-patients-with-newly-diagnosed-follicular-lymphoma-primary-analysis-of-the-mithic-fl1-trial/2024-12-19T15:59:45+00:00https://lymphoma-stg.clarovantdigital.com/library/outcomes-of-relapsed-or-refractory-diffuse-large-b-cell-lymphoma-treated-with-r-gemox-a-multi-center-retrospective-cohort-study/2024-12-19T15:59:46+00:00https://lymphoma-stg.clarovantdigital.com/library/risk-factors-for-severe-infection-in-patients-receiving-bispecific-antibody-therapies-for-lymphoma/2024-12-19T15:59:48+00:00https://lymphoma-stg.clarovantdigital.com/library/retreatment-with-r-chop-like-therapy-in-patients-with-late-relapse-of-diffuse-large-b-cell-lymphoma-dlbcl/2024-12-13T20:00:58+00:00https://lymphoma-stg.clarovantdigital.com/library/retreatment-with-r-chop-like-therapy-is-active-with-durable-responses-in-patients-with-late-relapse-of-diffuse-large-b-cell-lymphoma/2024-12-13T20:01:02+00:00https://lymphoma-stg.clarovantdigital.com/library/rapcabtagene-autoleucel-ytb323-in-patients-pts-with-relapsed-refractory-diffuse-large-b-cell-lymphoma-r-r-dlbcl-phase-ii-trial-clinical-update/2024-12-13T20:01:04+00:00https://lymphoma-stg.clarovantdigital.com/library/targeted-immunotherapy-in-the-treatment-of-childhood-and-adolescent-classic-hodgkin-lymphoma/2024-12-02T15:37:57+00:00https://lymphoma-stg.clarovantdigital.com/library/integrating-pre-and-post-treatment-biomarkers-into-prognostic-models-for-chronic-lymphocytic-leukemia-to-enhance-predictive-performance/2024-12-13T20:01:57+00:00https://lymphoma-stg.clarovantdigital.com/library/progression-of-disease-within-24-months-pod24-in-follicular-lymphoma-in-the-rituximab-era-incidence-clinicopathological-risk-factors-and-outcome-in-a-population-based-danish-cohort/2024-10-11T12:52:09+00:00https://lymphoma-stg.clarovantdigital.com/library/real-world-treatment-outcomes-for-hodgkin-lymphoma-in-south-africa-a-prospective-observational-study/2024-10-11T12:52:14+00:00https://lymphoma-stg.clarovantdigital.com/library/bridging-radiotherapy-prior-to-brexucabtagene-autoleucel-for-relapsed-refractory-mantle-cell-lymphoma/2024-10-11T12:52:15+00:00https://lymphoma-stg.clarovantdigital.com/library/intensity-of-survivin-expression-linked-to-features-of-aggressive-relapsed-refractory-diffuse-large-b-cell-lymphoma/2024-10-11T12:52:17+00:00https://lymphoma-stg.clarovantdigital.com/library/is-radiotherapy-still-the-optimal-initial-choice-for-patients-with-early-stage-low-grade-follicular-lymphoma-in-the-modern-era-a-population-based-study/2024-10-29T20:08:47+00:00https://lymphoma-stg.clarovantdigital.com/library/efficacy-and-effectiveness-outcomes-of-treatments-for-double-exposed-chronic-lymphocytic-leukemia-and-small-lymphocytic-lymphoma-patients-a-systematic-literature-review/2025-03-03T20:20:57+00:00https://lymphoma-stg.clarovantdigital.com/library/personalized-neoantigen-vaccines-as-early-intervention-in-untreated-patients-with-lymphoplasmacytic-lymphoma-a-non-randomized-phase-1-trial/2024-10-11T12:52:21+00:00https://lymphoma-stg.clarovantdigital.com/library/glofitamab-in-relapsed-refractory-mantle-cell-lymphoma-results-from-a-phase-i-ii-study/2024-10-11T12:52:23+00:00https://lymphoma-stg.clarovantdigital.com/library/hypophosphatemia-correction-reduces-icans-incidence-and-duration-in-car-t-cell-therapy-a-pooled-clinical-trial-analysis/2024-10-11T12:52:24+00:00https://lymphoma-stg.clarovantdigital.com/library/benefits-of-bv-avd-brentuximab-vedotin-doxorubicin-vinblastine-and-dacarbazine-versus-abvd-doxorubicin-hydrochloride-bleomycin-sulfate-vinblastine-sulfate-dacarbazine-in-patients-with-advanc/2024-10-11T12:52:26+00:00https://lymphoma-stg.clarovantdigital.com/library/pediatric-type-follicular-lymphoma-and-pediatric-nodal-marginal-zone-lymphoma-additional-evidence-to-support-they-are-a-single-disease-with-variation-in-the-histologic-spectrum/2024-10-11T12:52:27+00:00https://lymphoma-stg.clarovantdigital.com/library/a-german-perspective-on-the-impact-of-socioeconomic-status-in-diffuse-large-b-cell-lymphoma/2024-10-11T12:52:29+00:00https://lymphoma-stg.clarovantdigital.com/library/utility-of-p53-immunohistochemical-staining-for-risk-stratification-of-mantle-cell-lymphoma/2024-10-18T17:30:39+00:00https://lymphoma-stg.clarovantdigital.com/library/clinical-features-and-prognosis-of-patients-with-covid-19-and-b-cell-non-hodgkin-lymphoma/2024-10-18T17:34:14+00:00https://lymphoma-stg.clarovantdigital.com/library/preferences-of-patients-and-physicians-in-the-united-states-for-relapsed-refractory-follicular-lymphoma-treatments/2025-12-19T18:32:35+00:00https://lymphoma-stg.clarovantdigital.com/library/biological-findings-and-clinical-outcomes-in-patients-treated-with-r-chop-plus-high-dose-methotrexate-as-first-line-therapy-in-large-b-cell-lymphoma-with-testis-involvement/2024-10-18T18:08:47+00:00https://lymphoma-stg.clarovantdigital.com/library/the-effect-of-a-single-session-of-30-min-mindful-breathing-in-reducing-fatigue-among-patients-with-haematological-cancer-a-randomised-controlled-trial/2024-10-18T18:08:48+00:00https://lymphoma-stg.clarovantdigital.com/library/histomorphologic-spectrum-of-nodal-marginal-zone-lymphoma-as-defined-by-its-methylome/2024-10-18T18:08:50+00:00https://lymphoma-stg.clarovantdigital.com/library/limited-stage-high-grade-b-cell-lymphoma-with-myc-bcl2-and-or-bcl6-rearrangements-bcl2-rearrangements-drives-the-poor-outcomes/2024-10-18T18:08:51+00:00https://lymphoma-stg.clarovantdigital.com/library/frequently-asked-questions-on-surrogate-endpoints-in-oncology-opportunities-pitfalls-and-the-way-forward/2024-10-18T18:08:52+00:00https://lymphoma-stg.clarovantdigital.com/library/a-phase-2-study-of-frontline-pembrolizumab-in-follicular-lymphoma/2024-10-18T18:08:54+00:00https://lymphoma-stg.clarovantdigital.com/library/reduced-intensity-conditioning-prior-autologous-stem-cell-transplantation-in-elderly-dlbcl-patients/2025-12-19T15:11:26+00:00https://lymphoma-stg.clarovantdigital.com/library/end-point-surrogacy-in-first-line-chronic-lymphocytic-leukemia/2024-10-18T18:08:57+00:00https://lymphoma-stg.clarovantdigital.com/library/omission-of-radiotherapy-in-primary-mediastinal-b-cell-lymphoma-ielsg37-trial-results/2025-05-27T12:25:18+00:00https://lymphoma-stg.clarovantdigital.com/library/outpatient-administration-of-car-t-cell-therapies-using-a-strategy-of-no-remote-monitoring-and-early-crs-intervention/2024-10-18T18:09:00+00:00https://lymphoma-stg.clarovantdigital.com/library/pembrowm-a-phase-ii-trial-to-investigate-the-safety-and-efficacy-of-rituximab-and-pembrolizumab-in-relapsed-refractory-waldenstrom-macroglobulinaemia/2026-01-16T14:50:47+00:00https://lymphoma-stg.clarovantdigital.com/library/incidence-of-hematologic-cancer-types-in-japan-by-icd-o-3-code-analysis-of-national-cancer-registry/2024-10-18T18:09:03+00:00https://lymphoma-stg.clarovantdigital.com/library/maternal-and-obstetric-outcomes-in-women-with-pregnancy-associated-haematological-malignancies-an-observational-nationwide-cohort-study/2024-10-18T18:09:04+00:00https://lymphoma-stg.clarovantdigital.com/library/evaluation-of-ki-67-expression-and-large-cell-content-as-prognostic-markers-in-mzl-a-multicenter-cohort-study/2024-10-18T18:09:06+00:00https://lymphoma-stg.clarovantdigital.com/library/beta-2-microglobulin-maintains-overall-survival-prediction-in-binet-a-stage-chronic-lymphocytic-leukemia-patients-with-compromised-kidney-function-in-both-treatment-eras-of-chemoimmunotherapy-and-targ/2024-11-07T14:47:41+00:00https://lymphoma-stg.clarovantdigital.com/library/incidence-and-mortality-trends-and-geographic-patterns-of-follicular-lymphoma-in-canada-2/2024-11-22T17:56:14+00:00https://lymphoma-stg.clarovantdigital.com/library/long-term-three-year-follow-up-of-mosunetuzumab-in-relapsed-or-refractory-follicular-lymphoma-after-%e2%89%a52-prior-therapies/2024-10-29T11:08:44+00:00https://lymphoma-stg.clarovantdigital.com/library/impact-of-the-immune-landscape-in-follicular-lymphoma-insights-into-histological-transformation-in-the-rituximab-era/2024-10-29T11:13:10+00:00https://lymphoma-stg.clarovantdigital.com/library/cellular-therapy-in-older-adults-with-relapsed-refractory-diffuse-large-b-cell-lymphoma/2024-10-29T11:17:33+00:00https://lymphoma-stg.clarovantdigital.com/library/the-evolving-role-of-checkpoint-inhibitors-in-the-treatment-of-hodgkin-lymphoma/2024-10-29T13:31:45+00:00https://lymphoma-stg.clarovantdigital.com/library/tumor-biology-hides-novel-therapeutic-approaches-to-diffuse-large-b-cell-lymphoma-a-narrative-review/2024-10-29T13:56:43+00:00https://lymphoma-stg.clarovantdigital.com/library/pirtobrutinib-monotherapy-in-bruton-tyrosine-kinase-inhibitor-intolerant-patients-with-b-cell-malignancies-results-of-the-phase-i-ii-bruin-trial/2024-10-29T14:05:57+00:00https://lymphoma-stg.clarovantdigital.com/library/covid-19-in-patients-with-chronic-lymphocytic-leukemia-treated-with-venetoclax-what-is-the-role-of-anti-cd20-antibody/2024-10-29T18:50:10+00:00https://lymphoma-stg.clarovantdigital.com/library/sustained-benefit-of-zanubrutinib-vs-ibrutinib-in-patients-with-r-r-cll-sll-final-comparative-analysis-of-alpine/2025-03-03T19:51:26+00:00https://lymphoma-stg.clarovantdigital.com/library/genomic-landscape-of-testicular-follicular-lymphoma-is-characterized-by-frequent-1p36-tnfrsf14-alterations/2024-12-02T15:43:45+00:00https://lymphoma-stg.clarovantdigital.com/library/effectiveness-of-fractionated-rituximab-in-preventing-tumor-lysis-syndrome-in-aggressive-b-cell-lymphoma-insights-from-real-life-clinical-practice/2026-01-06T21:06:41+00:00https://lymphoma-stg.clarovantdigital.com/library/from-virus-to-cancer-epstein-barr-virus-mirna-connection-in-burkitts-lymphoma/2024-11-01T13:49:27+00:00https://lymphoma-stg.clarovantdigital.com/library/low-magnesium-levels-and-prognosis-in-newly-diagnosed-diffuse-large-b-cell-lymphoma/2024-11-01T13:49:28+00:00https://lymphoma-stg.clarovantdigital.com/library/patient-reported-outcomes-of-chimeric-antigen-receptor-t-cell-therapy-in-hematologic-malignancies-a-systematic-review-and-meta-analysis/2024-11-01T13:49:30+00:00https://lymphoma-stg.clarovantdigital.com/library/conditional-survival-of-younger-patients-with-mantle-cell-lymphoma-results-from-a-randomized-phase-iii-trial-of-the-european-mcl-network/2024-11-01T13:49:31+00:00https://lymphoma-stg.clarovantdigital.com/library/long-term-efficacy-and-safety-of-chemotherapy-free-first-line-iodine-131-rituximab-radioimmunotherapy-of-follicular-lymphoma/2024-11-01T13:49:32+00:00https://lymphoma-stg.clarovantdigital.com/library/matching-adjusted-indirect-comparison-of-acalabrutinib-versus-ibrutinib-in-relapsed-refractory-mantle-cell-lymphoma/2024-11-01T13:49:34+00:00https://lymphoma-stg.clarovantdigital.com/library/profiling-risk-factors-for-separation-of-infection-complications-in-patients-with-gastrointestinal-and-nodal-diffuse-large-b-cell-lymphoma/2024-11-01T13:49:35+00:00https://lymphoma-stg.clarovantdigital.com/library/uptake-of-health-economic-evaluations-alongside-clinical-trials-in-australia-an-observational-study/2024-11-01T13:49:37+00:00https://lymphoma-stg.clarovantdigital.com/library/sequencing-of-therapy-for-patients-with-diffuse-large-b-cell-lymphoma-in-the-era-of-novel-drugs/2024-11-01T13:49:38+00:00https://lymphoma-stg.clarovantdigital.com/library/machine-learning-to-predict-interim-response-in-pediatric-classical-hodgkin-lymphoma-using-affordable-blood-tests/2024-11-01T13:49:40+00:00https://lymphoma-stg.clarovantdigital.com/library/development-and-validation-of-the-post-car-prognostic-index-for-large-b-cell-lymphoma-patients-after-car-t-progression-in-third-or-later-line-treatment/2024-11-01T13:49:41+00:00https://lymphoma-stg.clarovantdigital.com/library/innovative-label-free-lymphoma-diagnosis-using-infrared-spectroscopy-and-machine-learning-on-tissue-sections/2024-11-01T13:49:42+00:00https://lymphoma-stg.clarovantdigital.com/library/prognostic-impact-of-concordant-and-discordant-bone-marrow-involvement-on-diffuse-large-b-cell-lymphoma/2024-11-01T13:49:44+00:00https://lymphoma-stg.clarovantdigital.com/library/venetoclax-obinutuzumab-for-previously-untreated-chronic-lymphocytic-leukemia-6-year-results-of-the-randomized-phase-3-cll14-study/2024-11-01T13:49:45+00:00https://lymphoma-stg.clarovantdigital.com/library/detection-of-notch1-mutation-among-chronic-lymphocytic-leukemia-in-sudanese-population/2024-11-04T14:48:44+00:00https://lymphoma-stg.clarovantdigital.com/library/treatment-patterns-and-real-world-outcomes-with-clinical-trials-for-patients-with-follicular-lymphoma-across-lines-of-therapy/2024-12-19T15:59:09+00:00https://lymphoma-stg.clarovantdigital.com/library/advanced-stage-hodgkin-and-diffuse-large-b-cell-lymphomas-is-there-still-a-role-for-consolidation-radiotherapy-in-the-pet-era/2024-12-19T15:59:00+00:00https://lymphoma-stg.clarovantdigital.com/library/eleven-cases-of-laryngeal-edema-after-tisagenlecleucel-infusion-a-3-year-single-center-retrospective-study-of-cd19-directed-chimeric-antigen-receptor-t-cell-therapy-for-relapsed-and-refractory-b-cell/2024-12-18T00:50:59+00:00https://lymphoma-stg.clarovantdigital.com/library/richter-transformation-rt-in-chronic-lymphocytic-leukemia-cll-and-small-lymphocytic-lymphoma-sll-a-comparison-of-two-eras/2024-12-13T20:03:05+00:00https://lymphoma-stg.clarovantdigital.com/library/cd19-car-t-cell-therapy-is-effective-in-richter-transformation-a-multicenter-retrospective-analysis-by-the-european-research-initiative-on-chronic-lymphocytic-leukemia/2024-12-13T20:02:59+00:00https://lymphoma-stg.clarovantdigital.com/library/efficacy-and-safety-of-tak-007-cord-blood-derived-cd19-car-nk-cells-in-adult-patients-with-relapsed-refractory-r-r-b-cell-non-hodgkin-lymphoma-nhl/2024-12-13T20:02:36+00:00https://lymphoma-stg.clarovantdigital.com/library/a-randomized-phase-ii-study-of-mosunetuzumab-sc-plus-polatuzumab-vedotin-demonstrates-improved-outcomes-versus-rituximab-plus-polatuzumab-vedotin-in-patients-pts-with-relapsed-or-refractory-r-r-la/2024-12-13T20:02:30+00:00https://lymphoma-stg.clarovantdigital.com/library/real-world-evidence-for-duvelisib-and-romidepsin-combination-in-patients-with-relapsed-refractory-peripheral-t-cell-lymphomas/2025-05-23T19:33:25+00:00https://lymphoma-stg.clarovantdigital.com/library/duvelisib-in-patients-with-relapsed-refractory-peripheral-t-cell-lymphoma-final-results-from-the-phase-2-primo-trial/2024-12-13T20:02:18+00:00https://lymphoma-stg.clarovantdigital.com/library/sustained-superiority-of-zanubrutinib-vs-bendamustine-rituximab-in-treatment-naive-chronic-lymphocytic-leukemia-small-lymphocytic-lymphoma-tn-cll-5-year-follow-up-of-cohort-1-from-the-sequoia-stu/2025-03-03T20:04:58+00:00https://lymphoma-stg.clarovantdigital.com/library/pembrolizumab-in-children-adolescents-and-young-adults-with-high-risk-classic-hodgkin-lymphoma-chl-with-slow-early-response-to-front-line-chemotherapy-updated-results-from-the-phase-2-keynote-667/2024-12-13T20:01:27+00:00https://lymphoma-stg.clarovantdigital.com/library/outcome-of-extra-nodal-follicular-lymphoma-affected-by-selection-of-induction-chemoimmunotherapy-and-maintenance-rituximab-real-world-retrospective-study/2024-12-13T20:01:15+00:00https://lymphoma-stg.clarovantdigital.com/library/lymphomas-with-primary-gastrointestinal-presentation-a-retrospective-study-covering-a-five-year-period-at-a-quaternary-care-center-in-southern-india/2024-12-06T19:45:57+00:00https://lymphoma-stg.clarovantdigital.com/library/proteomic-profiling-identifies-classic-hodgkin-lymphoma-patients-at-risk-of-bleomycin-pulmonary-toxicity/2024-12-06T19:45:56+00:00https://lymphoma-stg.clarovantdigital.com/library/long-term-breast-cancer-risk-in-hodgkin-lymphoma-survivors-evaluating-background-parenchymal-enhancement-and-radiotherapy-induced-toxicity/2024-12-06T19:35:52+00:00https://lymphoma-stg.clarovantdigital.com/library/a-avd-for-treatment-of-hodgkin-lymphoma-variant-of-richters-transformation/2024-11-08T19:43:27+00:00https://lymphoma-stg.clarovantdigital.com/library/the-utilization-of-cytology-for-intraoperative-diagnosis-of-primary-central-nervous-system-lymphoma/2024-11-08T19:43:30+00:00https://lymphoma-stg.clarovantdigital.com/library/ethical-and-regulatory-aspects-of-genome-editing/2024-11-08T19:43:32+00:00https://lymphoma-stg.clarovantdigital.com/library/availability-of-evidence-of-benefits-on-overall-survival-and-quality-of-life-of-cancer-drugs-approved-by-european-medicines-agency-retrospective-cohort-study-of-drug-approvals-2009-13/2024-11-08T19:43:33+00:00https://lymphoma-stg.clarovantdigital.com/library/patients-priorities-in-selecting-chronic-lymphocytic-leukemia-treatments/2024-11-08T19:43:34+00:00https://lymphoma-stg.clarovantdigital.com/library/what-is-next-for-patient-preferences-in-health-technology-assessment-a-systematic-review-of-the-challenges/2024-11-08T19:43:36+00:00https://lymphoma-stg.clarovantdigital.com/library/a-comparison-of-ema-and-fda-decisions-for-new-drug-marketing-applications-2014-2016-concordance-discordance-and-why/2025-12-19T18:32:11+00:00https://lymphoma-stg.clarovantdigital.com/library/is-car-t-a-drug-or-a-therapeutic-pathway-intention-to-treat-versus-per-protocol-analysis-of-real-world-studies-of-car-t-cell-therapy-in-relapsed-refractory-diffuse-large-b-cell-lymphoma/2024-11-08T19:43:38+00:00https://lymphoma-stg.clarovantdigital.com/library/interstitial-lung-disease-presents-with-varying-characteristics-in-patients-with-non-hodgkin-lymphoma-undergoing-rituximab-containing-therapies/2024-11-08T19:43:40+00:00https://lymphoma-stg.clarovantdigital.com/library/fifteen-years-of-non-hodgkin-lymphoma-in-an-indonesian-national-referral/2026-03-13T19:30:31+00:00https://lymphoma-stg.clarovantdigital.com/library/outcomes-of-autologous-stem-cell-transplantation-in-patients-with-primary-refractory-diffuse-large-b-cell-lymphoma-who-demonstrate-chemosensitivity-to-salvage-chemotherapy/2024-11-12T15:58:30+00:00https://lymphoma-stg.clarovantdigital.com/library/forty-years-after-mediastinal-radiotherapy-for-hodgkin-lymphoma-how-late-is-late-cardiotoxicity-a-case-report/2024-11-12T16:04:22+00:00https://lymphoma-stg.clarovantdigital.com/library/safety-landscape-of-bispecific-antibody-therapy-in-non-hodgkin-lymphoma-a-systematic-review-and-meta-analysis/2024-12-13T19:22:57+00:00https://lymphoma-stg.clarovantdigital.com/library/exploring-the-complexity-treatment-challenges-and-outcomes-in-pediatric-nodular-lymphocyte-predominant-hodgkin-lymphoma-a-perspective-from-a-low-middle-income-country/2024-11-13T18:43:29+00:00https://lymphoma-stg.clarovantdigital.com/library/primary-seminal-vesicle-diffuse-large-b-cell-lymphoma-a-case-report-and-review-of-the-literatures/2024-11-15T14:55:33+00:00https://lymphoma-stg.clarovantdigital.com/library/changes-of-t-cell-subsets-across-treatments-associated-with-prognosis-in-newly-diagnosed-follicular-lymphoma/2024-11-15T19:43:59+00:00https://lymphoma-stg.clarovantdigital.com/library/trbc1-car-t-cell-therapy-in-peripheral-t-cell-lymphoma-a-phase-1-2-trial/2026-01-16T15:03:50+00:00https://lymphoma-stg.clarovantdigital.com/library/risk-of-cardiovascular-disease-in-patients-with-classical-hodgkin-lymphoma-a-danish-nationwide-register-based-cohort-study/2024-11-15T19:44:03+00:00https://lymphoma-stg.clarovantdigital.com/library/ibrutinib-plus-rituximab-and-mini-chop-in-older-patients-with-newly-diagnosed-dlbcl-a-phase-2-allg-study/2024-11-15T19:44:04+00:00https://lymphoma-stg.clarovantdigital.com/library/a-decade-of-prevalence-and-clinicopathological-insights-into-classical-hodgkin-lymphoma-a-study-from-an-indonesian-tertiary-hospital/2024-11-15T19:44:06+00:00https://lymphoma-stg.clarovantdigital.com/library/incidence-trends-of-non-hodgkin-lymphoma-in-children-in-the-united-states-from-2000-to-2020/2024-11-15T19:44:07+00:00https://lymphoma-stg.clarovantdigital.com/library/efficacy-and-safety-of-zanubrutinib-monotherapy-for-chronic-lymphocytic-leukemia-small-lymphocytic-lymphoma-a-multicenter-real-world-study-in-china/2025-03-03T20:06:20+00:00https://lymphoma-stg.clarovantdigital.com/library/post-transplant-cyclophosphamide-plus-everolimus-as-gvhd-prophylaxis-in-refractory-t-and-b-cell-lymphoma/2024-11-15T19:44:10+00:00https://lymphoma-stg.clarovantdigital.com/library/real-world-comparison-of-health-care-costs-of-venetoclax-obinutuzumab-vs-brutons-tyrosine-kinase-inhibitor-use-among-us-medicare-beneficiaries-with-chronic-lymphocytic-leukemia-in-the-frontli/2025-12-19T18:31:54+00:00https://lymphoma-stg.clarovantdigital.com/library/advances-in-diagnosis-and-treatment-for-nodal-and-gastrointestinal-follicular-lymphomas-focused-on-gene-targeted-and-immune-therapeutic-agents/2024-11-20T19:35:49+00:00https://lymphoma-stg.clarovantdigital.com/library/the-importance-of-real-world-data-in-evaluating-the-safety-of-biosimilars-a-descriptive-study-of-clinical-practice-in-an-oncohematological-italian-population/2026-01-06T21:07:16+00:00https://lymphoma-stg.clarovantdigital.com/library/risk-factors-for-secondary-malignancies-in-hodgkins-lymphoma-patients-treated-with-radiation-therapy-a-seer-database-analysis/2024-11-22T18:15:51+00:00https://lymphoma-stg.clarovantdigital.com/library/the-impact-of-breast-implant-associated-anaplastic-large-cell-lymphoma-on-breast-implant-surgery-a-european-survey-based-study/2024-11-22T21:03:39+00:00https://lymphoma-stg.clarovantdigital.com/library/myc-rearranged-mature-b-cell-lymphomas-in-children-and-young-adults-are-molecularly-burkitt-lymphoma/2024-11-22T21:03:43+00:00https://lymphoma-stg.clarovantdigital.com/library/therapeutic-advances-in-the-targeting-of-ror1-in-hematological-cancers/2024-11-22T21:03:44+00:00https://lymphoma-stg.clarovantdigital.com/library/autoimmune-hemolytic-anemia-a-challenging-complication-of-allogeneic-hematopoietic-stem-cell-transplant/2024-11-22T21:03:45+00:00https://lymphoma-stg.clarovantdigital.com/library/health-related-quality-of-life-in-oncology-drug-reimbursement-submissions-in-canada-a-review-of-submissions-to-the-pan-canadian-oncology-drug-review/2024-11-22T21:03:47+00:00https://lymphoma-stg.clarovantdigital.com/library/diffuse-large-b-cell-lymphoma-presentation-at-an-early-age/2024-11-22T21:03:48+00:00https://lymphoma-stg.clarovantdigital.com/library/venetoclax-therapy-in-chronic-lymphocytic-leukaemia-patients-relapsed-after-allogeneic-haematopoietic-stem-cell-transplantation/2025-01-10T18:21:25+00:00https://lymphoma-stg.clarovantdigital.com/library/brentuximab-vedotin-combination-for-relapsed-diffuse-large-b-cell-lymphoma/2025-01-10T18:21:24+00:00https://lymphoma-stg.clarovantdigital.com/library/real-world-data-on-the-clinical-features-therapy-patterns-and-outcomes-of-older-adults-with-diffuse-large-b-cell-lymphoma-in-latin-america-a-study-from-the-grupo-de-estudio-latinoamericano-de-linfo/2025-01-10T18:21:22+00:00https://lymphoma-stg.clarovantdigital.com/library/bcl2i-based-therapies-and-emerging-resistance-in-chronic-lymphocytic-leukemia/2024-11-28T15:35:10+00:00https://lymphoma-stg.clarovantdigital.com/library/comparative-safety-of-novel-targeted-therapies-in-relapsed-refractory-chronic-lymphocytic-leukemia-a-network-meta-analysis/2024-11-28T15:47:22+00:00https://lymphoma-stg.clarovantdigital.com/library/nodular-lymphocyte-predominant-hodgkin-lymphoma-a-special-type-of-follicular-b-cell-lymphoma/2024-11-28T15:53:16+00:00https://lymphoma-stg.clarovantdigital.com/library/real-world-evidence-on-adverse-events-and-healthcare-resource-utilization-in-patients-with-chronic-lymphocytic-leukaemia-in-spain-using-natural-language-processing-the-srealcll-study/2025-04-14T20:51:33+00:00https://lymphoma-stg.clarovantdigital.com/library/global-disparities-in-cancer-care-bridging-the-gap-in-affordability-and-access-to-medications-between-high-and-low-income-countries/2024-11-29T19:46:07+00:00https://lymphoma-stg.clarovantdigital.com/library/dedicated-diagnostic-approaches-for-mature-b-cell-non-hodgkin-lymphomas-occurring-in-children-adolescents-and-young-adults/2024-11-29T19:46:09+00:00https://lymphoma-stg.clarovantdigital.com/library/outcomes-and-prognostic-factors-in-3306-patients-with-relapsed-refractory-chronic-lymphocytic-leukemia-treated-with-ibrutinib-outside-of-clinical-trials-a-nationwide-study/2024-11-29T19:46:11+00:00https://lymphoma-stg.clarovantdigital.com/library/indolent-nodal-t-follicular-helper-cell-lymphomas-a-case-series/2025-05-23T19:32:23+00:00https://lymphoma-stg.clarovantdigital.com/library/treatment-sequencing-and-impact-of-number-of-treatment-lines-on-survival-in-follicular-lymphoma-a-national-populatio-based-study/2024-11-29T19:46:14+00:00https://lymphoma-stg.clarovantdigital.com/library/vitamin-d-in-patients-with-low-tumor-burden-indolent-non-hodgkin-lymphoma-treated-with-rituximab-therapy-ilyad-a-randomized-phase-3-clinical-trial/2024-11-29T19:46:15+00:00https://lymphoma-stg.clarovantdigital.com/library/outcomes-with-loncastuximab-tesirine-following-car-t-cell-therapy-in-patients-with-relapsed-or-refractory-diffuse-large-b-cell-lymphoma/2024-11-29T19:46:17+00:00https://lymphoma-stg.clarovantdigital.com/library/association-of-abnormal-p-wave-parameters-with-all-cause-mortality-in-diffuse-large-b-cell-lymphoma/2024-11-29T19:46:18+00:00https://lymphoma-stg.clarovantdigital.com/library/associations-between-sexuality-body-image-and-health-related-quality-of-life-in-patients-treated-for-diffuse-large-b-cell-lymphoma-a-cross-sectional-study/2024-11-29T19:46:19+00:00https://lymphoma-stg.clarovantdigital.com/library/a-comparative-analysis-of-transformed-indolent-lymphomas-and-de-novo-diffuse-large-b-cell-lymphoma-a-population-based-cohort-study/2024-11-29T19:46:21+00:00https://lymphoma-stg.clarovantdigital.com/library/maximum-tumor-diameter-is-associated-with-relapse-risk-in-limited-stage-hodgkin-lymphoma-an-international-study/2025-01-17T20:56:20+00:00https://lymphoma-stg.clarovantdigital.com/library/impact-of-filgrastim-on-mortality-during-induction-chemotherapy-in-childhood-b-cell-non-hodgkin-lymphoma/2025-01-17T21:05:16+00:00https://lymphoma-stg.clarovantdigital.com/library/aplastic-anemia-triggered-by-the-bruton-tyrosine-kinase-inhibitor-acalabrutinib-in-two-patients-with-mantle-cell-lymphoma-a-case-report/2025-01-17T21:05:19+00:00https://lymphoma-stg.clarovantdigital.com/library/impact-of-minimal-residual-disease-analysis-in-the-era-of-rituximab-maintenance-in-follicular-lymphoma-data-from-foll12-phase-iii-trial-of-the-fondazione-italiana-linfomi/2025-01-17T21:05:21+00:00https://lymphoma-stg.clarovantdigital.com/library/potential-delayed-immune-related-adverse-events-in-patients-treated-with-frontline-pembrolizumab-avd-for-classic-hodgkin-lymphoma/2025-01-17T21:05:22+00:00https://lymphoma-stg.clarovantdigital.com/library/brentuximab-vedotin-based-regimens-for-older-patients-with-newly-diagnosed-classical-hodgkin-lymphoma-international-multi-center-real-world-experience/2025-01-17T21:05:24+00:00https://lymphoma-stg.clarovantdigital.com/library/safety-and-efficacy-of-chimeric-antigen-receptor-t-cell-therapy-in-octogenarian-patients-aged-80-with-relapsed-or-refractory-r-r-large-b-cell-lymphoma-lbcl/2025-01-17T21:05:25+00:00https://lymphoma-stg.clarovantdigital.com/library/multicenter-phase-ii-trial-of-zanubrutinib-obinutuzumab-and-venetoclax-boven-in-treatment-naive-chronic-lymphocytic-leukemia-5-year-follow-up-retreatment-outcomes-and-impact-of-mrd-kinetics-mr/2025-01-17T21:05:27+00:00https://lymphoma-stg.clarovantdigital.com/library/dual-targeted-therapy-with-ruxolitinib-plus-duvelisib-for-t-cell-lymphoma/2025-01-17T21:05:28+00:00https://lymphoma-stg.clarovantdigital.com/library/health-related-quality-of-life-in-patients-with-relapsed-refractory-cutaneous-t-cell-lymphoma-treated-by-lacutamab-patient-reported-outcomes-from-the-phase-2-tellomak-trial/2025-01-17T21:05:30+00:00https://lymphoma-stg.clarovantdigital.com/library/updated-analysis-of-brentuximab-vedotin-nivolumab-doxorubicin-and-dacarbazine-for-nonbulky-early-stage-classical-hodgkin-lymphoma/2025-01-17T21:05:31+00:00https://lymphoma-stg.clarovantdigital.com/library/omission-of-bleomycin-in-limited-stage-classic-hodgkin-lymphoma-patients-with-a-negative-pet-scan-following-2-cycles-of-abvd-is-associated-with-comparable-outcomes-and-reduced-pulmonary-toxicity/2025-01-17T21:05:33+00:00https://lymphoma-stg.clarovantdigital.com/library/brentuximab-vedotin-bv-and-nivolumab-nivo-for-untreated-patients-with-hodgkin-lymphoma-hl-long-term-results/2025-01-17T21:05:34+00:00https://lymphoma-stg.clarovantdigital.com/library/final-response-and-survival-results-from-a-phase-ii-trial-of-pembrolizumab-and-entinostat-in-relapsed-refractory-hodgkin-lymphoma/2025-01-17T21:05:36+00:00https://lymphoma-stg.clarovantdigital.com/library/outcomes-of-primary-mediastinal-b-cell-lymphoma-patients-treated-with-a-pet-guided-strategy-in-the-randomized-phase-3-gained-study-conducted-by-lysa/2025-01-17T21:05:37+00:00https://lymphoma-stg.clarovantdigital.com/library/final-analysis-of-the-safety-and-efficacy-of-venetoclax-in-combination-with-pola-r-chp-for-untreated-high-risk-bcl-2-positive-b-cell-lymphoma-including-double-triple-hit-lymphoma/2025-01-17T21:05:39+00:00https://lymphoma-stg.clarovantdigital.com/library/real-world-outcomes-of-frontline-polatuzumab-and-impact-of-frailty-in-older-adults-with-newly-diagnosed-diffuse-large-b-cell-lymphoma-dlbcl/2025-01-17T21:05:40+00:00https://lymphoma-stg.clarovantdigital.com/library/acalabrutinib-versus-chlorambucil-plus-rituximab-in-patients-with-previously-untreated-chronic-lymphocytic-leukemia-a-randomized-multicenter-open-label-phase-3-study/2025-01-17T21:05:41+00:00https://lymphoma-stg.clarovantdigital.com/library/bortezomib-in-combination-with-ibrutinib-rituximab-is-a-highly-effective-and-well-tolerated-first-line-treatment-for-waldenstrom-macroglobulinemia-results-of-the-multicenter-phase-ii-trial-ecwm-2/2025-01-17T21:05:43+00:00https://lymphoma-stg.clarovantdigital.com/library/iopofosine-i-131-in-previously-treated-patients-with-waldenstrom-macroglobulinemia-wm-efficacy-and-safety-results-from-the-international-multicenter-open-label-phase-2-study-clover-wam/2025-01-17T21:05:44+00:00https://lymphoma-stg.clarovantdigital.com/library/longer-follow-up-of-golcadomide-golca-a-cereblon-e3-ligase-modulator-celmod-agent-rituximab-rtx-in-patients-with-relapsed-refractory-r-r-diffuse-large-b-cell-lymphoma-dlbcl/2025-01-17T21:05:46+00:00https://lymphoma-stg.clarovantdigital.com/library/minimal-residual-disease-mrd-adapted-duration-of-front-line-venetoclax-and-obinutuzumab-treatment-for-fit-patients-with-chronic-lymphocytic-leukemia-cll/2025-01-17T21:05:47+00:00https://lymphoma-stg.clarovantdigital.com/library/prognostic-significance-of-immune-reconstitution-following-cd19-car-t-cell-therapy-for-relapsed-refractory-b-cell-lymphoma/2025-01-17T21:05:49+00:00https://lymphoma-stg.clarovantdigital.com/library/safety-and-efficacy-of-anti-cd30-car-t-cell-therapy-in-relapsed-refractory-classic-hodgkin-lymphoma-a-systematic-review-and-meta-analysis/2025-01-17T21:05:50+00:00https://lymphoma-stg.clarovantdigital.com/library/pet-ct-based-target-volume-definition-in-involved-site-radiotherapy-for-treatment-of-early-stage-nodal-follicular-lymphoma/2025-01-17T21:05:52+00:00https://lymphoma-stg.clarovantdigital.com/library/assessment-of-treatment-outcomes-and-associated-factors-among-pediatric-patients-with-burkitt-lymphoma-at-kenyatta-national-hospital/2026-03-13T18:14:50+00:00https://lymphoma-stg.clarovantdigital.com/library/targeted-next-generation-sequencing-of-cell-free-dna-to-detect-myc-immunoglobulin-translocation-and-epstein-barr-virus-dna-in-plasma-of-burkitt-lymphoma-patients-in-east-africa/2026-09-02T16:02:04+00:00https://lymphoma-stg.clarovantdigital.com/library/impact-of-circulating-lymphoma-cells-at-diagnosis-on-outcomes-in-patients-with-newly-diagnosed-de-novo-diffuse-large-b-cell-lymphoma/2025-01-17T21:05:56+00:00https://lymphoma-stg.clarovantdigital.com/library/long-term-results-of-a-phase-1-1b-study-of-ibrutinib-plus-umbralisib-for-relapsed-refractory-chronic-lymphocytic-leukemia/2025-01-17T21:05:57+00:00https://lymphoma-stg.clarovantdigital.com/library/brentuximab-vedotin-nivolumab-doxorubicin-and-dacarbazine-for-advanced-stage-classical-hodgkin-lymphoma-2/2025-01-17T21:05:59+00:00https://lymphoma-stg.clarovantdigital.com/library/real-world-assessment-to-estimate-multiple-attributes-related-to-treatment-cost-driver-for-mantle-cell-lymphoma-in-japan-by-econometric-modeling/2025-01-31T19:53:50+00:00https://lymphoma-stg.clarovantdigital.com/library/cd19-directed-cart-therapy-for-t-cell-histiocyte-rich-large-b-cell-lymphoma/2026-06-15T19:37:12+00:00https://lymphoma-stg.clarovantdigital.com/library/diagnosis-and-risk-stratification-in-waldenstrom-macroglobulinemia/2025-01-31T19:53:54+00:00https://lymphoma-stg.clarovantdigital.com/library/prognostic-value-of-the-controlling-nutritional-status-conut-score-in-patients-with-diffuse-large-b-cell-lymphoma-a-meta-analysis/2025-01-31T19:53:56+00:00https://lymphoma-stg.clarovantdigital.com/library/association-between-surgery-and-increased-survival-in-primary-central-nervous-system-lymphoma-a-retrospective-cohort-study/2025-01-31T19:53:57+00:00https://lymphoma-stg.clarovantdigital.com/library/virtual-biopsy-for-non-invasive-identification-of-follicular-lymphoma-histologic-transformation-using-radiomics-based-imaging-biomarker-from-pet-ct/2025-01-31T19:53:58+00:00https://lymphoma-stg.clarovantdigital.com/library/six-month-rituximab-lenalidomide-regimen-in-advanced-untreated-follicular-lymphoma-sakk-35-10-trial-10-year-update/2025-02-06T18:46:26+00:00https://lymphoma-stg.clarovantdigital.com/library/hyper-fractionated-radiotherapy-as-a-bridging-strategy-to-enhance-car-t-efficacy-by-regulating-t-cell-co-stimulatory-molecules-in-relapsed-refractory-diffuse-large-b-cell-lymphoma/2024-12-03T18:06:54+00:00https://lymphoma-stg.clarovantdigital.com/library/primary-uterine-non-hodgkins-lymphomaa-rare-case-report-and-review-of-the-literature/2024-12-20T18:13:40+00:00https://lymphoma-stg.clarovantdigital.com/library/obinutuzumab-in-combination-with-alternative-chlorambucil-schedules-in-front-line-treatment-of-chronic-lymphocytic-leukemia-a-study-by-krohem-the-croatian-cooperative-group-for-hematologic-diseases/2024-12-20T18:33:20+00:00https://lymphoma-stg.clarovantdigital.com/library/treatment-effectiveness-of-venetoclax-based-therapy-after-bruton-tyrosine-kinase-inhibitors-in-chronic-lymphocytic-leukemia-an-international-real-world-study/2024-12-20T18:41:34+00:00https://lymphoma-stg.clarovantdigital.com/library/whole-body-magnetic-resonance-imaging-provides-accurate-staging-of-diffuse-large-b-cell-lymphoma-but-is-less-preferred-by-patients/2025-01-21T15:36:30+00:00https://lymphoma-stg.clarovantdigital.com/library/testicular-large-b-cell-lymphoma-is-genetically-similar-to-pcnsl-and-distinct-from-nodal-dlbcl/2025-01-24T20:02:09+00:00https://lymphoma-stg.clarovantdigital.com/library/prognostic-significance-of-cdk1-expression-in-diffuse-large-b-cell-lymphoma/2025-01-24T19:19:33+00:00https://lymphoma-stg.clarovantdigital.com/library/similar-survival-between-non-western-immigrant-patients-and-danish-born-patients-with-lymphoma-a-danish-population-based-study/2025-01-23T21:27:52+00:00https://lymphoma-stg.clarovantdigital.com/library/complex-relationships-between-diagnostics-and-survival-in-chronic-lymphocytic-leukemia-in-denmark-finland-norway-and-sweden/2024-09-25T21:27:13+00:00https://lymphoma-stg.clarovantdigital.com/library/recent-advances-in-the-molecular-biology-of-chronic-lymphocytic-leukemia-how-to-define-prognosis-and-guide-treatment/2024-10-18T14:13:53+00:00https://lymphoma-stg.clarovantdigital.com/library/impact-of-prior-cancer-history-on-the-prognosis-of-extranodal-nk-t-cell-lymphoma/2024-10-18T17:17:48+00:00https://lymphoma-stg.clarovantdigital.com/library/efficacy-and-challenges-involving-combination-therapies-in-cll/2025-12-15T22:33:34+00:00https://lymphoma-stg.clarovantdigital.com/library/new-bispecific-antibodies-in-diffuse-large-b-cell-lymphoma/2025-02-18T13:09:46+00:00https://lymphoma-stg.clarovantdigital.com/library/real-world-outcomes-with-tisagenlecleucel-in-aggressive-b-cell-lymphoma-subgroup-analyses-from-the-cibmtr-registry/2025-02-18T14:17:10+00:00https://lymphoma-stg.clarovantdigital.com/library/low-rate-of-central-nervous-system-relapse-of-diffuse-large-b-cell-lymphoma-despite-limited-use-of-intrathecal-prophylaxis/2025-02-18T15:21:00+00:00https://lymphoma-stg.clarovantdigital.com/library/improving-treatment-options-for-patients-with-double-refractory-cll/2025-02-18T15:29:07+00:00https://lymphoma-stg.clarovantdigital.com/library/rituximab-and-lenalidomide-for-the-treatment-of-relapsed-or-refractory-indolent-non-hodgkin-lymphoma-real-life-experience/2025-02-18T20:03:05+00:00https://lymphoma-stg.clarovantdigital.com/library/outcomes-of-allogeneic-stem-cell-transplant-in-patients-with-relapsed-refractory-hodgkin-lymphoma/2025-02-18T20:08:42+00:00https://lymphoma-stg.clarovantdigital.com/library/prognostic-impact-of-rdi-of-vincristine-in-patients-with-dlbcl-receiving-r-chop-a-supplementary-analysis-of-jcog0601/2025-02-18T21:21:13+00:00https://lymphoma-stg.clarovantdigital.com/library/prognostic-and-clinicopathological-role-of-soluble-programmed-cell-death-ligand-1-in-patients-with-diffuse-large-b-cell-lymphoma-a-meta-analysis/2025-02-18T21:26:23+00:00https://lymphoma-stg.clarovantdigital.com/library/zanubrutinib-in-japanese-treatment%e2%80%91naive-and-relapsed-refractory-patients-with-waldenstrom-macroglobulinemia-and-cll-sll/2025-03-03T19:31:28+00:00https://lymphoma-stg.clarovantdigital.com/library/longitudinal-study-of-cognitive-and-mental-functions-among-adult-hodgkin-lymphoma-survivors-based-on-data-from-a-primary-treatment-center-in-hungary/2025-02-18T21:44:11+00:00https://lymphoma-stg.clarovantdigital.com/library/health-related-quality-of-life-in-long-term-survivors-of-non-hodgkin-lymphoma-a-french-population-based-study/2025-02-20T15:53:23+00:00https://lymphoma-stg.clarovantdigital.com/library/outcomes-of-follicular-lymphoma-with-leukemic-phase-in-the-modern-era-results-from-a-large-multicenter-study/2025-02-21T14:28:25+00:00https://lymphoma-stg.clarovantdigital.com/library/real-world-data-on-lymphoma-in-adolescents-and-young-adults-aya-report-from-the-lymphoma-and-related-diseases-registry-lardr/2025-02-21T18:05:23+00:00https://lymphoma-stg.clarovantdigital.com/library/rituximab-cyclophosphamide-doxorubicin-vincristine-and-prednisolone-combined-with-high-dose-methotrexate-plus-intrathecal-chemotherapy-for-newly-diagnosed-intravascular-large-b-cell-lymphoma-prim/2025-02-21T18:05:23+00:00https://lymphoma-stg.clarovantdigital.com/library/synchronous-lymphoma-diagnostic-challenges-in-a-case-of-coexisting-diffuse-large-b-cell-lymphoma-and-classical-hodgkin-lymphoma/2025-02-21T18:05:23+00:00https://lymphoma-stg.clarovantdigital.com/library/chimeric-antigen-receptor-t-cell-therapy-outcomes-in-t-cell-histiocyte-rich-large-b-cell-lymphoma-and-subsequent-treatment-strategies-after-disease-progression-a-geltamo-geth-study/2026-06-15T19:38:02+00:00https://lymphoma-stg.clarovantdigital.com/library/utilization-of-hematopoietic-cell-transplantation-and-cellular-therapy-technology-in-europe-and-associated-countries-using-the-2022-activity-survey-data-to-correlate-with-economic-and-demographic-fac/2025-02-21T18:05:23+00:00https://lymphoma-stg.clarovantdigital.com/library/the-prognostic-value-of-pod24-in-relapsed-refractory-follicular-lymphoma-a-scholar-5-analysis/2025-02-21T18:05:23+00:00https://lymphoma-stg.clarovantdigital.com/library/pi3k-inhibitor-linperlisib-combined-with-gemcitabine-and-oxaliplatin-for-relapsed-or-refractory-diffuse-large-b-cell-lymphoma-a-multicenter-single-arm-phase-ib-ii-trial/2025-02-21T18:05:24+00:00https://lymphoma-stg.clarovantdigital.com/library/real-world-effectiveness-and-safety-of-rituximab-and-reduced-dose-chp-with-polatuzumab-vedotin-pola-r-chp-in-patients-aged-80-years-with-diffuse-large-b-cell-lymphoma-a-retrospective-analysis/2025-02-21T18:05:24+00:00https://lymphoma-stg.clarovantdigital.com/library/genomic-characterization-of-chronic-lymphocytic-leukemia-in-patients-of-african-ancestry/2025-02-21T18:05:24+00:00https://lymphoma-stg.clarovantdigital.com/library/stakeholder-perspectives-on-the-current-status-and-potential-barriers-of-patient-involvement-in-health-technology-assessment-hta-across-europe/2025-02-21T18:05:24+00:00https://lymphoma-stg.clarovantdigital.com/library/bnt162b2-mrna-vaccination-affects-the-gut-microbiome-composition-of-patients-with-follicular-lymphoma-and-chronic-lymphocytic-leukemia/2025-04-14T21:13:15+00:00https://lymphoma-stg.clarovantdigital.com/library/optimal-dosing-regimen-for-epcoritamab-a-subcutaneous-bispecific-antibody-in-relapsed-or-refractory-large-b-cell-lymphoma/2026-01-14T17:54:46+00:00https://lymphoma-stg.clarovantdigital.com/library/bendamustine-and-rituximab-as-first-line-treatment-for-symptomatic-splenic-marginal-zone-lymphoma-long-term-outcome-and-impact-of-early-unmeasurable-minimal-residual-disease-attainment-from-the-brism/2025-02-21T18:05:24+00:00https://lymphoma-stg.clarovantdigital.com/library/circulating-tumor-dna-as-measurable-residual-disease-in-aggressive-b-cell-lymphoma/2025-02-21T18:05:24+00:00https://lymphoma-stg.clarovantdigital.com/library/outcomes-of-patients-with-relapsed-or-refractory-primary-mediastinal-b-cell-lymphoma-treated-with-anti-cd19-car-t-cells-carthym-a-study-from-the-french-national-descar-t-registry/2025-02-21T18:05:24+00:00https://lymphoma-stg.clarovantdigital.com/library/improved-prognosis-of-advanced-stage-extranodal-nk-t-cell-lymphoma-results-of-the-nkea-next-study/2025-02-21T18:05:24+00:00https://lymphoma-stg.clarovantdigital.com/library/long-term-3-year-follow-up-of-mosunetuzumab-in-relapsed-or-refractory-follicular-lymphoma-after-2-prior-therapies/2025-02-21T18:05:25+00:00https://lymphoma-stg.clarovantdigital.com/library/real-world-collection-of-secondary-myeloid-neoplasms-after-cd19-car-t-cell-therapy-first-report-of-the-clonhema-study/2025-02-21T18:05:25+00:00https://lymphoma-stg.clarovantdigital.com/library/diffuse-large-b-cell-lymphoma-examining-evolving-patterns-in-mortality-incidence-and-demographics/2025-12-19T18:30:41+00:00https://lymphoma-stg.clarovantdigital.com/library/outcomes-of-patients-with-richter-transformation-who-received-no-prior-chemoimmunotherapy-for-their-cll/2025-02-21T18:05:25+00:00https://lymphoma-stg.clarovantdigital.com/library/outcomes-of-the-covid-19-pandemic-in-chronic-lymphocytic-leukemia-focus-on-the-very-early-period-and-omicron-era/2025-02-23T19:59:21+00:00https://lymphoma-stg.clarovantdigital.com/library/the-heterogeneity-of-13q-deletions-in-chronic-lymphocytic-leukemia-diagnostic-challenges-and-clinical-implications/2025-02-23T20:03:33+00:00https://lymphoma-stg.clarovantdigital.com/library/survival-analysis-of-a-16-year-cohort-of-follicular-lymphoma-patients-receiving-systemic-treatment-in-brazil/2025-02-24T00:13:04+00:00https://lymphoma-stg.clarovantdigital.com/library/odronextamab-monotherapy-in-r-r-dlbcl-after-progression-with-car-t-cell-therapy-primary-analysis-of-elm-1-study/2026-03-23T18:25:18+00:00https://lymphoma-stg.clarovantdigital.com/library/follicular-lymphoma-contemporary-clinical-management-with-a-focus-on-recent-therapeutic-advances/2025-02-25T15:56:39+00:00https://lymphoma-stg.clarovantdigital.com/library/population-based-registry-study-on-large-b-cell-lymphoma-mortality-and-morbidity-in-finland/2025-02-25T19:49:42+00:00https://lymphoma-stg.clarovantdigital.com/library/18f-fdg-pet-or-pet-ct-in-detecting-high-grade-transformation-of-chronic-lymphocytic-leukaemia-and-indolent-lymphomas-a-systematic-review-and-meta-analysis/2025-02-26T17:32:30+00:00https://lymphoma-stg.clarovantdigital.com/library/real-world-effectiveness-of-frontline-treatments-among-patients-with-chronic-lymphocytic-leukemia-results-from-concertai/2025-02-26T17:48:37+00:00https://lymphoma-stg.clarovantdigital.com/library/ibrutinib-lead-in-followed-by-venetoclax-plus-ibrutinib-in-relapsed-refractory-chronic-lymphocytic-leukemia-sakk-34-17/2025-02-27T19:36:27+00:00https://lymphoma-stg.clarovantdigital.com/library/br-or-r-chop-induction-with-rituximab-maintenance-in-untreated-transplantineligible-patients-with-mantle-cell-lymphoma/2025-02-27T19:45:25+00:00https://lymphoma-stg.clarovantdigital.com/library/upfront-fixed-duration-treatment-strategies-for-chronic-lymphocytic-leukemia-in-arab-populations-a-position-statement-from-the-gulf-region/2025-02-27T19:51:41+00:00https://lymphoma-stg.clarovantdigital.com/library/combination-autologous-stem-cell-transplantation-with-chimeric-antigen-receptor-t-cell-therapy-for-refractory-relapsed-b-cell-lymphoma-a-single-arm-clinical-study/2025-02-27T20:01:22+00:00https://lymphoma-stg.clarovantdigital.com/library/longitudinal-patient-reported-outcomes-in-older-adults-with-aggressive-lymphomas-receiving-chemoimmunotherapy/2025-02-28T19:16:28+00:00https://lymphoma-stg.clarovantdigital.com/library/lenalidomide-combined-with-r-chop-r2-chop-in-the-treatment-of-newly-diagnosed-double-expressor-diffuse-large-b-cell-lymphoma-a-prospective-phase-ii-clinical-trial/2025-02-28T19:16:28+00:00https://lymphoma-stg.clarovantdigital.com/library/late-adverse-events-after-chimeric-antigen-receptor-t-cell-therapy-for-patients-with-aggressive-b-cell-non-hodgkin-lymphoma/2025-02-28T19:16:29+00:00https://lymphoma-stg.clarovantdigital.com/library/real-world-results-of-ibrutinib-in-patients-with-relapsed-or-refractory-chronic-lymphocytic-leukemia-a-meta-analysis-of-clinical-studies/2025-02-28T19:16:29+00:00https://lymphoma-stg.clarovantdigital.com/library/exploratory-biomarker-analysis-from-a-phase-iii-study-of-the-pi3k-inhibitor-copanlisib-in-combination-with-rituximab-in-patients-with-indolent-non-hodgkin-lymphoma-a-retrospective-study/2025-02-28T19:16:29+00:00https://lymphoma-stg.clarovantdigital.com/library/real-world-outcomes-of-car-t-cell-therapy-for-b-cell-lymphoma-in-adults-age-65-a-referral-center-experience/2025-02-28T19:16:29+00:00https://lymphoma-stg.clarovantdigital.com/library/outcomes-in-patients-with-late-relapse-of-diffuse-large-b-cell-lymphoma-a-systematic-review-and-meta-analysis/2025-02-28T19:16:29+00:00https://lymphoma-stg.clarovantdigital.com/library/evolution-of-outcomes-in-autologous-stem-cell-transplantation-for-hodgkins-lymphoma-over-2-decades-at-king-hussein-cancer-center/2025-02-28T19:16:29+00:00https://lymphoma-stg.clarovantdigital.com/library/optimal-use-of-bispecific-antibodies-for-the-treatment-of-diffuse-large-b-cell-lymphoma-in-canada/2026-01-14T18:17:55+00:00https://lymphoma-stg.clarovantdigital.com/library/outcome-of-high-grade-b-cell-lymphoma-compared-to-other-large-b-cell-lymphoma-after-car-t-rescue-a-descar-t-lysa-study/2025-03-03T22:32:50+00:00https://lymphoma-stg.clarovantdigital.com/library/survival-outcomes-in-diffuse-large-b-cell-lymphoma-patients-with-and-without-hiv-in-the-united-states-from-2001-to-2016-a-population-based-analysis/2025-12-19T18:07:23+00:00https://lymphoma-stg.clarovantdigital.com/library/cumulative-review-of-hypertension-in-patients-with-chronic-lymphocytic-leukemia-treated-with-acalabrutinib/2025-03-04T15:02:26+00:00https://lymphoma-stg.clarovantdigital.com/library/diffuse-large-b-cell-lymphoma-in-the-older-and-frail-patient/2025-03-07T13:44:30+00:00https://lymphoma-stg.clarovantdigital.com/library/prognostication-of-follicular-lymphoma-a-review-of-prognostic-scores-and-factors/2025-03-07T13:50:46+00:00https://lymphoma-stg.clarovantdigital.com/library/prognostic-value-of-ca125-in-diffuse-large-b-cell-lymphoma/2025-03-07T21:11:12+00:00https://lymphoma-stg.clarovantdigital.com/library/high-dose-mtx-based-polychemotherapy-for-primary-cns-lymphoma-in-younger-patients-long-term-efficacy-of-the-modified-bonn-protocol/2025-03-07T21:27:26+00:00https://lymphoma-stg.clarovantdigital.com/library/risk-factors-for-car-t-cell-manufacturing-failure-and-patient-outcomes-in-large-b-cell-lymphoma-a-report-from-the-uk-national-car-t-panel/2025-03-07T21:27:26+00:00https://lymphoma-stg.clarovantdigital.com/library/obesity-and-overweight-in-r-r-dlbcl-patients-is-associated-with-a-better-response-to-treatment-of-r2-gdp-gotel-trial-potential-role-of-nk-cd8cells-and-vitamin-d/2025-03-07T21:27:26+00:00https://lymphoma-stg.clarovantdigital.com/library/matching-adjusted-indirect-comparison-of-efficacy-and-safety-of-lisocabtagene-maraleucel-and-mosunetuzumab-for-the-treatment-of-third-line-or-later-relapsed-or-refractory-follicular-lymphoma/2025-03-07T21:27:26+00:00https://lymphoma-stg.clarovantdigital.com/library/randomized-controlled-trial-of-a-virtually-delivered-exercise-and-stress-management-program-to-improve-physical-performance-of-hematopoietic-cell-transplant-survivors/2025-03-07T21:27:26+00:00https://lymphoma-stg.clarovantdigital.com/library/venous-thromboembolism-in-children-with-hodgkin-lymphoma-a-population-based-study-in-sweden-finland-and-denmark/2025-03-07T21:27:26+00:00https://lymphoma-stg.clarovantdigital.com/library/subgroup-analysis-of-elderly-patients-%e2%89%a560-years-with-diffuse-large-b-cell-lymphoma-in-the-phase-3-polarix-study/2025-03-18T18:28:37+00:00https://lymphoma-stg.clarovantdigital.com/library/high-ki-67-expression-predicting-a-risk-factor-for-the-progression-of-disease-within-24-months-and-microenvironment-in-follicular-lymphoma/2025-03-18T18:28:21+00:00https://lymphoma-stg.clarovantdigital.com/library/zanubrutinib-plus-r-chop-improves-the-treatment-effect-of-newly-diagnosed-diffuse-large-b-cell-lymphoma-with-double-expression-of-myc-and-bcl-2/2025-03-18T19:27:25+00:00https://lymphoma-stg.clarovantdigital.com/library/genetic-subtyping-by-whole-exome-sequencing-across-diffuse-large-b-cell-lymphoma-and-plasmablastic-lymphoma/2025-03-18T19:33:19+00:00https://lymphoma-stg.clarovantdigital.com/library/case-report-triplet-combination-with-pirtobrutinib-venetoclax-rituximab-in-accelerated-phase-of-chronic-lymphocytic-leukemia/2025-03-18T19:38:47+00:00https://lymphoma-stg.clarovantdigital.com/library/ketone-bodies-are-potential-prognostic-biomarkers-in-relapsed-refractory-diffuse-large-b-cell-lymphoma-results-from-the-r2-gdp-gotel-trial/2025-03-20T17:21:33+00:00https://lymphoma-stg.clarovantdigital.com/library/long-term-outcomes-of-chemoimmunotherapy-with-obinutuzumab-chlorambucil-in-chronic-lymphocytic-leukemia/2025-03-20T17:25:24+00:00https://lymphoma-stg.clarovantdigital.com/library/surveillance-imaging-during-first-remission-in-follicular-lymphoma-does-not-impact-overall-survival/2025-03-20T17:35:37+00:00https://lymphoma-stg.clarovantdigital.com/library/atezolizumab-combined-with-immunogenic-salvage-chemoimmunotherapy-in-patients-with-transformed-diffuse-large-b-cell-lymphoma/2025-03-20T17:35:37+00:00https://lymphoma-stg.clarovantdigital.com/library/outcomes-and-prognostic-factors-in-patients-with-burkitt-lymphoma-leukemia-in-adolescents-and-adults-an-experience-from-hematology-cancer-consortium/2025-03-20T17:35:37+00:00https://lymphoma-stg.clarovantdigital.com/library/circulating-tumor-dna-in-lymphoma-technologies-and-applications/2025-03-20T17:35:37+00:00https://lymphoma-stg.clarovantdigital.com/library/pod24-based-prognostic-signature-enables-personalized-risk-stratification-in-mantle-cell-lymphoma/2025-03-20T17:35:38+00:00https://lymphoma-stg.clarovantdigital.com/library/lymphocyte-monocyte-to-lactate-dehydrogenase-ratio-prior-to-lymphodepletion-impact-the-outcomes-of-patients-with-diffused-large-b-cell-lymphoma-undergoing-car-t-cell-therapy/2025-03-20T17:35:38+00:00https://lymphoma-stg.clarovantdigital.com/library/efficacy-and-safety-of-denileukin-diftitox-cxdl-an-improved-purity-formulation-of-denileukin-diftitox-in-patients-with-relapsed-or-refractory-cutaneous-t-cell-lymphoma/2025-03-20T17:35:38+00:00https://lymphoma-stg.clarovantdigital.com/library/access-barriers-to-anti-cd19-cart-therapy-for-nhl-across-a-community-transplant-and-cellular-therapy-network/2025-12-19T18:30:09+00:00https://lymphoma-stg.clarovantdigital.com/library/peripheral-t-cell-lymphoma-nos-in-children-and-adolescents-a-review-from-the-childrens-oncology-group-nhl-committee/2025-03-20T17:35:38+00:00https://lymphoma-stg.clarovantdigital.com/library/temporal-trends-in-time-toxicity-of-r-chop-a-nationwide-hospital-based-database-analysis-in-japan/2025-03-20T17:35:38+00:00https://lymphoma-stg.clarovantdigital.com/library/tp53-deletion-is-associated-with-poor-survival-of-adult-alk-positive-alcl-patients-receiving-chop-based-chemotherapy/2025-03-20T17:35:38+00:00https://lymphoma-stg.clarovantdigital.com/library/the-optimal-time-and-clinical-implications-of-measurable-residual-disease-detection-in-mantle-cell-lymphoma/2025-03-20T17:35:38+00:00https://lymphoma-stg.clarovantdigital.com/library/cerebrospinal-fluid-proteomics-exerts-predictive-potential-for-immune-effector-cell-associated-neurotoxicity-syndrome-icans-in-car-t-cell-therapy/2025-03-20T17:35:38+00:00https://lymphoma-stg.clarovantdigital.com/library/combined-autologous-hematopoietic-stem-cell-transplantation-and-cd19-car-t-cell-therapy-for-relapsed-refractory-diffuse-large-b-cell-lymphoma-with-tp53-mutation-a-case-report/2025-03-20T17:35:38+00:00https://lymphoma-stg.clarovantdigital.com/library/treatment-of-non-hodgkin-lymphoma-with-point-of-care-manufactured-car-t-cells-a-dual-institution-phase-1-trial/2025-03-20T17:35:38+00:00https://lymphoma-stg.clarovantdigital.com/library/epidemiology-and-survival-of-marginal-zone-lymphoma-in-colombian-patients-an-observational-retrospective-study/2025-03-20T17:35:38+00:00https://lymphoma-stg.clarovantdigital.com/library/visual-presentation-of-age-differences-in-relative-survival-of-hematological-neoplasms-in-sweden-and-the-neighboring-countries/2025-03-20T17:35:38+00:00https://lymphoma-stg.clarovantdigital.com/library/prevalence-of-hematological-malignancies-in-africa-a-systematic-review-and-meta-analysis/2026-03-13T17:56:16+00:00https://lymphoma-stg.clarovantdigital.com/library/use-of-the-esmo-magnitude-of-clinical-benefit-scale-to-guide-hta-recommendations-on-coverage-and-reimbursement-for-cancer-medicines-a-retrospective-analysis/2025-03-20T17:35:39+00:00https://lymphoma-stg.clarovantdigital.com/library/use-of-surrogate-endpoints-in-health-technology-assessment-a-review-of-selected-nice-technology-appraisals-in-oncology/2025-07-09T19:43:01+00:00https://lymphoma-stg.clarovantdigital.com/library/value-and-implementation-of-patient-and-public-involvement-and-engagement-in-health-technology-assessment-for-japan-implications-from-systematic-searches/2025-03-20T17:35:39+00:00https://lymphoma-stg.clarovantdigital.com/library/driving-policy-dialogue-on-health-technology-assessment-in-eastern-europe-and-central-asia-reporting-from-an-initiative-of-health-technology-assessment-international/2025-03-20T17:35:39+00:00https://lymphoma-stg.clarovantdigital.com/library/prognostic-role-of-interim-pet-in-patients-with-follicular-lymphoma-a-post-hoc-study-of-foll12-trial-by-fil/2025-03-20T19:04:29+00:00https://lymphoma-stg.clarovantdigital.com/library/mrd-guided-zanubrutinib-venetoclax-and-obinutuzumab-in-relapsed-cll-primary-end-point-analysis-from-the-cll2-bzag-trial/2025-03-20T20:28:29+00:00https://lymphoma-stg.clarovantdigital.com/library/rituximab-in-pediatric-b-cell-non-hodgkin-lymphoma-clinical-outcomes-and-prognostic-implications/2025-03-24T16:24:43+00:00https://lymphoma-stg.clarovantdigital.com/library/primary-gastrointestinal-lymphoma-a-prospective-unicentric-study-on-a-romanian-cohort/2025-03-24T16:34:34+00:00https://lymphoma-stg.clarovantdigital.com/library/exploratory-study-to-evaluate-the-impact-of-interim-pet-ct-assessment-in-first-line-follicular-lymphoma/2025-03-24T16:37:38+00:00https://lymphoma-stg.clarovantdigital.com/library/assessing-the-relationship-between-blood-transfusion-products-and-non%e2%80%91hodgkins-lymphoma-incidence-a-longitudinal-retrospective-cohort-study-2004%e2%80%912022/2025-03-27T13:32:54+00:00https://lymphoma-stg.clarovantdigital.com/library/three-year-follow-up-analysis-of-first-line-axicabtagene-ciloleucel-in-high-risk-large-b-cell-lymphoma-zuma-12/2025-03-27T13:37:52+00:00https://lymphoma-stg.clarovantdigital.com/library/flow-cytometry-for-b-cell-non-hodgkin-and-hodgkin-lymphomas/2025-03-27T19:28:04+00:00https://lymphoma-stg.clarovantdigital.com/library/antiepileptic-drugs-failed-to-prevent-initial-seizures-or-improve-survival-outcomes-in-patients-with-primary-cns-lymphoma/2025-03-27T20:32:22+00:00https://lymphoma-stg.clarovantdigital.com/library/correlation-of-progression-free-survival-and-overall-survival-after-treatment-for-relapsed-hodgkin-lymphoma-individual-patient-data-analysis-of-randomized-german-hodgkin-study-group-ghsg-trials/2025-03-27T20:32:22+00:00https://lymphoma-stg.clarovantdigital.com/library/comparison-of-mortality-rates-between-patients-with-diffuse-large-b-cell-lymphoma-surviving-5-years-after-initial-diagnosis-and-a-matched-general-population-cohort/2025-03-27T20:32:22+00:00https://lymphoma-stg.clarovantdigital.com/library/comparative-analysis-of-bispecific-antibodies-and-car-t-cell-therapy-in-follicular-lymphoma/2025-03-27T20:32:22+00:00https://lymphoma-stg.clarovantdigital.com/library/brentuximab-vedotin-monotherapy-is-a-feasible-and-effective-treatment-for-older-patients-with-classical-hodgkin-lymphoma-unsuitable-for-curative-chemotherapy-results-from-the-prospective-ghsg-nlg-pha/2025-03-27T20:32:22+00:00https://lymphoma-stg.clarovantdigital.com/library/long-term-results-of-the-fil-mcl0208-trial-of-lenalidomide-maintenance-versus-observation-after-asct-in-mcl-patients/2025-03-27T20:32:22+00:00https://lymphoma-stg.clarovantdigital.com/library/feasibility-of-axicabtagene-ciloleucel-in-the-outpatient-setting-primary-analysis-of-prospective-trial/2025-03-27T20:32:22+00:00https://lymphoma-stg.clarovantdigital.com/library/impact-of-prior-car-t-cell-therapy-on-mosunetuzumab-efficacy-in-patients-with-relapsed-or-refractory-b-cell-lymphomas/2025-03-27T20:32:22+00:00https://lymphoma-stg.clarovantdigital.com/library/chimeric-antigen-receptor-t-cell-therapy-in-diffuse-large-b-cell-lymphoma-evaluating-axicabtagene-ciloleucel-in-the-zuma-7-trial/2025-03-27T20:32:22+00:00https://lymphoma-stg.clarovantdigital.com/library/double-hit-double-expressor-lymphomas-a-multicenter-analysis-of-survival-outcomes-with-cd19-directed-car-t-cell-therapy/2025-03-27T20:32:22+00:00https://lymphoma-stg.clarovantdigital.com/library/implementation-of-standard-of-care-car-t-cell-treatment-for-patients-with-aggressive-b-cell-lymphoma-and-acute-lymphoblastic-leukemia-in-sweden/2025-03-27T20:32:23+00:00https://lymphoma-stg.clarovantdigital.com/library/lymphodepletion-chemotherapy-in-chimeric-antigen-receptor-engineered-t-car-t-cell-therapy-in-lymphoma/2025-12-19T15:08:01+00:00https://lymphoma-stg.clarovantdigital.com/library/outcomes-in-patients-with-classic-hodgkin-lymphoma-refractory-or-intolerant-to-brentuximab-vedotin-and-anti-pd-1-therapy-a-real-world-analysis-from-15-u-s-academic-centers/2025-03-27T20:32:23+00:00https://lymphoma-stg.clarovantdigital.com/library/nivolumab-and-rituximab-in-treatment-naive-follicular-lymphoma-the-phase-2-1st-flor-study/2025-03-27T20:32:23+00:00https://lymphoma-stg.clarovantdigital.com/library/epigenetic-symphony-in-diffuse-large-b-cell-lymphoma-orchestrating-the-tumor-microenvironment/2025-04-03T11:57:16+00:00https://lymphoma-stg.clarovantdigital.com/library/efficacy-and-safety-of-tirabrutinib-monotherapy-in-relapsed-or-refractory-b-cell-lymphomas-leukemia-a-meta-analysis/2025-04-03T12:03:31+00:00https://lymphoma-stg.clarovantdigital.com/library/in-the-era-of-targeted-therapy-and-immunotherapy-advances-in-the-treatment-of-large-b-cell-lymphoma-of-immune-privileged-sites/2025-04-03T13:49:35+00:00https://lymphoma-stg.clarovantdigital.com/library/comparing-the-distribution-of-hodgkin-lymphoma-subtypes-and-survival-outcomes-between-latin-american-and-us-patients/2025-04-03T13:55:22+00:00https://lymphoma-stg.clarovantdigital.com/library/real-world-use-of-btk-inhibitors-for-chronic-lymphocytic-leukemia-in-japan-a-retrospective-observational-database-study/2025-04-03T14:02:29+00:00https://lymphoma-stg.clarovantdigital.com/library/prognostic-predictors-of-newly-diagnosed-diffuse-large-b-cell-lymphoma-treated-with-r-thp-cop-regimen/2025-04-03T14:14:39+00:00https://lymphoma-stg.clarovantdigital.com/library/autologous-stem-cell-transplantation-for-relapsed-refractory-large-b-cell-lymphoma-multicenter-geth-tc-geltamo-study/2025-04-04T20:36:40+00:00https://lymphoma-stg.clarovantdigital.com/library/dynamics-of-immune-reconstitution-and-impact-on-outcomes-across-car-t-cell-products-in-large-b-cell-lymphoma/2025-04-04T20:54:07+00:00https://lymphoma-stg.clarovantdigital.com/library/high-dose-methotrexate-usage-without-drug-level-monitoring-in-advanced-pediatric-mature-b-cell-non-hodgkin-lymphoma-in-a-resource-limited-setting-in-malawi/2026-03-13T17:55:27+00:00https://lymphoma-stg.clarovantdigital.com/library/fear-of-cancer-recurrence-and-associated-factors-in-lymphoma-survivors-and-their-family-caregivers-a-cross-sectional-study/2025-04-04T20:54:07+00:00https://lymphoma-stg.clarovantdigital.com/library/an-inflammatory-biomarker-signature-of-response-to-car-t-cell-therapy-in-non-hodgkin-lymphoma/2025-04-04T20:54:07+00:00https://lymphoma-stg.clarovantdigital.com/library/efficacy-and-safety-of-zanubrutinib-combined-with-chimeric-antigen-receptor-t-cell-therapy-targeting-cd19-in-refractory-or-relapsed-diffuse-large-b-cell-lymphoma-a-retrospective-analysis/2025-04-04T20:54:07+00:00https://lymphoma-stg.clarovantdigital.com/library/nine-year-follow-up-of-patients-with-relapsed-follicular-lymphoma-after-nonmyeloablative-allogeneic-stem-cell-transplant-and-autologous-transplant-2/2025-04-04T20:54:07+00:00https://lymphoma-stg.clarovantdigital.com/library/trends-and-projections-of-non-hodgkin-lymphoma-burden-1990-2040-a-global-burden-of-disease-2021-analysis/2025-04-04T20:54:07+00:00https://lymphoma-stg.clarovantdigital.com/library/loncastuximab-tesirine-versus-polatuzumab-vedotin-plus-bendamustine-and-rituximab-in-relapsed-refractory-dlbcl-after-2-lines-of-therapy-matching-adjusted-indirect-comparison/2025-04-04T20:54:07+00:00https://lymphoma-stg.clarovantdigital.com/library/clinical-outcomes-and-therapeutic-modalities-in-older-chinese-patients-with-mcl-a-multi-center-real-world-retrospective-study/2025-04-04T20:54:07+00:00https://lymphoma-stg.clarovantdigital.com/library/comparative-efficacy-of-venetoclax-based-regiments-in-the-management-of-chronic-lymphocytic-leukemia-a-systematic-review-and-metanalysis/2025-04-04T20:54:07+00:00https://lymphoma-stg.clarovantdigital.com/library/real-world-safety-and-effectiveness-of-alemtuzumab-for-relapsed-or-refractory-chronic-lymphocytic-leukaemia-results-from-postmarketing-surveillance-in-japan/2025-04-04T20:54:07+00:00https://lymphoma-stg.clarovantdigital.com/library/navigating-barriers-to-health-technology-assessment-development-in-iran-a-qualitative-exploration-of-stakeholder-perspectives/2026-03-13T17:44:15+00:00https://lymphoma-stg.clarovantdigital.com/library/upfront-management-of-blastoid-variant-mantle-cell-lymphoma-making-the-case-for-2nd-3rd-generation-bruton-tyrosine-kinase-inhibitor-based-therapies/2025-04-04T20:54:07+00:00https://lymphoma-stg.clarovantdigital.com/library/enhancing-car-t-efficacy-in-large-b-cell-lymphoma-with-radiation-bridging-therapy-a-real-world-single-center-experience/2025-04-04T20:54:07+00:00https://lymphoma-stg.clarovantdigital.com/library/first-reported-case-of-a-spontaneous-and-healthy-pregnancy-in-a-woman-with-persistent-car-t-cells-5-years-after-treatment-for-diffuse-large-b-cell-lymphoma/2025-04-04T20:54:08+00:00https://lymphoma-stg.clarovantdigital.com/library/causes-of-death-among-patients-diagnosed-with-chronic-lymphocytic-leukemia-a-population-based-study-in-the-netherlands-1996-2020/2025-04-04T20:59:46+00:00https://lymphoma-stg.clarovantdigital.com/library/the-cell-of-origin-of-diffuse-large-b-cell-lymphoma-is-it-a-predictor-for-response-rate/2025-04-07T17:45:31+00:00https://lymphoma-stg.clarovantdigital.com/library/reduced-cd20-expression-yields-inferior-survival-in-patients-with-b-cell-lymphoma-treated-with-cd20xcd3-antibodies/2025-04-07T17:57:42+00:00https://lymphoma-stg.clarovantdigital.com/library/characteristics-and-outcomes-of-patients-with-double-refractory-and-double-exposed-chronic-lymphocytic-leukemia/2025-04-07T18:02:59+00:00https://lymphoma-stg.clarovantdigital.com/library/continuous-r-da-edoch-alternated-with-high-dose-ara-c-induces-deep-remission-and-overcomes-high-risk-factors-in-young-patients-with-newly-diagnosed-mantle-cell-lymphoma/2025-04-09T23:06:16+00:00https://lymphoma-stg.clarovantdigital.com/library/immunological-consequences-of-car-t-cell-therapy-analysis-of-infectious-complications-and-immune-reconstitution/2025-04-09T23:14:30+00:00https://lymphoma-stg.clarovantdigital.com/library/accelerated-chronic-lymphocytic-leukemia-characteristics-and-retrospective-analysis-of-the-polish-adult-leukemia-study-group/2025-04-10T13:42:07+00:00https://lymphoma-stg.clarovantdigital.com/library/cd20-positive-peripheral-t-cell-lymphoma-not-otherwise-specified-a-case-series-and-review-of-the-literature/2025-04-10T13:48:29+00:00https://lymphoma-stg.clarovantdigital.com/library/evorpacept-plus-rituximab-for-the-treatment-of-relapsed-or-refractory-non-hodgkin-lymphoma-results-from-the-phase-i-aspen-01-study/2025-04-11T13:42:01+00:00https://lymphoma-stg.clarovantdigital.com/library/pembrolizumab-in-relapsed-or-refractory-mycosis-fungoides-or-sezary-syndrome/2025-04-11T19:24:07+00:00https://lymphoma-stg.clarovantdigital.com/library/a-3-week-pause-versus-continued-bruton-tyrosine-kinase-inhibitor-use-during-covid-19-vaccination-in-individuals-with-chronic-lymphocytic-leukaemia-improve-trial-a-randomised-open-label-superiorit/2025-04-11T19:24:07+00:00https://lymphoma-stg.clarovantdigital.com/library/meta-analysis-of-the-comparative-efficacy-and-safety-of-new-drugs-in-combination-with-chemotherapy-in-primary-plasmoblastic-lymphoma/2025-04-11T19:24:08+00:00https://lymphoma-stg.clarovantdigital.com/library/are-oldest-old-patients-with-diffuse-large-b-cell-lymphoma-different-than-their-younger-counterparts-results-from-the-realysa-real-life-cohort/2025-04-11T19:24:08+00:00https://lymphoma-stg.clarovantdigital.com/library/bendamustine-supercharge-plus-brentuximab-vedotin-as-early-salvage-therapy-following-failure-to-obtain-complete-metabolic-remission-after-two-cycles-of-adriamycin-bleomycin-vinblastine-dacarbazine-for/2025-04-11T19:24:08+00:00https://lymphoma-stg.clarovantdigital.com/library/primary-hodgkins-lymphoma-of-stomach-a-case-report-with-literature-review/2025-04-11T19:24:08+00:00https://lymphoma-stg.clarovantdigital.com/library/availability-and-financing-of-car-t-cell-therapies-a-cross-country-comparative-analysis/2025-04-11T19:24:08+00:00https://lymphoma-stg.clarovantdigital.com/library/incidence-and-risk-factors-of-severe-infections-in-diffuse-large-b-cell-lymphoma-patients-undergoing-immunochemotherapy/2025-12-15T19:36:01+00:00https://lymphoma-stg.clarovantdigital.com/library/the-impact-of-obesity-and-its-related-underlying-diseases-on-cytokine-release-syndrome-and-the-efficacy-of-car-t-therapy-in-treating-b-cell-malignancies/2025-04-11T19:24:08+00:00https://lymphoma-stg.clarovantdigital.com/library/targeting-the-immune-microenvironment-in-chronic-lymphocytic-leukemia-an-evolving-therapeutic-strategy/2025-12-15T22:01:17+00:00https://lymphoma-stg.clarovantdigital.com/library/mapping-the-research-landscape-of-pet-ct-in-lymphoma-insights-from-a-bibliometric-analysis/2025-04-11T19:24:08+00:00https://lymphoma-stg.clarovantdigital.com/library/radiotherapy-alone-with-curative-intent-in-a-case-of-limited-stage-extranodal-nk-t-cell-lymphoma-nasal-type-a-case-report-and-review-of-the-literature/2025-04-11T19:24:08+00:00https://lymphoma-stg.clarovantdigital.com/library/safety-and-efficacy-of-cd19-targeted-chimeric-antigen-receptor-car-t-cells-generated-using-dna-transposon-systems-a-meta-analysis/2025-04-11T19:24:08+00:00https://lymphoma-stg.clarovantdigital.com/library/global-landscape-and-trends-in-lifetime-risks-of-haematologic-malignancies-in-185-countries-population-based-estimates-from-globocan-2022/2025-04-11T19:24:08+00:00https://lymphoma-stg.clarovantdigital.com/library/frequent-association-of-malignant-effusions-in-plasmablastic-lymphoma-a-single-institutional-experience-of-nine-cases-in-taiwan/2026-09-02T16:01:28+00:00https://lymphoma-stg.clarovantdigital.com/library/guiding-clinical-management-of-patients-with-cns-lymphomas-by-minimal-invasive-detection-of-ctdna-in-cerebrospinal-fluid/2025-04-11T19:24:08+00:00https://lymphoma-stg.clarovantdigital.com/library/real-world-outcomes-of-brentuximab-vedotin-as-consolidation-therapy-after-autologous-stem-cell-transplantation-in-relapsed-refractory-hodgkin-lymphoma-a-systematic-review-and-meta-analysis/2025-04-11T19:24:08+00:00https://lymphoma-stg.clarovantdigital.com/library/epcoritamab-plus-gemox-in-transplant-ineligible-relapsed-refractory-dlbcl-results-from-the-epcore-nhl-2-trial-2/2026-01-14T18:17:20+00:00https://lymphoma-stg.clarovantdigital.com/library/follicular-lymphoma-grade-3a-aggressiveness-and-curability-in-an-asian-cohort-of-781-patients/2025-04-11T19:24:09+00:00https://lymphoma-stg.clarovantdigital.com/library/molecular-heterogeneity-of-cd30-peripheral-t-cell-lymphoma-with-prognostic-significance-and-therapeutic-implications-a-retrospective-multi-centre-study/2025-04-11T19:24:09+00:00https://lymphoma-stg.clarovantdigital.com/library/clonal-hematopoiesis-and-risk-of-heart-failure-after-autologous-hematopoietic-cell-transplantation-for-lymphoma/2025-04-11T19:24:09+00:00https://lymphoma-stg.clarovantdigital.com/library/micrornas-in-diffuse-large-b-cell-lymphoma-dlbcl-biomarkers-with-prognostic-potential/2025-04-14T14:12:28+00:00https://lymphoma-stg.clarovantdigital.com/library/comparative-efficacy-of-bruton-tyrosine-kinase-inhibitors-in-high-risk-relapsed-refractory-cll-a-network-meta-analysis/2025-04-14T14:16:26+00:00https://lymphoma-stg.clarovantdigital.com/library/analysis-of-stereotyped-b-cell-receptor-frequencies-among-portuguese-de-novo-diagnosed-chronic-lymphocytic-leukemia-patients-pais-study/2025-04-14T14:20:09+00:00https://lymphoma-stg.clarovantdigital.com/library/atopic-dermatitis-and-lymphoma-risk-a-systematic-review-and-meta-analysis/2025-04-15T20:43:04+00:00https://lymphoma-stg.clarovantdigital.com/library/identification-of-adjustment-variables-in-indirect-comparisons-a-rapid-review-of-car-t-therapies-for-diffuse-large-b-cell-lymphoma/2025-04-15T20:57:54+00:00https://lymphoma-stg.clarovantdigital.com/library/a-cost-effectiveness-analysis-of-mosunetuzumab-vs-tisagenlecleucel-for-treatment-of-third-or-higher-line-3l-relapsed-or-refractory-r-r-follicular-lymphoma-fl-in-italy/2025-04-15T21:02:13+00:00https://lymphoma-stg.clarovantdigital.com/library/revaccination-with-pneumococcal-conjugate-vaccine-five-years-after-primary-immunization-improves-immunity-in-patients-with-chronic-lymphocytic-leukemia/2025-04-17T20:46:30+00:00https://lymphoma-stg.clarovantdigital.com/library/impact-of-comorbidities-on-patients-with-waldenstrom-macroglobulinemia-in-taiwan-a-multicenter-study/2025-04-17T20:52:14+00:00https://lymphoma-stg.clarovantdigital.com/library/clinical-and-prognostic-factors-guiding-diagnosis-and-treatment-of-prostate-diffuse-large-b-cell-lymphoma/2025-04-17T20:52:14+00:00https://lymphoma-stg.clarovantdigital.com/library/alemtuzumab-for-haematological-malignancies/2025-04-17T20:52:14+00:00https://lymphoma-stg.clarovantdigital.com/library/validity-of-the-criteria-for-clinical-transformation-of-follicular-lymphoma-analysis-of-a-mostly-biopsied-cohort/2025-04-17T20:52:14+00:00https://lymphoma-stg.clarovantdigital.com/library/clinical-characteristics-treatment-patterns-and-outcomes-of-patients-with-follicular-lymphoma-in-colombia-a-real-world-evidence-cohort-study/2025-04-17T20:52:14+00:00https://lymphoma-stg.clarovantdigital.com/library/car-t-cell-therapy-response-varies-by-extranodal-disease-site-in-large-b-cell-lymphoma/2025-04-17T20:52:14+00:00https://lymphoma-stg.clarovantdigital.com/library/outcomes-of-patients-with-relapsed-refractory-lymphoplasmacytic-lymphoma-waldenstrom-macroglobulinemia-treated-with-venetoclax-a-multicenter-retrospective-analysis/2025-04-17T20:52:14+00:00https://lymphoma-stg.clarovantdigital.com/library/tailored-therapeutic-approach-in-a-patient-with-diffuse-large-b-cell-lymphoma-with-meningeal-infiltration-concurrent-classic-hodgkin-lymphoma-and-smoldering-multiple-myeloma-a-case-report/2025-04-17T20:52:14+00:00https://lymphoma-stg.clarovantdigital.com/library/epidemiology-characteristics-and-clinical-outcomes-of-composite-hodgkin-lymphoma-and-diffuse-large-b-cell-lymphoma-using-machine-learning/2025-04-17T20:52:14+00:00https://lymphoma-stg.clarovantdigital.com/library/ibrutinib-lenalidomide-and-rituximab-in-relapsed-mantle-cell-lymphoma-long-term-follow-up-of-the-nordic-lymphoma-group-mcl6-philemon-trial/2026-01-16T15:05:34+00:00https://lymphoma-stg.clarovantdigital.com/library/speaking-of-survival-oncologists-approaches-to-risk-behavior-conversations-with-cancer-survivors/2025-04-17T20:52:14+00:00https://lymphoma-stg.clarovantdigital.com/library/delving-deeper-into-the-pathogenesis-and-genomics-of-posttransplant-diffuse-large-b-cell-lymphoma/2026-09-02T16:00:38+00:00https://lymphoma-stg.clarovantdigital.com/library/lenalidomide-in-combination-with-rituximab-dexamethasone-high-dose-ara-c-and-cisplatinum-as-salvage-therapy-in-refractory-or-relapsed-aggressive-b-cell-non-hodgkin-lymphoma-an-open-label-multicen/2025-04-17T20:52:15+00:00https://lymphoma-stg.clarovantdigital.com/library/impact-of-lenalidomide-consolidation-on-health-related-quality-of-life-in-chronic-lymphocytic-leukemia-ancillary-study-of-the-phase-iii-cll6-residuum-trial/2025-04-17T20:52:15+00:00https://lymphoma-stg.clarovantdigital.com/library/odronextamab-monotherapy-in-patients-with-relapsed-refractory-diffuse-large-b-cell-lymphoma-primary-efficacy-and-safety-analysis-in-phase-2-elm-2-trial/2025-04-17T20:52:15+00:00https://lymphoma-stg.clarovantdigital.com/library/long-term-outcomes-and-clinical-phenotypes-associated-with-best-response-to-low-dose-alemtuzumab-in-cutaneous-t-cell-lymphoma/2025-04-17T20:52:15+00:00https://lymphoma-stg.clarovantdigital.com/library/acalabrutinib-obinutuzumab-improves-survival-vs-chemoimmunotherapy-in-treatment-naive-cll-in-the-6-year-follow-up-of-elevate-tn/2025-11-10T19:54:32+00:00https://lymphoma-stg.clarovantdigital.com/library/atezolizumab-consolidation-in-patients-with-high-risk-diffuse-large-b-cell-lymphoma-in-complete-remission-after-r-chop/2025-12-28T14:24:55+00:00https://lymphoma-stg.clarovantdigital.com/library/venetoclax-based-regimens-in-octogenarian-cll-patients-efficacy-safety-and-comparison-to-btki-in-a-multicenter-cohort/2025-04-23T18:40:36+00:00https://lymphoma-stg.clarovantdigital.com/library/statin-use-and-survival-in-sll-cll-treated-with-ibrutinib-pooled-analysis-of-four-randomized-controlled-trials/2025-04-23T18:45:28+00:00https://lymphoma-stg.clarovantdigital.com/library/impact-of-resource-availability-on-outcomes-of-diffuse-large-b-cell-lymphoma-real-world-data-from-pakistan/2025-04-24T15:34:11+00:00https://lymphoma-stg.clarovantdigital.com/library/coexistence-of-tuberculous-lymphadenitis-and-hodgkin-lymphoma-a-diagnostic-challenge/2025-04-25T19:24:30+00:00https://lymphoma-stg.clarovantdigital.com/library/using-patientreported-outcome-measures-in-clinical-trials-perspectives-for-and-against-a-modular-approach/2025-04-25T19:24:30+00:00https://lymphoma-stg.clarovantdigital.com/library/glofitamab-induces-deep-and-rapid-response-in-relapsed-primary-central-nervous-system-lymphoma/2025-04-25T19:24:30+00:00https://lymphoma-stg.clarovantdigital.com/library/safety-and-feasibility-of-4-1bb-co-stimulated-cd19-specific-car-nk-cell-therapy-in-refractory-relapsed-large-b-cell-lymphoma-a-phase-1-trial/2025-04-25T19:24:31+00:00https://lymphoma-stg.clarovantdigital.com/library/clinical-outcomes-of-japanese-patients-treated-with-out-of-specification-tisagenlecleucel-in-a-phase-3b-trial/2025-04-25T19:24:31+00:00https://lymphoma-stg.clarovantdigital.com/library/risk-of-lymphoid-malignancy-associated-with-cancer-predisposition-genes/2025-04-25T19:24:31+00:00https://lymphoma-stg.clarovantdigital.com/library/cd5-and-p53-immunohistochemistry-valuable-prediction-method-in-molecular-typing-of-cd5-positive-diffuse-large-b-cell-lymphoma/2025-04-25T19:24:31+00:00https://lymphoma-stg.clarovantdigital.com/library/real-world-data-analysis-of-survival-outcomes-of-patients-with-primary-mediastinal-large-b-cell-lymphoma-treated-with-immunochemotherapy-the-role-of-consolidative-radiation-therapy/2025-04-25T19:24:31+00:00https://lymphoma-stg.clarovantdigital.com/library/pediatric-relapsed-refractory-alk-positive-anaplastic-large-cell-lymphoma-treatment-and-outcomes-in-the-targeted-drug-era/2025-04-25T19:24:31+00:00https://lymphoma-stg.clarovantdigital.com/library/a-comparison-of-healthcare-resource-utilization-and-costs-between-patients-with-chronic-lymphocytic-leukemia-treated-with-first-line-ibrutinib-or-acalabrutinib-using-two-large-us-real-world-databases/2025-12-19T18:21:38+00:00https://lymphoma-stg.clarovantdigital.com/library/myeloid-neoplasms-after-cd19-directed-car-t-cells-therapy-in-long-term-b-cell-lymphoma-responders-a-rising-risk-over-time/2025-04-25T19:24:31+00:00https://lymphoma-stg.clarovantdigital.com/library/a-systematic-literature-review-of-the-economic-and-healthcare-resource-utilization-burden-of-relapsed-refractory-follicular-lymphoma/2025-04-25T19:24:32+00:00https://lymphoma-stg.clarovantdigital.com/library/cd28-costimulated-cd19-car-t-cells-for-pediatric-mature-non-hodgkin-b-cell-lymphoma/2025-04-25T19:24:32+00:00https://lymphoma-stg.clarovantdigital.com/library/temporal-trends-in-relative-survival-of-diffuse-large-b-cell-lymphoma-in-sweden-and-denmark-in-the-era-of-targeted-and-cellular-therapies/2025-04-25T19:24:32+00:00https://lymphoma-stg.clarovantdigital.com/library/validation-of-pod24-as-a-robust-early-clinical-indicator-of-poor-survival-in-mantle-cell-lymphoma-from-1280-patients-on-clinical-trials-a-lysa-study/2025-04-25T19:24:32+00:00https://lymphoma-stg.clarovantdigital.com/library/treatment-outcomes-of-btk-inhibitors-and-venetoclax-with-or-without-anti-cd20-monoclonal-antibody-in-relapsed-or-refractory-mantle-cell-lymphoma/2025-05-02T18:24:11+00:00https://lymphoma-stg.clarovantdigital.com/library/prospective-phase-ii-trial-of-first-line-rituximab-methotrexate-and-orelabrutinib-r-mo-in-primary-central-nervous-system-lymphoma/2025-05-02T18:24:11+00:00https://lymphoma-stg.clarovantdigital.com/library/the-clinical-features-management-and-outcomes-of-lymphoma-in-pregnancy-a-multicentre-study-by-the-australasian-lymphoma-alliance/2025-05-02T18:24:11+00:00https://lymphoma-stg.clarovantdigital.com/library/superior-survival-in-diffuse-large-b-cell-lymphoma-of-the-bone-with-immune-rich-tumor-microenvironment/2025-05-02T18:24:11+00:00https://lymphoma-stg.clarovantdigital.com/library/early-rituximab-monotherapy-versus-watchful-waiting-for-advanced-stage-asymptomatic-low-tumour-burden-follicular-lymphoma-long-term-results-of-a-randomised-phase-3-trial/2025-05-02T18:24:11+00:00https://lymphoma-stg.clarovantdigital.com/library/easy-as-abc-managing-toxicities-of-antibody-drug-conjugates-bispecific-antibodies-and-car-t-cell-therapies/2025-05-02T18:24:11+00:00https://lymphoma-stg.clarovantdigital.com/library/comparative-inhibitory-effects-of-bepotastine-and-diphenhydramine-on-rituximab-induced-infusion-reactions/2025-05-02T18:24:11+00:00https://lymphoma-stg.clarovantdigital.com/library/cardiac-events-in-three-phase-3-randomized-trials-including-acalabrutinib-in-chronic-lymphocytic-leukemia/2025-05-02T18:24:11+00:00https://lymphoma-stg.clarovantdigital.com/library/brentuximab-vedotin-and-nivolumab-for-untreated-patients-with-hodgkin-lymphoma-long-term-results/2025-05-26T18:43:45+00:00https://lymphoma-stg.clarovantdigital.com/library/long-term-follow-up-of-mrd-guided-treatment-of-ibrutinib-plus-venetoclax-for-relapsed-cll-phase-2-vision-ho141-trial/2025-05-07T19:12:39+00:00https://lymphoma-stg.clarovantdigital.com/library/clinical-and-imaging-features-of-primary-thyroid-malt-lymphoma/2025-05-08T18:15:41+00:00https://lymphoma-stg.clarovantdigital.com/library/cd38-prognostic-role-in-chronic-lymphocytic-leukemia-patients-treated-with-standard-chemotherapy-or-targeted-agents-a-monocentric-real-life-experience/2025-05-08T18:24:15+00:00https://lymphoma-stg.clarovantdigital.com/library/single-agent-and-associated-therapies-with-monoclonal-antibodies-what-about-follicular-lymphoma/2025-05-08T18:27:49+00:00https://lymphoma-stg.clarovantdigital.com/library/cardiovascular-toxicities-associated-with-chimeric-antigen-receptor-t-cell-therapy/2025-05-09T19:05:39+00:00https://lymphoma-stg.clarovantdigital.com/library/genomic-signatures-in-plasma-circulating-tumor-dna-reveal-treatment-response-and-prognostic-insights-in-mantel-cell-lymphoma/2025-05-09T19:22:04+00:00https://lymphoma-stg.clarovantdigital.com/library/cause-specific-mortality-in-a-cohort-of-1435-patients-with-hodgkin-lymphoma-treated-between-1985-and-2014-a-nationwide-chilean-cohort-study/2025-05-09T19:22:04+00:00https://lymphoma-stg.clarovantdigital.com/library/pfs24-as-a-prognostic-milestone-in-patients-with-newly-diagnosed-primary-cns-lymphoma/2025-05-09T19:22:04+00:00https://lymphoma-stg.clarovantdigital.com/library/association-of-car-t-approval-on-outcomes-in-patients-with-diffuse-large-b-cell-lymphoma-at-the-population-level-in-the-united-states/2025-12-19T18:20:58+00:00https://lymphoma-stg.clarovantdigital.com/library/predictors-and-implications-of-renal-injury-after-cd19-chimeric-antigen-receptor-t-cell-therapy/2025-05-09T19:22:04+00:00https://lymphoma-stg.clarovantdigital.com/library/allogeneic-chimeric-antigen-receptor-t-cell-products-cemacabtagene-ansegedleucel-allo-501-in-relapsed-refractory-large-b-cell-lymphoma-phase-i-experience-from-the-alpha2-alpha-clinical-studies/2025-05-09T19:22:04+00:00https://lymphoma-stg.clarovantdigital.com/library/the-role-of-fapi-pet-ct-in-patients-with-lymphoma-a-systematic-review/2025-05-12T17:02:07+00:00https://lymphoma-stg.clarovantdigital.com/library/real-world-outcomes-of-pet-adapted-treatment-for-classic-hodgkins-lymphoma-a-study-from-a-single-tertiary-care-center/2025-05-12T17:06:19+00:00https://lymphoma-stg.clarovantdigital.com/library/circulating-tumor-dna-from-biology-to-potential-clinical-applications-in-diffuse-large-b-cell-lymphomas/2025-05-12T17:12:42+00:00https://lymphoma-stg.clarovantdigital.com/library/the-murano-study-final-analysis-and-retreatment-crossover-substudy-results-of-venr-for-patients-with-relapsed-refractory-cll/2025-05-13T13:23:31+00:00https://lymphoma-stg.clarovantdigital.com/library/mosunetuzumab-plus-pola-chp-compared-with-pola-r-chp-in-previously-untreated-dlbcl-final-results-from-a-phase-ii-study/2025-05-13T13:28:11+00:00https://lymphoma-stg.clarovantdigital.com/library/evaluation-of-second-generation-brutons-tyrosine-kinase-inhibitors-for-the-treatment-of-mantle-cell-lymphoma/2025-05-14T20:41:09+00:00https://lymphoma-stg.clarovantdigital.com/library/clinical-benefit-of-tafasitamab-plus-lenalidomide-in-relapsed-or-refractory-diffuse-large-b-cell-lymphoma-real-world-data-from-the-earlymind-study/2025-05-16T14:13:38+00:00https://lymphoma-stg.clarovantdigital.com/library/a-comprehensive-genetic-study-of-classical-hodgkin-lymphoma-using-circulating-tumor-dna/2025-05-16T14:20:40+00:00https://lymphoma-stg.clarovantdigital.com/library/variability-in-primary-thyroid-lymphoma-a-clinicopathological-exploration-of-diffuse-large-b-cell-marginal-zone-and-follicular-lymphoma/2025-05-16T14:27:09+00:00https://lymphoma-stg.clarovantdigital.com/library/impact-of-cd3-expression-on-outcome-in-pediatric-anaplastic-large-cell-lymphoma/2025-05-16T14:33:27+00:00https://lymphoma-stg.clarovantdigital.com/library/real-world-survival-outcomes-in-first-line-ibrutinib-treated-patients-with-high-risk-cll-sll/2025-05-16T14:45:57+00:00https://lymphoma-stg.clarovantdigital.com/library/phase-2-trial-of-chop-with-anti-ccr4-antibody-mogamulizumab-for-elderly-patients-with-adult-t-cell-leukemia-lymphoma/2025-06-05T21:44:04+00:00https://lymphoma-stg.clarovantdigital.com/library/axicabtagene-ciloleucel-compared-to-standard-of-care-in-canadian-patients-with-relapsed-or-refractory-large-b-cell-lymphoma-a-cost-effectiveness-analysis-of-the-zuma-7-trial/2025-05-16T18:54:59+00:00https://lymphoma-stg.clarovantdigital.com/library/evaluating-the-safety-and-feasibility-of-allogeneic-nk-cell-infusion-in-high-risk-lymphoma-patients-post-autologous-stem-cell-transplantation/2025-05-16T18:54:59+00:00https://lymphoma-stg.clarovantdigital.com/library/acquired-mutations-in-patients-with-relapsed-refractory-cll-who-progressed-in-the-alpine-study/2025-05-16T18:54:59+00:00https://lymphoma-stg.clarovantdigital.com/library/phase-ii-study-of-venetoclax-added-to-bendamustine-and-obinutuzumab-in-patients-with-high-risk-follicular-lymphoma-as-front-line-therapy-pre0403/2025-05-16T18:54:59+00:00https://lymphoma-stg.clarovantdigital.com/library/identification-of-the-histologic-transformation-of-follicular-lymphoma-using-super-resolution-microcirculation-imaging/2025-05-16T18:54:59+00:00https://lymphoma-stg.clarovantdigital.com/library/racial-and-ethnic-disparities-in-cardiotoxicity-in-patients-with-cancer-treated-with-anthracyclines/2025-05-16T18:54:59+00:00https://lymphoma-stg.clarovantdigital.com/library/large-clones-of-clonal-hematopoiesis-affect-outcome-in-mantle-cell-lymphoma-results-from-the-fil-mcl0208-clinical-trial/2025-05-16T18:55:00+00:00https://lymphoma-stg.clarovantdigital.com/library/refining-histopathological-growth-pattern-based-risk-group-discrimination-in-nodular-lymphocyte-predominant-hodgkin-lymphoma-an-analysis-from-the-german-hodgkin-study-group/2025-05-16T18:55:00+00:00https://lymphoma-stg.clarovantdigital.com/library/phase-2-trial-of-ibrutinib-and-nivolumab-in-patients-with-relapsed-cns-lymphomas/2025-05-16T18:55:00+00:00https://lymphoma-stg.clarovantdigital.com/library/outcomes-of-allogeneic-haemopoietic-transplant-for-chronic-lymphocytic-leukaemia-in-the-modern-era/2025-05-16T18:55:00+00:00https://lymphoma-stg.clarovantdigital.com/library/trends-and-outcomes-of-chemotherapy-timing-in-critically-ill-patients-with-hematologic-malignancies-using-a-japanese-national-database/2025-05-16T18:55:00+00:00https://lymphoma-stg.clarovantdigital.com/library/primary-cardiac-diffuse-large-b-cell-lymphoma-managed-with-rituximab-etoposide-prednisone-vincristine-cyclophosphamide-and-doxorubicin-r-epoch-a-case-report-and-literature-review/2025-05-16T18:55:00+00:00https://lymphoma-stg.clarovantdigital.com/library/efficacy-and-safety-of-selinexor-based-regimens-as-first-line-treatments-for-elderly-patients-with-diffuse-large-b-cell-lymphoma-a-real-world-study/2025-05-16T18:55:00+00:00https://lymphoma-stg.clarovantdigital.com/library/comparing-hodgkin-and-non-hodgkin-lymphoma-mortality-between-latin-america-and-the-united-states-from-2008-to-2019-the-need-of-regional-based-lymphoma-registries/2025-05-16T18:55:00+00:00https://lymphoma-stg.clarovantdigital.com/library/glofitamab-results-in-cost-savings-versus-epcoritamab-in-relapsed-refractory-diffuse-large-b-cell-lymphoma-a-total-cost-of-care-analysis/2026-01-14T18:49:53+00:00https://lymphoma-stg.clarovantdigital.com/library/investigation-of-the-mechanism-of-hypertension-caused-by-btki-in-the-treatment-of-hematologic-diseases/2025-05-19T13:45:11+00:00https://lymphoma-stg.clarovantdigital.com/library/an-updated-understanding-of-follicular-lymphoma-transformation/2025-05-19T13:49:22+00:00https://lymphoma-stg.clarovantdigital.com/library/signal-mining-and-analysis-of-adverse-events-of-brentuximab-vedotin-base-on-faers-and-jader-databases/2025-05-19T14:04:42+00:00https://lymphoma-stg.clarovantdigital.com/library/assessment-of-the-role-of-hepatitis-c-virus-in-the-pathogenesis-of-hodgkin-lymphoma-patients/2025-05-21T14:37:18+00:00https://lymphoma-stg.clarovantdigital.com/library/the-impact-of-minimal-residual-disease-measurement-in-the-management-of-chronic-lymphocytic-leukemia/2025-05-21T14:47:21+00:00https://lymphoma-stg.clarovantdigital.com/library/outcomes-and-factors-influencing-survival-in-patients-with-diffuse-large-b-cell-lymphoma-a-population-based-analysis/2025-05-21T14:54:31+00:00https://lymphoma-stg.clarovantdigital.com/library/the-role-of-the-gut-microbiome-in-non-hodgkin-lymphoma-nhl-a-focus-on-diffuse-large-b-cell-lymphoma-follicular-lymphoma-cutaneous-t-cell-lymphoma-and-nk-t-cell-lymphoma/2025-05-21T15:00:51+00:00https://lymphoma-stg.clarovantdigital.com/library/impact-of-secondary-hematologic-malignancies-on-prognosis-of-hodgkins-lymphoma-survivors/2025-05-21T15:05:00+00:00https://lymphoma-stg.clarovantdigital.com/library/correlations-between-immunophenotypic-markers-and-clinical-progression-in-romanian-patients-diagnosed-with-diffuse-large-b-cell-lymphoma/2025-05-22T18:04:17+00:00https://lymphoma-stg.clarovantdigital.com/library/clinical-characteristics-of-diffuse-large-b-cell-lymphoma-complicated-with-multiple-primary-malignant-neoplasms/2025-05-22T18:09:04+00:00https://lymphoma-stg.clarovantdigital.com/library/clinical-experience-and-safety-of-venetoclax-in-the-treatment-of-patients-with-chronic-lymphocytic-leukemia-real-world-data-from-a-hemato-oncology-center/2025-05-22T18:15:40+00:00https://lymphoma-stg.clarovantdigital.com/library/extranodal-classical-hodgkin-lymphoma-involving-the-spinal-cord-case-report-and-review-of-the-literature/2025-05-23T18:42:14+00:00https://lymphoma-stg.clarovantdigital.com/library/prognostic-factors-and-effect-modifiers-in-patients-with-relapse-or-refractory-diffuse-large-b-cell-lymphoma-after-two-lines-of-therapy-a-systematic-literature-and-expert-clinical-review/2025-05-23T18:42:14+00:00https://lymphoma-stg.clarovantdigital.com/library/polatuzumab-vedotin-zanubrutinib-and-rituximab-pola-zr-achieved-rapid-and-deep-response-in-untreated-frail-and-elderly-dlbcl/2025-05-23T18:42:14+00:00https://lymphoma-stg.clarovantdigital.com/library/a-comparative-analysis-of-cardiovascular-events-associated-with-acalabrutinib-versus-ibrutinib-in-chronic-lymphocytic-leukemia-insights-from-a-global-federated-network/2025-05-23T18:42:15+00:00https://lymphoma-stg.clarovantdigital.com/library/cardiovascular-disease-in-adolescent-and-young-adult-survivors-of-non-hodgkin-lymphoma-in-korea/2026-04-24T19:52:21+00:00https://lymphoma-stg.clarovantdigital.com/library/evaluating-the-use-of-vincristine-as-a-substitute-in-hodgkin-lymphoma-treatment/2025-05-23T18:42:15+00:00https://lymphoma-stg.clarovantdigital.com/library/sex-specific-differences-in-reproductive-tract-lymphomas-epidemiology-clinical-features-and-treatment-outcomes/2025-05-23T18:42:15+00:00https://lymphoma-stg.clarovantdigital.com/library/management-of-relapsed-or-refractory-large-b-cell-lymphoma-a-british-society-for-haematology-guideline/2025-05-23T18:42:15+00:00https://lymphoma-stg.clarovantdigital.com/library/deep-learning-based-interpretable-prediction-of-recurrence-of-diffuse-large-b-cell-lymphoma/2025-05-23T18:42:15+00:00https://lymphoma-stg.clarovantdigital.com/library/subgroup-analysis-of-older-patients-60-years-with-diffuse-large-b-cell-lymphoma-in-the-phase-3-polarix-study/2025-05-23T18:42:15+00:00https://lymphoma-stg.clarovantdigital.com/library/pirtobrutinib-after-a-covalent-btk-inhibitor-in-chronic-lymphocytic-leukemia/2025-05-23T18:42:15+00:00https://lymphoma-stg.clarovantdigital.com/library/pet-ct-in-the-staging-and-treatment-response-assessment-of-patients-with-extranodal-marginal-zone-lymphoma/2025-05-23T18:42:15+00:00https://lymphoma-stg.clarovantdigital.com/library/quality-of-life-and-symptom-burden-among-hematologic-malignancy-patients-undergoing-car-t-therapy-a-cross-sectional-study/2025-05-23T18:42:15+00:00https://lymphoma-stg.clarovantdigital.com/library/a-retrospective-study-on-the-incidence-mortality-and-risk-factors-of-hodgkin-lymphoma-in-pakistan/2026-03-13T17:42:02+00:00https://lymphoma-stg.clarovantdigital.com/library/health-related-quality-of-life-in-patients-with-aggressive-non-hodgkin-lymphoma-results-from-the-petal-trial/2025-05-23T18:42:15+00:00https://lymphoma-stg.clarovantdigital.com/library/patients-in-complete-remission-after-r-chop-like-therapy-for-diffuse-large-b-cell-lymphoma-have-limited-excess-use-of-health-care-services-in-denmark/2025-05-23T18:42:15+00:00https://lymphoma-stg.clarovantdigital.com/library/high-intensity-interval-training-and-strength-conditioning-in-patients-with-chronic-lymphocytic-leukemia-a-systematic-review/2025-05-23T18:42:15+00:00https://lymphoma-stg.clarovantdigital.com/library/car-t-cell-therapy-provides-an-opportunity-for-further-consolidation-treatment-for-relapsed-or-refractory-adult-burkitt-lymphoma-patient/2025-05-26T14:22:49+00:00https://lymphoma-stg.clarovantdigital.com/library/zanubrutinib-is-well-tolerated-and-effective-in-cll-sll-patients-intolerant-of-ibrutinib-acalabrutinib-updated-results/2025-10-21T18:41:13+00:00https://lymphoma-stg.clarovantdigital.com/library/chronic-lymphocytic-leukemia-and-associated-chronic-lung-diseases/2025-05-29T18:34:09+00:00https://lymphoma-stg.clarovantdigital.com/library/clinical-features-and-outcomes-of-newly-diagnosed-classical-hodgkin-lymphoma-patients-in-saudi-arabia-a-multicenter-cohort-study/2025-05-30T15:33:51+00:00https://lymphoma-stg.clarovantdigital.com/library/low-dose-anti-pd1-immune-checkpoint-inhibitors-in-relapsed-refractory-hodgkin-lymphoma-a-systematic-review/2025-05-30T15:33:51+00:00https://lymphoma-stg.clarovantdigital.com/library/diagnostic-approach-to-leptomeningeal-involvement-in-diffuse-large-b-cell-lymphoma/2025-05-30T15:33:51+00:00https://lymphoma-stg.clarovantdigital.com/library/metabolic-tumor-volume-predicts-outcome-in-patients-with-advanced-stage-follicular-lymphoma-from-the-relevance-trial/2025-05-30T15:33:51+00:00https://lymphoma-stg.clarovantdigital.com/library/robust-car-t-cell-expansion-and-superior-outcomes-in-dlbcl-patients-in-complete-response-at-infusion/2025-05-30T15:33:51+00:00https://lymphoma-stg.clarovantdigital.com/library/relapses-and-outcomes-of-systemic-chemo-free-therapies-combined-with-intravitreous-methotrexate-in-isolated-primary-vitreoretinal-lymphoma-an-analysis-based-on-two-prospective-cohort-studies/2025-05-30T15:33:51+00:00https://lymphoma-stg.clarovantdigital.com/library/clinical-outcomes-of-a-new-local-cd19-car-t-cell-therapy-for-patients-with-relapsed-or-refractory-acute-lymphoblastic-leukemia-and-non-hodgkin-lymphoma-in-malaysia/2025-05-30T15:33:51+00:00https://lymphoma-stg.clarovantdigital.com/library/toxicity-progression-free-survival-and-quality-of-life-of-patients-treated-with-zanubrutinib-versus-ibrutinib-a-q-twist-analysis-from-the-alpine-study-in-relapsed-or-refractory-chronic-lymphocytic/2025-05-30T15:33:52+00:00https://lymphoma-stg.clarovantdigital.com/library/circulating-tumor-dna-in-alk-positive-anaplastic-large-cell-lymphoma-a-proof-of-concept-study/2025-05-30T15:33:52+00:00https://lymphoma-stg.clarovantdigital.com/library/indirect-comparisons-of-efficacy-of-zanubrutinib-versus-orelabrutinib-in-patients-with-r-r-mcl-an-extended-follow-up-analysis/2025-05-30T15:33:52+00:00https://lymphoma-stg.clarovantdigital.com/library/real-world-evidence-of-obinutuzumab-and-venetoclax-in-previously-treated-patients-with-chronic-lymphocytic-leukemia-or-small-lymphocytic-lymphoma/2025-12-15T20:11:31+00:00https://lymphoma-stg.clarovantdigital.com/library/risk-and-prognosis-of-second-primary-malignancies-in-patients-with-follicular-lymphoma-in-the-era-of-rituximab-a-population-study-based-on-the-seer-database/2025-05-30T15:33:52+00:00https://lymphoma-stg.clarovantdigital.com/library/toll-like-receptor-9-tlr9-expression-correlates-with-cell-of-origin-and-predicts-clinical-outcome-in-diffuse-large-b-cell-lymphoma/2025-05-30T15:33:52+00:00https://lymphoma-stg.clarovantdigital.com/library/beyond-maximum-grade-tolerability-of-immunotherapies-cellular-therapies-and-targeted-agents-in-haematological-malignancies/2025-05-30T15:33:52+00:00https://lymphoma-stg.clarovantdigital.com/library/efficacy-and-safety-of-epcoritamab-in-japanese-patients-with-relapsed-or-refractory-diffuse-large-b-cell-lymphoma-3-year-follow-up-from-the-epcore-nhl-3-trial/2026-01-14T18:49:22+00:00https://lymphoma-stg.clarovantdigital.com/library/management-strategies-for-car-t-cell-therapy-related-toxicities-results-from-a-survey-in-greece/2025-06-03T13:14:41+00:00https://lymphoma-stg.clarovantdigital.com/library/immunohistochemical-profile-of-diffuse-large-b-cell-in-a-pakistani-cohort-a-cross-sectional-study/2025-06-05T18:38:41+00:00https://lymphoma-stg.clarovantdigital.com/library/efficacy-and-safety-of-bendamustine-rituximab-for-nodular-lymphocyte-predominant-hodgkin-lymphoma/2025-06-06T14:08:03+00:00https://lymphoma-stg.clarovantdigital.com/library/chimeric-antigen-receptor-t-cell-therapy-and-bispecific-antibody-use-in-earlier-lines-of-treatment-of-large-b-cell-lymphoma-follicular-lymphoma-and-mantle-cell-lymphoma/2025-06-06T14:08:03+00:00https://lymphoma-stg.clarovantdigital.com/library/real-world-treatment-of-large-b-cell-lymphoma-with-chimeric-antigen-receptor-t-cell-therapy-after-loncastuximab-tesirine/2025-06-06T14:08:03+00:00https://lymphoma-stg.clarovantdigital.com/library/influence-of-hiv-on-outcomes-in-patients-with-diffuse-large-b-cell-lymphoma-treated-with-cd19-targeting-car-t-cell-therapy/2025-06-06T14:08:03+00:00https://lymphoma-stg.clarovantdigital.com/library/zanubrutinib-and-venetoclax-for-patients-with-treatment-naive-chronic-lymphocytic-leukemia-small-lymphocytic-lymphoma-with-and-without-del17p-tp53-mutation-sequoia-arm-d-results/2025-06-06T14:08:03+00:00https://lymphoma-stg.clarovantdigital.com/library/results-from-the-completed-dose-finding-part-of-phase-2-study-of-the-innate-cell-engager-acimtamig-afm13-in-combination-with-allonk-ab-101-in-relapsed-or-refractory-classical-hodgkin-lymphoma-lum/2025-06-06T14:08:03+00:00https://lymphoma-stg.clarovantdigital.com/library/fixed-duration-subcutaneous-sc-mosunetuzumab-mosun-in-patients-with-previously-untreated-high-tumor-burden-follicular-lymphoma-fl-interim-results-from-the-phase-ii-morningsun-study/2026-01-14T17:53:42+00:00https://lymphoma-stg.clarovantdigital.com/library/sintilimab-anti-pd-1-antibody-combined-with-chidamide-an-oral-subtype-selective-hdaci-followed-by-p-gemox-regimen-in-patients-with-treatment-naive-extranodal-natural-killer-t-cell-lymphoma-tn-enk/2025-06-06T14:08:03+00:00https://lymphoma-stg.clarovantdigital.com/library/sintilimab-anti-pd-1-plus-ifosfamide-carboplatin-and-etoposide-ice-in-second-line-classical-hodgkin-lymphoma-chl-results-of-a-multicenter-randomized-controlled-double-blind-phase-3-study/2025-06-06T14:08:03+00:00https://lymphoma-stg.clarovantdigital.com/library/glofitamab-plus-gemcitabine-and-oxaliplatin-glofit-gemox-in-patients-pts-with-relapsed-refractory-r-r-diffuse-large-b-cell-lymphoma-dlbcl-2-year-yr-follow-up-of-starglo/2025-06-06T14:08:03+00:00https://lymphoma-stg.clarovantdigital.com/library/waveline-003-phase-2-3-trial-of-zilovertamab-vedotin-plus-standard-of-care-in-relapsed-refractory-diffuse-large-b-cell-lymphoma/2025-06-06T14:08:04+00:00https://lymphoma-stg.clarovantdigital.com/library/optimizing-post-chimeric-antigen-receptor-car-t-cell-monitoring-evidence-across-lisocabtagene-maraleucel-liso-cel-pivotal-clinical-trials-and-real-world-experience/2025-06-06T14:08:04+00:00https://lymphoma-stg.clarovantdigital.com/library/ibrutinib-venetoclax-plus-cd20-monoclonal-ab-initial-results-of-oasis-ii-a-prospective-randomized-phase-2-trial-in-previously-untreated-mantle-cell-lymphoma-patients/2025-06-06T14:08:04+00:00https://lymphoma-stg.clarovantdigital.com/library/trends-and-outcomes-by-inpatient-and-outpatient-infusion-of-axicabtagene-ciloleucel-axi-cel-in-the-us-for-patients-pts-with-relapsed-refractory-large-b-cell-lymphoma-r-r-lbcl/2025-06-06T14:08:04+00:00https://lymphoma-stg.clarovantdigital.com/library/end-of-life-care-for-newly-diagnosed-diffuse-large-b-cell-lymphoma-patients-with-poor-survival-outcomes/2025-06-06T14:08:04+00:00https://lymphoma-stg.clarovantdigital.com/library/ezh-2-expression-and-prognostic-significance-in-patients-with-low-grade-non-hodgkin-lymphoma/2025-06-06T14:08:04+00:00https://lymphoma-stg.clarovantdigital.com/library/evaluation-of-eligibility-criteria-in-randomized-controlled-trials-for-chronic-lymphocytic-leukemia-over-15-years/2025-06-06T14:08:04+00:00https://lymphoma-stg.clarovantdigital.com/library/investigating-practice-patterns-in-bone-marrow-biopsies-for-cutaneous-t-cell-lymphoma-a-multicenter-clinician-survey/2025-06-06T14:08:04+00:00https://lymphoma-stg.clarovantdigital.com/library/combination-of-zanubrutinib-zanu-venetoclax-ven-for-treatment-naive-tn-cll-sll-results-in-sequoia-arm-d/2025-06-06T14:08:04+00:00https://lymphoma-stg.clarovantdigital.com/library/long-term-follow-up-of-autologous-hematopoietic-cell-transplantation-for-diffuse-large-b-cell-lymphoma-in-the-rituximab-era-realworld-data-from-a-retrospective-singlecenter-analysis/2025-06-06T14:08:04+00:00https://lymphoma-stg.clarovantdigital.com/library/final-analysis-of-fixed-duration-ibrutinib-venetoclax-for-chronic-lymphocytic-leukemia-cll-small-lymphocytic-lymphoma-sll-in-the-phase-2-captivate-study/2025-06-06T14:08:04+00:00https://lymphoma-stg.clarovantdigital.com/library/trends-in-incidence-and-five-year-relative-survival-analysis-of-classical-hodgkin-lymphoma-in-children-adolescents-and-young-adults-ages-20-a-population-based-study-using-national-childhood-canc/2025-06-06T14:08:04+00:00https://lymphoma-stg.clarovantdigital.com/library/efficacy-and-safety-of-the-r2-mtx-regimen-in-primary-central-nervous-system-lymphoma-pcnsl-a-single-center-retrospective-analysis/2025-06-06T14:08:04+00:00https://lymphoma-stg.clarovantdigital.com/library/potential-surrogate-endpoint-for-b-cell-hematologic-malignancy-a-systematic-review-and-meta-analysis/2025-06-06T14:08:05+00:00https://lymphoma-stg.clarovantdigital.com/library/the-combination-of-body-mass-index-and-serum-creatinine-levels-predicts-survival-in-patients-with-hodgkin-lymphoma-treated-with-nivolumab-in-the-checkmate-205-study/2025-06-06T14:08:05+00:00https://lymphoma-stg.clarovantdigital.com/library/comprehensive-precise-car-t-bridging-therapy-for-diffuse-large-b-cell-lymphoma-a-multicenter-study-from-the-chinese-southwest-study-group/2025-06-06T14:08:05+00:00https://lymphoma-stg.clarovantdigital.com/library/metabolic-only-response-assessment-for-omission-of-residual-node-radiation-therapy-rnrt-for-patients-with-classical-hodgkin-lymphoma-chl-and-impact-on-event-free-efs-and-overall-survival-os-a/2025-06-06T14:08:05+00:00https://lymphoma-stg.clarovantdigital.com/library/a-retrospective-cohort-study-of-chimeric-antigen-receptor-t-cell-therapy-in-follicular-lymphoma-patients-with-or-without-histological-transformation/2025-06-06T14:08:05+00:00https://lymphoma-stg.clarovantdigital.com/library/efficacy-and-safety-of-oral-tazemetostat-an-ezh2-inhibitor-in-relapsed-or-refractory-b-cell-non-hodgkin-lymphomas-a-systematic-review-and-proportionality-meta-analysis/2025-06-06T14:08:05+00:00https://lymphoma-stg.clarovantdigital.com/library/efficacy-and-safety-of-tazemetostat-in-patients-with-refractory-relapsed-follicular-lymphoma-or-diffuse-large-b-cell-lymphoma-systematic-review-and-meta-analysis/2025-06-06T14:08:05+00:00https://lymphoma-stg.clarovantdigital.com/library/location-specific-analysis-of-clinicopathological-characteristics-and-long-term-prognosis-of-primary-gastrointestinal-diffuse-large-b-cell-lymphoma/2025-06-06T14:08:05+00:00https://lymphoma-stg.clarovantdigital.com/library/socioeconomic-racial-ethnic-household-and-infrastructural-disparities-of-hematologic-cancer-outcomes-in-the-united-states/2025-06-06T14:08:05+00:00https://lymphoma-stg.clarovantdigital.com/library/observational-survey-of-financial-difficulties-among-patients-with-multiple-myeloma-and-chronic-lymphocytic-leukaemia-treated-at-us-community-oncology-clinics-alliance-a231602cd/2025-06-06T14:08:05+00:00https://lymphoma-stg.clarovantdigital.com/library/safety-and-efficacy-of-azd0486-a-cd19xcd3-t-cell-engager-in-relapsed-or-refractory-diffuse-large-b-cell-lymphoma/2025-06-06T14:08:05+00:00https://lymphoma-stg.clarovantdigital.com/library/value-adaptive-clinical-trial-designs-for-efficient-delivery-of-publicly-funded-trials-a-discussion-of-methods-case-studies-opportunities-and-challenges/2025-06-06T14:08:05+00:00https://lymphoma-stg.clarovantdigital.com/library/efficacy-and-safety-of-a-novel-cd19-cd22-dual-targeted-fully-human-loop-bi-car-t-for-the-treatment-of-relapsed-refractory-b-cell-non-hodgkin-lymphoma/2025-06-06T14:08:05+00:00https://lymphoma-stg.clarovantdigital.com/library/novel-analysis-of-3-y-results-from-the-pivotal-epcore-nhl-1-study-outcomes-in-patients-pts-with-relapsed-refractory-large-b-cell-lymphoma-r-r-lbcl-and-complete-response-cr-at-2-y-with-epcoritam/2026-01-14T18:48:47+00:00https://lymphoma-stg.clarovantdigital.com/library/cd20xcd3-bispecific-antibodies-in-b-nhl-a-review-of-translational-science-pharmacokinetics-pharmacodynamics-and-dose-strategy-in-clinical-research/2026-01-14T18:48:05+00:00https://lymphoma-stg.clarovantdigital.com/library/indirect-comparison-of-epcoritamab-vs-chemoimmunotherapy-mosunetuzumab-or-odronextamab-in-follicular-lymphoma/2026-03-12T12:58:03+00:00https://lymphoma-stg.clarovantdigital.com/library/molecular-features-accompanying-richters-transformation-in-patients-with-chronic-lymphocytic-leukemia/2025-06-10T19:26:25+00:00https://lymphoma-stg.clarovantdigital.com/library/contemporary-epidemiological-landscape-of-pediatric-non-hodgkin-lymphoma-a-global-burden-of-disease-analysis/2025-06-10T20:10:46+00:00https://lymphoma-stg.clarovantdigital.com/library/molecular-features-accompanying-richters-transformation-in-patients-with-chronic-lymphocytic-leukemia-2/2025-06-13T13:32:23+00:00https://lymphoma-stg.clarovantdigital.com/library/real-world-evidence-assessing-the-safety-of-administering-intravenous-rituximab-biosimilar-in-the-first-cycle-and-subcutaneous-rituximab-in-subsequent-cycles-in-b-cell-lymphoma-patients/2026-01-06T21:05:40+00:00https://lymphoma-stg.clarovantdigital.com/library/chemotherapy-free-combination-of-ibrutinib-and-obinutuzumab-for-untreated-advanced-follicular-lymphoma-results-of-a-phase-ii-study-from-the-german-lymphoma-alliance/2025-12-30T18:55:01+00:00https://lymphoma-stg.clarovantdigital.com/library/tumor-microenvironment-inflammation-and-inflammatory-prognostic-indices-in-diffuse-large-b-cell-lymphomas-a-narrative-review/2025-06-13T13:47:53+00:00https://lymphoma-stg.clarovantdigital.com/library/redefining-value-assessment-and-healthcare-funding-priorities-for-medicines-the-journey-to-patient-centric-decision-making-in-apac-a-systematic-literature-review/2026-04-24T19:51:43+00:00https://lymphoma-stg.clarovantdigital.com/library/patient-engagement-and-patient-experience-data-in-regulatory-review-and-health-technology-assessment-where-are-we-today/2025-06-13T14:57:44+00:00https://lymphoma-stg.clarovantdigital.com/library/the-role-and-value-of-real-world-evidence-in-health-technology-decision-making-in-france-germany-italy-spain-and-the-uk-insights-on-external-control-arms/2025-06-13T14:57:44+00:00https://lymphoma-stg.clarovantdigital.com/library/prognostic-value-of-early-post-treatment-18f-fdg-pet-ct-in-diffuse-large-b-cell-lymphoma-patients-receiving-chimeric-antigen-receptor-t-cell-therapy/2025-06-13T14:57:44+00:00https://lymphoma-stg.clarovantdigital.com/library/acalabrutinib-plus-bendamustine-rituximab-in-untreated-mantle-cell-lymphoma/2025-06-13T14:57:44+00:00https://lymphoma-stg.clarovantdigital.com/library/phase-ii-safety-and-preliminary-efficacy-of-amulirafusp-alfa-imm0306-in-combination-with-lenalidomide-in-patients-with-relapsed-or-refractory-cd20-positive-follicular-lymphoma/2025-06-13T14:57:44+00:00https://lymphoma-stg.clarovantdigital.com/library/2024-international-symposium-on-hodgkin-lymphoma-abstract-book/2025-06-13T14:57:44+00:00https://lymphoma-stg.clarovantdigital.com/library/car-t-cell-therapy-in-older-adults-with-relapsed-refractory-lbcl-benefits-and-challenges/2025-06-13T14:57:44+00:00https://lymphoma-stg.clarovantdigital.com/library/phase-iii-trial-of-pirtobrutinib-versus-idelalisib-rituximab-or-bendamustine-rituximab-in-covalent-bruton-tyrosine-kinase-inhibitor-pretreated-chronic-lymphocytic-leukemia-small-lymphocytic-lymphoma/2025-06-13T14:57:44+00:00https://lymphoma-stg.clarovantdigital.com/library/comparison-of-total-body-irradiation-tbi-and-non-tbi-conditioning-regimens-for-allogeneic-hematopoietic-stem-cell-transplantation-in-patients-with-peripheral-t-cell-lymphoma-a-multicenter-retrospec/2025-12-19T15:07:18+00:00https://lymphoma-stg.clarovantdigital.com/library/lack-of-effectiveness-of-routine-clinic-and-blood-test-based-follow-up-for-diffuse-large-b-cell-lymphoma/2025-06-13T14:57:44+00:00https://lymphoma-stg.clarovantdigital.com/library/outcomes-of-secondary-primary-malignancies-among-patients-with-diffuse-large-b-cell-lymphoma/2025-06-13T14:57:44+00:00https://lymphoma-stg.clarovantdigital.com/library/clinicopathological-genomic-and-transcriptomic-feature-analysis-of-primary-adrenal-large-b-cell-lymphoma/2025-06-13T14:57:45+00:00https://lymphoma-stg.clarovantdigital.com/library/outcomes-of-the-transformation-to-diffuse-large-b-cell-lymphoma-in-hodgkin-lymphoma-and-indolent-b-cell-non-hodgkin-lymphoma-a-population-based-study/2025-06-13T14:57:45+00:00https://lymphoma-stg.clarovantdigital.com/library/circulating-tumor-dna-assessment-in-patients-with-early-stage-classical-hodgkin-lymphoma-treated-with-combination-of-brentuximab-vedotin-and-nivolumab/2025-06-13T14:57:45+00:00https://lymphoma-stg.clarovantdigital.com/library/epcoritamab-monotherapy-demonstrates-deep-and-durable-responses-at-3-year-follow-up-in-patients-with-relapsed-refractory-follicular-lymphoma/2026-01-14T18:47:12+00:00https://lymphoma-stg.clarovantdigital.com/library/urable-efficacy-with-fixed-duration-epcoritamab-polatuzumab-vedotin-rituximab-cyclophosphamide-doxorubicin-and-prednisone-pola-r-chp-for-1l-diffuse-large-b-cell-lymphoma-epcore-nhl-5/2026-01-14T18:46:19+00:00https://lymphoma-stg.clarovantdigital.com/library/extracellular-vesicles-profile-and-risk-of-venous-thromboembolism-in-patients-with-diffuse-large-b-cell-lymphoma/2025-06-13T14:57:45+00:00https://lymphoma-stg.clarovantdigital.com/library/first-disclosure-of-epcoritamab-r-ice-in-patients-with-relapsed-refractory-diffuse-large-b-cell-lymphoma-r-r-dlbcl-eligible-for-autologous-stem-cell-transplantation-asct-epcore-nhl-2/2026-01-14T18:45:43+00:00https://lymphoma-stg.clarovantdigital.com/library/epcoritamab-with-gemcitabine-dexamethasone-and-cisplatin-epco-gdp-in-relapsed-refractory-large-b-cell-lymphoma-an-interim-analysis-of-phase-ii-multicenter-investigated-initiated-trial/2026-01-14T18:44:46+00:00https://lymphoma-stg.clarovantdigital.com/library/patient-preferences-for-attributes-of-bispecific-antibodies-indicated-for-the-treatment-of-relapsed-refractory-diffuse-large-b-cell-lymphoma-in-the-united-states/2025-06-13T14:57:45+00:00https://lymphoma-stg.clarovantdigital.com/library/epcoritamab-plus-lenalidomide-and-rituximab-achieves-high-response-rates-and-survival-benefits-compared-with-usual-care-in-relapsed-refractory-follicular-lymphoma-a-comparative-analysis/2026-01-14T18:44:02+00:00https://lymphoma-stg.clarovantdigital.com/library/ibrutinib-plus-venetoclax-with-mrd-guided-duration-of-treatment-is-superior-to-both-continuous-ibrutinib-monotherapy-and-fcr-for-previously-untreated-cll-report-of-the-phase-iii-uk-flair-study/2025-06-13T14:57:45+00:00https://lymphoma-stg.clarovantdigital.com/library/serious-infections-in-patients-with-cll-sll-treated-with-combination-venetoclax-and-obinutuzumab-compared-with-those-treated-with-zanubrutinib-a-real-world-study/2025-06-13T14:57:45+00:00https://lymphoma-stg.clarovantdigital.com/library/first-worldwide-real-life-data-on-fixed-duration-ibrutinibvenetoclax-treatment-for-previously-untreated-cll-sll-patients-initial-interim-analysis-of-spains-live-observational-study/2025-06-13T14:57:45+00:00https://lymphoma-stg.clarovantdigital.com/library/long-term-follow-up-of-venetoclax-monotherapy-in-previously-treated-patients-with-waldenstrom-macroglobulinemia/2025-06-13T14:57:45+00:00https://lymphoma-stg.clarovantdigital.com/library/real-world-analysis-of-glofitamab-in-relapsed-refractory-primary-central-nervous-system-lymphoma/2025-06-13T14:57:45+00:00https://lymphoma-stg.clarovantdigital.com/library/initial-results-from-lotis-7-a-phase-1b-study-of-loncastuximab-tesirine-plus-glofitamab-in-patients-with-relapsed-refractory-r-r-diffuse-large-b-cell-lymphoma-dlbcl/2025-06-13T14:57:46+00:00https://lymphoma-stg.clarovantdigital.com/library/a-multi-center-real-life-analysis-on-patients-with-large-b-cell-lymphoma-after-failure-of-car-t-cells-therapy/2025-06-13T14:57:46+00:00https://lymphoma-stg.clarovantdigital.com/library/incidence-of-cardiotoxicity-in-outpatient-chimeric-antigen-receptor-t-cell-car-t-therapy-in-patients-with-hematologic-malignancies-a-single-centre-retrospective-study/2025-06-13T14:57:46+00:00https://lymphoma-stg.clarovantdigital.com/library/three-year-real-world-mortality-analysis-of-car-t-therapies-tisa-cel-axi-cel-and-liso-cel/2025-06-13T14:57:46+00:00https://lymphoma-stg.clarovantdigital.com/library/cytokine-release-syndrome-crs-and-immune-effector-cell-associated-neurotoxicity-syndrome-icans-in-lymphoma-patients-receiving-axicabtagene-ciloleucel-analysis-by-year-of-treatment-and-indications/2025-06-13T14:57:46+00:00https://lymphoma-stg.clarovantdigital.com/library/real-world-effectiveness-and-safety-outcomes-among-key-subgroups-of-second-line-2l-axicabtagene-ciloleucel-axi-cel-for-patients-with-relapsed-refractory-r-r-large-b-cell-lymphoma-lbcl/2025-06-13T14:57:46+00:00https://lymphoma-stg.clarovantdigital.com/library/real-world-outcomes-of-brexucabtagene-autoleucel-brexu-cel-in-patients-pts-with-relapsed-refractory-r-r-mantle-cell-lymphoma-mcl-a-systematic-literature-review-slr-and-meta-analysis/2025-06-13T14:57:46+00:00https://lymphoma-stg.clarovantdigital.com/library/efficacy-and-safety-of-academic-anti-cd19-car-t-cell-therapy-for-relapsed-refractory-follicular-lymphoma/2025-06-13T14:57:46+00:00https://lymphoma-stg.clarovantdigital.com/library/the-global-landscape-of-country-level-health-technology-assessment-processes-a-survey-among-104-countries/2025-06-13T14:57:46+00:00https://lymphoma-stg.clarovantdigital.com/library/applications-of-artificial-intelligence-and-the-challenges-in-health-technology-assessment-a-scoping-review-and-framework-with-a-focus-on-economic-dimensions/2025-06-13T14:57:46+00:00https://lymphoma-stg.clarovantdigital.com/library/allogeneic-cart-progress-platforms-current-progress-and-limitations/2025-06-17T13:58:26+00:00https://lymphoma-stg.clarovantdigital.com/library/retrospective-analysis-of-hiv-associated-lymphomas-insights-from-a-single-romanian-center-over-15-years/2025-06-19T13:28:57+00:00https://lymphoma-stg.clarovantdigital.com/library/the-role-of-radiotherapy-in-relapsed-or-refractory-diffuse-large-b-cell-lymphoma-post-car-t-therapy-a-systematic-literature-review/2025-06-19T13:33:19+00:00https://lymphoma-stg.clarovantdigital.com/library/response-duration-during-treatment-of-patients-with-follicular-lymphoma/2025-06-19T20:09:12+00:00https://lymphoma-stg.clarovantdigital.com/library/follicular-lymphoma-current-therapeutic-landscape-and-future-prospects/2025-06-20T16:16:04+00:00https://lymphoma-stg.clarovantdigital.com/library/male-sex-b-symptoms-bone-marrow-involvement-and-genetic-alterations-as-predictive-factors-in-diffuse-large-b-cell-lymphoma/2025-12-15T22:14:47+00:00https://lymphoma-stg.clarovantdigital.com/library/combination-treatment-with-novel-bcl2-inhibitor-sonrotoclax-bgb-11417-and-zanubrutinib-induces-high-rate-of-complete-remission-for-patients-with-relapsed-refractory-mantle-cell-lymphoma/2026-07-05T16:24:20+00:00https://lymphoma-stg.clarovantdigital.com/library/reduced-cd20-expression-yields-inferior-survival-in-patients-with-b-cell-lymphoma-treated-with-cd20xcd3-antibodies-2/2026-01-06T20:56:44+00:00https://lymphoma-stg.clarovantdigital.com/library/sequoia-5-year-follow-up-in-arm-c-frontline-zanubrutinib-monotherapy-in-patients-with-del17p-and-treatment-naive-chronic-lymphocytic-leukemia-small-lymphocytic-lymphoma-cll-sll/2025-12-15T16:22:24+00:00https://lymphoma-stg.clarovantdigital.com/library/efficacy-and-safety-of-glofitamab-in-patients-with-r-r-dlbcl-in-real-life-setting-a-retrospective-study/2025-06-20T16:16:05+00:00https://lymphoma-stg.clarovantdigital.com/library/gh-igk-gene-rearrangement-in-the-diagnosis-of-b-cell-non-hodgkin-lymphoma-experience-from-three-centers/2025-06-20T16:16:05+00:00https://lymphoma-stg.clarovantdigital.com/library/insights-into-the-pathogenesis-and-biology-of-chronic-lymphocytic-leukemia-through-analysis-of-its-b-cell-receptor/2025-06-20T16:16:05+00:00https://lymphoma-stg.clarovantdigital.com/library/rapcabtagene-autoleucel-ytb323-in-patients-with-relapsed-refractory-diffuse-large-b-cell-lymphoma-a-phase-ii-trial-clinical-update/2025-06-20T16:16:05+00:00https://lymphoma-stg.clarovantdigital.com/library/first-line-therapy-in-mantle-cell-lymphoma-the-role-of-btki-in-the-initial-treatment-of-transplant-eligible-and-ineligible-patients/2025-06-20T16:16:05+00:00https://lymphoma-stg.clarovantdigital.com/library/advancing-mantle-cell-lymphoma-risk-assessment-navigating-a-moving-target/2025-06-20T16:16:05+00:00https://lymphoma-stg.clarovantdigital.com/library/comprehensive-analysis-of-relapsed-refractory-mature-b-cell-non-hodgkin-lymphoma-in-children-and-adolescents/2025-06-20T16:16:05+00:00https://lymphoma-stg.clarovantdigital.com/library/patient-reported-outcomes-from-bruin-cll-321-a-randomized-phase-3-trial-comparing-pirtobrutinib-to-idelalisib-rituximab-or-bendamustine-rituximab-in-covalent-btki-pretreated-cll-sll/2025-06-20T16:16:05+00:00https://lymphoma-stg.clarovantdigital.com/library/pretreatment-vitamin-d-deficiency-is-associated-with-impaired-progression-free-and-overall-survival-in-hodgkin-lymphoma/2025-06-20T16:16:05+00:00https://lymphoma-stg.clarovantdigital.com/library/pembrolizumab-and-radiation-therapy-alone-as-an-alternative-to-transplant-for-localized-failure-after-chemotherapy-in-hodgkin-lymphoma-a-multicenter-phase-ii-study/2025-06-20T16:16:05+00:00https://lymphoma-stg.clarovantdigital.com/library/nemtabrutinib-in-relapsed-or-refractory-follicular-lymphoma-updated-results-from-cohort-g-of-the-phase-2-bellwave-003-study/2025-06-20T16:16:06+00:00https://lymphoma-stg.clarovantdigital.com/library/nivolumab-for-relapsed-and-refractory-classical-hodgkin-lymphoma-retrospective-single-center-analysis/2025-12-28T13:48:06+00:00https://lymphoma-stg.clarovantdigital.com/library/5-year-update-on-frontline-brentuximab-vedotin-with-avd-for-stage-ii-iv-hiv-associated-classical-hodgkin-lymphoma-amc-085/2025-06-20T16:16:06+00:00https://lymphoma-stg.clarovantdigital.com/library/radiotherapy-as-a-car-t-bridging-strategy-for-patients-with-large-b-cell-lymphoma-a-south-wales-experience/2025-06-20T16:16:06+00:00https://lymphoma-stg.clarovantdigital.com/library/double-refractory-status-confirms-inferior-survival-in-large-b-cell-lymphoma-eligible-for-third-line-cd19-chimeric-antigen-t-cell-therapy/2025-06-20T16:16:06+00:00https://lymphoma-stg.clarovantdigital.com/library/nodular-lymphocyte-predominant-hodgkin-lymphoma-update-on-biology-and-treatment/2025-06-20T16:16:06+00:00https://lymphoma-stg.clarovantdigital.com/library/pneumonia-in-patients-with-chronic-lymphocytic-leukemia-treated-with-venetoclax-based-regimens-a-real-world-analysis-of-polish-adult-leukemia-group-palg/2025-06-20T16:16:06+00:00https://lymphoma-stg.clarovantdigital.com/library/early-epcoritamab-administration-revives-car-t-cells-in-relapsed-refractory-b-cell-lymphomas/2026-01-14T18:43:29+00:00https://lymphoma-stg.clarovantdigital.com/library/anti-cd19-chimeric-antigen-receptor-t-cells-therapy-is-effective-in-secondary-cns-lymphoma-refractory-to-high-dose-methotrexate-based-chemotherapy/2025-06-20T16:16:06+00:00https://lymphoma-stg.clarovantdigital.com/library/tafasitamab-tafa-plus-lenalidomide-len-and-rituximab-r-for-patients-with-relapsed-or-refractory-follicular-lymphoma-r-r-fl-results-from-the-phase-3-inmind-study/2025-06-20T16:16:06+00:00https://lymphoma-stg.clarovantdigital.com/library/sexual-health-in-hematopoietic-stem-cell-transplantation-survivors/2025-06-20T16:16:06+00:00https://lymphoma-stg.clarovantdigital.com/library/ibrutinib-and-rituximab-is-superior-to-immunochemotherapy-in-previously-untreated-mantle-cell-lymphoma-despite-lower-rates-of-mrd-negativity/2025-06-20T16:16:06+00:00https://lymphoma-stg.clarovantdigital.com/library/high-pfs-with-low-infield-recurrences-after-low-dose-radiotherapy-and-obinutuzumab-in-early-stage-nodal-follicular-lymphoma-final-results-of-the-gazai-study-gla-2018-3/2025-06-20T16:16:06+00:00https://lymphoma-stg.clarovantdigital.com/library/histological-transformation-in-marginal-zone-lymphoma-malt-nodal-and-splenic-risk-clinical-features-and-outcome/2025-06-20T16:16:07+00:00https://lymphoma-stg.clarovantdigital.com/library/follicular-lymphoma-epidemiology-and-outcomes-in-england-2014-2021-preliminary-analysis-from-the-uncover-study-group/2025-06-20T16:16:07+00:00https://lymphoma-stg.clarovantdigital.com/library/improved-outcomes-over-time-for-relapsed-hodgkin-lymphoma-after-autologous-and-allogeneic-stem-cell-transplant-from-ebmt-lymphoma-working-party/2025-06-20T16:16:07+00:00https://lymphoma-stg.clarovantdigital.com/library/lisocabtagene-maraleucel-in-r-r-fl-transcend-fl-impact-of-prior-lines-of-therapy-bendamustine-exposure-and-disease-progression-24-months-of-initial-systemic-therapy/2025-06-20T16:16:07+00:00https://lymphoma-stg.clarovantdigital.com/library/efficacy-and-safety-of-the-eva-chemotherapy-regimen-in-pregnant-patients-with-hodgkins-lymphoma-a-long-term-outcome-analysis/2025-06-20T16:16:07+00:00https://lymphoma-stg.clarovantdigital.com/library/long-term-follow-up-of-patients-with-mantle-cell-lymphoma-who-underwent-high-dose-chemotherapy-and-autologous-hematopoietic-cell-transplantation-in-first-remission/2025-06-20T16:16:07+00:00https://lymphoma-stg.clarovantdigital.com/library/high-dose-chemotherapy-with-autologous-haematopoietic-stem-cell-transplantation-in-patients-with-isolated-vitreoretinal-lymphoma-a-loc-network-study/2025-06-20T16:16:07+00:00https://lymphoma-stg.clarovantdigital.com/library/acalabrutinib-in-combination-with-rituximab-is-highly-effective-frontline-treatment-for-older-patients-with-mantle-cell-lymphoma/2025-06-20T16:16:07+00:00https://lymphoma-stg.clarovantdigital.com/library/treatment-approaches-and-clinical-outcomes-in-primary-colorectal-malt-lymphoma-a-single-institution-retrospective-study-of-66-patients/2025-06-25T12:52:35+00:00https://lymphoma-stg.clarovantdigital.com/library/t-cell-dysregulation-informs-radiotherapy-immunotherapy-response-in-b-cell-lymphoma-results-from-a-phase-i-trial/2025-11-06T21:00:33+00:00https://lymphoma-stg.clarovantdigital.com/library/gastrointestinal-manifestations-of-mature-b-cell-neoplasms-single-center-experiences-from-the-collective-perspective-of-hematology-and-pathology/2025-06-25T13:03:59+00:00https://lymphoma-stg.clarovantdigital.com/library/preferences-for-first-line-chronic-lymphocytic-leukemia-treatments-results-from-a-multinational-study-on-the-perspectives-of-patients-and-physicians/2025-06-25T20:32:17+00:00https://lymphoma-stg.clarovantdigital.com/library/comparative-analysis-of-patients-characteristics-treatment-and-survival-outcomes-in-cll-from-china-and-the-us/2025-12-19T18:06:32+00:00https://lymphoma-stg.clarovantdigital.com/library/global-burden-and-trends-of-childhood-non-hodgkin-lymphoma-from-1990-to-2021/2025-06-27T14:27:37+00:00https://lymphoma-stg.clarovantdigital.com/library/safe-administration-of-venetoclax-obinutuzumab-in-a-chronic-lymphocytic-leukemia-patient-with-brugada-syndrome/2026-01-06T21:04:16+00:00https://lymphoma-stg.clarovantdigital.com/library/impact-of-extranodal-involvement-at-car-t-cell-therapy-on-outcomes-in-patients-with-relapsed-or-refractory-large-b-cell-lymphoma-results-from-a-multicenter-cohort-study/2025-06-27T15:09:31+00:00https://lymphoma-stg.clarovantdigital.com/library/factors-associated-with-mortality-in-leukemia-and-lymphoma-with-covid-19-a-national-inpatient-sample-analysis-2020-2021/2025-06-27T15:09:31+00:00https://lymphoma-stg.clarovantdigital.com/library/large-b-cell-lymphoma-microenvironment-archetype-profiles/2025-06-27T15:09:31+00:00https://lymphoma-stg.clarovantdigital.com/library/epidemiologic-trends-for-pediatric-hodgkin-and-non-hodgkin-lymphomas-a-u-s-population-based-study/2025-06-27T15:09:31+00:00https://lymphoma-stg.clarovantdigital.com/library/mosunetuzumab-plus-polatuzumab-vedotin-is-superior-to-r-gemox-in-transplant-ineligible-patients-with-r-r-lbcl-primary-results-of-the-phase-iii-sunmo-trial/2025-06-27T15:09:31+00:00https://lymphoma-stg.clarovantdigital.com/library/pet-adapted-therapy-after-three-cycles-of-abvd-for-all-stages-of-hodgkin-lymphoma-long-term-follow-up-of-the-gatla-lh-05-trial/2025-06-27T15:09:31+00:00https://lymphoma-stg.clarovantdigital.com/library/minimal-residual-disease-with-bendamustine-rituximab-with-or-without-acalabrutinib-in-patients-with-previously-untreated-mantle-cell-lymphoma-results-from-the-echo-trial/2026-01-06T21:05:00+00:00https://lymphoma-stg.clarovantdigital.com/library/efficacy-and-safety-of-first-line-ibrutinib-plus-venetoclax-in-patients-with-mantle-cell-lymphoma-mcl-who-were-older-or-had-tp53-mutations-in-the-sympatico-study/2025-06-27T15:09:31+00:00https://lymphoma-stg.clarovantdigital.com/library/clinical-features-and-prognostic-factors-of-intravascular-large-b-cell-lymphoma-a-cohort-study-of-20-patients-from-2018-to-2024/2025-06-27T15:09:31+00:00https://lymphoma-stg.clarovantdigital.com/library/advances-in-strategies-to-improve-the-immunotherapeutic-efficacy-of-chimeric-antigen-receptor-t-cell-therapy-for-lymphoma/2025-06-27T15:09:31+00:00https://lymphoma-stg.clarovantdigital.com/library/real-world-treatment-patterns-and-out-of-pocket-costs-after-car-cell-therapy-in-commercially-insured-patients-with-b-cell-non-hodgkin-lymphoma-in-the-united-states/2025-12-19T18:20:22+00:00https://lymphoma-stg.clarovantdigital.com/library/mortality-outcomes-for-survivors-of-cancer-with-food-insecurity-in-the-us/2025-06-27T15:09:31+00:00https://lymphoma-stg.clarovantdigital.com/library/clinical-outcomes-and-long-term-effects-of-consolidative-radiotherapy-in-paediatric-hodgkins-lymphoma/2025-06-27T15:09:31+00:00https://lymphoma-stg.clarovantdigital.com/library/resistance-to-targeted-therapies-in-chronic-lymphocytic-leukemia-current-status-and-perspectives-for-clinical-and-diagnostic-practice/2025-06-27T15:09:31+00:00https://lymphoma-stg.clarovantdigital.com/library/efficacy-and-safety-of-car-t-cell-therapy-in-patients-with-primary-or-secondary-cns-lymphoma-a-study-on-behalf-of-the-ebmt-and-the-gocart-coalition/2025-06-27T15:09:32+00:00https://lymphoma-stg.clarovantdigital.com/library/cost-impact-of-brutons-tyrosine-kinase-inhibitor-selection-in-medicare-patients-with-chronic-lymphocytic-leukemia/2025-12-19T18:19:29+00:00https://lymphoma-stg.clarovantdigital.com/library/rituximab-lenalidomide-and-zanubrutinib-chemo-free-regimen-followed-by-immunochemotherapy-for-patients-with-newly-diagnosed-mantle-cell-lymphoma-an-investigator-initiated-single-arm-phase-2-trial/2025-06-27T15:09:32+00:00https://lymphoma-stg.clarovantdigital.com/library/machine-learning-model-predicts-abnormal-lymphocytosis-associated-with-chronic-lymphocytic-leukemia/2025-06-27T15:09:32+00:00https://lymphoma-stg.clarovantdigital.com/library/richter-transformation-in-diffuse-large-b-cell-lymphoma-in-patients-with-chronic-lymphocytic-leukemia-receiving-ibrutinib-risk-factors-and-outcomes/2025-06-27T15:09:32+00:00https://lymphoma-stg.clarovantdigital.com/library/tirabrutinib-for-the-treatment-of-relapsed-or-refractory-primary-central-nervous-system-lymphoma-efficacy-and-safety-from-the-phase-ii-prospect-study/2025-06-27T15:09:32+00:00https://lymphoma-stg.clarovantdigital.com/library/r-da-epoch-versus-da-epoch-r-impact-of-chemoimmunotherapy-sequencing-on-treatment-outcomes-in-patients-with-diffuse-large-b-cell-lymphoma/2025-06-27T15:09:32+00:00https://lymphoma-stg.clarovantdigital.com/library/artificial-intelligence-lymphoid-neoplasms-and-prediction-of-myc-bcl2-and-bcl6-gene-expression-using-a-pan-cancer-panel-in-diffuse-large-b-cell-lymphoma/2025-06-27T15:09:32+00:00https://lymphoma-stg.clarovantdigital.com/library/low-socioeconomic-status-is-associated-with-an-inferior-prognosis-in-diffuse-large-b-cell-lymphoma-patients-despite-the-age/2025-06-27T15:09:32+00:00https://lymphoma-stg.clarovantdigital.com/library/real-world-outcomes-of-pirtobrutinib-in-relapsed-refractory-mantle-cell-lymphoma-a-multicenter-analysis-with-a-control-cohort-from-the-european-mcl-registry/2026-01-16T15:05:02+00:00https://lymphoma-stg.clarovantdigital.com/library/the-triple-combination-of-venetoclax-ibrutinib-obinutuzumab-prolongs-progression-free-survival-compared-to-venetoclax-cd20-antibody-combinations-and-chemoimmunotherapy-in-treatment-naive-chronic-lymph/2025-06-27T15:09:32+00:00https://lymphoma-stg.clarovantdigital.com/library/long-term-responses-and-late-toxicities-in-advanced-stage-hodgkin-lymphoma-a-10-year-update-of-the-hd0607-trial/2025-06-27T15:09:32+00:00https://lymphoma-stg.clarovantdigital.com/library/prospective-validation-of-end-of-treatment-ctdna-mrd-by-phased-seq-in-dlbcl-patients-from-a-national-hovon-trial/2025-06-27T15:09:32+00:00https://lymphoma-stg.clarovantdigital.com/library/frail-is-not-fail-comorbidities-do-not-affect-non-relapse-mortality-and-safety-in-patients-with-lbcl-treated-with-car-t-therapy/2025-06-27T15:09:32+00:00https://lymphoma-stg.clarovantdigital.com/library/long-term-efficacy-and-survival-outcomes-with-odronextamab-for-patients-pts-with-relapsed-refractory-follicular-lymphoma-r-r-fl-2-year-follow-up-from-the-phase-2-elm-2-study/2025-06-27T15:09:33+00:00https://lymphoma-stg.clarovantdigital.com/library/a-phase-1-study-of-kite-363-anti-cd19-cd20-chimeric-antigen-receptor-t-cell-therapy-in-patients-with-relapsed-refractory-b-cell-lymphoma/2025-06-27T15:09:33+00:00https://lymphoma-stg.clarovantdigital.com/library/polatuzumab-vedotin-rituximab-gemcitabine-and-oxaliplatin-pola-r-gemox-for-relapsed-refractory-r-r-diffuse-large-b-cell-lymphoma-dlbcl-results-from-the-randomized-phase-iii-polargo-trial/2025-06-27T15:09:33+00:00https://lymphoma-stg.clarovantdigital.com/library/morningsun-open-label-phase-ii-trial-of-the-efficacy-and-safety-of-subcutaneous-mosunetuzumab-mosun-sc-as-frontline-1l-treatment-in-symptomatic-patients-with-marginal-zone-lymphoma-mzl/2025-06-27T15:09:33+00:00https://lymphoma-stg.clarovantdigital.com/library/efficacy-of-rituximab-bendamustine-with-or-without-acalabrutinib-in-patients-with-untreated-high-risk-mantle-cell-lymphoma-an-analysis-of-the-phase-3-echo-trial/2025-06-27T15:09:33+00:00https://lymphoma-stg.clarovantdigital.com/library/updated-results-from-the-phase-1-study-of-sonrotoclax-bgb-11417-a-novel-bcl2-inhibitor-in-combination-with-zanubrutinib-for-relapsed-refractory-cll-sll-demonstrate-deep-and-durable-responses/2026-07-05T16:23:31+00:00https://lymphoma-stg.clarovantdigital.com/library/frontline-phase-ii-rituximab-polatuzumab-glofitmab-r-pola-glo-trial-demonstrates-a-manageable-safety-profile-and-high-response-rates-in-elderly-and-medical-unfit-patients-with-aggressive-lymphoma/2025-06-27T15:09:33+00:00https://lymphoma-stg.clarovantdigital.com/library/excellent-outcome-with-interim-pet-adapted-treatment-reduction-in-elderly-dlbcl-pts-with-favourable-prognosis-results-of-288-pts-treated-in-optimal-60-trial-of-the-dshnhl-gla/2025-06-27T15:09:33+00:00https://lymphoma-stg.clarovantdigital.com/library/measurable-residual-disease-kinetics-with-fixed-duration-acalabrutinib-venetoclax-combinations-in-treatment-naive-chronic-lymphocytic-leukemia-data-from-the-phase-3-amplify-trial/2025-06-27T15:09:33+00:00https://lymphoma-stg.clarovantdigital.com/library/pet-adapted-therapy-after-three-cycles-of-abvd-for-all-stages-of-hodgkin-lymphoma-long-term-follow-up-of-the-gatla-lh-05-trial-2/2025-06-27T15:09:33+00:00https://lymphoma-stg.clarovantdigital.com/library/real-world-evidence-of-brentuximab-vedotin-bv-consolidation-after-autologous-transplant-asct-in-relapsed-refractory-hodgkin-lymphoma-rrhl-2-year-follow-up-of-gatla-rrhl-study/2025-06-27T15:09:33+00:00https://lymphoma-stg.clarovantdigital.com/library/pd-1-based-salvage-therapy-for-relapsed-and-refractory-hodgkin-lymphoma-a-multicenter-real-world-analysis/2025-12-28T13:48:36+00:00https://lymphoma-stg.clarovantdigital.com/library/patient-reported-outcomes-in-patients-with-relapsed-refractory-follicular-lymphoma-treated-with-epcoritamab-within-the-entire-study-cohort-and-in-patients-with-symptoms-at-baseline-2/2026-01-14T18:42:17+00:00https://lymphoma-stg.clarovantdigital.com/library/4-year-update-of-phase-2-elara-trial-clinical-outcomes-of-tisagenlecleucel-in-patients-pts-with-high-risk-relapsed-refractory-follicular-lymphoma-r-r-fl/2025-06-27T15:09:34+00:00https://lymphoma-stg.clarovantdigital.com/library/curative-treatment-of-pediatric-hodgkin-lymphoma-with-doxorubicin-bleomycin-vinblastine-and-dacarbazine-and-consolidation-radiotherapy-a-systematic-review-and-suggested-recommendations/2025-06-27T15:09:34+00:00https://lymphoma-stg.clarovantdigital.com/library/global-regional-and-national-burden-of-leukemia-epidemiological-trends-analysis-from-1990-to-2021/2026-03-13T13:36:19+00:00https://lymphoma-stg.clarovantdigital.com/library/rituximab-and-ibrutinib-combination-in-untreated-smzl-and-nmzl-long-term-outcome-and-the-impact-of-early-minimal-residual-disease-from-the-ielsg47-malibu-phase-ii-study/2025-06-27T15:09:34+00:00https://lymphoma-stg.clarovantdigital.com/library/distribution-of-lymphoma-cases-and-significance-of-diagnostic-immunohistochemistry-in-a-sample-of-iraqi-patients-a-cross-sectional-study-in-a-tertiary-center-in-baghdad/2025-07-02T20:47:18+00:00https://lymphoma-stg.clarovantdigital.com/library/comparative-infection-risk-in-car-t-vs-bispecific-antibodies-in-b-cell-lymphoma-a-systematic-review-and-meta-analysis/2025-07-02T20:51:35+00:00https://lymphoma-stg.clarovantdigital.com/library/characteristics-and-predictive-model-for-diffuse-large-b-cell-lymphoma-with-early-chemoimmunotherapy-failure/2025-07-02T21:04:53+00:00https://lymphoma-stg.clarovantdigital.com/library/brentuximab-vedotin-monotherapy-for-cd30-positive-adult-t-cell-leukemia-lymphoma-with-htlv-1-infected-hodgkin-and-reed-sternberg-like-cells/2025-07-02T21:06:43+00:00https://lymphoma-stg.clarovantdigital.com/library/international-consensus-statement-on-diagnosis-evaluation-and-research-of-richter-transformation-the-eric-recommendations/2025-07-02T21:11:34+00:00https://lymphoma-stg.clarovantdigital.com/library/toxicities-associated-with-lymphoma-targeting-bispecific-antibodies-a-review/2026-01-14T18:19:28+00:00https://lymphoma-stg.clarovantdigital.com/library/cd6-expression-is-an-independent-predictor-of-time-to-first-treatment-in-chronic-lymphocytic-leukemia/2025-07-03T15:20:46+00:00https://lymphoma-stg.clarovantdigital.com/library/angioimmunoblastic-t-cell-lymphoma-a-concise-overview-encompassing-the-pathogenetic-pathological-clinical-therapeutical-characteristics-and-recent-advances/2025-07-04T17:44:36+00:00https://lymphoma-stg.clarovantdigital.com/library/co-occurrence-of-myositis-and-neuropathy-after-anti-cd30-therapy-in-a-late-adolescent-hodgkin-lymphoma-patient/2025-07-04T17:44:36+00:00https://lymphoma-stg.clarovantdigital.com/library/daratumumab-plus-bortezomib-and-dexamethasone-as-a-bridge-to-allogeneic-transplantation-in-refractory-t-cell-lymphoblastic-lymphoma/2025-07-04T17:44:36+00:00https://lymphoma-stg.clarovantdigital.com/library/selection-bias-in-active-control-trials-implications-for-htas-and-recommendations/2025-07-04T17:44:36+00:00https://lymphoma-stg.clarovantdigital.com/library/rituximab-and-epcoritamab-as-first-line-therapy-for-patients-with-high-tumor-burden-follicular-lymphoma-first-results-of-a-multicenter-phase-ii-trial/2026-01-14T18:41:19+00:00https://lymphoma-stg.clarovantdigital.com/library/updated-efficacy-and-safety-results-from-the-phase-2-study-of-timdarpacept-in-combination-with-tislelizumab-in-patients-with-classical-hodgkin-lymphoma-for-whom-prior-anti-pd-1-therapy-failed/2025-07-04T17:44:36+00:00https://lymphoma-stg.clarovantdigital.com/library/population-based-analysis-of-twenty-year-incidence-trends-of-pediatric-hodgkin-lymphoma-in-the-united-states/2025-12-19T18:18:55+00:00https://lymphoma-stg.clarovantdigital.com/library/ptcy-vs-cni-based-gvhd-prophylaxis-in-hla-matched-transplants-for-hodgkin-lymphoma-a-study-of-the-lwp-of-the-ebmt/2025-07-04T17:44:37+00:00https://lymphoma-stg.clarovantdigital.com/library/risk-and-clinical-implications-of-histological-transformation-in-extranodal-marginal-zone-b-cell-lymphoma-of-mucosa-associated-lymphoid-tissue-a-population-based-analysis/2025-07-04T17:44:37+00:00https://lymphoma-stg.clarovantdigital.com/library/loncastuximab-tesirine-in-relapsed-refractory-diffuse-large-b-cell-lymphoma-drug-profile-and-expert-opinion-on-the-prevention-and-management-of-adverse-events/2025-07-04T17:44:37+00:00https://lymphoma-stg.clarovantdigital.com/library/randomized-phase-ii-trial-comparing-lenalidomide-obinutuzumab-and-umbralisib-obinutuzumab-with-chemoimmunotherapy-in-early-progressing-follicular-lymphoma-pod24/2025-07-04T17:44:37+00:00https://lymphoma-stg.clarovantdigital.com/library/ibrutinib-rituximab-versus-placebo-rituximab-in-patients-with-previously-untreated-follicular-lymphoma-fl-primary-analysis-of-the-phase-3-perspective-study/2025-07-04T17:44:37+00:00https://lymphoma-stg.clarovantdigital.com/library/therapeutic-landscape-of-primary-refractory-and-relapsed-diffuse-large-b-cell-lymphoma-recent-advances-and-emerging-therapies/2025-07-04T17:44:37+00:00https://lymphoma-stg.clarovantdigital.com/library/combination-of-fixed-low-dose-nivolumab-and-bendamustine-in-children-with-high-risk-relapsed-refractory-classical-hodgkin-lymphoma/2025-07-04T17:44:37+00:00https://lymphoma-stg.clarovantdigital.com/library/prognostic-implication-of-karyotypic-evaluation-in-patients-with-richter-transformation-in-the-modern-era/2025-07-04T17:44:38+00:00https://lymphoma-stg.clarovantdigital.com/library/trends-of-non-hodgkin-lymphoma-incidence-among-adults-in-the-united-states-from-2000-to-2020/2025-12-19T18:18:05+00:00https://lymphoma-stg.clarovantdigital.com/library/car-t-cell-therapy-for-cancer-current-challenges-and-future-directions/2025-07-04T17:44:38+00:00https://lymphoma-stg.clarovantdigital.com/library/incidental-vs-symptomatic-diagnosis-of-follicular-lymphoma-implications-of-earlier-detection/2025-07-04T17:44:38+00:00https://lymphoma-stg.clarovantdigital.com/library/next-generation-therapies-in-mantle-cell-lymphoma-mcl-the-evolving-landscape-in-treatment-of-relapse-refractory-after-car-t-cells/2025-07-04T17:44:38+00:00https://lymphoma-stg.clarovantdigital.com/library/what-is-still-unclear-or-unresolved-in-classic-hodgkin-lymphoma-pathobiology-diagnosis-and-treatment/2025-07-04T17:44:38+00:00https://lymphoma-stg.clarovantdigital.com/library/treatment-of-newly-diagnosed-follicular-lymphoma-with-rituximab-golcadomide-nivolumab-interim-analysis-of-the-phase-ii-top-flor-study/2025-07-04T17:44:38+00:00https://lymphoma-stg.clarovantdigital.com/library/evaluation-of-clinical-biomarkers-for-differential-diagnosis-of-intravascular-lymphoma-and-stills-disease/2025-07-04T17:44:38+00:00https://lymphoma-stg.clarovantdigital.com/library/minimal-residual-disease-status-predicts-outcomes-in-patients-with-follicular-lymphoma-treated-with-chemo-immunotherapy-on-the-swog-s0016-trial/2025-07-08T12:01:05+00:00https://lymphoma-stg.clarovantdigital.com/library/exploring-the-rarity-insights-into-primary-diffuse-large-b-cell-lymphoma-of-the-prostate-from-a-global-retrospective-analysis/2025-07-08T12:04:57+00:00https://lymphoma-stg.clarovantdigital.com/library/morphological-immunophenotypic-and-neuroradiological-characteristics-of-primitive-b%e2%80%91large-cell-diffuse-lymphoma-of-the-central-nervous-system-a-retrospective-cohort-analysis/2025-07-10T12:11:15+00:00https://lymphoma-stg.clarovantdigital.com/library/familial-forms-of-chronic-lymphocytic-leukemia-have-a-worse-prognosis-than-sporadic-forms-an-italian-case-control-study/2025-07-11T12:09:13+00:00https://lymphoma-stg.clarovantdigital.com/library/observations-on-seasonal-occurrence-in-lymphomas-with-proven-or-presumed-infectious-etiology/2025-07-11T12:12:30+00:00https://lymphoma-stg.clarovantdigital.com/library/favorable-impact-of-zanubrutinib-combined-with-r-chop-regimen-in-myd88-mutated-new-diagnosed-diffuse-large-b-cell-lymphoma-a-retrospective-study-with-propensity-score-matched-analysis/2025-07-11T12:31:34+00:00https://lymphoma-stg.clarovantdigital.com/library/covid-19-in-patients-with-chronic-lymphocytic-leukemia-a-multicenter-analysis-by-the-czech-cll-study-group/2025-07-11T12:31:34+00:00https://lymphoma-stg.clarovantdigital.com/library/population-pharmacokinetic-and-exposure-response-analyses-of-ibrutinib-combined-with-bendamustine-and-rituximab-in-patients-with-mantle-cell-lymphoma/2025-07-11T12:31:34+00:00https://lymphoma-stg.clarovantdigital.com/library/circulating-tumor-dna-in-pediatric-mature-b-cell-non-hodgkin-lymphoma-for-genotyping-and-minimal-disease-monitoring/2025-07-11T12:31:34+00:00https://lymphoma-stg.clarovantdigital.com/library/treatment-outcomes-of-abvd-in-classical-hodgkin-lymphoma-patients-from-thailand-without-procarbazine-access/2025-07-11T12:31:34+00:00https://lymphoma-stg.clarovantdigital.com/library/subgroup-analysis-of-treatment-pathways-and-clinical-outcomes-in-hodgkin-lymphoma-in-latin-america-from-the-retrospective-b-holistic-study/2025-07-11T12:31:34+00:00https://lymphoma-stg.clarovantdigital.com/library/rare-peritoneal-involvement-in-adult-t-cell-leukemia-lymphoma-a-diagnostic-conundrum/2025-07-11T12:31:34+00:00https://lymphoma-stg.clarovantdigital.com/library/p53-pd-l1-co-expression-predicts-poor-prognosis-in-diffuse-large-b-cell-lymphoma/2025-07-11T12:31:34+00:00https://lymphoma-stg.clarovantdigital.com/library/lisocabtagene-maraleucel-versus-standard-of-care-for-second-line-relapsed-refractory-large-b-cell-lymphoma-3-year-follow-up-from-the-randomized-phase-iii-transform-study/2025-07-11T12:31:35+00:00https://lymphoma-stg.clarovantdigital.com/library/systematic-literature-review-to-identify-prognostic-factors-of-efficacy-and-safety-outcomes-of-chimeric-antigen-receptor-t-cell-therapies-in-diffuse-large-b-cell-lymphoma/2025-07-11T12:31:35+00:00https://lymphoma-stg.clarovantdigital.com/library/linperlisib-plus-chidamide-in-relapsed-or-refractory-cutaneous-t-cell-lymphoma-a-nonrandomized-clinical-trial/2025-07-11T12:31:35+00:00https://lymphoma-stg.clarovantdigital.com/library/treatment-outcomes-for-patients-with-newly-diagnosed-or-relapsed-refractory-tp53-mutated-mantle-cell-lymphoma-a-systematic-review-and-meta-analysis/2025-07-11T12:31:35+00:00https://lymphoma-stg.clarovantdigital.com/library/shared-genomic-features-of-hiv-diffuse-large-b-cell-lymphoma-in-two-african-cohorts/2025-07-11T12:31:35+00:00https://lymphoma-stg.clarovantdigital.com/library/can-positron-emission-tomography-with-18f-fdg-substitute-bone-marrow-biopsy-for-detecting-bone-marrow-infiltration-in-patients-with-large-b-cell-lymphoma/2025-07-11T12:31:35+00:00https://lymphoma-stg.clarovantdigital.com/library/comprehensive-study-of-anaplastic-large-cell-lymphoma-clinicopathological-features-from-indonesia/2025-12-19T14:20:29+00:00https://lymphoma-stg.clarovantdigital.com/library/update-the-molecular-spectrum-of-virus-associated-high-grade-b-cell-non-hodgkin-lymphomas/2026-09-02T16:00:03+00:00https://lymphoma-stg.clarovantdigital.com/library/primary-esophageal-lymphoma-an-individual-participant-data-meta-analysis/2025-07-11T12:31:35+00:00https://lymphoma-stg.clarovantdigital.com/library/clinical-characteristics-of-duodenal-type-follicular-lymphoma/2025-07-11T12:31:36+00:00https://lymphoma-stg.clarovantdigital.com/library/immune-checkpoint-molecules-in-hodgkin-lymphoma-and-other-hematological-malignancies/2025-07-11T12:31:36+00:00https://lymphoma-stg.clarovantdigital.com/library/chronic-lymphocytic-leukemia-novel-therapeutic-targets-under-investigation/2025-07-11T12:31:36+00:00https://lymphoma-stg.clarovantdigital.com/library/subcutaneous-epcoritamab-monotherapy-in-japanese-patients-with-relapsed-or-refractory-follicular-lymphoma-primary-results-of-the-epcore-nhl-3-trial/2026-01-14T17:52:55+00:00https://lymphoma-stg.clarovantdigital.com/library/ibrutinib-added-to-standard-conditioning-and-as-maintenance-therapy-following-autologous-hematopoietic-stem-cell-transplantation-for-relapsed-or-refractory-activated-b-cell-type-diffuse-large-b-cell-l/2025-12-19T15:05:57+00:00https://lymphoma-stg.clarovantdigital.com/library/risk-assessment-with-ultra-low-pass-whole-genome-sequencing-of-cell-free-dna-for-large-b-cell-lymphoma/2025-07-11T12:31:36+00:00https://lymphoma-stg.clarovantdigital.com/library/efficacy-toxicity-and-effect-of-pretreatment-cardiologic-consultation-on-outcomes-of-ibrutinib-therapy-for-chronic-lymphocytic-leukemia-a-krohem-study/2025-07-11T12:31:36+00:00https://lymphoma-stg.clarovantdigital.com/library/pembrolizumab-plus-vorinostat-induces-responses-in-patients-with-hodgkin-lymphoma-refractory-to-prior-pd-1-blockade/2025-07-11T12:31:36+00:00https://lymphoma-stg.clarovantdigital.com/library/fertility-in-patients-with-advanced-stage-classic-hodgkin-lymphoma-treated-with-brecadd-versus-ebeacopp-a-secondary-analysis-of-the-multicentre-randomised-parallel-open-label-phase-3-hd21-trial/2025-07-11T12:31:37+00:00https://lymphoma-stg.clarovantdigital.com/library/integration-of-18ffdg-pet-radiomics-with-liquid-biopsy-improves-outcome-prediction-in-newly-diagnosed-diffuse-large-b-cell-lymphoma/2025-07-11T12:31:37+00:00https://lymphoma-stg.clarovantdigital.com/library/ibrutinib-versus-acalabrutinib-in-fixed-duration-chronic-lymphocytic-leukemia-therapy-a-comparative-analysis-of-efficacy/2025-07-14T18:49:22+00:00https://lymphoma-stg.clarovantdigital.com/library/brca1-2-impact-on-the-development-of-implant-associated-lymphoma-in-women-with-breast-cancer-and-textured-implants/2025-07-17T14:04:29+00:00https://lymphoma-stg.clarovantdigital.com/library/tafasitamab-plus-lenalidomide-as-salvage-therapy-in-diffuse-large-b-cell-lymphoma-real-world-experience-from-geltamo/2025-10-16T15:56:06+00:00https://lymphoma-stg.clarovantdigital.com/library/poor-clinical-outcome-of-relapsed-refractory-diffuse-large-b-cell-lymphoma-with-myc-translocation-treated-with-polatuzumab-vedotin-bendamustine-and-rituximab/2025-07-17T17:29:30+00:00https://lymphoma-stg.clarovantdigital.com/library/tracing-the-development-of-car-t-cell-design-from-concept-to-next-generation-platforms/2025-07-18T13:17:22+00:00https://lymphoma-stg.clarovantdigital.com/library/efficacy-of-zanubrutinib-versus-acalabrutinib-for-relapsed-or-refractory-chronic-lymphocytic-leukemia-r-r-cll-a-matching-adjusted-indirect-comparison-maic/2025-07-18T13:28:05+00:00https://lymphoma-stg.clarovantdigital.com/library/molecular-pathways-and-targeted-therapies-in-relapsed-refractory-diffuse-large-b-cell-lymphoma-dlbcl/2025-07-18T13:28:05+00:00https://lymphoma-stg.clarovantdigital.com/library/nodal-peripheral-t-cell-lymphoma-in-finland-between-2007-and-2019-incidence-late-morbidity-and-survival/2025-07-18T13:28:05+00:00https://lymphoma-stg.clarovantdigital.com/library/pharmacovigilance-study-for-the-identification-of-mogamulizumab-induced-immune-related-adverse-events-using-a-real-world-database/2025-07-18T13:28:05+00:00https://lymphoma-stg.clarovantdigital.com/library/diagnosis-and-treatment-of-plasmablastic-lymphoma-in-an-immunocompetent-patient-a-report-of-a-rare-case/2025-07-18T13:28:06+00:00https://lymphoma-stg.clarovantdigital.com/library/integrated-genomics-with-refined-cell-of-origin-subtyping-distinguishes-subtype-specific-mechanisms-of-treatment-resistance-and-relapse-in-diffuse-large-b-cell-lymphoma/2025-07-18T13:28:06+00:00https://lymphoma-stg.clarovantdigital.com/library/rituximab-high-dose-methotrexate-plus-orelabrutinib-as-induction-therapy-in-newly-diagnosed-primary-central-nervous-system-lymphoma/2025-07-18T13:28:06+00:00https://lymphoma-stg.clarovantdigital.com/library/effectiveness-of-rituximab-and-biosimilar-rituximab-in-untreated-diffuse-large-b-cell-lymphoma-a-danish-population-based-analysis/2025-07-18T13:28:06+00:00https://lymphoma-stg.clarovantdigital.com/library/a-charter-for-improving-care-for-people-living-with-chronic-lymphocytic-leukemia-six-principles-for-excellence/2025-07-18T13:28:06+00:00https://lymphoma-stg.clarovantdigital.com/library/primary-testicular-lymphoma-a-case-report-highlighting-18f-fdg-pet-ct-role/2025-07-18T13:28:06+00:00https://lymphoma-stg.clarovantdigital.com/library/late-infections-after-high-dose-therapy-and-autologous-stem-cell-transplantation-for-lymphoma-a-danish-population-based-study/2025-07-18T13:28:06+00:00https://lymphoma-stg.clarovantdigital.com/library/cd19-chimeric-antigen-receptor-t-cell-efficacy-and-toxicity-in-adults-with-richters-transformation-and-response-to-bridging-therapy/2025-07-18T13:28:06+00:00https://lymphoma-stg.clarovantdigital.com/library/primary-cardiac-diffuse-large-b-cell-lymphoma-patient-clinical-histologic-immunophenotypic-feature-and-a-novel-surgical-technology-a-case-report/2025-07-18T13:28:07+00:00https://lymphoma-stg.clarovantdigital.com/library/physical-activity-symptoms-quality-of-life-and-exercise-program-preferences-in-people-with-chronic-lymphocytic-leukaemia/2025-07-18T13:28:07+00:00https://lymphoma-stg.clarovantdigital.com/library/venetoclax-consolidation-after-bruton-tyrosine-kinase-inhibitor-treatment-for-patients-with-chronic-lymphocytic-leukemia/2025-07-18T13:28:07+00:00https://lymphoma-stg.clarovantdigital.com/library/qualitative-research-on-the-acceptance-of-evolving-evidence-for-hta-body-approval-of-innovative-health-technologies-in-selected-european-countries/2025-07-18T13:28:07+00:00https://lymphoma-stg.clarovantdigital.com/library/efficacy-of-tazemetostat-in-combination-with-r-chop-in-elderly-patients-newly-diagnosed-with-diffuse-large-b-cell-lymphoma-results-of-the-epirchop-phase-ii-study-of-the-lysa/2025-07-18T13:28:07+00:00https://lymphoma-stg.clarovantdigital.com/library/glofitamab-treatment-of-richter-transformation-with-isolated-central-nervous-system-involvement-a-case-report/2025-07-22T15:50:30+00:00https://lymphoma-stg.clarovantdigital.com/library/primary-bladder-diffuse-large-b-cell-lymphoma-a-rare-case-report-and-literature-review/2025-07-22T15:53:32+00:00https://lymphoma-stg.clarovantdigital.com/library/frontline-brentuximab-vedotin-based-therapy-for-newly-diagnosed-classical-hodgkin-lymphoma-a-meta-analysis-of-randomized-controlled-trials/2025-07-22T15:57:02+00:00https://lymphoma-stg.clarovantdigital.com/library/targeting-the-tumor-microenvironment-in-hodgkin-lymphoma-challenges-and-therapeutic-strategies/2025-07-25T16:47:27+00:00https://lymphoma-stg.clarovantdigital.com/library/revisiting-and-demystifying-primary-and-secondary-renal-lymphoma-a-series-of-two-cases/2025-07-25T16:59:46+00:00https://lymphoma-stg.clarovantdigital.com/library/inflammatory-and-nutritional-biomarker-in-different-subtypes-of-early-stage-diffuse-large-b-cell-lymphoma-towards-a-diagnostic-model/2025-07-25T16:59:46+00:00https://lymphoma-stg.clarovantdigital.com/library/histological-image-classification-between-follicular-lymphoma-and-reactive-lymphoid-tissue-using-deep-learning-and-explainable-artificial-intelligence-xai/2025-07-25T16:59:46+00:00https://lymphoma-stg.clarovantdigital.com/library/allogeneic-transplantation-after-failure-of-chimeric-antigen-receptor-t-cells-and-exposure-to-bispecific-antibodies-feasibility-safety-and-survival-outcomes/2025-07-25T16:59:46+00:00https://lymphoma-stg.clarovantdigital.com/library/enhancing-patient-engagement-in-hta-using-consensus-research-to-overcome-pico-scoping-challenges-under-the-eu-htar/2025-07-25T16:59:47+00:00https://lymphoma-stg.clarovantdigital.com/library/clinical-characteristics-and-treatment-evaluation-of-diffuse-large-b-cell-lymphoma-in-chinese-children-and-adolescents-a-multicenter-clinical-study-of-china-net-childhood-lymphoma-group-b-nhl-2017/2025-12-15T19:23:36+00:00https://lymphoma-stg.clarovantdigital.com/library/emerging-trends-and-disparities-in-mortality-due-to-coexisting-non-hodgkins-lymphoma-and-respiratory-infections-a-u-s-nationwide-retrospective-analysis-from-1999-to-2020/2025-07-25T16:59:47+00:00https://lymphoma-stg.clarovantdigital.com/library/pathological-findings-clinical-characteristics-and-outcomes-of-thyroid-lymphomas-a-single-tertiary-care-hospital-experience/2025-07-25T16:59:47+00:00https://lymphoma-stg.clarovantdigital.com/library/icans-risk-model-in-cd19-car-t-therapy-insights-from-serum-and-csf-cytokine-profiling/2025-07-25T16:59:47+00:00https://lymphoma-stg.clarovantdigital.com/library/a-finnish-nationwide-population-based-study-on-the-survival-of-patients-with-peripheral-t-cell-lymphoma/2025-07-25T16:59:47+00:00https://lymphoma-stg.clarovantdigital.com/library/lymphomas-of-the-breast-after-postmastectomy-implant-based-breast-reconstruction/2025-08-22T18:41:31+00:00https://lymphoma-stg.clarovantdigital.com/library/intercurrent-presentation-of-hairy-cell-leukemia-and-diffuse-large-b-cell-lymphoma-with-hemophagocytic-lymphohistiocytosis-a-case-report/2025-08-22T18:41:32+00:00https://lymphoma-stg.clarovantdigital.com/library/economic-burden-and-quality-of-life-caused-by-non-hodgkin-lymphoma-cancer-in-iran/2026-03-13T17:41:10+00:00https://lymphoma-stg.clarovantdigital.com/library/obinutuzumab-combined-with-bendamustine-for-the-treatment-of-hairy-cell-leukemia-variant-a-case-report-and-literature-review/2025-08-22T18:41:32+00:00https://lymphoma-stg.clarovantdigital.com/library/practical-guidance-for-the-expanded-implementation-and-provision-of-bispecific-antibodies-for-diffuse-large-b-cell-lymphoma-dlbcl-across-canada/2026-01-14T18:40:41+00:00https://lymphoma-stg.clarovantdigital.com/library/case-report-two-cases-of-primary-pulmonary-endobronchial-extranodal-marginal-zone-lymphoma-of-mucosa-associated-lymphoid-tissue-localized-in-the-trachea-and-bronchus/2025-08-22T18:41:32+00:00https://lymphoma-stg.clarovantdigital.com/library/real-world-outcomes-of-patients-with-aggressive-lymphoma-and-autoimmune-disease-treated-with-cart/2025-08-22T18:41:32+00:00https://lymphoma-stg.clarovantdigital.com/library/a-comprehensive-analysis-of-the-role-of-stem-cell-transplantation-in-mantle-cell-lymphoma-real-world-data-from-the-korean-society-of-blood-and-marrow-transplantation-registry-stem-cell-transplantati/2025-08-22T18:41:32+00:00https://lymphoma-stg.clarovantdigital.com/library/cost-effectiveness-of-polatuzumab-vedotin-plus-chemoimmunotherapy-for-untreated-diffuse-large-b-cell-lymphoma-in-china/2025-08-22T18:41:33+00:00https://lymphoma-stg.clarovantdigital.com/library/subsets-of-follicular-lymphoma-3b-have-divergent-outcomes-results-from-the-prospective-multicenter-mer-and-leo-cohorts/2025-08-22T18:41:33+00:00https://lymphoma-stg.clarovantdigital.com/library/prolonged-chimeric-antigen-receptor-t-apheresis-to-infusion-time-is-associated-with-inferior-outcomes-in-diffuse-large-b-cell-lymphoma/2025-08-22T18:41:33+00:00https://lymphoma-stg.clarovantdigital.com/library/matching-adjusted-indirect-comparison-of-lisocabtagene-maraleucel-versus-axicabtagene-ciloleucel-for-second-line-treatment-of-patients-with-early-relapsed-or-refractory-large-b-cell-lymphoma/2025-08-22T18:41:33+00:00https://lymphoma-stg.clarovantdigital.com/library/polypharmacy-independently-predicts-survival-hospitalization-and-infections-in-patients-with-lymphoid-cancer/2025-08-22T18:41:33+00:00https://lymphoma-stg.clarovantdigital.com/library/targeted-therapies-and-immunotherapies-for-diffuse-large-b-cell-lymphoma/2026-01-14T18:39:57+00:00https://lymphoma-stg.clarovantdigital.com/library/secondary-central-nervous-system-lymphoma-scnsl-in-mantle-cell-lymphoma-mcl-characteristics-and-risk-factors-in-a-danish-nationwide-population-based-study/2025-08-22T18:41:33+00:00https://lymphoma-stg.clarovantdigital.com/library/long-term-efficacy-and-safety-of-ct-p10-or-rituximab-in-untreated-advanced-follicular-lymphoma-a-randomized-phase-3-study/2025-08-22T18:41:33+00:00https://lymphoma-stg.clarovantdigital.com/library/constraints-on-delivering-cell-and-gene-therapies-identified-during-technology-appraisal-by-the-national-institute-for-health-and-care-excellence/2025-08-22T18:41:34+00:00https://lymphoma-stg.clarovantdigital.com/library/prospective-clinical-validation-of-a-combinatorial-functional-precision-medicine-platform-in-relapsed-refractory-non-hodgkin-lymphoma/2025-08-22T18:41:34+00:00https://lymphoma-stg.clarovantdigital.com/library/low-dose-total-skin-electron-beam-radiotherapy-in-stage-ib-iib-mycosis-fungoides-results-from-the-prospective-s-misr-study/2025-08-22T18:41:34+00:00https://lymphoma-stg.clarovantdigital.com/library/brentuximab-vedotin-cyclophosphamide-doxorubicin-and-prednisone-for-advanced-stage-hodgkin-lymphoma-in-older-patients/2025-08-22T18:41:34+00:00https://lymphoma-stg.clarovantdigital.com/library/real-world-efficacy-and-safety-outcomes-of-acalabrutinib-in-chronic-lymphocytic-leukemia-primary-results-of-a-french-multicentre-observational-study-naos/2025-08-22T18:41:34+00:00https://lymphoma-stg.clarovantdigital.com/library/prognostic-significance-of-in-patients-with-chronic-lymphocytic-leukemia-a-meta-analysis/2025-08-22T18:41:34+00:00https://lymphoma-stg.clarovantdigital.com/library/exploration-of-the-optimal-treatment-modality-for-vitreoretinal-lymphoma-a-prisma-compliant-meta-analysis-and-systematic-review/2025-08-22T18:41:34+00:00https://lymphoma-stg.clarovantdigital.com/library/retrospective-analysis-of-primary-pulmonary-lymphoma-cases-from-polish-lymphoma-research-group-centers-reveals-associations-between-initial-symptoms-and-outcomes/2025-08-22T18:41:34+00:00https://lymphoma-stg.clarovantdigital.com/library/outcome-and-challenges-in-the-treatment-of-pediatric-hodgkin-lymphoma-with-euronet-phl-c1-protocol-experience-from-a-resource-limited-country/2025-08-22T18:41:35+00:00https://lymphoma-stg.clarovantdigital.com/library/brentuximab-vedotin-plus-chemotherapy-for-the-treatment-of-front-line-systemic-anaplastic-large-cell-lymphoma-subgroup-analysis-of-the-echelon-2-study-at-5-years-follow-up/2025-08-22T18:41:35+00:00https://lymphoma-stg.clarovantdigital.com/library/comparison-of-frontline-therapies-in-older-adults-age80years-with-chronic-lymphocytic-leukemia-cll-a-mayo-clinic-and-danish-nation-wide-study/2025-08-22T18:41:35+00:00https://lymphoma-stg.clarovantdigital.com/library/mindfulness-and-tai-chi-for-cancer-health-match-study-primary-outcomes-of-a-preference-based-multisite-randomized-comparative-effectiveness-trial/2025-08-22T18:41:35+00:00https://lymphoma-stg.clarovantdigital.com/library/venetoclax-and-obinutuzumab-in-first-line-treatment-of-unfit-patients-with-cll-real-life-data-analysis-of-the-polish-adult-leukemia-group/2025-08-22T18:41:35+00:00https://lymphoma-stg.clarovantdigital.com/library/comprehensive-genetic-analysis-of-central-nervous-system-involvement-in-mycosis-fungoides-a-case-report/2025-08-22T18:41:35+00:00https://lymphoma-stg.clarovantdigital.com/library/risk-stratified-and-response-adapted-therapy-for-pediatric-hodgkin-lymphoma-in-argentina-the-gatla-experience/2025-08-22T18:41:35+00:00https://lymphoma-stg.clarovantdigital.com/library/pi3k-inhibitor-parsaclisib-in-japanese-patients-with-relapsed-or-refractory-follicular-lymphoma/2025-08-22T18:41:35+00:00https://lymphoma-stg.clarovantdigital.com/library/safety-and-efficacy-of-autologous-humanized-cd19-car-t-cell-therapy-for-relapsed-refractory-b-cell-non-hodgkin-lymphoma/2025-08-22T18:41:36+00:00https://lymphoma-stg.clarovantdigital.com/library/impact-of-socioeconomic-individual-and-ecological-factors-on-extreme-diagnosis-to-treatment-interval-in-diffuse-large-b-cell-lymphoma-in-the-french-realworld-cohort-realysa/2025-08-22T18:41:36+00:00https://lymphoma-stg.clarovantdigital.com/library/treatment-and-outcome-of-breast-implant-associated-anaplastic-large-cell-lymphoma-a-population-based-cohort-study-in-the-netherlands/2025-08-22T18:41:36+00:00https://lymphoma-stg.clarovantdigital.com/library/perfluorobutane-ceus-for-early-stage-cervical-lymphoma-diagnostic-value-of-the-postvascular-phase-starfield-sign/2025-08-22T18:41:36+00:00https://lymphoma-stg.clarovantdigital.com/library/exploration-of-biomarkers-for-predicting-the-prognosis-of-patients-with-diffuse-large-b-cell-lymphoma-by-machine-learning-analysis/2025-08-22T18:41:36+00:00https://lymphoma-stg.clarovantdigital.com/library/classification-of-patients-with-relapsed-refractory-large-b-cell-lymphoma-who-do-not-develop-early-crs-ne-toxicity-using-zuma-clinical-trial-data/2025-08-22T18:41:36+00:00https://lymphoma-stg.clarovantdigital.com/library/clinical-and-pathological-features-of-lymphomas-in-the-breast-a-comprehensive-multicentric-study/2025-08-22T18:41:36+00:00https://lymphoma-stg.clarovantdigital.com/library/frontline-acalabrutinib-lenalidomide-and-rituximab-for-advanced-stage-follicular-lymphoma-with-high-tumor-burden-phase-ii-trial/2025-08-22T18:41:36+00:00https://lymphoma-stg.clarovantdigital.com/library/influence-of-survivorship-care-on-health-related-quality-of-life-knowledge-of-late-effects-and-distress-levels-among-long-term-hodgkin-lymphoma-survivors/2025-08-22T18:41:36+00:00https://lymphoma-stg.clarovantdigital.com/library/working-towards-harmonization-of-clinical-trial-reporting-in-hodgkin-lymphoma/2025-08-22T18:41:37+00:00https://lymphoma-stg.clarovantdigital.com/library/safety-profile-of-first-line-targeted-therapies-in-elderly-and-or-comorbid-chronic-lymphocytic-leukaemia-patients-unfit-subpopulation-a-systematic-review-and-network-meta-analysis/2025-08-22T18:41:37+00:00https://lymphoma-stg.clarovantdigital.com/library/prognostic-impact-of-extranodal-disease-on-pet-ct-in-follicular-lymphoma-results-from-a-validation-study-with-ecog-2408/2025-08-22T18:41:37+00:00https://lymphoma-stg.clarovantdigital.com/library/characterizing-primary-mediastinal-large-b-cell-lymphoma-based-on-molecular-classification-a-multi-center-retrospective-pilot-study/2025-08-22T18:41:37+00:00https://lymphoma-stg.clarovantdigital.com/library/genetic-subtype-guided-immunochemotherapy-in-relapsed-and-refractory-diffuse-large-b-cell-lymphoma-a-phase-2-investigator-initiated-nonrandomized-clinical-trial-guidance-06/2025-08-22T18:41:37+00:00https://lymphoma-stg.clarovantdigital.com/library/pegylated-liposomal-doxorubicin-confers-a-high-risk-for-pneumocystis-jirovecii-pneumonia-in-patients-with-diffuse-large-b-cell-lymphoma/2025-08-22T18:41:37+00:00https://lymphoma-stg.clarovantdigital.com/library/evaluating-the-role-and-policy-implications-of-using-external-evidence-in-survival-extrapolations-a-case-study-of-axicabtagene-ciloleucel-therapy-for-second-line-dlbcl/2025-08-22T18:41:37+00:00https://lymphoma-stg.clarovantdigital.com/library/management-of-complicated-primary-intestinal-lymphoma-in-the-emergency-setting-experience-at-quaternary-hospital/2025-08-22T18:41:37+00:00https://lymphoma-stg.clarovantdigital.com/library/outcome-of-non-hodgkins-lymphoma-in-adults-real-world-experience-from-a-cancer-centre-in-north-east-india/2025-08-22T18:41:38+00:00https://lymphoma-stg.clarovantdigital.com/library/real-world-utilization-of-bruton-tyrosine-kinase-inhibitors-in-relapsed-refractory-chronic-lymphocytic-leukemia-in-australia/2025-08-22T18:41:38+00:00https://lymphoma-stg.clarovantdigital.com/library/mlr-corresponds-to-the-functional-status-of-monocytes-in-chronic-lymphocytic-leukemia/2025-08-22T18:41:38+00:00https://lymphoma-stg.clarovantdigital.com/library/management-of-adverse-reactions-to-loncastuximab-in-patients-with-relapsed-or-refractory-diffuse-large-b-cell-lymphoma/2025-08-22T18:41:38+00:00https://lymphoma-stg.clarovantdigital.com/library/overcoming-barriers-to-referral-for-car-t-cell-therapy-in-patients-with-non-hodgkin-aggressive-b-cell-lymphomas-a-delphi-consensus/2025-08-22T18:41:38+00:00https://lymphoma-stg.clarovantdigital.com/library/bispecific-antibodies-and-antibody-drug-conjugates-in-relapsed-refractory-aggressive-non-hodgkin-lymphoma-focusing-on-diffuse-large-b-cell-lymphoma/2026-01-14T18:39:08+00:00https://lymphoma-stg.clarovantdigital.com/library/cns-involvement-by-north-american-adult-t-cell-leukemia-lymphoma-is-associated-with-discrete-dissemination-patterns-and-molecular-profiles-involving-xpo1-e571-and-klf2-pi3kcd-in-selected-cases/2025-08-22T18:41:38+00:00https://lymphoma-stg.clarovantdigital.com/library/assessment-of-cd20-marker-as-a-prognostic-predictor-for-patients-with-classical-hodgkin-lymphoma/2025-08-22T18:41:38+00:00https://lymphoma-stg.clarovantdigital.com/library/patients-and-caregivers-perspectives-on-preparedness-for-and-experience-with-chimeric-antigen-receptor-t-cell-therapy/2025-08-25T17:49:13+00:00https://lymphoma-stg.clarovantdigital.com/library/considerations-for-the-practical-management-of-cardiovascular-risk-with-brutons-tyrosine-kinase-inhibitors-for-patients-with-cll/2025-08-25T17:57:32+00:00https://lymphoma-stg.clarovantdigital.com/library/immunoglobulin-use-survival-and-infection-outcomes-in-patients-with-chronic-lymphocytic-leukemia/2025-08-25T23:14:40+00:00https://lymphoma-stg.clarovantdigital.com/library/a-phase-2-study-of-zanubrutinib-in-combination-with-rituximab-and-lenalidomide-in-de-novo-diffuse-large-b-cell-lymphoma/2026-01-08T19:30:51+00:00https://lymphoma-stg.clarovantdigital.com/library/treatment-and-outcomes-of-progression-of-disease-post-car-t-cell-therapy-in-mantle-cell-lymphoma-a-multicenter-analysis/2025-08-26T00:13:35+00:00https://lymphoma-stg.clarovantdigital.com/library/final-analysis-of-the-resonate-2-study-up-to-10-years-of-follow-up-of-first-line-ibrutinib-treatment-for-cll-sll/2025-12-02T14:57:51+00:00https://lymphoma-stg.clarovantdigital.com/library/pirtobrutinib-a-highly-selective-non-covalent-reversible-btki-in-r-r-follicular-lymphoma-phase-1-2-bruin-study/2025-08-26T00:24:47+00:00https://lymphoma-stg.clarovantdigital.com/library/predicting-absolute-risk-of-first-relapse-in-classical-hodgkin-lymphoma-by-incorporating-contemporary-treatment-effects/2025-08-29T15:29:48+00:00https://lymphoma-stg.clarovantdigital.com/library/refining-the-risk-stratification-in-advanced-stage-classical-hodgkin-lymphoma-a-critical-analysis-of-clinical-prediction-models/2025-08-29T15:29:48+00:00https://lymphoma-stg.clarovantdigital.com/library/outpatient-brexucabtagene-autoleucel-in-b-cell-acute-lymphoblastic-leukemia-and-mantle-cell-lymphoma/2025-08-29T15:29:48+00:00https://lymphoma-stg.clarovantdigital.com/library/the-global-regional-and-national-burden-of-non-hodgkin-lymphoma-in-204-countries-and-territories-and-811-subnational-locations-1990-2021-an-update-from-the-global-burden-of-disease-study-2021/2025-08-29T15:29:48+00:00https://lymphoma-stg.clarovantdigital.com/library/clinical-outcomes-of-tisagenlecleucel-in-relapsed-refractory-diffuse-large-b-cell-lymphoma-insights-from-a-single-center-study/2025-08-29T15:29:48+00:00https://lymphoma-stg.clarovantdigital.com/library/role-of-remdesivir-for-the-treatment-of-covid-19-in-patients-with-hematologic-malignancy-a-narrative-review-and-expert-opinion/2025-08-29T15:29:48+00:00https://lymphoma-stg.clarovantdigital.com/library/obinutuzumab-induced-severe-acute-thrombocytopenia-a-case-report-and-literature-review/2026-01-06T21:17:43+00:00https://lymphoma-stg.clarovantdigital.com/library/treatment-patterns-and-survival-outcomes-of-peripheral-t-cell-lymphoma-in-saudi-arabia-a-12-year-retrospective-analysis/2025-08-29T15:29:48+00:00https://lymphoma-stg.clarovantdigital.com/library/real-world-australian-experience-with-tisagenlecleucel-for-relapsed-refractory-diffuse-large-b-cell-lymphoma-importance-of-pre-car-t-optimization/2025-08-29T15:29:48+00:00https://lymphoma-stg.clarovantdigital.com/library/comparison-of-efficacy-and-adverse-effects-of-cd19-20-cart-versus-cd19-single-target-cart-in-r-r-dlbcl-a-single-center-retrospective-study/2025-08-29T15:29:49+00:00https://lymphoma-stg.clarovantdigital.com/library/single-agent-rituximab-and-ultra-low-dose-adaptive-radiotherapy-for-the-treatment-of-indolent-b-cell-non-hodgkin-lymphomas/2025-08-29T15:29:49+00:00https://lymphoma-stg.clarovantdigital.com/library/whole-genome-sequencing-reveals-three-follicular-lymphoma-subtypes-with-distinct-cell-of-origin-and-patient-outcomes/2025-08-29T15:29:49+00:00https://lymphoma-stg.clarovantdigital.com/library/real-world-cardiovascular-risks-of-ibrutinib-in-chronic-lymphocytic-leukemia-a-retrospective-study/2025-12-15T20:18:23+00:00https://lymphoma-stg.clarovantdigital.com/library/an-open-label-multicenter-phase-ii-study-of-bexarotene-in-patients-with-adult-t-cell-leukemia-lymphoma/2026-01-20T19:13:33+00:00https://lymphoma-stg.clarovantdigital.com/library/optimization-and-validation-of-the-international-metabolic-prognostic-index-for-cd19-car-t-in-large-b-cell-lymphoma/2025-08-29T15:29:49+00:00https://lymphoma-stg.clarovantdigital.com/library/phase-i-study-of-subcutaneous-rituximab-hyaluronidase-combined-with-chop-chemotherapy-for-the-treatment-of-diffuse-large-b-cell-lymphoma-in-uganda-2/2025-08-29T15:29:49+00:00https://lymphoma-stg.clarovantdigital.com/library/beyond-bcl2-b-cell-lymphoma-and-btk-bruton-tyrosine-kinase-inhibitors-novel-agents-and-resistance-mechanisms-for-chronic-lymphocytic-leukemia/2025-08-29T15:29:50+00:00https://lymphoma-stg.clarovantdigital.com/library/cd19-car-t-outcomes-in-patients-with-relapsed-refractory-diffuse-large-b-cell-lymphoma-a-retrospective-cohort-study-from-the-calabria-referral-center-in-southern-italy/2025-08-29T15:29:50+00:00https://lymphoma-stg.clarovantdigital.com/library/evaluation-of-implementation-of-patient-involvement-in-taiwans-pharmaceutical-reimbursement-decision-making-process-2/2025-08-29T15:29:50+00:00https://lymphoma-stg.clarovantdigital.com/library/monoclonal-gammopathy-defines-distinct-clinical-subsets-in-chronic-lymphocytic-leukemia-across-therapeutic-eras/2025-09-04T18:47:55+00:00https://lymphoma-stg.clarovantdigital.com/library/abo-blood-group-and-the-risk-and-prognosis-of-diffuse-large-b-cell-lymphoma/2025-09-04T18:53:43+00:00https://lymphoma-stg.clarovantdigital.com/library/acalabrutinib-treatment-for-older-%e2%89%a580-years-old-and-or-frail-patients-with-cll-primary-end-point-analysis-of-the-cll-frail-trial/2025-12-10T14:29:20+00:00https://lymphoma-stg.clarovantdigital.com/library/tandem-combination-of-asct-and-car-t-cell-therapy-in-highly-refractory-cns-lymphomas/2025-09-05T17:24:42+00:00https://lymphoma-stg.clarovantdigital.com/library/gut-microbiota-dysbiosis-and-dietary-interventions-in-non-hodgkin-b-cell-lymphomas-implications-for-treatment-response/2025-09-05T17:24:42+00:00https://lymphoma-stg.clarovantdigital.com/library/a-case-of-cutaneous-t-cell-lymphoma-the-importance-of-a-dermatology-consultation/2025-09-05T17:24:42+00:00https://lymphoma-stg.clarovantdigital.com/library/treatment-outcomes-and-cns-relapse-risk-in-patients-with-primary-cutaneous-dlbcl-leg-type-in-the-rituximab-era/2025-09-05T17:24:42+00:00https://lymphoma-stg.clarovantdigital.com/library/outcomes-following-exposure-to-drug-interactions-with-ibrutinib-in-patients-with-chronic-lymphocytic-leukaemia/2025-09-05T17:24:42+00:00https://lymphoma-stg.clarovantdigital.com/library/real-world-safety-and-efficacy-of-venetoclax-in-chronic-lymphocytic-leukemia-a-single-center-comparative-analysis-with-randomized-clinical-trials/2025-09-05T17:24:42+00:00https://lymphoma-stg.clarovantdigital.com/library/patient-reported-symptom-burden-and-health-related-quality-of-life-in-patients-with-aggressive-non-hodgkin-lymphoma-a-cross-sectional-study/2025-09-05T17:24:43+00:00https://lymphoma-stg.clarovantdigital.com/library/follicular-lymphoma-or-diffuse-large-b-cell-lymphoma-a-population-based-analysis-of-epidemiological-and-health-economic-aspects-in-germany/2025-09-05T17:24:43+00:00https://lymphoma-stg.clarovantdigital.com/library/prognostic-value-of-clinicopathological-features-of-diffuse-large-b-cell-lymphoma-with-bone-marrow-involvement/2025-09-05T17:24:43+00:00https://lymphoma-stg.clarovantdigital.com/library/zanubrutinib-versus-acalabrutinib-indirect-treatment-comparison-in-relapsed-or-refractory-mantle-cell-lymphoma/2025-09-05T17:24:43+00:00https://lymphoma-stg.clarovantdigital.com/library/long-term-outcomes-of-venetoclax-and-ibrutinib-in-japanese-patients-with-relapsed-refractory-mantle-cell-lymphoma/2025-09-05T17:24:43+00:00https://lymphoma-stg.clarovantdigital.com/library/the-landscape-of-primary-central-nervous-system-lymphoma-pcnsl-clinicopathologic-and-genomic-characteristics-and-therapeutic-perspectives/2025-09-05T17:24:43+00:00https://lymphoma-stg.clarovantdigital.com/library/neutrophils-unveiled-in-chronic-lymphocytic-leukemia/2025-09-05T17:24:43+00:00https://lymphoma-stg.clarovantdigital.com/library/sequencing-anti-cd19-therapies-in-diffuse-large-b-cell-lymphoma-from-mechanistic-insights-to-clinical-strategies/2025-09-05T17:24:43+00:00https://lymphoma-stg.clarovantdigital.com/library/efficacy-of-mrd-triggered-anti-cd20-retreatment-in-patients-with-high-risk-chronic-lymphocytic-leukemia-a-case-series/2025-09-16T21:50:19+00:00https://lymphoma-stg.clarovantdigital.com/library/relapsed-and-refractory-peripheral-t-cell-lymphoma-treatment-challenges-and-future-perspectives/2025-12-15T20:23:38+00:00https://lymphoma-stg.clarovantdigital.com/library/richter-transformation-in-chronic-lymphocytic-leukemia-current-treatment-challenges-and-evolving-therapies/2025-12-15T20:35:01+00:00https://lymphoma-stg.clarovantdigital.com/library/circulating-tumour-dna-as-a-predictor-of-survival-of-patients-with-diffuse-large-b-cell-lymphoma-in-a-daily-practice/2025-12-15T20:22:41+00:00https://lymphoma-stg.clarovantdigital.com/library/non-inferior-outcome-of-abbreviated-r-chop-in-patients-with-stage-i-primary-testicular-lymphoma/2025-09-19T18:51:10+00:00https://lymphoma-stg.clarovantdigital.com/library/adoptive-cellular-therapies-in-non-hodgkin-lymphomas/2025-12-15T20:36:15+00:00https://lymphoma-stg.clarovantdigital.com/library/disease-management-landscape-in-patients-with-mantle-cell-lymphoma-in-japan-a-real-world-study/2025-09-19T18:51:10+00:00https://lymphoma-stg.clarovantdigital.com/library/indications-for-haematopoietic-cell-transplantation-and-car-t-for-haematological-diseases-solid-tumours-and-immune-disorders-2025-ebmt-practice-recommendations/2025-09-19T18:51:10+00:00https://lymphoma-stg.clarovantdigital.com/library/outcomes-and-prognostic-factors-of-alternative-treatment-regimens-for-angioimmunoblastic-t-cell-lymphoma-a-retrospective-analysis/2025-09-19T18:51:10+00:00https://lymphoma-stg.clarovantdigital.com/library/ai-in-digital-pathology-for-diffuse-large-b-cell-lymphoma-a-systematic-review-of-diagnosis-and-classification/2025-09-19T18:51:11+00:00https://lymphoma-stg.clarovantdigital.com/library/pirtobrutinib-in-chronic-lymphocytic-leukemia-navigating-resistance-and-the-personalisation-of-btk-targeted-therapy/2025-09-19T18:51:11+00:00https://lymphoma-stg.clarovantdigital.com/library/long-acting-lipegfilgrastim-and-antimicrobials-as-vigorous-primary-prophylaxis-in-bendamustine-treated-patients-with-indolent-b-cell-non-hodgkin-lymphoma-a-multicentric-real-life-experience/2025-09-19T18:51:11+00:00https://lymphoma-stg.clarovantdigital.com/library/extranodal-nk-t-cell-lymphoma-an-update-of-the-molecular-characterization-of-the-tumor-and-microenvironment-and-its-clinical-implications/2025-09-19T18:51:11+00:00https://lymphoma-stg.clarovantdigital.com/library/uncommon-manifestations-of-newly-diagnosed-b-cell-chronic-lymphocytic-leukemia-prompting-the-concurrent-diagnosis-of-advanced-prostate-cancer-a-case-report/2025-09-19T18:51:11+00:00https://lymphoma-stg.clarovantdigital.com/library/the-use-of-real-world-evidence-among-healthcare-payers-a-scoping-review/2025-09-19T18:51:11+00:00https://lymphoma-stg.clarovantdigital.com/library/plain-language-summaries-supporting-patient-involvement-lessons-and-guidance-from-htai-patient-and-citizen-involvement-interest-group-pcig/2025-09-19T18:51:11+00:00https://lymphoma-stg.clarovantdigital.com/library/real-world-study-on-patient-characteristics-treatment-patterns-and-outcomes-for-treated-patients-with-chronic-lymphocytic-leukemia-during-2013-2022-in-finland/2025-09-19T18:51:11+00:00https://lymphoma-stg.clarovantdigital.com/library/the-role-of-radiotherapy-after-full-course-of-chemotherapy-in-the-treatment-of-diffuse-large-b-cell-lymphoma-a-systematic-review-and-meta-analysis/2025-09-19T18:51:12+00:00https://lymphoma-stg.clarovantdigital.com/library/clinical-and-transcriptomic-characterization-of-patients-with-chronic-lymphocytic-leukemia-harboring-t1419-an-eric-study/2025-09-19T18:52:43+00:00https://lymphoma-stg.clarovantdigital.com/library/accelerated-chronic-lymphocytic-leukemia-expert-opinion-on-diagnosis-and-management/2025-09-23T13:22:20+00:00https://lymphoma-stg.clarovantdigital.com/library/clinical-features-and-prognosis-analysis-of-patients-with-follicular-lymphoma-a-real-world-study-in-china/2025-09-26T18:01:35+00:00https://lymphoma-stg.clarovantdigital.com/library/clinicopathologic-characteristics-and-survival-outcome-of-patients-with-mantle-cell-lymphoma-a-north-indian-tertiary-care-center-experience/2025-09-26T18:01:35+00:00https://lymphoma-stg.clarovantdigital.com/library/predictors-of-neurotoxicity-in-a-large-cohort-of-italian-patients-undergoing-anti-cd19-chimeric-antigen-receptor-car-t-cell-therapy/2025-09-26T18:01:35+00:00https://lymphoma-stg.clarovantdigital.com/library/hypertension-in-patients-with-chronic-lymphocytic-leukemia-small-lymphocytic-lymphoma-in-alpine-a-secondary-analysis/2025-12-15T19:32:55+00:00https://lymphoma-stg.clarovantdigital.com/library/interpretable-machine-learning-model-to-predict-90-day-radiographically-confirmed-pneumonia-after-chemotherapy-initiation-in-non-hodgkin-lymphoma-development-and-internal-validation-of-a-single-cente/2025-09-26T18:01:35+00:00https://lymphoma-stg.clarovantdigital.com/library/polatuzumab-vedotin-plus-bendamustine-and-rituximab-or-obinutuzumab-in-relapsed-refractory-follicular-lymphoma-a-phase-ib-ii-study/2025-09-26T18:01:35+00:00https://lymphoma-stg.clarovantdigital.com/library/bridging-gaps-in-clinical-trial-accessibility-and-reimbursement-for-large-b-cell-lymphoma-therapies-across-europe/2025-09-26T18:01:35+00:00https://lymphoma-stg.clarovantdigital.com/library/large-b-cell-lymphoma-lbcl-eha-clinical-practice-guidelines-for-diagnosis-treatment-and-follow-up/2026-01-20T19:47:57+00:00https://lymphoma-stg.clarovantdigital.com/library/favorable-outcomes-of-restrictive-treatment-indications-in-chronic-lymphocytic-leukemia-a-retrospective-analysis-of-brazilian-registry-of-cll/2025-09-26T18:01:36+00:00https://lymphoma-stg.clarovantdigital.com/library/five-year-outcomes-of-the-polarix-study-comparing-pola-r-chp-and-r-chop-in-patients-with-diffuse-large-b-cell-lymphoma/2025-09-26T18:01:36+00:00https://lymphoma-stg.clarovantdigital.com/library/zanubrutinib-as-a-salvage-therapy-for-ibrutinib-resistant-chronic-lymphocytic-leukemia-a-case-report/2025-09-26T18:01:36+00:00https://lymphoma-stg.clarovantdigital.com/library/indirect-comparisons-of-the-efficacy-and-safety-of-zanubrutinib-versus-venetoclax-plus-obinutuzumab-in-treatment-naive-chronic-lymphocytic-leukemia-small-lymphocytic-lymphoma/2025-09-26T18:01:36+00:00https://lymphoma-stg.clarovantdigital.com/library/efficacy-of-radiotherapy-in-primary-mediastinal-diffuse-large-b-cell-lymphoma-a-systematic-review-and-meta-analysis-of-1392-patients/2025-09-26T18:01:36+00:00https://lymphoma-stg.clarovantdigital.com/library/effectiveness-and-safety-of-polatuzumab-vedotin-plus-an-anti-cd20-monoclonal-antibody-rituximab-or-obinutuzumab-and-zanubrutinib-in-relapsed-refractory-diffuse-large-b-cell-lymphoma/2025-09-26T18:01:37+00:00https://lymphoma-stg.clarovantdigital.com/library/clinical-characteristics-and-short-term-outcomes-of-pediatric-lymphoma-a-retrospective-cohort-study-from-a-large-tertiary-hospital-in-a-low-and-middle-income-country/2025-09-26T18:01:37+00:00https://lymphoma-stg.clarovantdigital.com/library/a-swot-consensus-for-car-t-in-follicular-lymphoma-fine-tuning-of-patient-journey-and-selection/2025-09-26T18:01:37+00:00https://lymphoma-stg.clarovantdigital.com/library/efficacy-and-safety-of-anti-pd-1-pd-l1-antibodies-in-patients-with-relapsed-refractory-diffuse-large-b-cell-lymphoma-a-meta-analysis/2025-09-26T18:01:37+00:00https://lymphoma-stg.clarovantdigital.com/library/a-retrospective-study-of-myc-rearranged-diffuse-large-b-cell-lymphoma-in-the-context-of-the-new-who-and-icc-classifications/2025-10-03T17:53:08+00:00https://lymphoma-stg.clarovantdigital.com/library/clinical-and-molecular-features-of-primary-spinal-epidural-lymphomas/2025-10-03T17:53:08+00:00https://lymphoma-stg.clarovantdigital.com/library/nivolumab-plus-brentuximab-vedotin-bendamustine-combination-therapy-a-safe-and-effective-treatment-in-pediatric-recurrent-and-refractory-classical-hodgkin-lymphoma/2025-10-03T17:53:08+00:00https://lymphoma-stg.clarovantdigital.com/library/disease-control-and-manageable-toxicity-with-epcoritamab-in-refractory-diffuse-large-b-cell-lymphoma-type-richter-syndrome-a-case-report-in-an-elderly-patient/2026-01-14T18:38:18+00:00https://lymphoma-stg.clarovantdigital.com/library/clinical-outcome-and-immunophenotype-of-axicabtagene-ciloleucel-axi-cel-and-relmacabtagene-autoleucel-relma-cel-in-relapsed-refractory-large-b-cell-lymphoma-on-chinese-population-a-single-center/2025-10-03T17:53:09+00:00https://lymphoma-stg.clarovantdigital.com/library/notch1-mutation-is-associated-with-response-to-bruton-tyrosine-kinase-inhibitors-in-chronic-lymphocytic-leukemia-a-retrospective-study/2025-10-03T17:53:09+00:00https://lymphoma-stg.clarovantdigital.com/library/atrial-fibrillation-following-bendamustine-in-three-lymphoma-patients/2025-10-03T17:53:09+00:00https://lymphoma-stg.clarovantdigital.com/library/efficacy-and-safety-of-the-academic-anti-cd19-chimeric-antigen-receptor-t-cell-product-varnimcabtagene-autoleucel-for-the-treatment-of-relapsed-refractory-follicular-lymphoma/2025-10-03T17:53:09+00:00https://lymphoma-stg.clarovantdigital.com/library/efficacy-and-safety-of-tazemetostat-an-ezh2-inhibitor-in-chinese-patients-with-relapsed-refractory-follicular-lymphoma-a-multicentre-single-arm-phase-2-study/2025-10-03T17:53:09+00:00https://lymphoma-stg.clarovantdigital.com/library/car-t-cells-vs-bispecific-antibodies-as-third-or-later-line-treatment-for-relapsed-refractory-follicular-lymphoma-a-literature-review-and-meta-analysis/2025-10-03T17:53:09+00:00https://lymphoma-stg.clarovantdigital.com/library/from-chronic-lymphocytic-leukemia-to-plasmablastic-myeloma-beyond-the-usual-richter-transformation/2025-10-03T17:53:10+00:00https://lymphoma-stg.clarovantdigital.com/library/fundamental-prognostic-difference-of-atm-gene-mutation-and-deletion-in-newly-diagnosed-mantle-cell-lymphoma/2025-10-03T17:53:10+00:00https://lymphoma-stg.clarovantdigital.com/library/early-treatment-related-morbidity-and-mortality-of-children-with-non-hodgkin-lymphoma-treated-at-tikur-anbesa-specialized-hospital-with-modified-alcl-protocol-prospective-cohort-study/2025-10-03T17:53:10+00:00https://lymphoma-stg.clarovantdigital.com/library/allogeneic-hematopoietic-cell-transplant-in-cutaneous-t-cell-lymphomas-recommendations-from-the-ebmt-phg-committee/2025-10-03T17:53:10+00:00https://lymphoma-stg.clarovantdigital.com/library/clinical-tumor-and-product-features-associated-with-outcomes-after-axicabtagene-ciloleucel-therapy-in-follicular-lymphoma/2025-10-03T17:53:10+00:00https://lymphoma-stg.clarovantdigital.com/library/zanubrutinib-for-high-risk-waldenstrom-macroglobulinemia-with-complex-karyotype-and-hyperleukocytosis-a-case-report-and-literature-review/2025-10-03T17:53:10+00:00https://lymphoma-stg.clarovantdigital.com/library/prognostic-impacts-of-marital-status-and-other-socioeconomic-factors-in-patients-with-chronic-lymphocytic-leukemia-an-analysis-of-seer-database/2025-10-03T17:53:11+00:00https://lymphoma-stg.clarovantdigital.com/library/longitudinal-health-related-quality-of-life-among-patients-with-high-risk-pediatric-hodgkin-lymphoma-treated-on-the-childrens-oncology-group-ahod-1331-study/2025-10-03T17:53:11+00:00https://lymphoma-stg.clarovantdigital.com/library/total-costs-of-different-lines-of-treatment-in-diffuse-large-b-cell-lymphoma-in-denmark-a-real-world-data-analysis/2025-10-03T17:53:11+00:00https://lymphoma-stg.clarovantdigital.com/library/ibrutinib-combined-with-rituximab-and-high-dose-methotrexate-in-newly-diagnosed-primary-cns-diffuse-large-b-cell-lymphoma-a-pilot-study-with-long-term-follow-up/2025-10-03T17:53:11+00:00https://lymphoma-stg.clarovantdigital.com/library/cost-effectiveness-of-hlx01-hanlikang-vs-rituximab-combined-with-chop-in-treatment-naive-diffuse-large-b-cell-lymphoma-a-partitioned-survival-model-analysis/2025-10-03T17:53:11+00:00https://lymphoma-stg.clarovantdigital.com/library/outpatient-axicabtagene-ciloleucel-for-relapsed-refractory-large-b-cell-lymphoma-zuma-24-primary-analysis/2025-10-16T17:40:22+00:00https://lymphoma-stg.clarovantdigital.com/library/outcome-of-patients-with-mantle-cell-lymphoma-after-failure-of-anti-cd19-car-t-cell-therapy-a-descar-t-study-by-lysa-group/2025-10-16T19:37:26+00:00https://lymphoma-stg.clarovantdigital.com/library/population-wide-introduction-of-dose-adjusted-epoch-r-in-high-grade-b-cell-lymphoma-with-myc-bcl2-rearrangements-dlbcl-morphology/2025-10-16T19:43:03+00:00https://lymphoma-stg.clarovantdigital.com/library/colorectal-follicular-lymphoma-a-single-center-retrospective-study/2025-10-16T19:46:02+00:00https://lymphoma-stg.clarovantdigital.com/library/management-of-canadian-patients-with-refractory-or-relapsed-diffuse-large-b-cell-lymphoma-in-the-real-world-a-subanalysis-of-the-re-mind2-study/2025-10-16T19:53:55+00:00https://lymphoma-stg.clarovantdigital.com/library/priming-with-dnmt-inhibitors-potentiates-pd-1-immunotherapy-by-triggering-viral-mimicry-in-relapsed-refractory-nk-t-cell-lymphoma/2025-10-16T19:59:19+00:00https://lymphoma-stg.clarovantdigital.com/library/brentuximab-vedotin-and-radiotherapy-for-cd30-positive-cutaneous-t-cell-lymphoma-a-retrospective-multicenter-analysis/2025-10-17T18:05:07+00:00https://lymphoma-stg.clarovantdigital.com/library/gender-disparities-in-health-related-quality-of-life-in-patients-with-chronic-lymphocytic-leukemia-impact-of-treatment-modality/2025-10-17T18:05:07+00:00https://lymphoma-stg.clarovantdigital.com/library/remission-assessment-by-circulating-tumor-dna-in-large-b-cell-lymphoma/2025-10-17T18:05:07+00:00https://lymphoma-stg.clarovantdigital.com/library/enhancing-prognostic-accuracy-in-pmbcl-semiquantitative-analysis-of-interim-pet-ct-scans/2025-10-17T18:05:07+00:00https://lymphoma-stg.clarovantdigital.com/library/global-burden-of-childhood-burkitt-lymphoma-1990-2021-epidemiological-trends-regional-disparities-and-projections-for-2035-from-the-global-burden-of-disease-study/2026-03-13T13:37:53+00:00https://lymphoma-stg.clarovantdigital.com/library/ocular-manifestations-of-patients-with-extranodal-nk-t-cell-lymphoma/2025-10-17T18:05:08+00:00https://lymphoma-stg.clarovantdigital.com/library/ibrutinib-and-rituximab-versus-immunochemotherapy-in-patients-with-previously-untreated-mantle-cell-lymphoma-enrich-a-randomised-open-label-phase-2-3-superiority-trial/2025-10-17T18:05:08+00:00https://lymphoma-stg.clarovantdigital.com/library/lenalidomide-rituximab-with-high-dose-methotrexate-for-treatment-of-patients-with-newly-diagnosed-primary-cns-lymphoma-a-promising-first-line-approach/2025-10-17T18:05:08+00:00https://lymphoma-stg.clarovantdigital.com/library/pirtobrutinib-in-the-treatment-of-chronic-lymphocytic-leukemia-or-small-lymphocytic-lymphoma/2025-10-17T18:05:08+00:00https://lymphoma-stg.clarovantdigital.com/library/predicting-one-year-overall-survival-in-patients-with-aitl-using-machine-learning-algorithms-a-multicenter-study/2025-10-17T18:05:08+00:00https://lymphoma-stg.clarovantdigital.com/library/early-life-exposures-and-risk-of-hematological-malignancies-in-adulthood-a-cohort-study-meta-analysis-and-mendelian-randomization-analysis/2025-10-17T18:05:08+00:00https://lymphoma-stg.clarovantdigital.com/library/assessing-remission-in-diffuse-large-b-cell-lymphoma-will-minimal-residual-disease-add-value-to-positron-emission-tomography/2025-10-17T18:05:08+00:00https://lymphoma-stg.clarovantdigital.com/library/clinical-implications-of-ctdna-based-minimal-residual-disease-detection-in-newly-diagnosed-peripheral-t-cell-lymphoma-a-single-center-cohort-study/2025-10-17T18:05:08+00:00https://lymphoma-stg.clarovantdigital.com/library/healthcare-cost-comparison-between-first-line-ibrutinib-and-acalabrutinib-in-chronic-lymphocytic-leukemia-patients-in-the-veterans-affairs/2025-10-17T18:05:09+00:00https://lymphoma-stg.clarovantdigital.com/library/achieving-patient-centered-value-health-technology-assessment-recommendations-from-a-multistakeholder-edelphi-panel/2025-10-17T18:05:09+00:00https://lymphoma-stg.clarovantdigital.com/library/advances-in-the-combination-of-car-t-therapy-with-small-molecule-reagents-for-hematologic-malignancies/2025-10-17T18:05:09+00:00https://lymphoma-stg.clarovantdigital.com/library/real-world-treatment-patterns-and-outcomes-of-zanubrutinib-in-chronic-lymphocytic-leukemia-and-small-lymphocytic-leukemia-cll-sll-2/2025-10-17T18:05:09+00:00https://lymphoma-stg.clarovantdigital.com/library/germline-determinants-of-toxicity-and-efficacy-in-patients-with-large-b-cell-lymphoma-treated-with-car-t-cell-therapy/2025-10-17T18:05:09+00:00https://lymphoma-stg.clarovantdigital.com/library/complete-remission-of-recurrent-primary-cutaneous-anaplastic-large-cell-lymphoma-following-bexarotene-therapy-a-case-report/2025-10-17T18:05:09+00:00https://lymphoma-stg.clarovantdigital.com/library/glofitamab-vs-real-world-regimens-in-chinese-patients-with-third-or-later-line-relapsed-refractory-diffuse-large-b-cell-lymphoma-an-external-control-study/2025-10-17T18:05:10+00:00https://lymphoma-stg.clarovantdigital.com/library/prognostic-impact-of-organ-involvement-in-aggressive-adult-t-cell-leukemia-lymphoma-definition-of-risk-organ-and-proposal-of-a-prognostic-index/2026-01-20T19:11:23+00:00https://lymphoma-stg.clarovantdigital.com/library/venetoclax-rituximab-and-emerging-treatment-strategies-after-c-btki-exposure-in-relapsed-refractory-cll-a-real-world-cohort-and-literature-overview/2025-10-17T18:05:10+00:00https://lymphoma-stg.clarovantdigital.com/library/challenges-in-predicting-outcomes-for-watch-and-wait-follicular-lymphoma-patients-insights-into-clinical-pathological-and-molecular-factors/2025-10-17T18:05:10+00:00https://lymphoma-stg.clarovantdigital.com/library/invasive-fungal-infections-after-cd19-car-t-cell-therapy-for-b-cell-lymphoma-a-lysa-study-from-the-descar-t-registry/2025-10-17T18:05:10+00:00https://lymphoma-stg.clarovantdigital.com/library/five-year-follow-up-analysis-of-zuma-5-axicabtagene-ciloleucel-in-relapsed-refractory-indolent-non-hodgkin-lymphoma/2025-10-17T18:05:10+00:00https://lymphoma-stg.clarovantdigital.com/library/advanced-stage-classical-hodgkin-lymphoma-patients-with-a-positive-interim-pet-pet-2-deauville-score-5-after-2-abvd-cycles-a-pooled-analysis-of-three-multicenter-trials/2025-10-17T18:05:10+00:00https://lymphoma-stg.clarovantdigital.com/library/cns-infiltration-by-zamtocabtagene-autoleucel-tandem-cd20-cd19-car-t-cells-leading-to-complete-remission-in-a-patient-with-primary-cns-lymphoma/2025-10-24T18:10:34+00:00https://lymphoma-stg.clarovantdigital.com/library/the-role-of-laparoscopy-in-diffuse-large-b-cell-lymphoma-with-high-18f-fluorodeoxyglucose-uptake-lymph-node-in-the-retroperitoneum-after-chemotherapy/2025-10-24T18:44:16+00:00https://lymphoma-stg.clarovantdigital.com/library/prognostic-impact-of-gnri-ipi-score-in-octogenarians-with-diffuse-large-b-cell-lymphoma-treated-with-r-chop/2025-10-24T19:11:20+00:00https://lymphoma-stg.clarovantdigital.com/library/acute-obinutuzumab-induced-thrombocytopenia-in-follicular-lymphoma-case-report-and-literature-review/2025-10-24T19:11:20+00:00https://lymphoma-stg.clarovantdigital.com/library/efficacy-and-safety-of-glofitamab-plus-polatuzumab-vedotin-in-relapsed-refractory-large-b-cell-lymphoma-including-high-grade-b-cell-lymphoma-results-from-a-phase-ib-ii-trial/2025-10-24T19:11:20+00:00https://lymphoma-stg.clarovantdigital.com/library/preventing-secondary-primary-malignancies-spms-in-car-t-cell-therapy-through-site-specific-transgene-integration-into-genomic-safe-harbors-gshs/2025-10-24T19:11:20+00:00https://lymphoma-stg.clarovantdigital.com/library/evaluation-and-forecasting-methods-to-estimate-number-of-patients-with-non-hodgkin-lymphoma-a-systematic-literature-review/2025-10-24T19:11:21+00:00https://lymphoma-stg.clarovantdigital.com/library/evaluating-the-effectiveness-of-integrated-care-in-targeted-therapy-for-patients-with-chronic-lymphocytic-leukemia/2025-10-24T19:11:21+00:00https://lymphoma-stg.clarovantdigital.com/library/quality-and-duration-of-responses-with-mogamulizumab-in-cutaneous-t-cell-lymphomas-insights-into-long-lasting-outcomes/2025-10-24T19:11:21+00:00https://lymphoma-stg.clarovantdigital.com/library/real-life-efficacy-of-immunotherapy-for-sezary-syndrome-a-multicenter-observational-cohort-study/2025-10-24T19:11:21+00:00https://lymphoma-stg.clarovantdigital.com/library/chemotherapy-and-anti-cd20-monoclonal-antibody-impact-on-sars-cov-2-nucleic-acid-amplification-tests-in-hematologic-malignancies-a-retrospective-study/2025-10-24T19:11:21+00:00https://lymphoma-stg.clarovantdigital.com/library/sudden-death-and-asymptomatic-arrhythmia-in-chronic-lymphocytic-leukemia-patients-treated-with-ibrutinib/2025-10-24T19:11:21+00:00https://lymphoma-stg.clarovantdigital.com/library/diffuse-large-b-cell-lymphoma-in-the-new-era-prognostic-tools-for-mapping-risk/2025-10-24T19:11:21+00:00https://lymphoma-stg.clarovantdigital.com/library/hodgkin-lymphoma-treatment-patterns-and-outcome-disparities-in-low-and-middle-income-countries/2026-03-13T13:38:55+00:00https://lymphoma-stg.clarovantdigital.com/library/patient-preferences-for-attributes-of-bispecific-antibodies-for-relapse-refractory-diffuse-large-b-cell-lymphoma-in-the-us/2026-01-14T18:37:26+00:00https://lymphoma-stg.clarovantdigital.com/library/eha-eu-mcl-network-guidelines-for-diagnosis-and-treatment-of-mantle-cell-lymphoma/2025-10-24T19:11:22+00:00https://lymphoma-stg.clarovantdigital.com/library/cd19-car-t-cell-therapy-in-richter-transformation-a-multicentre-retrospective-analysis-by-the-european-research-initiative-on-chronic-lymphocytic-leukaemia/2025-10-24T19:11:22+00:00https://lymphoma-stg.clarovantdigital.com/library/peripheral-t-cell-lymphoma-management-in-east-and-southeast-asia-real-world-challenges-and-aspirations-of-the-asian-lymphoma-study-group/2025-10-24T19:11:22+00:00https://lymphoma-stg.clarovantdigital.com/library/zanubrutinib-lenalidomide-and-rituximab-plus-cyclophosphamide-doxorubicin-vincristine-and-prednisone-as-initial-treatment-in-non-germinal-center-b-cell-diffuse-large-b-cell-lymphoma-a-multi-cente/2025-10-24T19:11:22+00:00https://lymphoma-stg.clarovantdigital.com/library/bispecific-monoclonal-antibodies-in-diffuse-large-b-cell-lymphoma-dawn-of-a-new-era-in-targeted-therapy/2026-01-14T18:36:35+00:00https://lymphoma-stg.clarovantdigital.com/library/brexucabtagene-autoleucel-for-btki-naive-relapsed-refractory-mantle-cell-lymphoma-primary-analysis-of-zuma-2-cohort-3/2026-03-30T15:46:04+00:00https://lymphoma-stg.clarovantdigital.com/library/marked-survival-gains-in-patients-%e2%89%a4-65-years-with-advanced-stage-mantle-cell-lymphoma-a-pooled-analysis-of-six-randomized-phase-iii-trials-1996-2020/2025-10-31T13:10:28+00:00https://lymphoma-stg.clarovantdigital.com/library/outcomes-of-patients-with-relapsed-or-refractory-primary-mediastinal-b-cell-lymphoma-after-frontline-da-epoch-r/2025-10-31T13:14:12+00:00https://lymphoma-stg.clarovantdigital.com/library/t-cell-receptor-clonotypes-and-aggressive-subtypes-in-cutaneous-t-cell-lymphoma/2025-10-31T17:42:11+00:00https://lymphoma-stg.clarovantdigital.com/library/ctdna-dynamics-demonstrates-rapid-treatment-response-to-tafasitamab-r-chop-lenalidomide-and-predicts-outcome-in-diffuse-large-b-cell-lymphoma-results-from-the-phase-1b-first-mind-study/2025-10-31T17:42:12+00:00https://lymphoma-stg.clarovantdigital.com/library/optimizing-markers-for-chronic-lymphocytic-leukemia-diagnosis-by-flow-cytometry-results-from-the-nationwide-thai-lymphoma-study-group/2025-10-31T17:42:12+00:00https://lymphoma-stg.clarovantdigital.com/library/autologous-stem-cell-transplantation-meets-car-t-therapy-a-synergistic-strategy-for-b-cell-lymphoma/2025-10-31T17:42:12+00:00https://lymphoma-stg.clarovantdigital.com/library/clinical-features-and-outcomes-of-primary-colorectal-diffuse-large-b-cell-lymphoma-a-multicenter-retrospective-study/2025-10-31T17:42:12+00:00https://lymphoma-stg.clarovantdigital.com/library/occupational-exposure-to-formaldehyde-and-risk-of-lymphoma-subtypes-results-of-a-multicentre-italian-case-control-study/2025-10-31T17:42:12+00:00https://lymphoma-stg.clarovantdigital.com/library/prognostic-relevance-of-the-neutrophil-lymphocyte-ratio-in-diffuse-large-b-cell-lymphoma-a-systematic-review-and-meta-analysis-and-dose-response-evidence/2025-10-31T17:42:12+00:00https://lymphoma-stg.clarovantdigital.com/library/real-world-outcomes-of-ibrutinib-therapy-in-korean-patients-with-relapsed-or-refractory-mantle-cell-lymphoma-a-multicenter-retrospective-analysis/2026-04-24T19:48:17+00:00https://lymphoma-stg.clarovantdigital.com/library/randomized-phase-ii-study-of-brentuximab-vedotin-with-high-dose-chemotherapy-in-cd30-positive-lymphoma/2025-10-31T17:42:12+00:00https://lymphoma-stg.clarovantdigital.com/library/associations-between-the-gut-microbiome-and-outcomes-in-autologous-stem-cell-transplantation-a-systematic-review/2025-10-31T17:42:13+00:00https://lymphoma-stg.clarovantdigital.com/library/maintenance-low-dose-braf-inhibition-and-rituximab-in-relapsed-hairy-cell-leukemia-a-therapeutic-alternative/2025-10-31T17:42:13+00:00https://lymphoma-stg.clarovantdigital.com/library/testicular-lymphoma-of-63-patients-a-chinese-retrospective-real-world-study/2025-10-31T17:42:13+00:00https://lymphoma-stg.clarovantdigital.com/library/overall-survival-outcomes-with-first-line-continuous-ibrutinib-and-fixed-duration-ibrutinib-venetoclax-treatments-in-patients-with-chronic-lymphocytic-leukemia-comparison-with-an-age-matched-european/2025-10-31T17:42:13+00:00https://lymphoma-stg.clarovantdigital.com/library/comparative-efficacy-and-safety-of-modified-beam-and-beam-beac-as-conditioning-regimens-for-autologous-hematopoietic-stem-cell-transplantation-in-patients-with-non-hodgkin-lymphoma/2025-12-19T15:04:49+00:00https://lymphoma-stg.clarovantdigital.com/library/intravascular-complications-of-central-venous-catheterization-in-chronic-hematological-diseases-low-risk-with-peripherally-inserted-catheters-in-a-single-center-retrospective-large-study/2025-10-31T17:42:13+00:00https://lymphoma-stg.clarovantdigital.com/library/enhancing-lymphoma-cancer-detection-using-deep-transfer-learning-on-histopathological-images/2025-10-31T17:42:14+00:00https://lymphoma-stg.clarovantdigital.com/library/distinct-immunologic-kinetics-and-cytomegalovirus-reactivation-incidence-with-rituximab-versus-obinutuzumab-bendamustine-in-follicular-lymphoma-a-single-center-case-series-study/2025-11-07T18:59:21+00:00https://lymphoma-stg.clarovantdigital.com/library/first-line-treatment-with-polatuzumab-vedotin-improves-efficacy-and-survival-in-newly-diagnosed-patients-with-advanced-diffuse-large-b-cell-lymphoma-a-multicentre-retrospective-analysis/2025-11-07T18:59:21+00:00https://lymphoma-stg.clarovantdigital.com/library/breast-primary-follicular-lymphoma-two-cases-of-a-rare-entity-treated-with-radical-radiotherapy-and-rituximab/2025-11-07T18:59:21+00:00https://lymphoma-stg.clarovantdigital.com/library/antibody-drug-conjugates-in-cancer-therapy-current-landscape-challenges-and-future-directions/2025-11-07T18:59:21+00:00https://lymphoma-stg.clarovantdigital.com/library/peripheral-blood-involvement-in-extra-nodal-marginal-zone-lymphoma/2025-11-07T18:59:22+00:00https://lymphoma-stg.clarovantdigital.com/library/glofitamab-combined-with-tislelizumab-in-relapsed-refractory-diffuse-large-b-cell-lymphoma-a-single-center-pilot-trial/2025-11-07T18:59:22+00:00https://lymphoma-stg.clarovantdigital.com/library/enhancing-confidence-in-complex-health-technology-assessments-by-using-real-world-evidence-highlighting-existing-strategies-for-effective-drug-evaluation/2025-11-07T18:59:22+00:00https://lymphoma-stg.clarovantdigital.com/library/relapsed-or-refractory-central-nervous-system-lymphoma-successfully-treated-by-glofitamab-combined-with-lenalidomide/2026-01-15T13:49:12+00:00https://lymphoma-stg.clarovantdigital.com/library/safety-profiles-in-elderly-patients-with-dlbcl-on-first-line-pola-r-chp-a-claims-database-study-in-japan/2025-11-07T18:59:22+00:00https://lymphoma-stg.clarovantdigital.com/library/pilot-evaluation-of-optical-genome-mapping-in-chronic-lymphocytic-leukemia-complementing-fish-analysis/2025-11-07T18:59:22+00:00https://lymphoma-stg.clarovantdigital.com/library/synthetic-control-arm-from-mixed-clinical-trials-and-real-world-data-from-the-lysa-group-for-untreated-diffuse-large-b-cell-lymphoma-patients-aged-over-80-years-a-bona-fide-strategy-for-innovative-cl/2025-11-07T18:59:22+00:00https://lymphoma-stg.clarovantdigital.com/library/treatment-outcomes-of-zanubrutinib-based-regimen-in-newly-diagnosed-patients-with-myc-bcl2-double-expressor-diffuse-large-b-cell-lymphoma-a-retrospective-multicenter-real-world-study/2025-11-07T18:59:23+00:00https://lymphoma-stg.clarovantdigital.com/library/functional-genomics-and-tumor-microenvironment-analysis-reveal-prognostic-biological-subtypes-in-mantle-cell-lymphoma/2025-11-07T18:59:23+00:00https://lymphoma-stg.clarovantdigital.com/library/increased-risk-of-hip-and-other-major-osteoporotic-fractures-within-18-months-of-lymphoma-diagnosis-a-national-registry-study-of-36864-swedish-lymphoma-patients/2025-11-07T18:59:23+00:00https://lymphoma-stg.clarovantdigital.com/library/disease-progression-more-than-6years-after-treatment-impacts-overall-survival-in-mantle-cell-lymphoma/2025-11-07T18:59:23+00:00https://lymphoma-stg.clarovantdigital.com/library/sequential-pd-1-inhibitors-as-consolidative-therapy-post-cd19-cart-in-relapsed-refractory-nhl-a-propensity-score-matching-cohort-study/2025-11-07T18:59:23+00:00https://lymphoma-stg.clarovantdigital.com/library/the-integration-of-gene-mutations-and-copy-number-variations-refines-the-prognosis-of-mantle-cell-lymphoma-long-term-results-of-the-fondazione-italiana-linfomi-mcl0208-clinical-trial/2025-11-07T18:59:23+00:00https://lymphoma-stg.clarovantdigital.com/library/skin-and-soft-tissue-mucormycosis-in-patients-receiving-brutons-tyrosine-kinase-inhibitors-case-report-and-literature-review/2025-11-13T20:32:35+00:00https://lymphoma-stg.clarovantdigital.com/library/improved-therapies-incomplete-data-late-toxicity-after-modern-classical-hodgkin-lymphoma-radiotherapy/2025-11-13T20:35:44+00:00https://lymphoma-stg.clarovantdigital.com/library/pros-vs-clinician-reported-adverse-events-in-a-large-clinical-trial-findings-from-the-phase-3-polarix-study/2026-02-23T17:51:07+00:00https://lymphoma-stg.clarovantdigital.com/library/noninvasive-genotyping-and-early-disease-dynamics-demonstrate-the-efficacy-of-ibrutinib-in-combination-with-immunochemotherapy-in-patients-with-mantle-cell-lymphoma-treated-in-the-triangle-trial/2025-11-14T14:11:33+00:00https://lymphoma-stg.clarovantdigital.com/library/epcoritamab-plus-gemcitabine-and-oxaliplatin-versus-rituximab-plus-gemcitabine-and-oxaliplatin-in-transplant-ineligible-relapsed-refractory-diffuse-large-b-cell-lymphoma-a-match-adjusted-comparative/2026-01-14T18:35:50+00:00https://lymphoma-stg.clarovantdigital.com/library/investigating-the-prognostic-value-of-non-coding-rnas-in-chronic-lymphocytic-leukemia-insights-from-a-systematic-review-and-meta-analysis/2025-11-14T14:11:33+00:00https://lymphoma-stg.clarovantdigital.com/library/atf6-and-ps6k-as-prognostic-biomarkers-in-newly-diagnosed-diffuse-large-b-cell-lymphoma/2025-11-14T14:11:33+00:00https://lymphoma-stg.clarovantdigital.com/library/lisocabtagene-maraleucel-for-r-r-lbcl-in-patients-not-intended-for-hsct-final-results-of-the-phase-2-pilot-study/2025-11-14T14:11:33+00:00https://lymphoma-stg.clarovantdigital.com/library/primary-cutaneous-lymphomas-in-thailand-a-10-year-retrospective-study/2025-11-14T14:11:33+00:00https://lymphoma-stg.clarovantdigital.com/library/polatuzumab-vedotin-plus-rituximab-with-chemotherapy-in-newly-diagnosed-pediatric-stage-iv-burkitt-lymphoma-case-report-highlighting-early-complete-remission/2025-11-14T14:11:34+00:00https://lymphoma-stg.clarovantdigital.com/library/case-report-rare-adverse-events-following-car-t-therapy-in-patients-with-relapsed-refractory-diffuse-large-b-cell-lymphoma/2025-11-14T14:11:34+00:00https://lymphoma-stg.clarovantdigital.com/library/ct-derived-myosteatosis-for-baseline-risk-stratification-of-cardiotoxicity-in-patients-with-diffuse-large-b-cell-lymphoma-receiving-anthracyclines/2025-11-14T14:11:34+00:00https://lymphoma-stg.clarovantdigital.com/library/efficacy-and-safety-of-fixed-duration-venetoclax-plus-obinutuzumab-in-untreated-japanese-cll-and-sll-a-phase-2-study/2025-11-14T14:11:34+00:00https://lymphoma-stg.clarovantdigital.com/library/time-from-symptom-recognition-to-cancer-diagnosis-and-factors-linked-to-delayed-diagnosis-of-hematological-childhood-cancers-at-a-tertiary-hospital-in-uganda-a-mixed-methods-study/2026-03-13T17:39:06+00:00https://lymphoma-stg.clarovantdigital.com/library/xpo-1-targeting-in-chronic-lymphocytic-leukemia-is-there-potential-for-therapeutic-strategy/2025-11-14T14:11:34+00:00https://lymphoma-stg.clarovantdigital.com/library/cost-effectiveness-of-first-line-zuberitamab-chop-versus-rituximab-chop-regimens-in-untreated-cd20-diffuse-large-b-cell-lymphoma-in-china/2025-11-14T14:11:34+00:00https://lymphoma-stg.clarovantdigital.com/library/racial-differences-in-the-molecular-genetic-biomarkers-of-diffuse-large-b-cell-lymphoma/2025-11-14T14:11:35+00:00https://lymphoma-stg.clarovantdigital.com/library/mutational-landscape-and-clinical-impact-of-spen-mutations-in-patients-with-chronic-lymphocytic-leukemia/2025-11-14T14:11:35+00:00https://lymphoma-stg.clarovantdigital.com/library/axicabtagene-ciloleucel-in-combination-with-atezolizumab-in-patients-with-refractory-diffuse-large-b-cell-lymphoma-the-phase-1-2-zuma-6-trial/2025-11-17T16:10:28+00:00https://lymphoma-stg.clarovantdigital.com/library/outcomes-following-transition-from-ibrutinib-to-zanubrutinib-in-patients-with-waldenstrom-macroglobulinemia-from-aspen/2025-11-17T16:18:34+00:00https://lymphoma-stg.clarovantdigital.com/library/routine-monitoring-of-car-t-cells-expansion-and-persistence-in-patients-with-aggressive-large-b-cell-lymphoma-by-flow-cytometry-a-single-center-experience/2025-11-21T20:42:00+00:00https://lymphoma-stg.clarovantdigital.com/library/portuguese-real-world-experience-with-ibrutinib-for-the-treatment-of-relapsed-refractory-mantle-cell-lymphoma/2025-11-21T20:42:01+00:00https://lymphoma-stg.clarovantdigital.com/library/blnk-as-an-important-prognostic-indicator-for-survival-in-pediatric-classic-hodgkin-lymphoma-patients-a-single-center-retrospective-study/2025-11-21T20:42:01+00:00https://lymphoma-stg.clarovantdigital.com/library/radiotherapy-alone-versus-combined-therapy-in-stage-i-natural-killer-t-cell-lymphoma-impact-of-local-invasion-on-treatment-outcomes/2025-11-21T20:42:01+00:00https://lymphoma-stg.clarovantdigital.com/library/richters-transformation-status-quo-and-quo-vadis/2025-11-21T20:42:01+00:00https://lymphoma-stg.clarovantdigital.com/library/a-matching-adjusted-indirect-comparison-of-survival-outcomes-with-pirtobrutinib-bruin-versus-standard-of-care-scholar-2-in-relapsed-refractory-mantle-cell-lymphoma-previously-treated-with-a-covale/2025-11-21T20:42:01+00:00https://lymphoma-stg.clarovantdigital.com/library/a-retrospective-analysis-of-the-clinicopathological-spectrum-and-survival-outcome-of-non-hodgkin-lymphoma-from-a-tertiary-care-hospital-in-saudi-arabia/2025-11-21T20:42:01+00:00https://lymphoma-stg.clarovantdigital.com/library/mortality-prediction-in-diffuse-large-b-cell-lymphoma-using-supervised-machine-learning-models-a-retrospective-study/2025-12-15T20:20:16+00:00https://lymphoma-stg.clarovantdigital.com/library/incidence-and-risk-factors-of-hypothyroidism-in-patients-with-hematological-malignancies-compared-to-healthy-population-a-systematic-review-and-meta-analysis/2025-11-21T20:42:02+00:00https://lymphoma-stg.clarovantdigital.com/library/mosunetuzumab-is-effective-and-well-tolerated-in-older-patients-with-relapsed-refractory-follicular-lymphoma-subgroup-analysis-of-a-phase-i-ii-study/2025-11-21T20:42:02+00:00https://lymphoma-stg.clarovantdigital.com/library/five-year-analysis-of-the-juliet-trial-of-tisagenlecleucel-in-patients-with-relapsed-refractory-large-b-cell-lymphoma/2025-11-21T20:42:02+00:00https://lymphoma-stg.clarovantdigital.com/library/ebv-positive-diffuse-large-b-cell-lymphoma-not-otherwise-specified-2022-update-on-diagnosis-risk-stratification-and-management/2025-11-21T20:42:02+00:00https://lymphoma-stg.clarovantdigital.com/library/comprehensive-assessment-of-devic-therapy-for-relapsed-or-refractory-diffuse-large-b-cell-lymphoma/2025-11-21T20:42:02+00:00https://lymphoma-stg.clarovantdigital.com/library/outcomes-of-tafasitamab-and-lenalidomide-in-large-b-cell-lymphoma-based-on-prior-cd19-directed-car-t-exposure/2025-11-21T20:42:02+00:00https://lymphoma-stg.clarovantdigital.com/library/renal-interstitial-infiltration-by-non-hodgkin-lymphoma-clinicopathological-features-outcomes-and-prognostic-markers-from-a-chinese-biopsy-cohort/2025-11-21T20:42:02+00:00https://lymphoma-stg.clarovantdigital.com/library/rituximab-is-associated-with-an-increased-risk-of-malaria-among-adult-lymphoma-patients-in-malawi-a-prospective-observational-cohort/2025-11-21T20:42:03+00:00https://lymphoma-stg.clarovantdigital.com/library/primary-non-hodgkin-lymphoma-in-the-muscle-of-left-lower-extremity-a-case-report-and-literature-review/2025-11-21T20:42:03+00:00https://lymphoma-stg.clarovantdigital.com/library/associations-between-gut-microbiota-and-immune-status-in-untreated-b-cell-lymphoma-patients/2025-11-21T20:42:03+00:00https://lymphoma-stg.clarovantdigital.com/library/cumulative-review-of-cardiac-failure-with-acalabrutinib-in-the-treatment-of-chronic-lymphocytic-leukemia-using-data-from-clinical-trials-and-postmarketing-experience/2025-11-21T20:42:03+00:00https://lymphoma-stg.clarovantdigital.com/library/site-specific-prognosis-and-temporal-trends-in-extranodal-marginal-zone-lymphoma-patients-in-the-united-states/2025-11-21T20:42:03+00:00https://lymphoma-stg.clarovantdigital.com/library/eal-world-comparative-effectiveness-of-bruton-tyrosine-kinase-inhibitors-in-relapsed-refractory-mantle-cell-lymphoma/2026-05-08T13:17:07+00:00https://lymphoma-stg.clarovantdigital.com/library/outcomes-of-transplant-eligible-and-transplant-ineligible-patients-with-mantle-cell-lymphoma-in-ontario/2026-04-22T21:48:10+00:00https://lymphoma-stg.clarovantdigital.com/library/mrd-driven-initial-therapy-of-acalabrutinib-and-lenalidomide-plus-rituximab-alr-or-obinutuzumab-alo-for-mantle-cell-lymphoma/2026-03-17T14:19:18+00:00https://lymphoma-stg.clarovantdigital.com/library/practical-considerations-for-clinical-translation-of-pet-imaging-of-adoptive-cell-therapies/2025-11-28T19:01:26+00:00https://lymphoma-stg.clarovantdigital.com/library/occupational-lifestyle-and-medical-risk-factors-for-non-hodgkin-lymphoma-a-case-control-study-in-ethiopia/2025-11-28T19:01:26+00:00https://lymphoma-stg.clarovantdigital.com/library/artificial-intelligence-for-risk-stratification-in-diffuse-large-b-cell-lymphoma-a-systematic-review-of-classification-models-and-predictive-performances/2025-11-28T19:01:26+00:00https://lymphoma-stg.clarovantdigital.com/library/clonal-identification-and-homology-differentiate-primary-central-nervous-system-lymphoma-from-non-central-nervous-system-lymphoplasmacytic-lymphoma-a-case-report/2025-11-28T19:01:26+00:00https://lymphoma-stg.clarovantdigital.com/library/ruxolitinib-as-second-line-therapy-for-bronchiolitis-obliterans-syndrome-after-hematopoietic-cell-transplantation-a-retrospective-multicenter-study/2025-11-28T19:01:26+00:00https://lymphoma-stg.clarovantdigital.com/library/global-burden-of-hodgkin-lymphoma-among-children-and-adolescents-a-population-based-study-using-gbd-2021/2026-03-13T13:39:29+00:00https://lymphoma-stg.clarovantdigital.com/library/de-diagnosing-chronic-lymphocytic-leukaemia-an-ethical-and-scientific-case-for-changing-diagnostic-criteria/2025-11-28T19:01:26+00:00https://lymphoma-stg.clarovantdigital.com/library/consensus-recommendations-on-the-management-of-toxicity-associated-with-cd3xcd20-bispecific-antibody-therapy/2026-01-14T18:35:17+00:00